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Abstract 
Background: Disease-specific patient-based questionnaires are being used 
increasingly to evaluate treatment outcomes in coronary heart disease (CHD) 
from the patient's perspective. However, most have been developed to evaluate 
health-related quality of life (HRQoL) in medically rather than surgically treated 
patients and many have not been rigorously evaluated against required 
standards. There are currently no validated questionnaires to measure patient-
based outcomes after coronary revascularisation, the surgical treatment for CHD. 
Objectives: To develop a new patient-based instrument, the Coronary 
Revascularisation Outcome Questionnaire (CROQ), to measure health outcomes 
and HRQoL before and after coronary artery bypass graft surgery (CABG) and 
percutaneous transluminal coronary angioplasty (PTCA). To evaluate the 
psychometric properties of the CROQ using classical psychometric methods. 
Design: Psychometric study. 
Subjects: A total of 725 (79% male) patients undergoing CABG and 643 (71% 
male) patients undergoing PTCA at three hospitals in the UK. 
Methods: Qualitative methods (literature review, review of existing instruments, 
patient interviews, and expert opinion) were used to develop two versions of the 
eROQ (CROQ-CABG and CROQ-PTCA). Two field tests were then conducted 
by postal survey to patients before and 3-months after revascularisation firstly, to 
identify possible items for elimination (item reduction) and secondly, to evaluate 
the psychometric properties (reliability, validity, responsiveness) of the item-
reduced CROa in independent samples. 
Results: The CROQ was acceptable to patients, satisfied tests of scaling 
assumptions, showed good internal consistency, test-retest reliability, validity, and 
responsiveness. 
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Conclusions: The CROQ is a newl psychometrically rigorous patient-based 
measure of outcome for coronary revascularisation. The CROQ has many 
potential uses in evaluative research l such as in clinical trials of effectiveness I 
and as a routine clinical audit tool to assist providers of CABG and PTCA in 
monitoring the outcomes of care. 
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CHAPTER 1 
INTRODUCTION 
1.1 Study rationale 
All health care interventions need to be evaluated to ensure that patients receive 
the best available care. Health care outcomes have traditionally been evaluated 
on the basis of mortality and morbidity. However, this limited approach to the 
evaluation of outcome has changed over the past few decades. The current focus 
is on establishing the effectiveness of health care based on scientific evidence 
using a wider range of outcome measures. A new discipline within health services 
research, health measurement, focuses on evaluating health outcomes from the 
patient's perspective using scientifically validated instruments. These health 
outcome instruments need to be rigorously evaluated against explicit criteria for 
use in evidence-based health care. 
Coronary heart disease (CHD) is the most common single cause of death in the 
UK and is associated with considerable illness and disability. For a disease of 
such public health importance, it is essential to have appropriate outcome 
measures to evaluate the impact of treatment from the patient's perspective. 
There are currently no rigorously validated questionnaires developed specifically to 
measure patient-based outcomes after coronary revascularisation, the surgical 
treatment for CHD. Although numerous disease-specific measures have been 
developed for CHD, there are two limitations with using existing measures to 
evaluate outcomes after coronary revascularisation. First, many of the current 
CHD-specific instruments have not been developed and validated against rigorous 
scientific standards. Second, those with established psychometric properties have 
largely been developed for use with medically not surgically treated patients, and 
are conceptually inappropriate for the comprehensive measurement of the impact 
of coronary revascularisation. This thesis describes the development and scientific 
evaluation of a new patient-based measure of outcome for coronary 
revascularisation. 
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1.2 Evaluating treatment outcomes 
The evaluation of health care interventions is an integral part of evidence-based 
medicine. In recent years there have been two important changes in the approach 
to the evaluation of health outcomes. Firstly, a more systematic and rigorous 
scientific approach to evaluation has been adopted and secondly, patient-based 
assessments of outcome have been increasingly incorporated into the evaluation 
of health care. 
Traditionally, the evaluation of health care consisted of clinical judgment as to 
whether or not a treatment had been a success. Clinicians' assessments about 
treatment successes were often based on personal experience and anecdotal 
evidence rather than sound scientific evidence. The concern that many 
procedures are of no benefit, or may even be harmful, and the increasing 
awareness that health care resources are scarce, have been important factors in 
encouraging rigorous evaluation of health care interventions.1 The current focus is 
on establishing the effectiveness of treatments and interventions based on critical, 
objective, and rigorous scientific evidence using a wide range of outcome 
measures.2 This is one reason why the measurement of health outcomes has 
become a key issue in health services research;3 health care interventions need to 
be evaluated to ensure that patients receive the best available care. 
In the UK, the creation of the internal market and the division of health care into 
purchaser and provider organisations directly influenced the evaluation of health 
care and health outcomes research. Changes outlined in the 1989 White Paper 
Working for Patients4 led to a greater need for purchasers to obtain evidence of 
cost-effectiveness in the contracting process.3 Clinical audit, the systematic 
assessment and improvement of care, was introduced as a means of monitoring 
the structure, process and outcome of health care. It involves routine monitoring of 
health care, thus recogniSing the need for more systematiC study of the relationship 
between health care and outcomes. 
Health care outcomes are central to the definition of the quality of care.5 By linking 
the care patients receive to health outcomes, outcomes research has become the 
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key to developing better ways to monitor and improve the quality of care. The 
growing interest in the assessment of health outcomes reflects increased 
awareness of the variations in effectiveness of interventions and the quality of care. 
In the 1997 White Paper, The New NHS,6 the Government outlined its commitment 
to a new agenda devoted to improving quality standards, efficiency, openness and 
accountability in the NHS. It promoted the use of national standards for services 
supported by consistent evidence-based guidelines to raise quality standards. 
Evidence-based medicine encourages clinical decision-making from the best 
available evidence from systematic research. 7 
The Government has launched a series of new initiatives and monitoring systems 
to assess and improve quality and performance in the NHS. The process of 
Clinical Governance was introduced to provide a mechanism for quality assurance 
of clinical decisions.8 The National Institute for Clinical Effectiveness (NICE) was 
set up to provide consistent guidance to clinicians about the clinical and cost-
effectiveness of new and existing interventions.9 A series of National Service 
Frameworks have been proposed to define standards for service provision in an 
attempt to tackle unacceptable variations in quality across the country.10 The 
National Service Framework for Coronary Heart Disease11 was one of the first 
published, reflecting the government's commitment to improving the quality of care 
in this area. The Performance Assessment Framework9 was designed to 
encourage the NHS to address performance across the whole range of its 
activities. It focuses on six key areas, including health outcomes and patient and 
carer experience, to judge how well each part of the NHS is doing in delivering 
quality services. The Commission for Health Improvement (CHI), a new statutory 
body, was set up to provide independent assessments of local action to improve 
quality.9 The Commission visits NHS Trusts to ensure that clinical governance 
arrangements are in place and that NICE guidance is implemented throughout the 
NHS. Its role is also to check the implementation of National Service Frameworks. 
The use of clinical indicators and high level performance indicators12 is being 
encouraged nationally to measure aspects of clinical care and performance that 
affect quality. These indicators are intended to help NHS organisations 'to compare 
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performance with similar organisations and with the national average, identify 
areas for further investigation and possible action, share information and good 
practice to achieve the best results for patients, and provide information to the 
public about local health service performance. 12 
With the recognition of the importance of rigorous evaluation, there has been a 
change in the type and breadth of health outcomes that are measured. Evaluation 
has moved beyond the measurement of traditional clinical outcomes, such as 
mortality and morbidity, towards increasingly diverse aspects of outcome, such as 
health-related quality of life and patient reports of satisfaction. This change in 
approach to outcomes measurement over the past few decades is a result of 
several factors, some of which are described below. 
The acceptance of the World Health Organisation's broader definition of health in 
1948 as "a state of complete physical, mental, and social well-being and not merely 
the absence of disease or infirmity"13 has encouraged health service researchers to 
look beyond clinical indicators of disease. It has encouraged a shift of focus away 
from the narrow and negative disease-based definition, towards a more positive 
concept of health. This positive definition of health encourages researchers to 
assess functional, social, cultural, subjective and social-psychological variables 
that have an impact on role performance, independent living and perceived well-
being.14 The traditional biomedical model of ill health is based on the belief that ill 
health is an objective and measurable state. III health is a pathological abnormality 
indicated by signs and symptoms. It is based on a pathophysiological 
understanding of the consequences of disease, defining disease by organ-systems 
and pathogenic mechanisms such as neoplasm or infection.15 In contrast illness 
refers to a person's subjective experience of ill health and is indicated by reported 
symptoms and subjective accounts of pain, distress, discomfort and so on. It is an 
important distinction that a person might feel ill without medical science being able 
to detect disease.16 Illness is a social phenomenon rather than a physical entity or 
property of individuals.17 Disease (the biophysical state) and illness (the social 
state) are distinct entities and "illness became the providence of sociology".18 
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To evaluate health outcomes, it is important to go beyond the measurement of 
presence/absence and severity of symptoms of the disease, and to show how 
manifestations of an illness or treatment are experienced by individuals. There is 
increasing recognition that patients are not always passive, as they are regarded in . 
the traditional biomedical model, and indeed often take an active role in their 
treatment. Interpretative sociology has developed a view that people act as 
agents, rather than being merely the products of the contexts in which they Iive.19 
Qualitative studies are increasingly being used to report on the lived reality of 
chronic illness, exploring the diversity of everyday experience which lie beyond 
indices of disability and mortality.19 Chronic illness passes though stages with the 
course of time which may have different meanings as the individual ages and their 
position in life changes. Individuals need to make trade-offs between adherence to 
medical regimes and the social impact they have on daily life. Adherence to 
medical regimes can influence the course of disease. There is a need for a 
multidimensional view of the impact of disease on every-day life. Bury 
distinguishes two types of 'meaning' in chronic iIIness.19 The 'meaning' of illness 
lies in the consequences for the individual, i.e. the effect of the onset of disruptive 
symptoms on everyday functioning. The 'meaning' of chronic illness is also seen in 
terms of its Significance, as different conditions carry with them different 
connotations and imagery. These differences may have a profound effect on how 
individuals regard themselves and how they think others perceive them. 
Experiences are not only influenced by the social context in which the person lives, 
but by the nature of the symptoms, and their perception by self and others.19 
Whilst there is no agreement on a definition of health, there is wide consensus that 
it includes physical, mental and social components.20 The WHO's classification of 
Impairments, Disabilities and Handicaps,21 provides a useful framework for 
considering the consequences of health and disease. Impairment refers to any 
loss or abnormality of psychological, physiological or anatomical function. 
Disability refers to any restriction or lack of ability to perform an activity in ways 
considered normal for an individual. Handicap results from impairment or disability 
that limits the fulfilment of a role that is normal for that individual. 
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Another reason for the shift away from strictly clinical measures of outcome is that 
although mortality is an appropriate outcome to measure if the health technology in 
question is intended to save lives, most technologies aim to prevent, cure or 
alleviate the effects of diseases and conditions which do not threaten Iife.22 Indeed, 
many interventions have little effect on mortality.16 As advances in medical 
technology have made death a relatively rare event, it is no longer considered an 
appropriate indication of outcome if used in isolation. Advances in medical care 
and technology have led to a shift in attention from acute illness to chronic disease, 
where the goal of therapy is not cure but symptom alleviation and improved 
functional capacity.23 24 Most health care is provided to relieve symptoms, restore 
functioning, reduce pain or discomfort, and assist patients in coping with disease. 
Measures of mortality and morbidity are thus inadequate in measuring these 
aspects of outcomes. The ageing of the population has also led to an increasing 
emphasis on the treatment of chronic diseases, which are more likely to have an 
impact on diverse aspects of a patient's life.25 26 Therapeutic interventions in 
chronic diseases, such as chemotherapy for cancer, can cause serious side-effects 
and functional impairment which need to be evaluated. 27 Some treatments have 
both beneficial and harmful effects. For example, some drugs used to treat cancer 
can prolong survival but are so toxic that they may lead to nausea and depression. 
In the evaluation of treatment outcomes in chronic disease, measures of outcome 
need to be able to detect small or subtle changes in physical and mental health. 
Traditional clinical measures of morbidity are often poorly related to subjective 
accounts of health and well-being.28-34 As Jenkinson states, "it is possible to feel ill 
without any signs of underlying disease, and possible to have disease without any 
subjective awareness of illness". 31 , p.2 For example, Juniper at al.3o found only 
modest correlations between clinical assessments of asthma and how patients felt 
and functioned in daily activities. Similarly, Leidy and Coughlin33 found no 
relationship between forced expiratory volume and patients' self-reports of asthma 
using the Asthma Quality of Life Questionnaire. Guyatt at al.26 reported poor 
correlations (.30 or lower) between cycle ergometer results and scores on 
functional status questionnaires in patients with chronic heart and lung disease. 
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Clinical measures of mortality and morbidity clearly do not reflect the whole 
concept of health. Reliance on clinical measures alone is now considered to be of 
limited value in the evaluation of the effectiveness of treatments.35 
In recent years, patients have become increasingly involved in treatment 
decisions.36 There is growing acceptance that patients and carers are "experts" in 
their own conditions; that is, they know what it is like to live with or care for 
someone with a particular health problem and often know what is best for 
recovery.3236 It is for these reasons that outcomes of importance to the patient 
have been incorporated increasingly into health outcome assessments. Patients 
are the best informant about symptoms, feelings, and the ways in which illness 
affects what is important to them.37 Patients' preferences for treatment options 
have also been shown to differ from those of health care professionals. Slevin et 
al.,38 for example, reported differences between patients and medical staff in 
treatment choices for chemotherapy regimens; contrary to the expectations of 
medical staff, patients were willing to accept toxic chemotherapy for a minute 
chance of possible benefit. Wynne39 reported that patients with multiple sclerosis 
in a randomised controlled trial of hyperbaric oxygen therapy, used different criteria 
than clinicians to judge the success of their treatment. 
The UK government has also promoted the involvement of patients in planning and 
evaluating care. In 1983, the National Health Service Management Inquiry40 
known as the Griffiths' report, recommended that information about patients' 
experiences and perceptions be gathered to demonstrate how well the service was 
being delivered locally. The aim was to ensure that services are planned and 
delivered in response to such information. The 1989 White Paper Working for 
Patients4 aimed to make the NHS more responsive to patients' needs and thus of a 
better quality. In 1991 the Patient's Charier41 was launched setting out patients' 
rights to care in the NHS and introducing national standards (e.g. respect for 
privacy, dignity, and religious and cultural beliefs). The Patient's Charier has since 
been updated42 with a greater emphasis on ensuring that users are involved in 
decision-making. The VVhite Paper The New NHS6 committed the Government to 
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carry out an annual national survey (National Survey of Patient and User 
Experience) that would allow systematic comparisons of the experience of patients 
and their carers over time and between different parts of the country. The survey is 
a key part of the quality agenda set out in The New NHS and will be used to help 
monitor the delivery of quality standards locally, in line with the framework set out 
in A First Class Service.9 The survey will enable local managers and health 
professionals to take direct account of users' views in improving services. Part of 
the survey looks in depth at patients' experiences in selected areas. The initial 
survey of CHD patients covered a wide range of issues including access, 
communications, patients' views about doctors and nurses and how involved 
patients were in the care that they received. The Patient Partnership Strategy aims 
to improve service quality by providing patients with information enabling them to 
make informed decisions about their health and health care. 36 
1.3 Patient-based assessments 
The now widespread use of patient-based assessments in evaluating health care 
interventions has also lead to greater patient involvement. The following section 
describes what is meant by the term patient-based assessments and outlines the 
origins of health measurement. 
1.3.1 What are patient-based assessments? 
Patient-based assessments of outcome provide an evaluation of the impact of 
treatment from the patient's point of view. They include questionnaires (self- and 
interviewer-administered) to elicit responses from patients about their health 
condition and I or treatments. Terms that are widely used in reference to these 
patient-based assessments include quality of life (QoL), health-related quality of life 
(HRQoL), health status, subjective well-being, functional status, and patient 
satisfaction. Several of these terms are used interchangeably, causing 
considerable confusion. The terms are often used loosely and many authors fail to 
define the terms they use. 
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HRQoL was first mentioned in the medical literature in 1966,32 and the term quality 
of life was first listed in Index Medicus in 1977.3 Since the late 1980s, the 
assessment of HRQoL has increased rapidly, with over 1000 new articles each 
year indexed under this term.43 A range of different types of instruments are 
indexed under the term QOL. For example, some instruments focus exclusively on 
physical function such as mobility and activities of daily living and as such can be 
viewed as functional status instruments. Whereas others assess the impact of 
health on a broad spectrum of the individual's life, for example family life and life 
satisfaction, and as such might be best described as QOL instruments.44 The use 
of the term QOL is often inappropriate and misleading as it suggests an abstract or 
philosophical set of judgements relating to life in the broadest sense i.e. factors 
outside of the person such as living standards, political or physical environment. 
The vast majority of so-called QOL instruments do not assess these wider aspects 
and as such the term QOL is inappropriate. 
QOL and HRQoL should not be used interchangeably: there is a need to 
"distinguish those features of quality of life which will yield to medical 
influence from its other features which depend upon economics, 
politics, or culture within the broader sOciety...... otherwise quality of 
life may become so banalized that it will lose its original meaning, 
intent, and even possible usefulness". 45, p.4 
Several researchers have helped to narrow the definition of HRQoL. Mostellor et 
al. 's«' minimum core set of health concepts includes measures of physical, social, 
and role functioning, general mental health, and health perceptions. An 
international group of HRQoL researchers reached a consensus on the 
fundamental dimensions essential to any HRQoL assessment: physical, 
psychological, and social functioning, and global perceptions of function and well-
being.2O Researchers interested in measuring outcomes in specific conditions 
suggest the additional inclusion of disease-specific symptoms and somatic 
discomfort. 25 
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HRQoL has been poorly defined in the literature and a single definition "remains 
iIIusive".47 Several contrasting definitions are described below. Calman46 defined 
QOL as the difference, or the gap, at a particular period of time, between the hopes 
and expectations of the individual and that individual's experiences. Gill and 
Feinstein49 defined quality of life, rather than being a description of patients' health 
status, as a reflection of the way that patients perceive and react to their health 
status and to other non-medical aspects of their lives. Patrick and Erickson50 have 
defined HRQoL as "the value assigned to duration of life as modified by the 
impairments, functional states, perceptions, and social opportunities that are 
influenced by disease, injury, treatment or policy". F arquhar51 reviewed the range 
of definitions of QOL and developed a typology distinguishing between global, 
component and focused definitions. Global definitions express QOL in general 
terms such as degree of satisfaction with life; component definitions break down 
QOL into specific parts such as health, life satisfaction ad psychological well-being; 
and focused definitions emphasise only one or two of the range of possible 
component parts. The common link between all these definitions is that they all 
address aspects of the patient's subjective experience of health and the 
consequences of illness; they all elicit perceptual information from the patient. 44 
Within the growing literature on health outcomes, there is little agreement about the 
meaning of the term QOL, with rival factions urging the adoption of a different 
approach using different types of measures. This has led some researchers, such 
as Hunt,52 to caution against using QOL as an outcome which can influence 
patie~ts'lives, but that the "soliciting of patients' perceptions of their health state 
and functioning" should continue to be an important component of outcomes 
research. The term HRQoL is used throughout this thesis to operationalise the 
definition given by Wenger et a/ as: 
those attributes valued by patients, including their resultant comfort or 
sense of well-being; the extent to which they are able to maintain 
reasonable physical, emotional, and intellectual function; and the 
degree to which they retain their ability to partiCipate in valued activities 
within the family, in the workplace, and in the community. 53, p.884 
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The term HRQoL is taken to exclude the widely valued aspects of life, such as 
income, freedom, and quality of the environment, that are not generally considered 
as 'health'. 54 However, it should also be recognised that when a patient becomes 
ill, almost all aspects of life can become health-related. 54 HRQoL encompasses the 
dimensions of QOL which are affected by a disease and its treatment and which 
have the potential to be changed by the therapeutic situation. 55 Throughout this 
thesis, the Coronary Revascularisation Questionnaire is referred to as a patient-
based measure of outcome as it measures both HRQoL and other health 
outcomes, such as readmission to hospital. It assesses the patient's perception of 
the impact of the disease and treatment on their functioning. 
Patient satisfaction is another ill-defined term56 that falls under the umbrella term of 
patient-based assessments. It is an important indicator of the quality of health care 
and is commonly used in the process of monitoring and improving care. It is a 
separate concept from HRQoL, but one that can influence HRQoL. Dissatisfaction 
has been linked to poorer health outcomes,57 poorer compliance with treatment58 
and poor attendance for follow-up care,59 all of which can affect health outcomes 
and HRQoL. It is important to measure the impact of services in terms of both 
patient satisfaction and health outcomes.56 
It is now increasingly accepted that patient-based assessments of HRQoL and 
satisfaction provide invaluable information about the impact of medical 
interventions.3 35 44 47 50 60 61 These instruments provide useful and important 
additional information to traditional phYSiological or biological indicators of health 
status because they describe what the patient has experienced as a result of 
health care.61 Patient-based assessments are not designed to replace traditional 
clinical endpoints, but are intended to complement existing measures and to 
provide a more complete picture of health state than can be gained by clinical 
measures alone.35 47 Enhancing HRQoL is as important as other goals of health 
and medical care, such as preventing disease, effecting a cure, alleviating 
symptoms or pain, averting complications, providing humane care, and prolonging 
life. 50 
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The discipline of health measurement concerns the development of methods for 
measuring patient-based health outcomes, such as HRQoL. Whilst the field of 
health measurement is relatively new, it derives directly from the well-established 
theories and methods of psychometrics. The next section outlines the 
development of health measurement. 
1.3.2 From psychometrics to health measurement 
The foundation of health measurement is in the field of psychometrics. The 
development of psychometrics can be traced to the mid 1800s; by the mid 1950s 
the methodologies for the scientific evaluation of measuring instruments were well 
established. However, until recently, there was little transfer of this knowledge from 
the social sciences to medicine. 
McDowell and Newell62 provide a historical overview of the development of 
methods to measure subjective phenomena. Psychophysics, a sub-discipline of 
experimental psychology, demonstrated that subjective judgements are a valid 
approach to measurement. Psychophysics is concerned with the way in which 
people perceive and make judgements about physical phenomena, for example 
the loudness of a sound or the intensity of pain. In the 1860s, one of the 
pioneering psychophysicists, Gustav Fechner, searched for a mathematical 
relationship between the intensity of a stimulus and its perception. He concluded 
that small differences at lower levels of a stimulus are easier to detect than at 
higher levels and that this relationship can be expressed as a natural logarithm. 
Over the next 70 years, evidence from various sources showed that the logarithmic 
relationship did not fit all types of stimuli. However, it was not until the mid-1950s 
that Stevens' power law replaced the logarithmic approach. Stevens' power law 
recognised that people can provide consistent numerical estimates of. sensory 
stimuli and that the relationship between stimulus and response is not linear. 
Stevens' view differed from that of Fechner in that he stated that the exact form of 
the relationship varied from one sensation to another. 
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Stevens' power law has been subjected to numerous tests which have produced 
some convincing evidence that people can make subjective judgements in a 
remarkably consistent manner, even when asked to make abstract comparisons -
comparisons of the type that are frequently incorporated into subjective health 
measurements. Research to validate the power law suggests that people can 
make accurate judgements of stimuli on a ratio scale rather than merely on an 
ordinal scale of measurement. This implies that people can consistently judge how 
many times stronger one stimulus is than another. 
Psychometrics, which grew out of psychophysics, produced the methods to 
measure other behavioural phenomena. In the 1950s, psychologists working in the 
field of psychometrics adapted the principles of psychophysical methods to 
measure constructs such as intelligence and personality, for which there is no 
physical scale. Psychometrics developed at the beginning of the twentieth century 
with Binet's intelligence test to measure mental age. The idea of standardised 
intelligence testing spread rapidly and was applied to different situations. The 
need for large-scale group testing to screen new World War I recruits en masse 
added momentum to the psychological testing movement. 63 Tests were developed 
to measure educational achievement, aptitude, personality and psychopathology. 
The massive interest in psychological testing was motivated by the practical need 
for ways to measure diverse outcomes such as how to identify children with special 
education needs, psychiatric patients in need of treatment, and personnel for 
certain jobs. Accompanying this practical need was the development of a more 
specific. interest in the methodology and technology of testing, which lead to 
psychometrics coming to prominence in the 1940s-60s. 
Health, like intelligence and personality, cannot be measured directly as there is no 
physical scale to measure it. There will always be debate about how best to 
measure health due to its complex and abstract nature.62 The measurement of 
health relies on the use of health indicators to represent different elements. Health 
services researchers often need to measure something which has not previously 
been evaluated, for example severity of chest pain or satisfaction with treatment.54 
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Objective measurements, such as weight and height, refer to IItangible 
phenomena, occurring as external realities" and can be measured by generally 
accepted standards and criteria that make them IIscientifically attractive". 65 
Subjective measurements, such as intensity of pain and satisfaction with treatment, 
lack such criteria. However, these subjective measurements are important in 
health care because patients' personal responses to phenomena like pain are 
often the most important outcomes of clinical treatment. 65 
As laboratory data and physically observable findings are the traditional methods 
for evaluating health care, patient self-reports of outcomes have been labelled as 
subjective, unreliable and 'soft'.66 However, through the use of psychometric 
methods, instruments can be developed which are reliable and valid and which 
may even perform better on tests of reliability than many traditional medical tests. 66 
67 Read68 criticises clinicians' inappropriate use of terms such as reliable and 
reproducible to describe their 'hard' clinical data. Notes in medical records may be 
subject to numerous types of measurement error and bias,67 which standardised 
subjective measures are not prone to. There can be no excuse for rejecting 
HRQoL assessment as unsatisfactory 'soft' information if scientifically rigorous 
measures are used. Neither should HRQoL assessment be rejected because it is 
considered difficult to measure. There is strong evidence that patients can provide 
reliable and valid judgements of outcomes and that these perceptions are 
important and relevant. 3252744 47 55 6769-73 
Clinimetrics,65 74 a field related to psychometriCS, refers to indices or rating scales 
of clinical phenomena such as symptom severity, co-morbidity and functional 
disability. In contrast to psychometrics, clinimetrics usually concerns the 
measurement of multiple attributes with a single index score. The aim is usually to 
develop an index which is "clinically sensible" with desirable properties for 
prognOSis and prediction.27 The most important attributes of sometimes complex 
clinical phenomena are combined without expecting the items to be homogeneous. 
Clinimetric indices usually consist of a single-item IIglobal" rating to facilitate ease 
of use in the clinical setting.65 VVhilst clinimetric indices have the advantage of 
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being easy to develop, short and easily applied, they are frequently developed on 
an ad hoc basis with little attention to their measurement properties (reliability, 
validity and responsiveness). Many indices that are widely accepted and have 
proven to be useful may in fact lack evidence of their reproducibility and validity.65 
The two most widely used clinimetric indices in cardiology, the New York Heart 
Association75 and the Canadian Cardiovascular Society76 classifications of angina 
and dyspnoea on exertion are no exception. 
Since health measurement was recognised as a new discipline in the late 1980s 
several books have been published in this field. In 1989, Streiner and Norman 
published the first textbook on the methodological aspects of health 
measurement,n which was revised in 1995.64 Around the same time, a number of 
health measurement books were also published that summarised and evaluated 
the wide range of clinical and research instruments used to evaluate patient-based 
outcomes in health care settings.3 16 62 78 These texts are a valuable source for 
identifying appropriate and validated instruments for use in health care research. 
1.3.3 Measures of health-related quality of life 
Traditionally, HRQoL was evaluated by indirect inference from medical variables.58 
For example, improved exercise tolerance was used as a sign of symptom relief 
and consequently improved HRQoL for cardiac patients. The move towards 
patient-centred outcomes began with the introduction in 1947 of the Karnofsky 
Performance Scale, a clinician-rated scale of patients' functional abilities.79 
Clinicians were interested in looking beyond the functional capacity of the patient in 
the clinical setting towards the impact of disease and treatment on a patient's daily 
life. Following this, a number of activities of daily living (ADL) scales were 
developed, for example the Barthel Index. eo For practical reasons, clinicians 
usually provided information about HRQoL. However, clinician and patient 
perceptions of HRQoL and outcome are generally poorly correlated. 16 26 27 37 61 81-84 
This may be because clinicians usually judge patients' clinical responses rather 
than how the clinical responses might be altered by a patient's value system or 
beliefs.83 Patients provide the most accurate measure of HRQoL.202781 
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In the late 1970s and early 1980s, a few general health status measures linking 
functional capacity to HRQoL were developed, for example the Sickness Impact 
Profile (SIP)85 and the Nottingham Health Profile (NHP).86 These self-administered 
instruments were the first to focus on physical functioning, psychological health, 
perceived distress and life satisfaction. Since the late 1980s, there has been a 
tremendous surge in the development of new patient-based measures of outcome 
and the emergence of 'gold standard' instruments, such as the SF-36 Health 
Survey (SF-36).87-89 The SF-36 is a 36-item generic measure that covers eight 
dimensions: physical functioning, physical role limitations, bodily pain, general 
health perceptions, vitality, social functioning, emotional role limitations, and mental 
health. The SF-36 has been evaluated in many populations and is probably the 
most widely used measure of health status world-wide.47 
With the proliferation of treatment options that may have similar effects on mortality 
and morbidity, HRQoL has become an increasingly important measure of outcome. 
Since the 1980s, measures of HRQoL and patient satisfaction have been used 
increasingly to evaluate patients' perceptions of outcome after a wide range of 
treatments. Researchers are developing new tools to monitor the quality of care, 
which incorporate patients' experiences, self-perceived needs and health status. 
There has recently been a proliferation of measures with little attention paid to their 
measurement (psychometric) properties. Instruments must be reliable, valid and 
responsive to change if we want to be confident about their use,64 90 and also need 
to be useful and interpretable in the clinical setting.91 Chapter 2 presents the key 
psychometric properties (including acceptability, reliability, validity, and 
responsiveness) that need to be assessed when evaluating a patient-based 
questionnaire and provides recommended criteria for each property. It also 
describes some practical aspects in evaluating patient-based instruments. 
There are two main types of HRQoL instruments - generic and disease-specific. 54 
92 The usefulness of each of these approaches depends on the purpose of 
measurement. Generic measures provide comprehensive, general evaluations of 
HRQoL applicable to patients with any acute or chronic condition. They enable 
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comparison of outcome across different patient populations and interventions, 
which is useful for cost-effectiveness analysis, and can provide the opportunity to 
make policy decisions across a variety of diseases.92 Whilst generic measures are 
likely to be robust as they have been tested in different contexts, they lack the 
range, sensitivity, and flexibility to deal with the particular problems of specific 
conditions.9394 Generic measures, such as the SF-36 and the NHP, are widely 
used in research studies and clinical trials. 
Disease-specific measures of HRQoL provide useful additional information about 
response to specific conditions and treatments and can enable greater 
discrimination between treatments.70 Disease-specific measures are more 
sensitive for the detection and quantification of small changes that are important to 
clinicians and patients. 54 70 92 93' They can reduce patient burden and increase 
acceptability by including only relevant dimensions.93 95 96 However, the inability to 
compare results with other disease groups can be seen as a disadvantage. 
Comprehensive assessment of health outcomes should incorporate both generic 
and disease-specific instruments as they complement each other.46 92 95 Generic 
measures enable comparison with other studies, thus enhancing the 
generalisability of findings, whereas the use of disease-specific measures ensures 
good content validity and increased responsiveness to change in specific 
populations.92 97 
Utility or preference measures are HRQoL instruments that are designed 
specifically for economic evaluations.9899 These measures provide a single health 
index scored from 0 to 1, where 1 reflects full health and 0 dead. These measures 
can be used to calculate quality-adjusted life-years (QALYs) to assess the cost-
effectiveness of interventions. QALYs integrate mortality and morbidity to give a 
value of health status in terms of the equivalent of well years of life. Widely-used 
utility measures and techniques include the Rosser Index,1OO Quality of Well Being 
Scale,99 time trade-off,98 and standard gamble101 techniques and the EuroQoL EQ-
50.102 Utility measures are being used increasingly in clinical trials to evaluate the 
cost-effectiveness of treatment. 
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Other researchers have recently taken a different approach to measuring 
HRQoL.103-106 Instead of using fixed format questions, patients are asked to select 
areas of their life that have been adversely affected by their condition and to 
assess the extent of this impact. This individualised method allows respondents to 
define HRQoL in a way that is meaningful for them and to select and weight their 
own chosen areas for relative importance, and avoids imposing pre-existing 
definitions of health state.106 Responses can be scored to form a single index 
suitable for utility assessments. Examples of the individualised approach include 
the Schedule for the Evaluation of Individual Quality Of Life {SEIQoL),103-105 the 
Patient Generated Index (PGI),106 and the Patient Specific Index (PSI).107 These 
individualised instruments have not yet been widely used. 
1.3.4 Application of patient-based assessments of HRQoL 
Patients' evaluations of their health status and HRQoL are becoming increasingly 
important in several contexts: determining the appropriateness and quality of 
health care; evaluating the clinical and cost effectiveness of health care 
interventions; clinical decision-making; evaluating health policy programmes; 
health care planning and for prioritising health care treatments and containing 
costS.2371 93106-112 The main applications of patient-based measures of HRQoL are 
briefly described below. 
An important application of HRQoL instruments is their use as outcome measures 
in evaluative research. HRQoL instruments are being used increasingly in clinical 
trials alongside more traditional measures of outcome, such as mortality and 
morbidity, to provide a more comprehensive assessment of treatment and to 
improve knowledge of treatments. 113 114 Some clinical trial organisations have 
introduced the assessment of HRQoL as a standard part of new trials.27 The 
majority of clinical trials use generic instruments, but in recent years there has 
been progress towards including disease-speCific instruments. Patient-based 
instruments are usually used as secondary outcome measures, but several trials 
have used them as the primary outcome. For example, Croog et al.115 
demonstrated major differences in HRQoL between three anti-hypertensive 
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therapies and Bulpitt73 measured the effects of drug treatments (ACE inhibitors) on 
HRQoL in patients with heart failure. 
Patient-based measures of HRQoL can also be used in audit, quality assurance, 
and routine evaluation of health care treatments and providers of treatment.35113114 
Practitioners, providers, purchasers and policy makers are increasingly seeking to 
enhance the level of sophistication of commissioning and audit in the NHS. 
Routine audit using reliable and valid outcome measures provides valuable 
information for evaluating the effectiveness of health care treatments and can 
assist clinicians in monitoring the outcomes of care. Clinical audit is a means of 
ensuring high quality health care by identifying and rectifying deficiencies in health 
care provision; these deficiencies can be identified by using patient-based 
measures of outcome. Patient-based measures of HRQoL and satisfaction can 
also be used to monitor quality within and between provider institutions. Involving 
service users and carers is an important part of improving service quality in the 
NHS as it provides a different view of problems.36 Listening and responding to the 
needs of those who use the NHS is an important part of making effective change. 36 
The views and experiences of patients are vital indicators of and contributors to 
service quality. 
HRQoL data can also be used to assist health professionals in individual patient 
care. The data can be used to provide information about patients' progress and 
response to treatment, assessing need, and setting treatment goals for screening 
patients.26 114 116 HRQoL measures can quantify the magnitude and duration of 
problems experienced by patients and the extent to which such problems affect 
everyday functioning. This in tum, can help to identify key areas in which 
additional support and or rehabilitation should be directed in clinical practice. 37 
They can also be used to screen for health or psychosocial problems that may not 
otherwise have become apparent from the clinical consultation.44117 By presenting 
patients with information about HRQoL together with clinical data, patients might 
be able to judge better which treatment they would prefer. Patients could also be 
better informed about the range of problems which they can expect in the 
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immediate and long-term from a particular illness and its treatment.27 Realistic 
expectations might help to improve health outcomes. 118 
There is some evidence that it is feasible to incorporate short measures into 
routine practice,119 and that clinicians find the information useful and informative.120 
However, trials evaluating the impact of providing this information to clinicians have 
found little evidence that clinical decisions are changed as a result of the additional 
information.120 Oeyo and Patrick suggest that patient-based measures of outcome 
may have failed to infiltrate clinical practice because information needs to be 
processed rapidly, it is not clear how to present the data in a useful format and 
clinicians do not know how best to use the evidence. 121 
Commissioners and purchasers of health care increasingly require evidence of the 
effectiveness of interventions before placing contracts. Policy makers are 
interested in the effects of medical interventions on HRQoL because the case-mix 
of patients affects use of services and expenditure pattems.28 Commissioning 
agencies can use HRQoL data in conjunction with measures of other treatment 
outcomes and costs to compare the cost-effectiveness of different methods of 
treatment. Those responsible for the allocation of resources to treatments should 
attempt to maximise the amount of health gain by balancing the ratio between 
benefits and costs. Ebrahim15 emphasises the importance of careful selection of 
HRQoL instruments for measurement in clinical (Le. individual) and public health 
(i.e. population) settings. He warns that such wide-ranging purPoses of 
measurement are unlikely to be satisfied by a single scale or indicator. 
HRQoL assessments can also be used to provide an indication of ill health and 
need in speCific groups in population surveys,114 as a basis for determining 
appropriate and efficient allocation of resources for health care,35 and as a basis 
for assessing the impact of policy initiatives.93 108 HRQoL instruments provide more 
specific information about perceived need beyond existing measures of need such 
as mortality or socio-demographic data. Surveys have been conducted on specific 
geographical populations and social groups to provide evidence of inequalities in 
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health status between specific groups.109 122 For example, Ahmad et al.109 
measured the influence of ethnicity and unemployment on perceived health in a 
sample of general practice attenders. Population-based surveys can also be used 
to measure the impact of changes in health care provision over time as a result of 
policy initiatives. In the population setting, instruments need to provide specific 
information that indicates needs for particular kinds of health or other services; 
these are rarely included in validated instruments. There is little evidence that 
patient-based assessments add to other sources of health status in informing 
population-level decision-making.44 
The two most widely adopted applications are the use of patient-based 
assessments in evaluative research, such as clinical trials, and in clinical audit as 
indicators of the quality of care provided. With increasing use and greater 
familiarity with these instruments, it is possible that they will be used on an even 
wider scale and be used routinely in clinical practice. 
Patient-based assessments have been used extensively in the evaluation of 
treatments for CHD. CHD is a chronic disease of great public health importance as 
it is the most common single cause of death in the UK and causes considerable 
illness and disability. As such, it has attracted much rigorous research into the 
relative effectiveness of various treatments. The government has identified CHD 
as an area of high priority11123 and is committed to improving the standard of care 
for this disease. It is now clearly recognised that patient-based assessments 
provide useful information to help evaluate the effectiveness of treatments in CHD, 
as the goal of treatment is to improve HRQoL rather than cure. Consequently, 
many patient-based instruments have been developed and used to measure the 
impact of CHD from the patient's perspective. 
Subsequent sections of this chapter describe the changing approach to health 
outcome measurement in CHD - the increasing use of patient-based assessments 
and the adoption of a systematic and rigorous scientific methodology. This thesis 
concerns the development of a new patient-based measure of outcome for 
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coronary revascularisation, the surgical treatment for CHD. The next section 
briefly describes the epidemiology and costs of CHD, psychosocial aspects of the 
disease, and methods of treatment, before presenting the range of outcome 
measures (clinical and patient-based) that have been used to evaluate health 
outcomes in CHD. Chapter 3 provides a critical review of the psychometric 
properties of disease-specific, patient-based measures of outcome in CHD. 
1.4 Coronary heart disease 
1.4. 1 Epidemiology and costs 
CHD is the single most common cause of death in the UK and is associated with 
considerable illness and suffering.124 It is a major public health problem due to its 
high prevalence and the significant health care expenditure directed towards its 
prevention and treatment. It kills more than 110,000 people a year in England, of 
whom more than 41,000 are under 75 years of age.11 Although CHD mortality 
rates are falling, rates in the UK are still amongst the highest in the world,124 with 
26% of all deaths in England in 1992125 and 148,186 deaths in 1996 attributable to 
CHD.124 
In the UK mortality rates from CHD are considerably higher amongst males than 
females, though in recent years rates have been decreasing in both men and 
women. CHD is traditionally considered a male disease, but one in four men and 
one in five women die from heart disease in the UK.124 Female deaths from CHD 
account for almost 46% of all CHD deaths; CHD is the single most frequent cause 
of death in women, both above and below the age of 65 years.125 Table 1.1 shows 
the mortality rates in England and Wales for CHD in 1999 for males and females by 
age group. For each age group, mortality rates are higher for males than females, 
except ages 15-24 years. The magnitude of difference between the sexes peaks 
at 45-54 years, when mortality rates in males are 4.7 times higher than in females. 
With increasing age, the difference between the sexes falls and in the age group 
85 years and over, mortality rates for males are only 1.4 times higher than for 
women. 
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Variations in CHD mortality rates have increased in certain social and ethnic 
groups and across regions. 11 CHD is more prevalent in manual than non-manual 
workers in the UK and there have been widening differences in death rates 
between these groups.124 126 In the UK during the period 1991 to 1993, men in 
social Class V were 3.1 times more likely to die for CHD than those in Social Class 
1.127 However there was a geographic difference in this social gradient. As for all-
causes, the Social Class gradient was flatter in England than in Wales, Scotland 
and Northern Ireland. Within England, gradients in the southern regions were 
flatter than those in the north.127 Since the 1970s, there has been a greater 
reduction in CHD deaths among non-manual groups than among manual 
groups.126 This pattern is also reflected in morbidity rates, with angina and heart 
attacks being more common in people in manual occupations.128 South Asians 
living in the UK (Indians, Bangladeshis, and Sri Lankans) have particularly high 
rates of CHD. The British Heart Foundation reported an increase in the proportion 
of South Asians dying from and living with CHD between 1997 and 1998.124 
Table 1.2 presents age-standardised mortality rates for CHD in the UK by country 
and region for males and females (1991-97). This table shows the considerable 
geographic variation in mortality from CHD.127 Scotland, Northern Ireland and 
Wales all have higher mortality from CHD than England for both males and 
females. Across age groups the pattern was very similar to this, although the rates 
were low for those aged 15-44 years, particularly for females. Within England 
there was a north-south divide in mortality from CHD, similar to that seen for all 
cause mortality; rates are significantly higher in northern parts of England than the 
overall UK rate, whereas they are lower in southern parts of England. 
Improvements in medical treatments for CHD have led to reduced mortality, but the 
disease also causes considerable illness and disability. The proportion of ill health 
caused by CHD may be rising. 124 Routine UK hospital data show that 3% of all 
admissions are for CHD.11124 Every year, more than 1.4 million people suffer from 
angina and 300,000 have heart attacks." Table 1.3a presents prevalence rates for 
treated CHD in England and Wales by age and sex in 1994-8. Rates are higher in 
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Wales than in England, and among males compared to females. Table 1.3b 
presents prevalence rates for treated CHD in Scotland by age and sex in 1998. In 
Scotland, rates are higher among males compared to females at all ages.129 
CHD is the most costly disease in the UK, accounting for 2.5% of total NHS 
expenditure,'23 and adding a burden of £10 billion per year to the UK economy.130 
CHD cost the UK health care system about £1,600 million in 1996 (more than any 
other disease).130 However, these costs grossly underestimate the total cost of the 
disease as the majority of costs fall outside healthcare. Costs due to illness 
caused by CHD (65 million lost working days per year)'28 and the economic effects 
on caregivers are not included in these cost estimates. These production losses 
have been estimated to cost an extra £8,500 billion in 1996 to the UK economy.130 
In 1995, CHD was identified as a key area for improvement by Health of the 
Nation'23 and in 2000, the UK government established its first comprehensive 
national program for tackling heart disease, laid out in the National Service 
Framework for CHD.131 This 10-year programme of modernisation aims to 
transform the prevention, diagnosis and treatment of CHD and to save 20,000 lives 
a year when fully implemented. 
1.4.2 Manifestations and diagnosis 
CHD develops as a result of narrowing of the blood vessels (coronary arteries) 
which supply the heart muscle with oxygen and its energy supply. Coronary 
arteries narrow due to the accumulation of fat deposits (atherosclerosis) in their 
walls, thus limiting blood flow to the heart muscle. In the vast majority of cases, 
CHD is the result of the build-up of atherosclerosis in the coronary arteries. The 
cause of atherosclerosis is not fully understood, but a number of risk factors have 
been identified: increasing age, family history of CHD, smoking, high blood 
pressure, obesity, diabetes, high cholesterol, physical inactivity, diet and stress.132 
133 When the blockage is severe, it produces chest pain on exertion and can 
produce a heart attack when some of the heart muscle dies. Ejection fraction is a 
term used to describe how well the heart is pumping. A good heart ejects 50-70% 
of blood with each beat from the ventricle, its main pumping chamber. 
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The major clinical manifestations of CHD are angina pectoris, myocardial infarction 
(heart attack), sudden cardiac death, silent ischaemia (reduced blood flow to the 
heart muscle in the absence of chest pain), and ischaemic cardiomyopathy.133 
Silent ischaemia and ischaemic cardiomyopathy are the less common 
presentations of CHD. Angina pectoris (chest pain) is the symptom that brings 
most patients with CHD to medical attention. It is typically described as pain in the 
chest, but can also be experienced as radiating pain in the arms, shoulders, neck, 
back, epigastrium and jaw.134 135 These radiating pains are described as atypical. 
Some patients do not describe angina as pain, but instead use the following 
adjectives to describe the sensation: "discomfort", "tightness", "dull ache", 
"fullness", "squeezing", "pressing", '"strangling", "constricting", "bursting", or 
"burning sensation".134 135 Some studies suggest that women describe their 
experience of angina differently from men,136-139 and that they do not always fit the 
classic textbook symptoms, which were modelled on male patients when CHD was 
believed to be essentially a male disease. 
Angina occurs when the heart muscle does not get sufficient oxygen for its energy 
expenditure. It is for this reason that symptoms are frequently induced on exertion 
and are relieved after several minutes of rest. Angina is often worse in cold 
weather or after food. 135 Angina is termed unstable if it is induced by progressively 
less physical exertion over a short time period, often developing in episodes of 
angina brought on by minimal exertion or at rest. A heart attack (myocardial 
infarction) occurs when the heart muscle is damaged from the blood supply being 
completely cut off due to a spasm or blood clot in the coronary arteries (coronary 
thrombosis). Heart attacks and angina can cause electrical conduction 
disturbances in the heart, which can result in abnormal heart rhythms 
(arrhythmias), such as ventricular fibrillation. Ventricular fibrillation is a fatal 
condition if it is not treated within minutes of occurrence. Repeated heart attacks, 
when substantial portions of heart muscle have died, can lead to ischaemic 
cardiomyopathy (heart failure). Heart failure is predominantly caused by CHD, but 
there are several causes, including hypertension, cardiomyopathy and heart valve 
disease.140 It is usually a chronic condition requiring drug therapy to help reduce 
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the load to allow the heart to work effectively. In end-stage heart failure, heart 
transplantation becomes necessary. 
The diagnosis of CHD and angina is usually made on the basis of the clinical 
history and an assessment of risk factors for atherosclerosis. However, clinical 
tests are used to confirm the diagnosis. The electrocardiogram (ECG) is usually 
used to confirm the diagnosis of CHD by recording the heart's electrical activity. 
An ECG during exercise on a treadmill or exercise bicycle can be used to identify 
abnormal heart function or rhythm not present at rest. Sometimes, thallium scans 
are used for diagnOSiS, which involve the injection of small doses of radio-isotopes 
into the blood during exercise. However, the most accurate test involves cardiac 
catheterisation, where a catheter is threaded through an artery in the arm or leg 
into the coronary arteries. An x-ray dye is then injected during x-ray filming which 
is used to identify narrowing of the coronary arteries. Cardiac catheterisation 
carries a small risk of producing a heart attack or heart rhythm disturbance, so is 
only undertaken when precise diagnosis is essential (e.g. when interventional 
treatment is being conSidered). 
1.4.3 Psychosocial factors 
The importance of psychosocial variables in the development of CHD and in the 
prognosis of patients with established CHD has attracted considerable research.141 
Traditional risk factors for example, smoking, hypertenSion, hypercholesterolemia, 
obesity, physical activity, diabetes and hormonal factors do not fully explain the 
occurrence of CHD. Numerous studies have focused on Type-A behaviour pattern, 
hostility, depreSSion, anxiety, and social isolation as possible risk factors for the 
development of CHD and as predictors of outcome for patients with established 
CHD.142 This section provides a brief overview of the psychosocial factors which 
play an important role in the development of CHD and in predicting outcome after 
treatment. 
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1.4.3.1 Psychosocial risk factors 
The psychological variable that has received the most attention as a risk factor for 
CHD is Type-A behaviour pattem. Type-A individuals typically display hard-driving 
competitiveness, a persistent sense of time urgency, and easily evoked hostility. 
Results from research studies have produced inconsistent findings as to whether 
Type-A is an independent risk factor for CHD.141 143 One possible reason for 
inconsistent findings is the global definition of Type-A. For this reason, the focus 
has shifted towards the hostility component of this behaviour pattem as the 'toxic' 
risk factor for CHD. Although there is some evidence that high levels of hostility 
and anger are associated with CHD and adverse health outcomes,144 results are 
conflicting due to the lack of a standardised assessment methodology.141 Type-D 
(distressed) personality, characterised by chronic suppression of negative 
emotions, has also been reported to be a Significant predictor of long-term mortality 
in patients with established CHD that is independent of biomedical risk factors.145 
Personality is important as it can promote disease indirectly through health-related 
behaviours. Failure to alter risk factors and poor treatment adherence are related 
to a greater extent of coronary disease and an increased risk of death in patients 
with CHD.146 
Depression, anxiety and hostility have all been demonstrated to be associated with 
the risk of CHD143 147-151 and of adverse outcomes after coronary events such as 
myocardial infarction.152 153 Multiple studies have shown that high levels of 
depressive symptoms increase the risk of mortality in patients with established 
CHD. Many studies have focused on the association between depression and 
mortality in myocardial infarction patients.152 153 For example, Frasure-Smith at 
al.152 reported that patients who met DSM-III-R criteria for major depression were 
three to four times more likely to die during the first 6 months following myocardial 
infarction than non-depressed patients and these effects were independent of 
disease severity. Directing interventions toward depressed post-MI patients whilst 
hospitalised could result in reduced mortality; however, this has yet to be 
demonstrated. Barefoot at al.154 assessed depression in a group of patients with 
established CHD, and did a follow-up of subsequent mortality. They reported that 
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depression may be persistent or frequently recurrent in patients with CHD and is 
associated with disease progression and triggering of acute events. 
Anxiety is characterised as a strong negative emotion with a component of fear 
and is associated with perceptions of unpredictability, accompanied by a marked 
apprehension concerning the future. 147 Individuals who are in situations that are 
more likely to induce anxiety, for example those with stressful jobs, or low socio-
economic status, may be at increased risk of CHD.147 Rates for CHD vary 
markedly between occupations;142 manual workers have higher morbidity and 
mortality rates than non-manual workers.124128 
Depression may be associated with social isolation, which may also serve as an 
independent risk factor. Lack of social support (the subjective experience of other 
people as agents of help) could exacerbate the role of psychosocial stress in the 
progression of CHD.155 Conversely, social support, or the degree to which one is 
connected to others in the community, has been identified as an inverse risk factor 
for CHD. For example, studies with coronary artery bypass graft surgery (CABG) 
patients have found positive relationships between perceived social support 
availability and recovery from surgery.156-158 Social support has been measured in 
a variety of ways, including the number of relationships and frequency of social 
contacts. In their review of studies evaluating the role of psychosocial risk factors, 
Alan and Scheidt141 conclude that of all the risk factors, the social support literature 
is the most con"sistent in establishing a relationship between behavioural factors 
and CHD. The results provide a powerful rationale for support groups for CHD 
patients. 
Depression and anxiety are commonly the consequence of CHD. Psychological 
morbidity prior to CABG can be high. For example one study reported that a third 
of patients had clinically significant levels of anxiety and depression.159 Another 
reported that 47% and 28% of patients on the waiting list for CABG scored in the 
Clinically significant range of depression and anxiety, respectively, on the Hospital 
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Anxiety and Depression Scale prior to CABG.160 Depression is also estimated to 
precede myocardial infarction in 33-50% of patients.161 
1.4.3.2 Psychosocial predictors of outcome 
A subgroup of patients experience poor psychosocial outcomes after CABG. 
Despite general improvements in psychological functioning, approximately one 
patient in four has an unfavourable psychological situation 1 year after CABG.159 162 
For example, Heller et al.163 found the following forms of psychological distress in 
one third of patients 1 year after open heart surgery: anxiety, depression, somatic 
preoccupation, poor self-esteem, passive dependency, paranoid tendency, and 
withdrawal from social life. Improvement in physical condition in terms of symptom 
relief is not necessarily accompanied by improvement in psychosocial condition. 
It has been suggested that psychosocial factors can predict psychosocial 
outcomes after CABG.164 Magni165 found that patients with high preoperative 
scores on the Zung Depression Scale were at high risk of depression 1 year after 
successful CABG. Pinna Pintor et al.166 reported that patients who experienced 
postoperative cardiac events had significantly higher preoperative levels of anxiety 
and depression than those without. Jenkins et al. 167 found that low preoperative 
levels of anxiety and depression and good social support can predict freedom from 
cardiac symptoms 6 months after CABG. Perski et al.168 found that patients who 
reported a high level of distress before CABG on the emotional scale of the NHP 
(anxiety, depression and tiredness) assessed their own status (in terms of angina 
and HRQoL) as much worse both before and 1 year after revascularisation 
compared with initially non-distressed patients. Distressed patients also had 
significantly higher rates of cardiac events in a 3-year follow-up period compared 
with non-distressed patients. Grossi et al.159 also found that preoperative negative 
emotional state (measured by the State-Trait Anxiety Inventory), predicted poor 
HRQoL 1 year after CABG and that patients in the preoperative moderate and high 
anxiety groups perceived a higher degree of residual angina than the non-anxious 
group. 
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Findings from these studies have important implications for the selection and 
preparation of patients for surgery and identification of those who might benefit 
from extra rehabilitation.164 Preoperative identification of patients at high risk for 
poor psychosocial outcome after treatment might help to target early psychosocial 
interventions aimed at improving HRQoL in this patient group. Successful 
intervention could significantly improve psychosocial outcomes in these patients. 
Research is necessary to identify other risk factors so that prevention strategies 
can be targeted at the right individuals. Psychosocial and lifestyle interventions 
can have enormous potential for modifying the course of CHD.141 Education, 
counselling, and psychosocial interventions can result in improved psychological 
well-being; training in behaviour modification, stress management, and relaxation 
techniques is effective in lowering self-reported emotional stress, and in modifying 
Type-A behaviour.161 
Psychosocial factors clearly play an important role in the development of CHD and 
predicting outcome after treatment. Further rigorous research using rigorous 
outcome measures is needed to help establish the causal relationships between 
specific psychosocial variables and CHD. The next section describes the main 
treatments for CHD. 
1.4.4 Treatment 
Treatments for CHD include attention to risk factors, medical therapy and coronary 
revascularisation. Although preventing CHD is important, this thesis is concerned 
only with treatments for established CHD. 
1.4.4.1 Medical treatment 
Medical therapy is the first line treatment for CHD, and surgical intervention the 
second. Pharmacological therapy for angina includes five categories of drugs: 
beta-blockers, calcium blockers, nitrates, aspirin and other antiplatelet drugs, and 
antilipid drugs. Most of these drugs act by dilating the blood vessels in the body 
and redUCing the amount of work the heart has to perform, i.e., they reduce the 
demands made on the heart' and its need for oxygen.133 Sublingual glyceryl 
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trinitrate (GTN) is the standard treatment for immediate symptom control; the other 
drugs can be classed as background antianginal medication used to help prevent 
angina attacks.135 GTN is used during an angina attack or prior to a task which 
might induce an attack. It is taken under the tongue as a tablet or spray, where it is 
quickly absorbed to provide fast symptom relief. Drug therapy for angina can be 
successful for some patients for a number of years, but many patients need 
interventional therapy to alleviate their symptoms. 
1.4.4.2 Coronary revascularisation 
There are two main interventional treatments for CHD, coronary artery bypass graft 
surgery {CABG} and percutaneous transluminal coronary angioplasty (PTCA). 
These two surgical methods for improving the blood flow through the narrowed 
coronary arteries are referred to collectively as coronary revascularisation. They 
are nearly always performed to alleviate symptoms and improve quality of life, and 
in some cases to extend survival. 135 170 
For many years, CABG was the accepted surgical method for the treatment of 
CHD. Standard CABG involves an incision in the chest to cut the breastbone 
(stemum) lengthways, which provides good access to the heart. During the 
procedure, it is necessary to stop the heart and the flow of blood through the heart 
and lungs. A heart/lung bypass machine artificially takes over the heart's job of 
pumping and the lungs' job of breathing. A blood vessel (usually from the leg or 
arm) or the intemal mammary artery from inside the chest wall is used as the graft. 
The graft is attached to the aorta, the main blood vessel of the heart, and to the 
coronary artery to bypass the site of the blockage. Patients usually receive three 
grafts, but some require more and others less. 171 Clinical complications after 
CABG include mortality, myocardial infarction, chest wall pain, palpitations, atrial 
arrhythmias, fluid retention and peripheral oedema, pleural effusions, low grade 
pyrexias, leg wound pain and inflammation, wound infections, stemal dehiscence, 
ventricular arrhythmias, heart block, pulmonary oedemas and acute lung injury, 
deep vein thrombosis, and pulmonary embolus.132 
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Due to the invasive nature of the CABG procedure, full recovery can take some 
time. The majority of patients stay in hospital between 6 and 10 days after 
surgery. 171 Patients are then advised not to exert themselves during the first 6 
weeks after surgery to enable their wounds to heal. Around 3 months after CABG, 
most patients should have returned to at least their former level of functioning prior 
to surgery. However, there are several reports of "recovery problems" after 
CABG172-178 which can persist for long periods after surgery.174 175 179 Many 
patients report pain and numbness in their leg or arm from where the veins or 
arteries were removed to be used as grafts. These sensations may continue for as 
long as 12 months after CABG in some patients.175 Some patients also experience 
problems with wound healing in the chest, legs and arms.175 180 Problems 
experienced by patients after discharge are less well documented in the literature 
than pre-discharge problems.178 However, problems associated with CABG such 
as chest and leg wounds can cause great distress.175 Patients can find it difficult to 
distinguish between sternal discomfort as a result of CABG and angina pain;181 fear 
of recurrent angina and of a failed operation can also be distressing. 
Cognitive impairment after CABG is a common adverse event and has been 
extensively documented. Impairments include short-term subtle cognitive deficits, 
such as problems with short-term memory, concentration, attention, new learning 
ability, thinking clearly, processing information, and making decisions,182-184 as well 
as major neurological complications, such as stroke and transient ischaemic 
attacks. 185 Impairments can be subtle and detectable only through 
neuropsychological testing, which is sensitive in identifying cognitive complications. 
Neuropsychological testing typically includes evaluating memory, attention, visuo-
constructional ability, and motor and psychomotor speed;186 examples include the 
Wechsler Memory Scale, 187 Wechsler Adult Intelligence Scale-Revised,'87 and the 
Reitan Trail Making Test. '88 Questions concerning cognitive functioning are rarely 
included in self-administered questionnaires. This might 1)& because formal 
neuropsychological testing is usually required to detect· subtle changes in 
cognition, or because there is growing evidence that there is a poor relationship 
between self-reports of cognitive function and actual changes in cognition.'82 
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Patients with high levels of depressed mood or anxiety might also report 
deterioration in cognitive functioning, such as the ability to concentrate.182189190 
Perioperative cognitive dysfunction can be attributed to transient effects of 
anaesthesia, medication, and the need for circulatory support during surgery.191-193 
Cognitive impairment usually resolves in the first few months after CABG, but it can 
persist as long as 6191 194 and 12195 months after CABG. For a subgroup of 
patients, cognitive dysfunction may persist in the long-term. 191 192 There is 
controversy about the degree and duration of cognitive impairment.185 In a review 
of 35 studies, Borowicz et al.186 reported the incidence of short-term cognitive 
deficits (studied less than 2 weeks postoperatively) to range between 26% and 
79% and long-term deficits (studied more than 1 month postoperatively) to range 
from 0% to 37%. They suggest that differences in study design, sampling and 
outcome definitions have led to these variations in incidence rates. A very recent 
study196 measured cognitive functioning before discharge, and 6 weeks, 6 months, 
and 5 years after CABG. The findings confirmed the relatively high prevalence and 
persistence of cognitive decline after CABG and suggested a pattern of early 
improvement followed by later decline (at 5 years) that is predicted by the presence 
of early postoperative cognitive decline. 
Recent advances in cardiac surgery have resulted in the development of some 
novel procedures that are currently being evaluated. CABG performed directly on 
the beating heart, without the use of cardiopulmonary bypass via a median 
sternotomy, is now a well-established procedure that is used extenSively by some 
surgeons.197 198 Other surgeons are performing CABG using smaller incisions and 
utilising cardiopulmonary bypass and aortic clamping (port access procedures). 
Recently, minimally invasive CABG procedures (MIDCAB), which do not require 
the use of cardioplumonary bypass or median stemotomy, have been introduced. 
In such procedures, the surgeon operates directly on the beating heart through a 
small (10-12 em) incision in the chest. There is no need for a heart/lung bypass 
machine as the heart and lungs continue to function independently. Early results 
suggest that these procedures are effective for selected patients,199 but as they are 
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only performed in a few specialist centres they are not part of routine treatment. 
Postoperative hospital stay can be reduced to 2 days, possibly due to avoidance of 
cardiopulmonary bypass rather than to the position or length of the incision.199 
Beating heart surgery appears to produce a lower incidence of cognitive 
dysfunction in short-term follow-up than conventional CABG using cardiopulmonary 
bypass. 200 
In the late 1970s, PTCA was developed as a less invasive method of coronary 
revascularisation. It involves the insertion of a fine catheter into a vein in the groin 
then up through the coronary artery and across the blocked section. A balloon 
mounted on the end of the catheter is inflated to stretch the vessel and squeeze 
and disrupt the material blocking it. The balloon is then deflated and removed, 
resulting in an enlarged channel through which blood can flow to the heart muscle. 
PTCA is carried out under local anaesthesia and patients are mobilised the 
following day. The advantages of PTCA over CABG are a shorter hospital staY,201 
less discomfort for the patient, rapid convalescence and return to work,202 and 
lower initial procedural costS.203 The most important long-term limitation of PTCA 
is restenosis (>50% diameter stenosis at follow-up angiography). Restenosis 
occurs in 30-50% of patients, usually within the first 4 months after PTCA, with 20-
30% of patients requiring further revascularisation of the diseased vessel. 204 
Knowledge of high restenosis rates can lead to anxiety about symptoms returning 
or the need for further heart operations. These concerns about reocclusion may 
contribute to poorer psychological functioning. 205 The unknown long-term outcome 
and the high restenosis rate can create a situation of high uncertainty for PTCA 
patients.206 
In 1986, the method of implanting intracoronary stents during PTCA was 
developed. Stents are tiny metal devices that are delivered by a catheter in a 
collapsed state to the site of an obstruction and then expanded so as to 
mechanically support the atherosclerotic lesion and mechanically prevent collapse 
of the vessel or regrowth of atherosclerosis.133 Stenting has improved PTCA by 
reducing the chance of acute closure and restenosis.207 Consequently, rates of 
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emergency CABG for acute closure and re-interventions for restenosis have been 
reduced.208 Results from randomised controlled trials show that coronary stenting 
significantly reduces 6-month restenosis rates and improves clinical outcomes.209-
211 The use of stents has increased from 2.6% per PTCA in 1991 to approximately 
69% in 1998, thus substantially reducing the need for re-interventions and 
emergency CABG.212 Interventional cardiologists perform PTCA in cardiac 
catheterisation laboratories with very low complication rates. The mortality rate is 
approximately 0.5%, MI occurs as a complication in about 1%, and emergency 
CABG is needed due to acute closure of a vessel in about 1% of patients.133 
The use· of coronary revascularisation procedures is increasing in the UK. The 
Society of Cardiothoracic Surgeons reported a 111 % increase in CABG procedures 
in the UK between 1985 and 1995 (see Table 1.4). In 1997/8,25,639 procedures 
were performed. 171 Similarly, the British Cardiovascular Intervention SOCiety, 
reported a 2.8-fold increase in all percutaneous coronary interventions between 
1991 and 1999 (see Table 1.5).212 
The rate of coronary revascularisation is increasing at a slower rate in the UK than 
in several other countries. 11 135 There is currently insufficient coronary 
revascularisation provision in England, and waiting times for diagnosis and 
treatment are considerably longer than in other countries.11213 Time on the waiting 
list has been found to be Significantly related to anxiety, depression, impairment of 
work, family relationships and social functioning,1E10214 and perceived HRQoL.215 
There is inequitable provision of services for CHD.11 213 216 There are marked 
geographical,217218 gender21 9-222 and ethnic223 variations in cardiac diagnostic and 
therapeutic intervention rates. The rates of coronary revascularisation in areas 
with the highest prevalence of CHD are often lower than rates in areas with a much 
lower burden of CHD.11 Considerable systematic variations across districts in rates 
of CABG in the UK have been reported, with demand factors such as the level of 
need in the population, measured by CHD mortality, inversely associated with the 
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rate of intervention.224 Fewer women220 221 and Asians223 are referred for coronary 
angiography and cardiac surgery. 
In October 1999, the Secretary of State announced a £50 million boost to cardiac 
surgery to increase the number of heart operations nationally by 10% (3,000) by 
2002.11 In March 2000, a further £50 million was committed to "kick-start the 
crusade against heart disease".131 The NHS National Framework for CHD11 aims 
to increase the national rate of both CABG and PTCA to 750 per million population. 
It also aims to reduce inequalities and increase all health authorities to an 
equivalent rate relative to the burden of disease. A national goal has been set for 
treating high-risk priority CABG and all angioplasty patients within 3 months of the 
decision to operate, and all other CABG patients within 6 months.11 
1.4.4.3 Effectiveness of treatments 
In studies evaluating the effectiveness of treatments for CHD, the two changes in 
the approach to health outcome measurement described in Section 1.2 can be 
seen: the adoption of a systematic and rigorous scientific approach to evaluation of 
outcomes and the incorporation of patient-based assessments of outcome into the 
evaluation process. 
Numerous randomised controlled trials have been performed to evaluate the 
clinical and cost-effectiveness of treatments for CHD; many are ongoing. The 
purpose is to gather rigorous, evidence-based findings of the relative effectiveness 
of various treatments in the short-, medium- and long-term. The majority of trials 
have focused on the use of clinical outcomes, such as mortality and morbidity, but 
in recent years patient-based assessments have been used as secondary outcome 
measures. Many trials now use standardised generic HRQoL instruments. For 
example, the first RITA trial225 of outcomes after CABG and PTCA used the NHP, 
and RITA-2 used the SF-36 to compare PTCA with medical treatment.226 Fewer 
trials are using validated disease-specific instruments, although their use is 
increasing to meet the need for more comprehensive measurements of treatment 
outcome to help establish relative effectiveness. This section presents the main 
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research findings of some of the key clinical trials to evaluate the effectiveness of 
treatments for CHD, and describes the outcome measures used. 
CABG has been shown to be superior to medical treatment in terms of symptom 
relief and survival. 227-230 A systematic review reported improved survival rates in 
CABG compared with medically treated patients at 5 and 10 years.231 Compared 
with patients treated medically, PTCA patients show better symptom relief and 
exercise test performance, reduced need for nitroglycerin medication and more 
improvement in psychological well-being.226 232 233 However, PTCA has not been 
shown to reduce the incidence of mortality or rate of myocardial infarction in 
patients with stable angina. 232 233 
CABG has been shown to be effective in patients who have left main artery 
disease, three-vessel disease and left ventricular dysfunction.228 234-237 CABG has 
not been shown to prevent myocardial infarction or to postpone cardiovascular 
death in certain subsets of patients, but increasing numbers are being operated on 
for these reasons.238 PTCA has proven to be effective in patients with single 
vessel disease,209 210239 but the clinical benefit of PTCA as compared with CABG 
for patients with multivessel coronary artery disease has not been fully established, 
despite t~e use of PTCA on these patients since the early 1980s. 239 240 
Several randomised controlled trials are currently being undertaken to evaluate the 
relative clinical effectiveness of CABG versus PTCA. 240-248 In a meta-analysis of 
nine randomised controlled trials comparing initial treatment by CABG versus 
PTCA,203 Henderson concluded that whilst both procedures are effective 
treatments for angina, CABG is slightly more effective during the first 1-3 years 
after revascularisation. However, the advantage of CABG over PTCA reduces 
over time, probably because of occlusion of saphenous vein grafts in CABG 
patients and treatment of incomplete revascularisation and restenosis in PTCA 
patients. In all trials, patients treated with PTCA required additional 
revascularisation procedures more often than did those treated with CABG, 
confirm ing the findings of an earlier meta-analysis.248 About one-third of patients 
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assigned to initial treatment by PTCA required an additional revascularisation 
procedure within 1 year, but thereafter the re-intervention rate was lower. 203 
However, the long term effects of PTCA and CABG on clinical outcome are yet to 
be evaluated. Individual trials may have limited statistical power to detect 
differences in mortality between the two procedures.203 However, two other meta-
analyses report no evidence of a treatment difference in mortality between the 
procedures.248 249 Subanalyses have found no difference in HRQoL (measured by 
the RAND Mental Health Inventory) or return to employment over 3 to 5 years of 
follow-up. 250 
The results of economic analyses are remarkably consistent, with CABG shown to 
be initially twice the cost of PTCA. 203 This reflects a greater requirement for 
specialised nursing and inpatient care during the initial surgical procedure. 
However, this cost difference decreases during subsequent follow-up, because of 
the greater need for additional procedures in the PTCA group, with little difference 
in cost between the two procedures over 3-5 years.251 A more recent cost benefit 
analysis showed that the need for repeat procedures reduces the initial cost 
advantage of PTCA over CABG until this becomes insignificant at about 5 years.252 
There are several clinical trials evaluating the effectiveness of minimally invasive 
CABG procedures in comparison to standard CABG, PTCA and medical treatment, 
but these studies are ongoing. Preliminary case series199 253 254 indicate that 
MIDCAB is safe, relatively inexpensive and less invasive compared with CABG, 
and potentially more effective than PTCA for patients with proximal stenosis of the 
left anterior descending artery. Long-term outcomes of these procedures need to 
be evaluated. 253 
1.4.5 Methods for evaluating treatment outcomes in CHD 
Previous sections of this chapter describe the changing approach to health 
outcome assessment with an increasing emphasis on patient-based measures of 
outcome. This section describes the range of outcome measures that have been 
used to evaluate outcomes in CHD (clinical and patient-based). 
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1.4.5.1 Clinical outcomes 
There have been two major reviews of the literature of the methods used to 
evaluate outcome and recovery in cardiac patients, including coronary 
revascularisation. 175 255 The most frequently used measures are those related to 
mortality I length of survival, followed by morbidity I serious complications, physical 
condition (exercise testing, cardiac function, angiography), patency of grafts, 
symptoms (pain, dyspnoea), and return to work.175 Survival, clinical test results, 
return to work, and clinical ratings of outcome are the most frequently used 
methods because they are easily measured. The frequency of angina attacks and 
the quantity of nitroglycerin are also commonly used as outcome measures for the 
treatment of angina pectoris.256 
Clinical outcomes after coronary revascularisation are measured in terms of clinical 
. events (such as death, myocardial infarction, cerebrovascular accidents), 
complications (such as arrhythmias, atrial fibrillation, infection, and need for pleural 
effusion), clinical status assessed by diagnostic testing (e.g. ECG results, ejection 
fractions, graft patency, the number of diseased vessels shown on angiograms), 
and functional status measured by exercise testing. 
Several professional societies hold audit databases of clinical outcomes after 
cardiac interventions, based on information received from hospitals (e.g. the 
Society of Cardiothoracic Surgeons Surgical Register, the British Cardiovascular 
Intervention Society Intervention Register). Several methods of risk stratification 
before CABG have been developed based on clinical parameters, including 
Parsonnat,257 Euroscore,258 and UK Bayes. 171 The NHS funded Central Cardiac 
Audit Database is a pilot project to illustrate the feasibility of implementing a 
national risk stratified outcome audit for all cardiac interventions including CABG 
and PTCA.11 NICE will soon recommend a method for a national audit for coronary 
revascularisation for use throughout the NHS.11 
Whilst mortality has been used as a key outcome indicator for coronary 
revascularisation in many studies, it is evident that mortality is no longer an 
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adequate measure of outcome.259 Mortality has become a relatively rare event 
after coronary revascularisation, with the overall average mortality for elective 
CABG or PTCA in stable angina being around 1 %.135 The UK mortality rate in 
1997 for all patients who underwent CABG was 3%, but included patients with 
unstable angina and emergencies.135 Coronary revascularisation procedures 
significantly improve survival relative to medical therapies for only selected 
subgroups of patients.228 260 261 Prolonged life after CABG has been demonstrated 
for patients who have left main coronary artery disease, triple vessel disease and 
left ventricular dysfunction, but enhanced survival for other patient groups remains 
controversial. 262 Recognition of the limited improvements in survival for some 
patients after coronary revascularisation has been a key factor in raising the 
awareness of the importance of assessing changes in HRQoL after CABG and 
PTCA.260 
As a result of improvements in revascularisation techniques, attention has shifted 
away from survival rates to improvement in symptomatic and functional status. It is 
widely recognised that coronary revascularisation improves functional status and 
reduces chest pain and the need for anti-anginal drugs.227 228 263 Outcome 
assessment has focused largely on improvement in physical activities and the 
alleviation of symptoms,264-267 with the assumption that decreased angina and 
improved functional capacity translate into improved social and psychological 
adjustment. 181 Early efforts to include performance or activity measures in clinical 
studies include the New York Heart Association classification (NYHA),75 the 
Canadian Cardiovascular SOCiety Classification (CCS) of angina on exertion,76 and 
the Specific Activity Scale (SAS).264 The CCS and the NYHA scales are still widely 
used in routine clinical practice. However, these functional measures are limited by 
their weak measurement properties (reliability, validity and responsiveness). For 
example, measures such as the NYHA and CCS classifications of angina have 
shown considerable imprecision and interobserver variability.3 29 264268 289 The four 
coarse grades of the NYHA are unable to show distinct changes in functional 
capacity that can occur while the patient retains the same rating.256 270 Compared 
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with the CCS, the SF-36 Physical Functioning scale has shown to be more 
responsive to change after PTCA.271 
\Nhilst physiological measures provide information to the clinician, they are of 
limited interest to patients.54 Results from clinical assessments do not reflect 
patients' ability to cope or their HRQoL because they are not related to people's 
everyday life and environment. 2n 273 In patients with chronic heart disease, 
exercise capacity in the laboratory is only weakly related to exercise capacity in 
daily Iife.28 The treadmill exercise test is an attempt to reproduce the daily 
exertional pattern of patients in a controlled environment. However, it is an artificial 
setting that does not take into account the realities of life, and is thus an 
inadequate measure of possible lifestyle activities.256 272 274 Patients alter their 
lifestyle to prevent or minimise anginal pain,272 for example, they may avoid 
strenuous activities that have caused previous attacks. The frequency of angina 
attacks as a measure of outcome is also inadequate as patients might have the 
same number of attacks, but only as a result of having reduced their level of 
activity. Self-reported activity may be a better predictor of exercise treadmill 
performance than a clinician's interpretation of functional capacity.275 Objective 
measures of ischaemia, such as electrocardiogram ST~segment depression on 
exercise testing, can be inaccurate because of false-positives and negatives and 
are poorly correlated with the patient's assessment of angina.2n Clinical measures 
such as exercise capacity have also been shown to correlate poorly with the 
number of diseased vessels and with left ventricular ejection fraction.29 Clinical 
outcome measures do not adequately reflect the impact of treatment for CHD on 
patients' daily lives, health and HRQoL. 
1.4.5.2 Patient-based outcomes 
A plethora of studies have used patient-based assessments to measure outcome 
in CHD.181 260 262 276-281 CHD is a condition that is very well-suited to evaluating 
HRQoL as treatments are usually directed toward symptom relief and improving 
HRQoL rather than cure. 282 Although there is extensive research on HRQoL in 
patients with CHD, few investigators are willing to commit to a definition of HRQoL 
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in the cardiac literature.283 VVhilst there are several conceptual models of HRQoL 
in heart disease,24 179 260 284-290 Wenger et al. 's model24 is the most comprehensive. 
HRQoL in cardiovascular disease is defined in terms of three interrelated major 
components: 
Functional capacity: 
Perceptions: 
Symptoms: 
Ability to carry out the activities of daily life (mobility, 
independence, self-care) 
Social function (social interaction, marital satisfaction) 
Intellectual function (memory, alertness, and judgement) 
Emotional function (mood changes, anger, guilt, hostility, 
depression, helplessness, sick-role behaviour, satisfactions, 
expectations) 
Ability to maintain a satisfactory standard of living, income, 
employment, insurance eligibility 
Perceptions of general health status 
Perceptions of well-being (life satisfaction) 
Symptoms of the disease (pain, dyspnoea, amount of 
medication, alteration of activity to limit symptoms, 
hospitalisations) 
Symptoms induced by treatment or concurrent illness 
Symptoms reduced or abolished by the intervention. 
With the exception of models for hypertension, such as that developed by Bulpitt 
and Fletcher for the Hypertension Questionnaire,288 the Wenger at al. model is the 
only one to distinguish symptoms induced by treatment from symptoms of the 
disease. This is a useful and relevant distinction for the measurement of outcome 
in coronary revascularisation, as it incorporates new symptoms and problems 
associated with CABG and PTCA, such as pain from opening the chest or bruising 
in the groin area. 
Table 1.6 summarises the main content domains that have been included in 
conceptual models of HRQoL in coronary revascularisation. Three core domains 
have been identified in each of these models: physicall, psychologicall, and social! 
functioning. 179 260 284-287 289 290 These same core domains are usually included in 
HRQoL instruments. However, some conceptual models have additional domains 
including neuro-psychological (intellectual functioning),260 285-287 symptom relief,179 
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260286287289 mood (general well-being),284 287 289 socio-economic status (return to 
work),260 284 286 287 289 290 and satisfaction and expectations. 24179285287 
Early assessments of HRQoL after CABG were based solely on the relief of 
angina291 292 or return to work.293 294 For many years, return to work was used as a 
surrogate for HRQoL53 and probably arose from the debates related to the 
economics and the cost-benefit ratio of cardiac surgery and the ease of its 
measurement.295 It has become increasingly recognised that the decision not to 
work is often the patient's choice and is not necessarily related to surgical 
outcome, but to multiple physical, social, economic, occupational and 
psychological factors.53181 278287296-298 
A plethora of studies have used generic measures of HRQoL to evaluate outcomes 
after coronary revascularisation; several authors have reviewed the main findings 
of this large literature.181 260 276 278 279 HRQoL after cardiac surgery has become the 
focus of international interest. 285 299 Although PTCA has received relatively less 
attention than CABG, research on CABG is conceptually relevant to HRQoL in 
angioplasty patients because PTCA and CABG are both coronary revascularisation 
procedures.255260284 Generic patient-based measures of outcome have been used 
before and after coronary revascularisation to assess health status (e.g. SF-36,87 
271 300-305 NHP,176 225 306-308 General Health Questionnaire,309 310), psychological 
aspects of HRQoL (e.g. Psychological General Well-being Index,311 312 
Psychosocial Adjustment to Illness Scale,159 313-315 Profile of Moods States,284 316 
Speilberger's State-Trait Anxiety Inventory, 166 255 317 Zung's Self Rating Depression 
Scale,166318), and social interaction (e.g. Social Support Scale,297 Social Activities 
Questionnaire319). 
Numerous studies have demonstrated improvements in HRQoL,159 166 205 225 255 271 
289 290 297 310 314 315 320-325 functional capaclty.159 176 179 205 239 300 310 320 32EI emotional I 
psychological162 176 181 310326 and social functioning159 176 179205 310 320 327 328 after 
CABG and PTCA. Table 1.7 illustrates how generic measures have been used to 
evaluate changes in HRQoL after coronary revascularisation. Included in this table 
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are selected examples of studies in which the most widely-used generic measures 
of HRQol, including the SF-36, NHP, GHQ, have been applied. The table also 
includes selected examples of studies in which other widely-used measures that 
evaluate specific components of HRQol, such as functional status, psychosocial 
adjustment, mood, well-being and social activities, have been applied. There is no 
question that CABG and PTCA have beneficial effects on HRQoL in terms of 
improved physical, psychological and social functioning. 
With the recognition that health status and health outcomes are multidimensional, 
there is a growing trend to use several generic questionnaires that measure 
different domains in an attempt to capture all important dimensions.289 320 Jenkins 
at al., 167 320 for example, evaluated an extensive battery of 58 scales and items to 
evaluate the benefits of CABG. The battery included measures of: cardiac 
symptoms, psycho-neurological! emotional! physical! role functioning and 
occupational, social, family. sexual. and attitudinal variables. Although this battery 
approach may be useful for research, it is impractical for routine use due to the 
increased burden on the patient and the demands of a busy clinical setting. 
Whilst generic measures have been shown to be responsive to clinical change in 
coronary revascularisation patients,176 271 273 329 they are not designed to detect 
changes in health that are specific to CABG or PTCA. As generic measures are 
designed for use across different patient populations, they do not address specific 
areas of health change related to coronary revascularisation, such as cardiac 
symptoms, or adverse effects and satisfaction with treatment. It is important to 
measure these treatment-specific outcomes in a patient-based evaluation of the 
impact of coronary revascularisation. 
As in other conditions, generic measures have been shown to be less responsive 
to clinical change in CHD than disease-specific measures. One study that 
compared the SF-36 with the Seattle Angina Questionnaire325 (SAO) found that the 
SF-36 was relatively insensitive to large changes in cardiac status assessed by the 
ees compared to the SAO, and that it showed only limited responsiveness to 
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adjustment in anti-anginal medication.282 Cleary et al. administered a battery of 
measures to patients undergoing PTCA and reported the disease-specific 
symptom scales to be more responsive than the generic scales.289 Spertus et a/. 
found the SAQ to be more responsive than the SF-36 to clinical change in angina 
patients.329 These results are not surprising, as· disease-specific measures are 
developed to capture the effects of a specific treatment, whereas generic 
measures provide an assessment of general HRQoL, including co-existing 
diseases and health problems. Disease-specific questionnaires that ask specific 
questions about changes in a patient's heart condition are likely to be more 
responsive than generic questions that measure change in general health status. 
In the evaluation of treatments for CHD, disease-specific measures provide more 
detailed information about treatment-specific changes in functional status and 
HRQoL. As with other patient groups, there is a need for more head-to-head 
comparisons of the relative responsiveness of different instruments. 
Numerous disease-specific questionnaires have been developed to measure 
outcome in patients with CHD.168 176 214 215 255 266 267 286 289 292 325326330-364 These 
measures range in quality in terms of psychometric properties and methods of 
instrument development. Chapter 3 provides a critical review of these cardiac-
specific patient-based questionnaires. The majority of these questionnaires has 
been developed to measure outcomes in medically rather than surgically treated 
patients, for example patients with angina, heart failure, and post myocardial 
infarction. 
Some cardiac-specific instruments have been developed specifically for use with 
patients undergoing coronary revascularisation.168 176 214 215 255 286 289 326 330-336 
However, the majority of the coronary revascularisation measures were developed 
ad hoc for descriptive use in a single study and no steps were taken to evaluate 
their measurement properties. The psychometric properties of these 
questionnaires are critically reviewed in Chapter 3. V\lhilst there is increasing 
recognition that it is important to measure the impact of adverse events after 
coronary revascularisation from the patient's perspective,172-178 there are no 
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available validated scales to measure these aspects of outcome. A few 
instruments have included items about complications, 176 179 326 such as chest or leg 
wound discomfort, but none of these measures have been scientifically evaluated 
for their psychometric properties. Information generated from these instruments 
about complications has only been used for descriptive purposes. There have 
been no attempts to routinely ask patients about these complications using a 
systematic standardised method. The majority of research into the impact of 
complications after coronary revascularisation has been conducted using 
qualitative research methods.172.175178 
Due to the lack of a comprehensive validated disease-specific instrument for 
coronary revascularisation, some study investigators have used cardiac-specific 
measures that were originally developed for evaluating outcomes in medically 
treated patients. For example, Fruitman et 81.,365 MacDonald et 81.,301 and Seto et 
81.305 used the Seattle Angina Questionnaire and the SF-3S to measure HRQoL in 
elderly patients after coronary revascularisation. There are important 
methodological limitations in using such instruments, developed specifically for 
measuring outcomes in medically treated patients, to assess outcomes in surgical 
patients. If a disease-specific measure is used with a different patient group from 
that in which it was developed, the instrument needs to be re-evaluated in the new 
patient group to confirm its psychometric properties. It is not scientifically valid to 
use a measure that is developed in a specific patient population and assume that 
its psychometric properties are retained when used in a different patient group. A 
full psychometric validation is necessary to establish the measurement properties 
in the new patient group. Re-validation in the relevant patient sample has not been 
carried out in the studies described above. 
Another limitation of existing measures concerns conceptual relevance. HRQoL 
instruments developed to measure specific outcomes for a particular patient group 
might not be conceptually relevant to a different patient group, even within the 
same condition. Domains of interest can vary with the stage or severity of illness; 
different dimensions of HRQoL may be of interest to the CHD patient with stable 
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angina as compared with a patient who is recovering from myocardial infarction or 
who has undergone coronary revascularisation.53 Similarly, issues that are 
pertinent to a group of patients at a particular point in time, such as CHD patients 
prior to revascularisation, might not remain relevant after treatment. 
The Seattle Angina Questionnaire, for example, comprises a series of questions 
about the impact of chest pain (angina) on exertional capacity and enjoyment of 
life. For patients who have undergone successful CABG or PTCA, angina pain has 
been relieved. Asking patients about the effects of having a symptom that they no 
longer experience without provision of a response option to indicate that they 
currently do not have angina can be frustrating to the respondent. Indeed, even 
the term chest pain can have a different meaning for patients after coronary 
revascularisation. Patients experience a new type of chest pain as a result of 
having their chest opened. Questionnaires developed for use with medically 
treated patients that ask about chest pain (angina) might be misunderstood by 
CABG patients as the new procedural-related pain sensation that they are 
experiencing. Another conceptual limitation is that instruments developed to 
measure outcome in medically treated patients do not include items specific to 
coronary revascularisation procedures, such as adverse effects and satisfaction 
with outcome. 
For comprehensive patient-based assessments of coronary revascularisation, a 
new single instrument covering all relevant domains is needed. This will remove 
the need for study investigators to administer a series of instruments each 
measuring a specific domain, such as one measure for depression, another for 
symptoms, and another for satisfaction. A comprehensive patient-based measure 
of outcome for coronary revascularisation should include disease-specific 
symptoms, limitations in daily activities, psychological! cognitivel social functioning, 
and outcomes related to the procedure rather than the condition per se, including 
readmission to hospital, physical and psychological complications and satisfaction 
with treatment. 
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In selecting a patient-based measure of outcome for a specific study, it is essential 
that careful consideration is directed at issues of conceptual relevance and that the 
psychometric properties are evaluated. An instrument should be conceptually 
relevant and psychometrically sound if results are to be interpreted with 
confidence. As will be shown in Chapter 3, there is clearly a need for a disease-
specific, patient-based measure of outcome developed specifically for coronary 
revascularisation. This thesis presents the development and psychometric 
evaluation of a new questionnaire, the Coronary Revascularisation Outcome 
Questionnaire (CROQ). 
1.5 Summary 
Health care interventions, including medical and surgical treatment, need to be 
rigorously evaluated to ensure that patients receive the best available care. The 
outcomes of health care have traditionally been evaluated on the basis of clinical 
indicators such as mortality and morbidity. However, this" limited approach to health 
outcomes assessment has changed radically over the past few decades. The 
current focus is on establishing the effectiveness of health care based on scientific 
evidence using a wider range of outcome measures. The focus of the discipline of 
health measurement is on evaluating health outcomes from the patient's 
perspective using scientifically validated instruments. 
This chapter focused on CHD and coronary revascularisation to illustrate the 
changing approach to health outcome measurement. CHD is the most common 
single cause of death in the UK and causes considerable illness and disability. For 
a disease of such public health importance, it is essential to have appropriate and 
scientifically sound outcome measures to evaluate treatment. The relative 
effectiveness of treatments for CHD has attracted much research. In recent years, 
patient-based assessments have been used increaSingly to evaluate the impact of 
these treatments from the patient's perspective. Whilst there are validated 
disease-specific patient-based instruments to measure HRQoL in CHD patients 
treated medically, none of these are sufficient for comprehensive assessment of all 
relevant content domains after coronary revascularisation. As will be shown in 
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Chapter 3, existing instruments specific to coronary revascularisation are either 
weak in terms of psychometric properties, or conceptually inadequate, or both. 
There is clearly a need for a new instrument appropriate for measuring HRQoL and 
health outcomes in coronary revascularisation. 
Chapter 2 describes the psychometric criteria and practical aspects for evaluating 
patient-based questionnaires. Chapter 3 presents a critical review of the 
psychometric properties of the cardiac-specific patient-based questionnaires in 
CHD. 
72 
CHAPTER 2 
EVALUATING PATIENT-BASED QUESTIONNAIRES: PSYCHOMETRIC 
CRITERIA, SCORING AND PRACTICAL ASPECTS 
This chapter discusses psychometric criteria, methodological issues related to 
scoring and practical aspects of evaluating patient-based questionnaires. The 
methods described in this chapter are used to critically evaluate existing cardiac-
specific questionnaires (Chapter 3) and to evaluate the psychometric properties of 
the CROO (Chapter 5). 
2.1 Psychometric properties 
Patient-based questionnaires must be formally evaluated against psychometric 
criteria to ensure that they are acceptable, reliable, valid and responsive. Current 
guidelines for the development of patient-based questionnaires and the evaluation 
of their measurement properties,3 44 64 69 90 366-368 developed from psychometrics, 
are briefly described below. 
2. 1. 1 Conceptual and measurement model 
An instrument should be based on a clear model of what it is intended to measure. 
The conceptual model is a rationale for and description of the concepts that the 
instrument is intended to measure and the relationship between these concepts.90 
Each summary scale should measure a single distinct content domain or construct 
and its scoring procedures should be justified. 
2. 1.2 Acceptability 
A questionnaire should be acceptable to respondents. Indicators of data quality 
such as response rates, item non-response, and the distribution of responses 
across categories can be used as an indication of respondents' understanding and 
acceptance of a questionnaire. 369 
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The average response rate to mail surveys published in medical joumals has been 
reported to be 68%;370 however, higher rates are not uncommon. 371 372 The 
frequent omission of an item suggests that the item might be difficult to understand, 
distressing, or unacceptable in some other way.44 The recommended criterion is 
that missing data for items and scales should not exceed 10%. Acceptability is 
further evaluated on the basis of floor I ceiling effects (percentage of respondents 
endorsing the bottom I top of the scale). Ideally, a questionnaire should contain 
items that can discriminate well and produce an even distribution of responses 
across the item, m 374 without too many or too few endorsements of one response 
alternative.64 The recommended aiterion is that response options should be 
endorsed between 20% and 80%.64 and that the distribution should not be skewed 
(i.e. skewness value8 should be in the range +1 to -1). 
2.1.3 Reliability 
Reliability is the degree to which an instrument is free from random error. A 
reliable instrument is internally consistent and produces consistent results in 
repeated use. There are four types of reliability: intemal consistency, test-retest, 
inter-rater and parallel (alternate) forms. 
2.1.3.1 Internal COOsistenqy 
Intemal consistency measures the extent to which items in a scale measure the 
same concept. It is expressed by Kuder-Richardson formula 20 (KR_20)375 for 
dichotomous data and by Cronbach's alpha coefficient376 for items with more than 
two response alternatives. CoeffICients range between 0 and 1, with higher values 
indicating higher internal conSistency. Alpha coeffICients should be above .70 for 
group comparisons and above .90 for individual assessment. 366 It has been 
suggested that reliability estimates in the range of .70 to .80 are good enough for 
most purposes, but where a test is used to make important decisions in clinical 
settings, values greater than .95 should be sought.63 377 Although the value of 
alpha if an item is deleted should not 'substantially increase',378 no specific values 
have been suggested for this definition. CoeffICient alpha provides a good 
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estimate of reliability because sampling of content is usually the major source of 
measurement error for static constructs. 366 
It is important to note that internal consistency reflects both the number of items in 
a scale and the average correlation between items.366 If the alpha coefficient is 
very low, the scale is either too short or the items have little in common and are 
measuring different constructs. Each scale should measure a single distinct 
conceptual domain or construct; that is, the scale should be homogeneous. Item-
total correlations are used to evaluate the homogeneity of a scale. An item-total 
correlation is the correlation between an item and its own scale, after the item has 
been eliminated from the calculation of the scale score. Item-total correlations 
should be in the moderate range; values of >.20,64 >.30366 and >.4()369 have been 
recommended. A low item-total correlation indicates that the item may be 
measuring something different from the other items in the scale,53 
2.1.3.2 Test-retest reliability 
Test-retest reliability is the degree to which an instrument reproduces stable scores 
over time in respondents who are assumed not to have changed on the domain 
being assessed. It is the relationship between scores obtained by the same 
person on two or more separate occasions.3n The same instrument is 
administered twice separated by a short interval. The test-retest period is usually 2 
to 14 days, as this period is short enough to assume that the underlying process is 
unlikely to have changed and long enough for patients not to remember their first 
response.64 Test-retest reliability is usually expressed by Pearson or intraclass 
correlation coefficients (ICC), with a recommended minimum criterion of .70.90 The 
ICC is the proportion of total variability accounted for by the variability among 
individuals. High values indicate that not much of the variability is due to variability 
in measurement on different occasions and that the reproducibility is high.379 
Systematic changes in the mean level of responding (e.g. every individual's score 
decreasing by a constant) are not reflected by Pearson coefficients.380 However, 
ICCs are sensitive to systematic changes and also to the strength of the correlation 
and as such are increasingly recommended for reporting test-retest reliability. 379 
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2.1.3.3 Inter-rater reliability 
Inter-rater reliability refers to the level of agreement between two or more 
independent raters of the same individual. Cohen's Kappa statistic381 can be used 
to estimate exact agreement between raters for a variable measured on a nominal, 
ordinal or interval-level scale.382 Kappa compares observed agreement with 
agreement expected by chance. Cohen's Kappa is appropriate for measuring total 
agreement and for scales that are rated by an observer. Inter-rater reliability is 
therefore not relevant for self-report questionnaires that do not involve raters or 
observers. 
2.1.3.4 Parallel (altemate) forms reliability 
Parallel (alternate) forms reliability refers to the agreement between scores on two 
or more versions of an instrument that are designed to measure the same attribute 
using different items. 382 If the item content of the two forms is equivalent, the 
correlation between the scores provides a good estimate of the reliability of the 
measure. The Pearson product moment correlation coefficient is used as an 
estimate of reliability. Parallel forms reliability has been widely used in educational, 
personality and cognitive assessment, where two or more different versions of a 
questionnaire are needed for repeat assessments (e.g. two word lists to test 
memory before and after a drug intervention). However, parallel forms reliability is 
rarely used in HRQoL assessment as few measures have parallel forms due to the 
practical constraint of having to develop two measures of the same outcome.63 377 
Reliability is necessary but not sufficient for valid measurement. 366 377 382 It is 
essential to evaluate validity as an instrument can be reliable, but may not actually 
be measuring what it is intended to measure. 
2.1.4 Tests of scaling assumptions 
Tests of scaling assumptions are performed to ensure that items are correctly 
grouped in scales.- 374383 Items should be more highly correlated with their own 
scale (item convergent validity) than with other scales (item discriminant validity). 
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Scaling assumptions can be tested by evaluating items in relation to their 
hypothesised scale, as well as in relation to other scales. 
Ware et al.374 have defined standard criteria to evaluate item convergent and 
discriminant correlations. A 'scaling success' (55) indicates that an item correlates 
significantly higher, by at least two standard errors, with its own scale than with 
another scale. A 'probable scaling success' (PSS) is defined as an item that 
correlates higher with its own scale than with another scale, but not significantly, 
i.e. by less than two standard errors. A 'probable scaling failure' (PSF) indicates 
that an item correlates higher with another scale than with its own scale but not 
significantly, i.e. by less than two standard errors. A 'scaling failure' (SF) defines 
an item that correlates significantly higher, by at least two standard errors, with 
another scale than with its own scale. 
Large data sets are needed to carry out these tests so that estimates of the 
correlations between items are precise. Sample size determines the standard 
error of a correlation: the smaller the sample, the larger the standard error. The 
above criteria for scaling successes and failures are recommended for use with 
samples of at least 300.374 In recent years, computer programmes, such as 
Multitrait I Multi-item Analysis Program-Revised (MAP-R)374 have been developed 
to test scaling assumptions. 
2. 1.5 Validity 
The validity of an instrument concerns the degree to which an instrument 
m~asures what it purports to measure. There are three types of validity: content, 
criterion-related, and construct validity. All address the level of confidence that can 
be placed in the inferences drawn from scores.64 
2.1.5.1 Content validity 
Content validity refers to the extent to which an instrument covers a representative 
sample of the domains to be measured.44 64 This is usually assessed by subjective 
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judgement rather than through a statistical approach. It can be assessed in a 
number of ways: a comparison of the content of the questionnaire with the content 
of existing measures of the same domains; expert opinion of what should be 
measured; and interviews with target respondents.44 Evidence from lay and expert 
panel judgements of the clarity, comprehensiveness and redundancy of the items 
~nd scales is often used to evaluate content validity. Streiner and Norman64 
recommend that an explicit statement regarding content validity, based on a review 
by an expert panel, should be a minimum prerequisite for acceptance of a 
measure. Others propose the need for direct involvement of patients with the 
specific health problem in generating and confirming the content of the 
questionnaire.44 Content validity can also be evaluated by comparing responses to 
open-ended questions, for example "Is there anything else you would like to tell us 
about your condition or treatment that is not covered in this questionnaire?", with 
the content covered in the questionnaire. Any new domains identified by several 
respondents in the open-ended questions would suggest inadequate content 
validity. 
2.1.5.2 Criterion-related validity 
Criterion-related validity refers to the degree to which the instrument correlates with 
gold-standard (criterion) measures obtained either at the same point in time 
(concurrent validity) or subsequently (predictive validity). As there is rarely a gold-
standard in HRQoL assessment, construct validity is usually evaluated instead of 
criterion-related validity. 
2.1.5.3 Construct validity 
Construct validity is evaluated by testing hypotheses about how a measure should 
'behave' and about the expected relationships between the measure and other 
variables or measures of the same construct.384 An evaluation of construct validity 
is based on the accumulation of different types of evidence through within-scale 
analyses and comparison with external criteria. There is no single test to establish 
construct validity; rather, it is an ongoing process. 
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2.1.5.3.1 Construct validity: within-scale analyses. A series of within-scale 
analyses can be used to evaluate construct validity. 
Internal consistency. Good internal consistency, as evidenced by high inter-item 
and item-total correlations greater than .30,366 and high alpha coefficients (greater 
than .7090 366), indicate that a single construct is being measured and that items 
can be combined into a scale. 
Intercorre/ations between scales. Correlations between scales demonstrate the 
extent to which scales measure separate but related constructs. High correlations 
between scales and total scores and moderate intercorrelations between scales 
indicate that scales are measuring related but separate domains. There should 
also be evidence of unique reliable variance, indicated by reliability coefficients 
with values greater than the intercorrelations between scales.374 
Factor analysis. Factor analysis is often performed to confirm or empirically derive 
the scaling structure of a questionnaire. It can be performed to confirm that items 
are correctly grouped together, that items in the same scale measure the same 
construct, that items in different scales measure different constructs, and to identify 
items that contribute little to their intended scale. Items that measure a particular 
construct, such as psychological functioning, should load as highly on the same 
factor as other items in the scale and not on the other factors measuring different 
constructs, such as physical functioning. 
Unrotated Principal Component factor analysis can be used as a starting point to 
check that all items are measuring the same underlying construct and that they all 
load on the same first factor. Common criteria for acceptable factor loadings 
include .30 and .40.385 Rotated factor analysis (Principal Components or PrinCipal 
Axis) should then be performed to identify the solution with the simplest structure. 
The most commonly used method of rotation is Verimax rotation, which attempts to 
minimise the number of variables that have high loadings on each factor.385 
Eigenvalues indicate how much of the variation in the data is accounted for by each 
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factor. The criterion of eigenvalues greater than one is the most commonly used 
method to identify the number of underlying constructs and the number of factors to 
be extracted; however, in general this rule includes too many factors.385 Another 
method is to extract the number of factors above the break in the scree plot. Rotated 
factor analyses can be repeated by modelling one more and one less factor with 
eigenvalues greater than one until the clearest structure is identified. 
Some items load on more than one factor (crossload) and it is not always clear 
which factor they belong to. If the value of the difference between the crossloading 
items is greater than .20, the item is generally assumed to load on the factor for 
which it had the highest 10ading.386 If the difference is less than .20, the item 
should be 'flagged' as being related to more than one factor. Other recommended 
criteria are that the Kaiser-Meyer-Olkin (KMO) test of sampling adequacy should 
be is at least 0.5 and 8artlett's test of sphericity (8S) should be significant.386 KMO 
indicates whether the association between the variables in the correlation matrix 
can be accounted for by a smaller number of factors, and 88 tests the null 
hypothesis that no relationship exists between any of the variables i.e. a significant 
statistic indicates there are discoverable relationships in the data. 386 
Known groups / hypothesiS testing (within scale analyses). Intemal construct 
validity can also be evaluated by testing hypotheses of differences between groups 
that are expected to differ on the outcome of interest. For example, patients who 
report improvement after their operation as measured by a questionnaire would be 
expected to report fewer symptoms (as measured by the same questionnaire) than 
those who do not report improvement. 
2.1.5.3.2 Construct validity: comparison with extemal criteria. Construct validity 
can also be evaluated by examining the relationship between the instrument and 
extemal criteria, such as other HRQoL scales and clinical indicators. 
Convergent and discriminant validity. There are two types of evidence essential for 
establishing construct validity: convergent and discriminant validity.387 It is 
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important to show that scale scores are correlated with independent measures of 
the same domain (convergent validity), and that there is minimal association with 
measures of unrelated constructs (discriminant validity). Convergent and 
discriminant validity are expressed by Pearson product moment correlation 
coefficients. 
Items and scales should be moderately correlated with external criteria that 
measure similar constructs. The expected magnitude of the correlation depends 
on how closely the constructs are related on a conceptual basis. Scales and items 
that measure similar constructs should be more highly correlated (i.e. greater than 
.40339) than with items and scales measuring different constructs. Similarly, items 
and scales should not be highly correlated with measures of different constructs. 
Scale scores should not be highly correlated with demographic data such as age, 
sex and social class or with other unrelated constructs. 
Known groups / hypotheSis testing (analyses against external criteria). Construct 
validity can also be evaluated by testing hypotheses of differences between groups 
known to differ according to an external criterion. For example, one would expect 
patients with more symptoms, measured by a clinical rating scale, to report poorer 
health outcomes on a disease-specific instrument than those with fewer symptoms. 
In the case of CHD, one would expect patients with greater disease severity, as 
measured by the CCS or the NYHA classifications of angina and dyspnoea, to 
report poorer health outcomes on a disease-specific questionnaire. 
2. 1.6 Responsiveness 
Responsiveness is an aspect of validity that has particular relevance in the 
measurement of health outcomes.377 Responsiveness is the degree to which an 
instrument is able to detect clinically Significant change over time. An instrument 
must be able to demonstrate that it can detect small but clinically important 
differences in outcome which clinicians and patients regard as important. 379 A 
clinically important change might be represented by an indication of a therapeutic 
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effect or through a meaningful reduction in symptoms from the patient's 
perspective. There are two types of responsiveness: internal and external. 388 
There are several ways of expressing the intemal responsiveness of an instrument: 
t-statistics,379 effect sizes,389 390 standardised response means,391 and the 
responsiveness statistic. 392 The most common method of demonstrating 
responsiveness is through a comparison of scores before and after a treatment of 
known efficacy using paired t-tests.379 Scales that demonstrate a significant 
difference between the two time points are judged to be responsive. There are 
several criticisms of this method: it is dependent on sample size and so needs to 
be supplemented with other measures of responsiveness;388 it does not account for 
systematic changes in scores across the group (including apparently stable 
respondents) which could occur, for example, due to learning effects; and 
statistically Significant change over time may not be synonymous with clinically 
important change. 390 
The effect size statistic relates change in mean scores over time to the standard 
deviation of baseline scores.389 Effect sizes are used to translate before and after 
changes into a standard unit of measurement, rather than comparing raw score 
changes. Cohen defined effect sizes of 0.20 as small, 0.50 as moderate and 0.80 
or greater as large.389 The standardised response mean is a variant of the effect 
size. It is calculated as the mean change score divided by the standard deviation 
of the change score. 391 The responsiveness statistic measures change relative to 
variability for clinically stable respondents.392 It is a variant of the effect size 
statistic, with a different denominator - the standard deviation of score changes 
among stable subjects. This statistic accounts for the non-specific score changes 
observed in patients who are apparently clinically unchanged. An instrument that 
has high variability in stable subjects in relation to typical change scores is 
considered to have poor responsiveness. The responsiveness statistic is 
inappropriate for studies that do not define clinically stable respondents. 
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External responsiveness reflects the extent to which changes in the measure relate 
to corresponding changes in a 'referenCe' measure (for example a validated 
HRQoL instrument) in a specified ti~e frame.388 The reference measure acts as an 
external standard against which comparisons are made. Change in the reference 
measure is regarded as an accepted indication of change. If the measure 
demonstrates changes seen in the reference measure, it can be used as a 
substitute outcome measure. Measures should be sensitive and specific; a 
measure should reflect both change and no change in the external standard. 388 
There are several ways of expressing the external responsiveness of an 
instrument: receiver operating characteristic method, correlation, and regression 
models. The external responsiveness of an instrument is rarely evaluated. 
2. 1. 7 Interpretability 
Interpretability is defined as the degree to which qualitative meaning can be 
assigned to quantitative scores derived from an instrument. 90 Clinicians need to be 
able to make meaningful interpretations of results. Some leading health outcomes 
methodologists propose the use of clinical data to help calibrate HRQoL measures 
and facilitate interpretation.393 394 There is some consensus that changes in a 
HRQoL instrument should be 'anchored' to other clinical changes or results i.e. to 
ideas that mean something to users.395 In the case of generic instruments, data on 
the distribution of scores derived from a variety of patient populations and a 
representative sample of the general population facilitates interpretation across 
disease groups.87-89 In the case of disease-specific instruments, comparisons can 
be made between changes in health status and changes in clinical measures. 
Descriptive statistics (means, standard deviations, floor and ceiling effects) should 
be provided alongside characteristics of the sample (socio-demographic 
characteristics, disease groups) to enable direct comparisons of samples.90396 The 
use of effect sizes, which have standardised units of measurement, should help 
interpretation across measures.390 Leading health outcomes methodologists are 
currently investigating methods to help facilitate the interpretation of HRQoL 
scores.394 397396 
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2. 1.8 Cultural and language adaptations 
As the measurement of HRQoL is of intemational interest,399-403 instruments have 
been developed in many different languages. In selecting an instrument it is 
essential to check whether the language version of interest has indeed been 
validated. Adaptations of an instrument for use in other cultures and languages 
must be evaluated in terms of conceptual and linguistic equivalence and the 
psychometric properties of the adapted instrument must be re-evaluated. For 
example, the psychometric properties of an instrument validated for use with 
Swedish patients must be re-evaluated for use with English patients, to confirm 
that the psychometric properties are retained when used in this group. Herdman et 
al.404 propose six types of equivalence that should be evaluated when adapting 
HRQoL instruments: conceptual, item, semantic, operational, measurement, and 
functional equivalence. Guidelines have been proposed for the cross-cultural 
adaptation of HRQoL measures.402 403 These include recommendations for 
obtaining semantic, idiomatic, experiential and conceptual equivalence in 
translation, by using back-translation techniques and committee review, pre-testing 
techniques and re-examining the weight of scores.402 
2.2 Methodological Issues related to scoring 
Methods of scoring the questionnaire should be evaluated to ensure that 
assumptions have not been violated. It is commonly accepted that the ordinal type 
of data used in questionnaires can be treated as interval level data,54 although 
there has been considerable debate about this for some tim e. 405-407 
2.2. 1 Summated-rating scaling assumptions 
The most common method for creating summary scale scores is to simply add the 
relevant items. This method is based on the assumption that all of the items in the 
scale are of equal importance. Some instrument developers have devised weights 
for each item relative to their contribution to the total score. However, it is 
generally accepted that the differential weighting of items is rarely worthwhile,54 
The following criteria are widely used to test the assumption that items can be 
summed to form scales without standardisation or weights: symmetry of item-
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response distributions, equivalence of item means and standard deviations, and 
roughly equivalent item-total correlations.408 Each item in a scale should show the 
same pattern of endorsement frequencies across response categories. Means and 
standard deviations should be 'roughly equivalent' for all items in a scale. Ware et 
al.374 suggest that standard deviations should be around 1.0 for items with 5-point 
response scales. 'Roughly equal' item-total correlations indicate that all the items 
are contributing equally to the underlying construd and that equal weights can be 
applied to all items in the scale.369 
Having tested the assumption that items can be summed to form scales without 
standardisation or weights, items in a scale which are measured on the same number 
of response categories (e.g. all items measured on a 5-point Likert scale) can be 
summed to create a summary score. Many instrument developers recommend 
transforming the scores to a 0-100 scale using the following formula:87 
Transformed scale = (adual raw score-lowest possible raw score range) X 100 
possible raw score range 
2.2.2 Items with a varying number of response categories 
For scales in which items are measured on response scales with a varying number of 
response categories (e.g. 5-point and 6-point Likert scales) it is not appropriate to 
simply sum the items to form a scale, as items with more response categories would 
be contributing more to the overall score. One option is to re-calibrate the items to 
the same response format before summing the items. This is an acceptable method 
where only a small amount of re-calibration is necessary, such as within a subscale. 
However, if a large amount of re-calibration is required, for example in the calculation 
of a total score, this method is less acceptable. Rather the scores need to be 
transformed (e.g. to percentiles, standardised scores, or normalised scores) before 
summating.64 
The most commonly used method in psychometrics for standardising items is to . 
transform items to z-score equivalents using the following formula.64371372 
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Z score = X - X 
SD 
Because transforming raw scores to z-scores generates negative scores which are 
not easily interpretable, z-scores are frequently transformed to T-scores for 
reporting purposes.64 371 372 T-scores are usually based on a mean of 50 and a 
standard deviation of 10 to give an easily understood range of scores (T = 50 + 10 
z). In order to minimise the effect of missing data, mean z-scores rather than total 
z-scores are often used.371 372 This is based on the sum of the z-score 
transformations of each item divided by the number of items in the scale. 
2.3 Practical aspects 
This section discusses practical aspects that should be considered when selecting 
or evaluating a patient-based questionnaire: feasibility, appropriateness, and 
methods of instrument development. 
2.3. 1 Feasibility 
The feasibility of the mode of administration of an instrument should be evaluated. 
For example, poor response rates for an instrument administered by postal survey 
might indicate that this method is inappropriate for gathering the information and 
that a different method should be used to gain the information. However, if the 
mode of administration is changed from its original use, e.g. from interview-
administered to self-administered postal survey, the psychometric properties of the 
instrument need to be re-evaluated. Ideally an instrument should be easy to 
administer and should cause minimal burden on both respondents and staff. 
Respondent burden includes the time required to complete the questionnaire and 
any psychological stress experienced by respondents . .0t09 Heavy respondent 
burden may affect both the willingness of individuals to participate in the study and 
the quality of the data (including the amount of missing data).93 Administrative 
burden is defined as the demands associated with administering, scoring and 
interpreting the instrument. Some instruments developed for research purposes 
are quite lengthy and as such may be impractical for routine use. 
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2.3.2 Appropriateness 
In selecting a measure for use in a specific study, several issues related to 
appropriateness of use should be considered. Conceptual relevance is an issue of 
central importance. The content of the questionnaire should be appropriate to the 
aims of the study. The questionnaire should include all domains of interest and all 
the questions should be relevant to the patient group under study. Questionnaires 
are validated for use in specific patient groups, for example a particular disease or 
age group. The patient group under study should be similar to that in which the 
questionnaire was originally developed. If a disease-specific measure is used with 
a different patient group from that in which it was developed, the instrument needs 
to be re-evaluated in the new patient group to confirm its psychometric properties. 
Similarly, the choice of assessment point should be considered. Established 
psychometric properties of an instrument for use in one point in time, such as 3 
months after surgery, cannot be assumed to be transferable to another pOint in 
time, such as 1 year after surgery. Factors that are important to patients in the 
short-term may be different from the long-term. 
2.3.3 Methods for instrument development 
Several stages of instrument development are necessary to ensure that the final 
version of the questionnaire is acceptable to patients and contains only items with 
the strongest measurement properties. VVhen evaluating an instrument, it is 
important that the following assessments have been performed. 
2.3.3.1 Pre-testing 
The first draft of an instrument should be pre-tested by face-to-face interview with a 
small number (approximately 15-35) of individuals for whom the questionnaire is 
intended.410 The purpose is to evaluate content validity, clarity of wording and 
appropriateness of phrasing, typographical errors, faulty instructions, inadequate 
arrangements for recordings answers, and completion time.410 Pre-testing is 
performed to identify any necessary revisions before field testing the questionnaire 
in large samples. 
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2.3.3.2 Preliminary field test (item reduction) 
There should be two stages in a full psychometric evaluation, a preliminary and a 
final field test. The objective of the preliminary field test is to determine response 
rate and patient acceptability and to obtain psychometric data to select items for 
the final version of the questionnaire (item reduction). In an attempt to include all 
appropriate items, the preliminary field test version of a questionnaire is generally 
much longer than the questionnaire that is intended for final use. The preliminary 
field test is carried out to determine which items have the strongest measurement 
properties and to select items on the basis of quantitative (psychometric)64 366 411 
and qualitative (clinimetric)6574 criteria. 
Another purpose of the preliminary field test is to perform scaling analyses. Scales 
can be created on the basis of both a priori conceptualisations of which items would 
be expected to be grouped together (e.g. separate scales for symptoms, physical and 
psychological functioning) and empirical criteria (e.g. factor analysiS, Cronbach's 
alpha). Standard tests of scaling assumptions,64 369 383411 can then be conducted to 
confirm that the items are correctly grouped together, that items in the same scale 
measure the same construct, that items in different scales measure different aspects 
of outcome, and that items can be summed to produce scale scores. Preliminary 
tests of reliability, validity and responsiveness are then performed to confirm that the 
remaining item pool contains items with the strongest measurement properties. The 
item reduction phase in instrument development is often omitted. However, it is an 
essential step in identifying the most robust items and reducing the length of a 
questionnaire. 
2.3.3.3 Final field test (psychometric evaluation) 
The objective of the final field test is to confirm that the scales identified in the 
preliminary field test meet scaling assumptions and to evaluate the psychometric 
properties (reliability, validity, responsiveness) of the item-reduced version of the 
instrument in an independent sample. The item-reduced questionnaire should be 
administered with other validated measures of HRQoL and related outcomes to 
enable extensive tests of construct validity to be performed. 
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2.4 Summary 
This chapter discussed key psychometric properties and standard criteria, as well 
as practical aspects of evaluating patient-based questionnaires. These guidelines 
and criteria are used in subsequent chapters to evaluate the psychometric 
properties of existing cardiac-specific questionnaires (Chapter 3), and to evaluate 
the CROO (Chapter 5). 
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CHAPTER 3 
CRITICAL REVIEW OF CARDIAC·SPECIFIC PATIENT·BASED 
QUESTIONNAIRES 
This chapter describes the methods and results of a literature review to identify 
existing cardiac-specific, patient-based questionnaires for patients with CHD. This 
is followed by a critical review of selected measures. The purpose of the literature 
review was to determine if there was an existing questionnaire suitable for 
measuring HRQoL and health outcomes in coronary revascularisation, which met 
i 
practical and scientific criteria,' and if not, to identify items for possible inclusion in a 
new questionnaire. 
3.1 Methods 
3. 1. 1 Search strategy 
The main strategy was to identify articles describing the measurement of HRQoL in 
CHD, with the purpose of identifying all cardiac-specific, patient-based 
questionnaires that address aspects of CHD patients' experience of health and the 
consequences of illness or treatment. A comprehensive literature review was 
undertaken. A series of consecutive searches were carried out during the period 
1997 -2000 using computerised bibliographic databases. These were 
supplemented by reference follow-up, hand searching of key journals, consultation 
with experts, and website searches to identify other articles not detected in the 
computerised bibliographic searches. 
Three computerised bibliographic databases were comprehensively searched to 
identify articles for inclusion in the literature review: Medline (searched from 1960-
2000), Health Star (searched from 1974-2000),and PsychLit (searched from 1980-
2000). Table 3.1 summarises the search strategy for a series of consecutive 
searches carried out over the period 1997-2000. As can be seen in this table, 
several thesaurus terms (key words) were combined with a list of "free text" words. 
Where possible, search terms were exploded to include all associated terms. The 
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searches were limited to abstracts published in English. The abstract of each 
article identified in the bibliographic searches was reviewed to determine whether 
the article was relevant to this study. All articles reporting the use of a cardiac-
specific, patient-based questionnaire to measure HRQoL or satisfaction with 
treatment in CHD patients were obtained. This included questionnaires developed 
specifically for patients with CHD, as well as questionnaires that were validated in 
cardiac patients in general, including some patients with CHD. Abstracts that did 
not describe the direct measurement of HRQoL in CHD were discarded. Abstracts 
that reported only the use of a generic HRQoL instrument in CHD were also 
excluded, as the purpose was to identify cardiac-specific measures. Articles 
published in English about questionnaires developed in other languages were 
included. Reference follow-up of the articles obtained was then used to identify 
other articles not detected in the computerised bibliographic searches. 
Hand searches of eight major cardiac journals (American Heart Journal, American 
Journal of Cardiology, Heart, European Heart Journal, Heart and Lung, Coronary 
Artery Disease, Coronary Health Care, Circulation) and three general journals 
(Medical Care, Quality of Ufe Research, Journal of Clinical Epidemiology) were 
also carried out to identify additional articles. Published conference abstracts in 
Quality of Ufe Research were reviewed between 1997-2000 to identify 
questionnaires still under development and relevant authors were contacted in 
writing. 
Experts in cardiac surgery, health measurement and health services research were 
consulted to identify additional studies and questionnaires that may not have been 
identified or published. Relevant Internet Websites were searched for international 
research in this field that may not have been published: the UK Clearing House for 
Health Outcomes, European Research Group on Health Outcomes, Map; 
Research, and Quality of Life in Medicine. 
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3. 1.2 Selection of measures for critical review 
The aim of the critical review was to: i) determine if any of the identified cardiac-
specific measures were appropriate for comprehensive measurement of HRQoL 
and health outcomes in coronary revascularisation; and ii) if not, to identify 
validated questionnaires which could provide items for a new instrument for 
coronary revascularisation. 
Questionnaires identified from the searches were reviewed and further articles 
rejected based on the following exclusion criteria. Only questionnaires developed 
for completion by the patient (self- or interview-administered) were included. Non 
patient-based measures, such as clinician or observer-ratings (including 
interviews), were excluded. Instruments developed for use with patients with heart 
failure were included, as ischaemia is a common cause of heart failure, but 
questionnaires developed specifically for hypertension were excluded, as this is a 
risk factor for CHD. Instruments that measured mediators of outcome, such as 
personality, were excluded as the purpose of the review was to identify patient-
based questionnaires developed for CHD patients to measure outcomes. 
The psychometric properties and general characteristics of all identified cardiac-
specific questionnaires were reviewed to determine their appropriateness 'as a 
comprehensive outcome measure for coronary revascularisation. Evidence of 
each instrument's reliability (internal consistency, test-retest), validity (content, 
criterion, construct) and responsiveness was collated and summarised. The 
following descriptive information about general characteristics was also collected to 
help guide decisions of appropriateness: number of items, type of response format, 
methods of scaling and scoring, use of item reduction techniques, patient group, 
method of administration, assessment points used in the study, age of sample, and 
information about validated language versions. . 
Questionnaires that met minimum reliability criteria (i.e. Cronbach's alpha or test-
retest correlations >.70) and that provided at least minimum evidence of validity 
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(i.e. expected convergent or discriminant correlations with external criteria) were 
selected for further review. 
3.2. Results 
3.2.1 Results of searches 
A very large number of articles (approximately 2000 including duplicates) were 
identified from the consecutive searches across the three computerised 
bibliographic databases. A large number of articles were subsequently discarded 
after reviewing the abstract, as they did not describe the measurement of HRQoL 
in CHD. The large majority of articles that were excluded were indexed as HRQoL 
articles, but actually involved proxy not direct measurement of HRQoL. For 
example, many articles indexed as HRQoL in fact reported on the proportion of 
patients able to return to work or able to perform well on exercise testing. A large 
number of articles that reported only the use of generic HRQoL instruments with 
patients with CHD were also excluded. All articles that described the 
measurement of HRQoL in CHD using a cardiac-specific, patient-based 
questionnaire were obtained. 
Although the exact number of articles and questionnaires identified from the 
various searches was not recorded, the majority of questionnaires (approximately 
90%) were identified through Medline searches. Psych Lit did not identify any 
questionnaires included in the critical review that were not identified by other 
methods. Hand searching of conference abstracts in Quality of Ute Research 
resulted in the identification of two questionnaires still under development, one of 
which has recently been published in a peer-reviewed journal. The remaining 
questionnaires were identified through reference follow-up and hand searching of 
key journals. Reference follow-up proved useful in identifying the source paper 
that described the development of the questionnaires. Hand searching of key 
journals identified further relevant articles for review, particularly articles which had 
only recently been published and had not yet been indexed on the computerised 
bibliographic databases .. 
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3.2.2 Measures for critical review 
Using the methods described above, 60 cardiac-specific, patient-based 
questionnaires developed for use with patients with CHD (or heart failure) were 
identified. Table 3.2 summarises the psychometric properties of these 60 patient-
based questionnaires. Information about reliability (internal consistency, test-
retest, inter-rater), validity (content, criterion, construct), and responsiveness is 
summarised in Table 3.2 to facilitate the comparison of measures. The table is 
sub-divided into five sections: measures for coronary revascularisation, angina, 
myocardial infarction, heart failure, and general (non-specific) cardiac measures 
developed for a range of conditions. Within subsections, questionnaires are 
, 
presented in alphabetical order for ease of reference. For some measures, various 
psychometric properties have been evaluated in different studies rather than in a 
single study; where possible this information has been combined in Table 3.2. 
Actual values for statistical tests have been used where possible, but in some 
cases this information had to be summarised. 
Of the 60 questionnaires identified, only a minority has actually been 
comprehensively evaluated for psychometric properties. Of the psychometric 
properties that have been evaluated, reliability has been most frequently assessed. 
Only 28 (47%) of the 60 questionnaires identified met minimum reliability criteria 
(Cronbach's alpha or test .. retest correlations >.70) and provided at least minimum 
evidence of validity. These questionnaires are identified with asterisks (**) in Table 
3.2, and are reviewed in more detail later in this ch~pter. The majority of 
instruments have not been adequately validated and many of their psychometric 
properties are unknown. Many were developed ad hoc for a specific research 
study with no attempt to evaluate psychometric properties. Consequently, they do 
not meet the required criterion of showing evidence of psychometric robustness. 
General characteristics of the 60 questionnaires were also reviewed (see Appendix 
3.1 for a summary). As can be seen in Appendix 3.1, the instruments varied 
considerably in length. Although the majority of measures used Likert response 
scales, several used dichotomous items or visual analogue scales. The majority of 
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measures are scored by summing items, although a few used weighting formulae. 
Only a few questionnaires were developed using item reduction techniques, and 
where these techniques were employed, few details are provided about how and 
which items were eliminated from the original instrument. Most questionnaires 
were developed for self-administration, although a few were developed for 
interview administration. Questionnaires have been validated for use at a range of 
assessment points, but all questionnaires were validated for use at a single point in 
time. For example, questionnaires were validated for use at baseline before 
treatment, but no attempt was made to validate the instrument again after 
treatment. The majority of questionnaires were developed for patients undergoing 
medical rather than surgical treatment; 17 for general cardiac samples including 
patients with a range of conditions, 15 were developed specifically for coronary 
revascularisation, 11 for angina, 11 for heart failure, and 6 for myocardial infarction. 
The majority of cardiac-specific questionnaires have been validated for patients 
under 75 years of age, and women have been largely underrepresented or 
excluded. Whilst 41 (68%) of the 60 questionnaires have been developed with or 
validated in English-speaking patients, only 10 have been validated in the UK. 
This reflects the strong interest in HRQoL assessment in North America. Of the 
ten measures developed or validated in the UK, only three met minimum reliability 
and validity criteria. 
Table 3.3 summarises the subset of 28 of the 60 measures which met minimum 
reliability criteria (Cronbach's alpha or test-retest correlations >.70) and which 
provided at least minimum evidence of validity. As can be seen in this table, only 
18 of the 28 questionnaires have an English-language version, 16 have been 
evaluated for responsiveness, and 15 included item reduction techniques in the 
instrument development phase. These 28 questionnaires are critiqued in more 
detail later in this chapter. 
In selecting a patient-based measure of outcome, it is essential that careful 
consideration be given to issues of conceptual relevance. Table 3.4 presents the 
content domains that have been evaluated in the subset of 28 reliable and valid 
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measures to clarify their conceptual relevance to patients undergoing coronary 
revascularisation. Chapter 1 described the content domains that should be 
measured in evaluating HRQoL and treatment outcomes in coronary 
revascularisation: disease-specific symptoms, limitations in daily activities, 
psychologicall cognitivel social functioning, and post-procedural outcomes 
(adverse effects and satisfaction with treatment). As can be seen in Table 3.4, the 
majority of instruments cover the core domains of disease-specific symptoms, 
physicall psychological! and social functioning, but few cover procedure-related 
outcomes such as satisfaction with treatment. None of the reliable and valid 
cardiac-specific patient-based questionnaires include items on adverse effects 
such as readmission to hospital or complications (Table 3.4). 
3.3 Critical review of selected cardiac-specific patient-based 
questionnaires 
This section presents a critical review of the subset of 28 of the 60 questionnaires, 
which met minimum psychometric criteria. Instruments listed in Table 3.2 that did 
not demonstrate minimal evidence of reliability and validity are not critically 
reviewed. The review of questionnaires has been divided into five sections: 
coronary revascularisation, angina, myocardial infarction, heart failure and general 
cardiac (non-specific) measures. 
3.3. 1 Coronary revascularisation 
Of the 28 questionnaires, only 3 were developed specifically for coronary 
revascularisation: Cleary at a/.'s battery,269 Perception of the Waiting Period 
Questionnaire,331 and Quality of Life Index-Novi Sad(QOLi-NS).333412 These three 
measures were critically reviewed to evaluate the strength of their psychometric 
properties, to determine whether they were suitable for the comprehensive 
measurement of HRQoL and health outcomes in coronary revascularisation, and to 
identify items for inclusion in a new questionnaire for coronary revascularisation. 
As part of a clinical trial, Cleary et al.289 developed and validated a battery of ten 
generic and disease-specific scales to measure HRQoL after PTCA. This battery, 
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administered via telephone interview, proved to be reliable (Cronbach's alpha >.80 
for all scales), valid (moderate inter-scale correlations and tests of scaling 
assumptions) and responsive (detected significant change between pre- and 1-
month post-revascularisation). The content of the battery was derived from a 
review of the most sensitive dimensions in clinical trials that measured HRQoL in 
cardiovascular disease. It covers a number of important domains including 
symptoms, physical well-being, perceived health, emotional well-being, home 
management, work, recreation, and social and sexual functioning. 
Although the Cleary et al. battery shows good psychometric properties, it is not 
appropriate for the purpose of this study for several reasons. The scales are 
largely taken from generic questionnaires and so do not focus on the experience of 
coronary revascularisation or CHD. The only disease-specific component is the 
inclusion of the London School of Hygiene Dyspnoea and Cardiovascular 
Questionnaires343 and the Specific Activity Scale264 to measure cardiac symptoms 
on exertion. The generiC items do not enquire whether any limitations are the 
direct result of the patient's heart condition, as opposed to other factors or 
illnesses, and are less responsive than the disease-specific scales. Cleary at a/.'s 
battery does not assess the impact of PTCA; it does not include some important 
domains such as adverse events (e.g. physical and psychological complications 
and readmission to hospital). These complications are bothersome for many 
patients in the early stages of recovery. There is no assessment of satisfaction, for 
example with the outcome of treatment, or with the information given about the 
procedure or recovery period. Satisfaction is an important aspect of outcome that 
can influence HRQoL. There are no items concerning cognitive functioning or the 
sense of uncertainty about restenosis that many PTCA patients report. Cleary at 
a/.'s battery is further limited for the purpose of this study by not having been 
validated for use as a self-administered questionnaire or for use with CABG 
patients. As the items in this battery are largely generic, they are not the optimal 
choice for inclusion in a new coronary revascularisation specific questionnaire. 
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The Perception of the Waiting Period Questionnaire331 is a 23-item instrument 
developed in the US to evaluate the perceived effect of waiting for CABG. This 
questionnaire, developed for use in a single study, has demonstrated only 
minimum reliability and validity in a very small sample of patients. Limited 
evidence of its psychometric properties, together with its narrow focus on the 
experience of waiting for surgery, precludes this questionnaire for the purposes of . 
our study; it does not provide a comprehensive assessment of HRQoL in coronary 
revascularisation. However, the questionnaire was reviewed to determine whether 
it could provide items for inclusion in a new questionnaire for coronary 
revascularisation. 
An 18-item reliable and valid cardiac surgery questionnaire for patients undergoing 
CABG and heart valve replacement has been developed in Yugoslavia: the Quality 
of Life Index - Novi Sad (QOLi-NS).333 412 It includes questions on physical and 
mental health status, social interaction and self-perception of health and is scored 
as an index measure (0 to 1). Whilst the QOLi-NS contains some items of 
relevance to this study, it does not include any items specific to the experience of 
coronary revascularisation. It has been translated into English, but the standard 
procedures for forward-backward translation399 402 have not been followed and the 
translation does not read well. The authors do not plan to psychometrically 
evaluate the English version (0 Jakovljevic and Z Potic, personal communication, 6 
April, 1998). Whilst the QOLi-NS satisfies the minimum criteria for reliability and 
validity, outlined in Section 3.1.2, evidence in support of its psychometric properties 
is not strong. Test-retest reliability has been confirmed, but evidence of internal 
conSistency is lacking. Similarly, there is only weak support for validity. It is highly 
correlated with pre-operative risk scores calculated using Parsonnet's algorithm, 
but there is no further evidence of construct validity. It has not demonstrated the 
ability to detect groups known to differ and there is no evidence to support its 
scaling structure. Although it may be possible to translate the aOLi-NS into 
English using the appropriate methods and re-evaluate its psychometric properties, 
the fact of its lim ited psychometric properties and narrow conceptual focus 
precludes this option. It was also not considered appropriate to borrow items from 
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the QOLi-NS for inclusion in a new instrument as the translation into English is of 
poor quality. 
As there is no single validated questionnaire' specific to coronary revascularisation, 
which provides a comprehensive assessment of all content domains of interest, the 
remaining reliable and valid cardiac-specific questionnaires were critically 
reviewed. The purpose was to determine their appropriateness for measuring 
outcomes in coronary revascularisation and to determine whether they were a 
possible source of items for incorporation into a new questionnaire for coronary 
revascularisation. These 25 measures have been subdivided into measures 
specifically for angina, myocardial infarction, heart failure and finally general (non-
specific) cardiac questionnaires. 
3.3.2 Angina 
Five questionnaires developed to measure the severity and impact of angina met 
minimum criteria for reliability and validity. These include: Seattle Angina 
Questionnaire,325 Summary Index for Quality of Life in Angina337 the Angina 
Pectoris Quality of Life Questionnaire,338 339 341 the Quality of Life Questionnaire for 
Angina,341 and the Angina-Related Limitations at Work Questionnaire.340 Of these, 
only two (Seattle Angina Questionnaire and Angina-Related Limitations at ·Work 
Questionnaire) have a validated English language version. 
Of the five questionnaires, the Seattle Angina Questionnaire (SAQ)325 has 
demonstrated the strongest psychometric properties (reliability, validity and 
responsiveness). The SAQ is a widely-used, 19-item instrument developed in the 
US to measure functional status in CHD. It has been adapted cross-culturally for 
use in 13 countries, including the UK, and is recommended by the Medical 
Outcomes Trust. The Summary Index for Quality of Life in Angina (SI}337 413 also 
appears to be a reliable, valid and responsive instrument. It has been validated in 
Finnish only and is not widely used, but has demonstrated some convincing 
preliminary evidence in support of its psychometric properties; results need to be 
confirmed in further studies. The remaining three of these five instruments (Angina 
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Pectoris Quality of Life Questionnaire (APQLQ),338 339 341 Quality of Life 
Questionnaire for Angina Pectoris,341 and Angina-Related Limitations at Work 
Questionnaire340) have demonstrated minimum evidence of reliability and validity. 
Further testing of their psychometric properties is required, particularly of test-
retest reliability and responsiveness. 
Whilst the primary clinical reason for coronary revascularisation is to relieve angina 
in order to improve functional capacity and HRQoL, angina relief is only one 
outcome of interest in evaluating outcomes in CABG and PTCA. These five 
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angina-specific instruments focus exclusively on the experience and relief of 
angina. They are, therefore, too narrow in focus to measure outcome 
comprehensively after coronary revascularisation. However, some of these 
instruments were identified as sources of items for inclusion in a new coronary 
revascularisation questionnaire. 
3.3.3 Myocardial infarction 
Four questionnaires developed specifically for myocardial infarction patients met 
minimum criteria for reliability and validity: the Heart Patients Psychological 
Questionnaire,345 414 Quality of Life after Acute Myocardial Infarction (QLMI),346 
Modified Quality of Life after Acute Myocardial Infarction (QLMI-1),347 and Modified 
Quality of Life after Acute Myocardial Infarction (QLMI-2).346 All instruments, 
except the Heart Patients Psychological Questionnaire, have been validated in 
English, but none have been widely used.· 
The oldest of these instruments, the Heart Patients Psychological Questionnaire, 345 
414 is a 40-item instrument developed in The Netherlands and validated for use only 
in Dutch. Whilst it met the minimum criteria for reliability and validity, its 
psychometric properties have been poorly documented in English. The Quality of 
Life after Acute Myocardial Infarction questionnaire was originally developed as an 
interview-administered instrument (QLMI). It has since been revised twice to form 
two different versions of the same instrument, the QLMI-1 and QLMI-2.347 348 
Whilst the first two versions of the instrument have demonstrated some evidence 
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of reliability and validity, the third version (QlMI-2) has generally surpassed the 
earlier versions. The QlMI-2 is a 27-item self-administered instrument that covers 
emotional, physical and social functioning. It has demonstrated excellent internal 
consistency (Cronbach's alpha greater than .90 for all three scales). The test-
retest reliability of this version of the instrument has not been evaluated, but the 
original version (QlMI) was shown to be reproducible. Evidence in support of its 
construct validity and responsiveness to detect clinical change is not strong; future 
studies should evaluate these properties. The QlMI-2 is currently being translated 
into German, Italian and Spanish. 
Whilst there is considerable overlap of HRQol and symptoms in MI patients and 
CABG/PTCA patients, the specific outcomes pertinent to coronary 
revascularisation, such as adverse effects and satisfaction with outcome, are not 
measured by these questionnaires. The QlMI-2 was identified as a source of 
appropriate items for inclusion in a new questionnaire for coronary 
revascularisation. 
3.3.4 Heart failure 
Five questionnaires developed specifically for patients with heart failure met the 
minimum criteria for reliability and validity: Chronic Heart Failure Questionnaire 
(CHQ),415 416 Kansas City Cardiomyopathy Questionnaire (KCCQ),417 left 
Ventricular Dysfunction Questionnaire (lVD-36),418 Minnesota Living with Heart 
Failure Questionnaire (UhFE),419 420 and Self Assessment of Quality of Life in 
Severe Heart Failure Questionnaire (QlQ-SHF).421 These questionnaires have all 
been validated in English, with the exception of the QlQ-SHF, a Swedish 
instrument. 
The most widely used measure of outcome in heart failure is the Minnesota Living 
with Heart Failure Questionnaire (UhFE). The LlhFE is a 21-item instrument 
covering symptoms, physical, emotional and social functioning, which has been 
validated for use in 12 different languages. The LlhFE has been shown to be 
reliable, valid and responsive to medications known to benefit patients with heart 
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failure and to be insensitive to the effects of placebo.420 422 However, it does not 
clearly discrim inate between patients with heart failure of differing severity.270 The 
Chronic Heart Failure Questionnaire (CHQ)415 416 is also widely used and has 
strong psychometric properties (reliability, validity and responsiveness) but has 
only been developed for interview-administration. It has been suggested that it 
compares favourably with the LlhFE but takes longer to complete.27o 
A new instrument, the Kansas City Cardiomyopathy Questionnaire (KCCQ),417 has 
recently been developed and has proven to be reliable, valid and responsive. This 
23-item instrument should prove to be a useful tool for future studies of HRQoL in 
heart failure as the instrument developers report it to be more sensitive to 
important clinical change than the LlhFE. The Left Ventricular Dysfunction 
Questionnaire (LVD-36)418 is a 36-item questionnaire developed specifically to 
measure HRQol in patients with left ventricular dysfunction that has demonstrated 
preliminary evidence of reliability, validity and responsiveness. This instrument 
needs to be further evaluated before being recommended for widespread use. The 
Self Assessment of Quality of Life in Severe Heart Failure Questionnaire (OlO-
SHF)421 has been used in a few drug trials in Sweden. There are conflicting results 
about its ability to discriminate between active treatment and placebo, but it has 
demonstrated moderate sensitivity to small changes in HRQoL. This questionnaire 
has not been translated into English and is not widely used. 
These five questionnaires have been included in this critical review because heart 
failure is commonly the consequence of ischaemia. However, heart failure is not 
always caused by ischaemia, and some of the measures reviewed have been 
developed for heart failure of varying causes. As such, they may not be relevant to 
measuring outcomes in patients with CHD. However, there is some overlap of 
HRQol and symptoms in patients with heart failure and patients undergoing 
coronary revascularisation. These questionnaires contain some items that could 
be included in a new coronary revascularisation questionnaire. 
102 
3.3.5 General cardiac (non-specific) 
Eleven questionnaires developed for cardiac patients in general met the minimum 
criteria for reliability and validity. Five of these are profile instruments measuring a 
range of dimensions: Ferrans and Powers Quality of Life Index (QU-Cardiac 
Version 1II},255355423 Cardiac Health Profile (CHP},353 Multidimensional Index of Life 
Quality (MILQ},358 Cardiac Quality of Life Index (CQU}359 and the Utility Based 
Quality of Life-Heart Questionnaire. 363 The remaining six questionnaires have a 
single focus i. e. physical or psychological functioning: Duke Activity Status 
Index,266 Reduced Duke Activity Status Index,267 Cardiac Denial of Impact Scale 
(CDIS},351 Global Mood Scale (GMS},356 Health Complaints Scale (HCS},357 and 
Cardiac Depression Scale.352 
The most widely used profile instrument is the Ferrans and Powers Quality of Life 
Index (QU-Cardiac Version 111),255355423 which includes items on physical health 
and functioning, social and economic aspects, psychological and emotional 
functioning, and relationships with family members. However, as it is conceptually 
weak in the area of emotional functioning, the developers recommend the 
concurrent use of the Profile of Mood States.284 In another study, the authors 
supplemented the QU with questions on cardiac symptoms, physical activity and 
Iifestyle.290 Although Faris and Stotts255 validated the QU in 20 PTCA patients 
and report it to be reliable and sensitive to improvements in health, such a small 
sample is generally considered insufficient for a definitive psychometric evaluation. 
. Papadantonaki284 evaluated the QU in 44 CABG and 32 PTCA patients and 
reported it to be reliable, but did not evaluate any other psychometric properties. 
Therefore, it would be inappropriate to describe this measure as having been 
validated for use with coronary revascularisation patients. Dougherty and 
colleagues282 found the QU to be insensitive to changes in clinical status 
measured by the Canadian Cardiovascular Society Classification of angina on 
exertion (CCS). 
The remaining four profile questionnaires have not been widely used and require 
more extensive psychometric testing. The Cardiac Health Profile (CHP)353 is a 
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psychometrically sound Swedish questionnaire developed to measure HRQoL in 
CHD. The CHP has been translated into English, but the standard procedures for 
forward-backward translation399402 have not been followed, and the English version 
has not yet been psychometrically evaluated (P Wahrborg, personal 
communication, 5 June, 1998). The CHP includes items on emotional and social 
functioning, general health status, severity of angina and satisfaction with 
treatment. It is currently undergoing expansion and is now available for use with 
patients with heart failure and arrhythmias (P Wahrborg, personal communication, 
5 June, 1998). All items in the CHP are phrased in a generic fashion, with the 
exception of two questions on chest pain. 
The. Multidimensional Index of Life Quality (MILQ)358 is a reliable and valid 
questionnaire developed in the US in 348 cardiovascular disease patients with a 
wide range of disease conditions, including hypertension, heart failure, stable 
angina, and post-revascularisation patients. The MILQ covers nine life domains: 
mental health, physical! cognitivel social functioning, physical health, intimacy, 
productivity, financial status, and relationship with health professionals. None of 
the MILQ items are cardiac-specific and the authors claim that the domains and 
items are relevant to most chronic diseases. As such, it is limited in its capacity as 
a sensitive outcome measure for coronary revascularisation. 
The Cardiac Quality of Life Index359 was derived from Padilla and Grant's Quality of 
. Life Index for cancer patients and modified to measure the outcome of cardiac 
rehabilitation programmes. It has demonstrated preliminary evidence of reliability 
and validity in a sample of 222 patients, but further testing of its psychometric 
properties in independent samples is required. The responsiveness of this 
instrument has not been evaluated. 
Recently, a new measure has been developed and validated for patients with 
cardiovascular disease: the Utility Based Quality of Life-Heart Questionnaire (UBQ-
H).363 The UBQ-H can be used to estimate a summary utility index for overall 
HRQoL and has proven to be reliable, valid and responsive in a sample of 322 
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cardiovascular outpatients, largely consisting of patients with severe heart failure. 
It includes items to assess psychological distress, self-care, social activities, 
physical ability, and overall quality of life. The U8Q-H represents an important new 
development as it will facilitate the calculation of quality adjusted survival time in 
studies of cardiovascular patients. The U8Q-H was published in 1999 after this 
study had been started. 
Six reliable and valid instruments were identified which specifically measure a 
single aspect, i.e. psychological or physical aspects of CHD: Cardiac Denial of 
Impact Scale (CDIS},351 Cardiac Depression Scale (CDS},352 Global Mood Scale 
(GMS},356 Health Complaints Scale (HCS},357 Duke Activity Status Index266 and the 
Reduced Duke Activity Status Index.267 Although these questionnaires are narrow 
in focus, they were included in the review as a possible source of items for the 
development of a new questionnaire for coronary revascularisation. 
These eleven general cardiac measures were considered conceptually and 
methodologically inadequate for the comprehensive measurement of HRQoL and 
health outcomes in coronary revascularisation as they failed to capture the full 
impact of CHD and coronary revascularisation on outcome. Some of the 
questionnaires reviewed required further psychometric testing and some ·were 
narrow in focus. The questionnaires were considered as possible sources of items 
for inclusion in a new questionnaire for coronary revascularisation. 
3.4 Summary 
The purpose of this review was to determine whether there was an existing 
psychometrically sound, patient-based questionnaire appropriate for 
comprehensive measurement of HRQoL and health outcomes in coronary 
revascularisation. A total of 60 cardiac-specific patient-based questionnaires were 
identified. Many of these questionnaires were developed for specific heart 
conditions such as angina, myocardial infarction and heart failure, and so focus on 
issues relevant to patients receiving medical therapy, rather than all outcomes 
relevant to coronary revascularisation. Many of these questionnaires only address 
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a partial aspect of HRQoL or have been developed on an ad hoc basis and have 
not been fully tested for reliability, validity and responsiveness. Since undertaking 
this critical review, Dempster and Donnelly424 have· published a short review of 
HRQoL instruments used to evaluate outcomes in CHD. They came to similar 
conclusions: few of the existing disease-specific measures are psychometrically 
sound and amongst the best are the QLMI-2 and the SAQ. 
A coronary revascularisation outcome questionnaire must be conceptually relevant 
and psychometrically sound. Questionnaires need to be carefully selected to 
ensure that they are sensitive to change, and that they contain items that are 
relevant to the impact of the coronary revascularisation. Of the 60 cardiac-specific 
questionnaires identified, only 28 met minimum criteria for reliability and validity. 
Of these, three were developed specifically for patients undergoing coronary 
revascularisation and none provided a comprehensive assessment of HRQoL and 
health outcomes. Existing coronary revascularisation questionnaires do not 
assess all the domains of interest; significant areas of importance to patients' 
experience of coronary revascularisation are not covered. None measure 
procedure-related outcomes, such as readmission to hospital, physical and 
psychological complications, satisfaction with results and information given about 
the procedure. Rather, most measures focus on the same core elements that are 
included in disease-specific questionnaires (symptoms, physical, psychological and 
social functioning). 
As there was no single psychometrically sound questionnaire appropriate for 
comprehensive measurement of HRQoL and health outcomes in coronary 
revascularisation, other reliable and valid cardiac-specific questionnaires were 
critically reviewed to identify items for possible inclusion in a new questionnaire for 
coronary revascularisation. Whilst these instruments, largely developed for 
patients maintained on medical treatment, were not appropriate for measuring 
outcomes after coronary revascularisation per se, several included items of 
relevance to CABG and PTCA 
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Subsequent chapters describe the development and psychometric validation of a 
new instrument, the Coronary Revascularisation Outcome Questionnaire (CROQ), 
to measure patient-based outcomes for patients undergoing CABG and PTCA. 
Where possible, items from existing questionnaires reviewed in this chapter were 
considered for inclusion in the CROQ. 
107 
CHAPTER 4 
QUESTIONNAIRE DEVELOPMENT: METHODS & RESULTS 
This chapter describes the development of the CROQ. The chapter begins with a 
description of the qualitative methods used to refine the conceptual model. . 
Subsequent sections describe the development and pre-testing of the 
questionnaire. 
4.1 Refining the conceptual model and generating items 
The conceptual model for the CROQ was developed from four sources: review of 
the literature, review of existing instruments, qualitative interviews with patients, 
and expert opinion and consultation with health care professionals and 
researchers. Full details of the review of the literature and of existing 
questionnaires are presented in Chapters 1 and 3. 
4. 1. 1 Qualitative interviews with patients 
The use of qualitative interviews to guide the development phase of questionnaires 
is a necessary step to ensure that the patient's perspective is incorporated. 
Qualitative, in-depth interviews were conducted with CABG and PTCA patients to 
help develop the conceptual model and generate items. The purpose was to 
determine the "critical components" to be included as items, and to identify the 
words used by patients to ensure that the CROQ content was developed in a 
meaningful way. 425 
4.1.1.1 Recruitment 
In August 1998, a total of 20 English-speaking patients at the Royal Brompton 
Hospital including 18 who had undergone CABG or PTCA in the previous 18 
months, and 2 who were about to undergo CABG, were invited to participate. 
Patients were identified during visits to Outpatient clinics or from computerised 
patient lists at the Royal Brompton Hospital. An opportunistic sampling strategy 
was used to identify patients from Outpatient clinics. A more systematic sampling 
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strategy was used to identify patients from computerised lists, with every fifth name 
being selected until the required sample size was achieved. 
Patients were recruited in two ways. The 11 patients identified during Outpatient 
. clinic visits were invited by their Consultant to meet with the researcher, who then 
took patients to a private room to explain the purpose of the interview. The nine 
patients recruited from computerised patient lists were sent a letter from the 
researcher describing the study and inviting them to be interviewed (Appendix 4.1). 
These patients were telephoned a few days later to enquire whether they wanted 
to take part and, if so, to arrange a time for a home interview. All patients were 
asked to read and sign a patient consent form (Appendix 4.2). They were told the 
interview would involve questions about their personal experience of having CHD 
and the impact of CABG/PTCA on their day-to-day lives. Patients were assured 
that the interview was strictly confidential, that the researcher was not involved in 
their care, and that the information was for research purposes only. 
All 20 patients (10 CABG, 10 PTCA) who were invited to participate agreed. The 
sample included 15 men and 5 women ranging in age from 41 to 76 (mean = 62) 
years. 
4.1.1.2 Interview techniques 
Interviews in both settings followed the same two-phase format. The first phase 
used an unstructured approach to determine areas of importance to seven 
patients. The interviewer asked .. Tell me about your experience of heart disease 
and the impact your heart operation has had on your day-to-day life? Please 
describe anything that you feel is relevant because I want to understand what it is 
like to have heart disease and heart operations." The interviewer was deliberately 
vague about the purpose of the interview as spontaneous responses were 
desired.425 No prompts were given as the purpose was to hear their ··stories" and 
to generate ideas rather than impose a structure. Patients were interviewed until 
they indicated that there was no more to say. 
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The second phase of the interviews, carried out with 13 patients, used a general 
topic list (Table 4.1) generated from the findings of the first phase. This allowed 
issues identified in the first phase of interviews to be explored in this phase. The 
interviewer asked patients the same general question as in the first phase, but also 
used prompts to elicit patients' views about specific areas in the topic list if these 
areas were not spontaneously covered. These topics were covered in a different 
order depending on how the interview progressed. Patients were engaged in 
conversation until no new themes emerged or until they indicated that there was no 
more to say. 
The interviewer made effort ~o keep eye contact with the patient, especially when 
sensitive issues were being disc~ssed, to encourage them to speak freely, and to 
reassure them that they were being listened to. All patients were informed that the 
interview was confidential and that the care they received at the hospital would not 
be influenced by their taking part in the interview. The decision was made not to 
use a tape-recorder as it was felt that patients might feel inhibited to speak freely. 
Field notes were taken during all interviews and then supplemented with more 
detail immediately after. The researcher transcribed all field notes later the same 
day. The material generated from the interviews was then categorised into content 
domains. For each domain, the specific comments made by patients were 'listed 
(see Table 4.2 for selected excerpts from the patient interviews grouped by content 
domain) and the frequency of comments tabulated (see Appendix 4.3). This 
information was used to generate items for the CROQ. 
4.1.1.3 Main findings 
The qualitative interviews confirmed the conceptual model described in Chapter 1. 
Several key content domains were identified for inclusion in the new questionnaire: 
cardiac symptoms, limitations in daily activities, psychological functioning (worry I 
anxiety, fear of death and pain, depressed mood, uncertainty, self-efficacy, 
frustration, irritation, avoidance of activities), cognitive functioning (memory, 
concentration, attention, decision making, completing activities), social functioning 
(impact on family and friends, independence, feeling a burden), adverse effects 
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(cardiac-related readmissions to hospital, physical and psychological 
complications) and satisfaction with treatment (information received and 
expectations about the impact of the operation). 
Although the general topic list used in the second phase helped to ensure that all 
topics were covered, patients tended to discuss these areas of their own accord, 
just as they had in the unstructured interviews in the first phase, suggesting that 
both methods produce similar results. There did not appear to be any qualitative 
difference in the content generated from interviews carried out in a private room in 
the hospital clinic and those conducted at home. There was no difference between 
patients interviewed in hospital after an appointm~lnt and those interviewed at 
home in the emphasis placed on symptoms relative to other aspects of HRQoL. In 
all interviews, patients began by describing their symptoms without being prompted 
to do so. The majority of patients began with a history of their heart disease, which 
typically began when they first became aware of their symptoms. The qualitative 
interviews largely confirmed the findings from the literature review. However, s<?me 
notable exceptions are described below. . 
Patients described a range of complications and the length of time they persisted 
after CABG (e.g. pain, infection, oozing, tendemess, numbness and tingling i·n and 
around the wounds in the chest and leg; bruising on the chest and leg; new painful 
sensations in the chest and neck area; swollen feet and ankles; weakness and 
lethargy; nausea, loss of appetite and general eating problems). Some CABG 
patients also expressed concem over the appearance of surgical scars. The 
interviews indicated that many of these complications continued to be a problem 
for some patients for up to 12 months. In contrast, complications from PTCA were 
less common and did not persist over a long period. This is not surprising as 
PTCA is less invasive and the required recovery time is shorter. A number' of 
patients reported some complications in the first few weeks after PTCA (e.g. pain, 
infection, oozing, tendemess, numbness in the grOin wound and surrounding area; 
bruising in the groin and thigh; discomfort in the chest due to the operation; swollen 
feet and ankles; problems in the groin where the catheter was inserted). Some 
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patients were bothered by the appearance of bruising in the groin and thigh area. 
Several qualitative studies of patients' perceptions and experiences of. the post-
procedural period for coronary revascularisation were identified in the literature 
review. 172 173 175 178426 However, patients attached far more importance to these 
complications than has been documented previously. Little previous research has 
routinely monitored or quantified the impact of complications from the patient's 
perspective. 
Patients also described new fears and concerns that arose after coronary 
revascularisation. Several patients reported being afraid of their symptoms ' 
returning and worried that they might need further heart operations in the future. 
Some explained that these fears were always in their mind and never went away. 
PTCA patients were especially concerned about their symptoms returning. 
Restenosis is an accepted complication of PTCA, yet few studies assess the . 
impact of this uncertainty on the patient. Findings from one study suggest that 
patients' concerns about re-occlusion can contribute to poorer psychological 
functioning.205 Many patients had been told that there was a significant chance 
that their angina would return, and in some cases they believed it had and that the 
PTCA had failed. 
Several patients made a distinction between "chest pain", "chest tightness" and 
"chest discomfort" when describing their angina. Clinicians frequently ask patients 
about chest pain, but findings from these interviews suggest that some patients 
clearly experience discomfort as opposed to pain, and are not inclined to use the 
term pain, whilst others describe it as "a definite pain". These findings influenced 
the choice and phraSing of items in the CROa. Patients' descriptions of severe 
radiating pain to other parts of the body including arms, shoulders, hands, neck, 
throat, jaw and back, not always accompanied by chest pain, also influenced the 
choice and phrasing of items in the CROa. 
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4.1.2 . Expert opinion and consultation 
Expert opinion was sought from key heal~h care professionals involved in cardiac 
patient care before, during and after coronary revascularisation. Experts, including 
cardiac surgeons, cardiologists, Cardiac Specialist Nurses, a Pain Control Nurse, 
and a Cardiac Liaison Nurse were asked to describe the impact of CABG I PTCA 
on patients' daily lives. They were asked to describe changes patients might· 
notice in the short- and long-term in relation to symptoms, general and emotional 
functioning, and any complications. They were also asked to identify domains that 
they thought should be covered in the CROa. In addition, researchers with 
experience in evaluating patient-based outcomes were consulted regarding 
methodological aspects of questionnaire development. 
The content domains identified through expert opinion and consultation were 
sim ilar to those identified by the literature review. However, the nursing staff 
provided further support for the findings from the patient interviews concerning the 
extent of complications after CABG. The Royal Brompton Hospital runs a 
telephone helpline service that provides advice to patients about any problems 
after discharge from hospital. This service is used frequently by CABG patients, 
with all calls documented in a ward diary. These diaries were reviewed to identify 
commonly reported problems and concerns. The diaries covered the same 
problems described in the patient interviews, literature, and consultations with 
nursing staff. Clinicians, whilst recognising the importance of psychosocial issues, 
tended to focus on pre-revascularisation symptoms and adverse events after 
revascularisation, such as stroke and myocardial infarction. 
4.2 CROQ conceptual model (pre-teat version) 
Results of the qualitative work described above and the literature review formed 
the basis for the development of the conceptual model for the pre-test version of 
the CROa (see Figure 4.1). Most importantly, findings clarified the need for two 
separate versions of the CROa, one to evaluate outcomes before 
revascularisation and another similar but slightly different version to evaluate 
outcomes after revascularisation. Core content domains identified for inclusion in 
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the pre- and post-revascularisation versions included: cardiac symptoms, 
limitations in daily activities (including work), psychological functioning (worry I 
anxiety, fear of death and pain, depressed mood, uncertainty, self-efficacy, 
frustration, irritation, avoidance of activities), cognitive functioning (reasoning, 
memory, attention, concentration, decision making, speed of reaction, completing 
activities), and social functioning (impact on family and friends, independence, 
interference with social activities). Additional post-revascularisation domains 
identified for inclusion in only the post-revascularisation version included: adverse 
effects (e.g. cardiac related readmissions to hospital, physical and psychological 
complications) and satisfaction (with treatment including information received and 
expectations about the impact of the operation). 
Qualitative interviews with patients confirmed the findings of the literature review 
and provided clear examples within each content domain. In addition, patient 
interviews revealed the importance of measuring both physical and psychological 
complications that can have a· significant impact on HRQoL. The CROQ 
conceptual model is also based on existing conceptual models in heart disease, 
particularly Wenger at al. 'S24 (see Chapter 1). Wenger at al. distinguish symptoms 
induced by treatment from symptoms of the disease, and also incorporate 
expectations, both of which are supported by the findings from the patient 
interviews. 
The CROQ conceptual model does not include two dimensions which were 
identified in existing models: economic circumstance I income and sexual 
functioning. Economic circumstance I income was excluded as this is generally 
believed to be part of "quality of life" in the general sense of the term, as opposed 
to HRQoL. Questions about sexual activity were excluded from the CROa for 
several reasons. Firstly, as the topic did not arise in the patient interviews and was 
not mentioned as a missing domain during pre-testing, it was not considered to be 
an important problem for all patients. Secondly, the CROa was developed with the 
aim of appropriateness for use with all patients, including the elderly, some of 
whom no longer have partners and some of whom might hEwe stopped sexual 
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activities; only items applicable to all respondents should be included in a 
questionnaire.427 Further justification for the exclusion of questions on sexual 
activity comes from the examination of responses to the open-ended question ("ls 
there anything else that you would like to tell us about your heart condition or heart 
operation that is not covered in this questionnaire?"). During preliminary and final 
field testing, participants made no voluntary references to sexual functioning. 
4.3 Development of the pre-test version of the CROQ 
Two versions of the CROa were developed for each procedure: a pre- and a post-
revascularisation version. The pre-revascularisation CROa covers the same five 
core content domains (symptoms, limitations in daily activities, psychological, 
cognitive, and social functioning) in both the CABG and PTCA versions. The post-
revascularisation version covers the same five core domains, but includes two 
additional domains (adverse effects and satisfaction), see Figure 4.1. The post-
revascularisation CROa-CABG and CROa-PTCA are identical with the one 
exception; the items addressing complications in the adverse effects domain are 
different for the two procedures. Domains included in both the pre- and post-
revascularisation versions of the CROa are referred to as the core pre- I post-
revascularisation domains. Domains included only in post-revascularisation 
versions are referred to as the post-revascularisation domains. 
Items were generated for each content domain. Items were either borrowed from 
existing instruments after obtaining permission from the developers, or newly 
created. The CROa includes two types of items: evaluative and descriptive. 
Evaluative items are scored, whereas descriptive items are not scored and are 
used for descriptive purposes only. Demographic questions were also included, 
but these are not formally a part of the CROa. The 78-item pre-test version of the 
CROa-CABG (Appendix 4.4) includes 76 evaluative and 2 descriptive items. The 
72-item pre-test version of the CROa-PTCA (Appendix 4.5) includes 70 evaluative 
and 2 descriptive items. Appendix 4.6 presents the source of each of the CROa 
items, the original phrasing of borrowed items and their re-phrasing in the pre-test 
version of the CROa. 
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4.3. 1 Borrowed items 
Where possible, items were borrowed from existing validated cardiac-specific 
questionnaires (see Appendix 4.6). For each content domain in the CROQ, 
relevant items were identified for inclusion. For some domains, such as symptoms 
(particularly angina) there were several alternative items available to choose from. 
The item that was phrased in the simplest language and which most closely· 
matched the "language" used by patients in the qualitative interviews was selected. 
However, some of the other content domains, such as cognitive functioning and 
satisfaction with treatment, were not well covered by existing cardiac-specific 
questionnaires. The wider literature of HRQoL questionnaires in other diseases 
was therefore consulted to identify items for possible inclusion after modification. A 
total of 33 items borrowed from existing psychometrically sound questionnaires 
were incorporated into the CROQ. 
Nine cardiac-specific items were identified for inclusion in the CROQ. Three items 
were borrowed from the Seattle Angina Questionnaire325 (medication frequency, 
fear of having a heart attack or dying suddenly, and the degree to which anginal 
symptoms interfered with the enjoyment of life), five items from the Quality of Life 
after Acute Myocardial Infarction - QLMI2348 (lack of confidence, frustration, feeling 
excluded from social activities, family being overprotective feeling a burden) and 
one item from the Angina Impact Questionnaire337 (difficulty completing activities). 
Minor changes in wording were made to these items to make them appropriate to 
the question stems (see Appendix 4.6). 
Three multi-item scales from generic health status questionnaires were 
incorporated into the CROQ: the SF-36 Physical Functioning (10 items) and Role-
Physical (4 items) scales87 and the MaS Cognitive Functioning scale (6 items).428 
Minor changes in wording were made to the question stems to make these 
questions specific to heart disease (see Appendix 4.6). A single item (restricted in 
social activities) was also borrowed from the SF-36. 
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Three items from non-cardiac disease-specific questionnaires were borrowed and 
modified to make them specific to heart disease: two items from the Menorrhagia 
Outcomes Questionnaire - MOQ372 (global change after surgery and expected 
speed of recovery) and one item from the Prostate Outcomes Questionnaire -
POQ371 (expectation of results). 
4.3.2 New items 
New items were constructed for content domains that were not adequately covered 
by existing questionnaires. The pre-test versions of the CROQ-CABG and CROQ-
PTCA included 45 and 39 new items, respectively. 
Effort was made to write simple and specific questions. Unfamiliar and ambiguous 
terms429 and double-barrelled questions64 were avoided. The words and phrases 
used by patients to describe, for example a symptom such as chest tightness, were 
used in the questionnaire as language use can influence response by how closely 
it represents a patient's personal experience.43o Items were kept as short as 
possible, as longer items have poorer validity.431 Items were grouped in a logical 
order in sections of similar content, based on the conceptual model, as the 
interpretation of the intended meaning of items can be influenced by the content of 
adjacent items.429 Only items applicable to all respondents were included as 
questions not applicable to some patients can result in missing responses.27 
General health status measures tend to use 4 weeks as the time of reference.3 
This reference point was used throughout the CROQ as changing times of 
reference can be difficult for patients to follow. Underlining and the use of bold font 
were used to emphasise the most salient parts of each question.427 The time of 
reference was underlined in each question stem and wherever possible, the terms 
"heart condition" or "heart operation" were included in bold font. This was done to 
help the patient focus on the specific problem and the impact of their heart 
condition I operation on their day-to-day life. 
117 
Dichotomous and Likert-type scales were used for all evaluative items. Response 
categories were chosen so as not to have more than seven options.64 Wherever 
possible the response categories were modelled on existing measures: SF-36,87 
Seattle Angina auestionnaire,325 Prostate Outcomes auestionnaire,371 and MOS 
Cognitive Functioning scale. 428 Dichotomous response categories were used 
where a Yes I No answer was required. Pre-testing was used to check that· 
response categories were mutually exclusive and exhaustive.427 
4.3.3 Descriptive and demographic questions 
Two descriptive items are included in the CROa. One item asks about the level of 
exertion that induces chest pain, chest tightness or angina. As this item is not 
scored on a Likert response scale, it is not treated as an evaluative item and is not 
included in any of the scales of the CROa. It provides descriptive information of 
interest to clinicians. The second descriptive item asks about cardiac-related re-
admissions to hospital. As the use of self-reported information about re-
admissions to hospital has not been validated against hospital records, it was 
decided that this item should be used for descriptive information only and that it 
should not be scored in the scales of the CROa, until further testing could confirm 
its validity. 
A series of demographic questions are also included for descriptive and validation 
purposes only. Included are sociodemographic questions about: gender, age, date 
of completion of questionnaire, ethnicity, other long-standing iIInesses,432 current 
work situation, occupational class (e.g. job title and occupation, partner's job title 
and occupation433), time to return to work, living situation, date of CHD diagnosis, 
and the need for help to complete the questionnaire. Where possible, questions 
were borrowed from large surveys.432-434 The final item in the CROa asks "Is there 
anything else you would like to tell us about your heart condition or heart operation 
that is not covered in this questionnaire?" This open-ended question was included 
as another means of evaluating the content validity of the questionnaires and to 
allow patients to include other relevant information. 
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4.3.4 Questionnaire format and instructions 
Attention was given to the layout and appearance of the questionnaire as this can 
affect response rate and the accuracy of responses.425 427 The CROO was printed 
in an A3 size booklet to make it easy to read and turn pages.427 The aim of the 
questionnaire design was to produce a very simple "uncluttered" format with 
sufficient space between items.427 Each question was framed in a box to make a 
clear distinction between items. All coding details were excluded from the CROO 
as there is evidence that changing the numbers used to code response categories 
can influence responses.435 Response categories for each item were listed in the 
same order of magnitude, scoring from high to low, to avoid confusing the patient. 
Simple instructions were included on the front page. As recommended,427 a 
statement at the outset of the questionnaire informed patients that the information 
provided would be completely confidential. A unique patient identifier was written 
at the top of each questionnaire and no names were used. 
4.4 Questionnaire pre-testing 
As described in Chapter 2, there are several necessary steps in instrument 
development and the refining of a questionnaire. The first draft of an instrument 
(pre-test version) should be pre-tested with a small sample of patients to evaluate 
overall acceptability. Modifications should then be made before undertaking a 
preliminary field test in a large sample of patients (using the preliminary field test 
version). Item reduction analysis should then be performed to develop a shorter 
item-reduced questionnaire containing items with the strongest measurement 
properties (final field test version) which should then be further evaluated in the 
final field test. This section describes the methods and results of the first stage of 
questionnaire refinement (pre-testing). The methods and results of the preliminary 
and final field tests are reported in subsequent chapters. 
4.4. 1 Methods 
All pre-testing was done on the post-revascularisation versions of the 
questionnaires as they contain every item of the CROO. The purpose of the pre-
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testing was to evaluate the content validity, readability, clarity of wording, 
appropriateness of phrasing, exhaustiveness of response categories, item 
sequence, questionnaire format and instructions, before use in the postal survey. 
Preliminary versions of the post-revascularisation CROQ-CABG and CROQ-PTCA 
questionnaires were pre-tested by face-to-face interview, between December 1998 
and January 1999, with patients 6 weeks to 4 months after revascularisation. 
Patients were invited to take part whilst waiting in the Outpatient clinics at the 
Royal Brompton and Harefield Hospitals. Patients were informed that they were 
helping to test a new questionnaire and that they should tell the researcher of any 
difficulties in answering the questions. Patients were observed whilst completing 
the questionnaires so that the researcher could see if the patient expressed 
difficulty answering an item by spending a longer time answering it.41o Following 
completion of the questionnaire, a" patients were interviewed as recommended427 
to address the following pOints: 
• Does each question measure what it is intended to measure? 
• Are a" the words understood? 
• Are the questions interpreted similarly by a" respondents? 
• Does each closed-ended question have an answer that applies to each 
respondent? 
• Does the questionnaire create a positive impression that motivates people to 
reply? 
• Are questions answered correctly? 
• Are any questions missed out? 
• Do any questions elicit un interpretable answers? 
Fowler4'o suggests that changes should b~ made when an item is problematic for 
20-40% of the sample. In addition to pre-testing with patients, the questionnaires 
were peer reviewed by a panel of health services researchers and experts in health 
measurement. Revisions were made to the questionnaires on the basis of the 
results from the pre-testing. Preliminary field test versions of the CROQ were then 
developed. 
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4.4.2 Results 
All 19 patients (11 CABG, 8 PTCA) who were invited to take part in pre-testing 
agreed to participate. Some patients talked through their response options and 
explained their personal understanding of the meaning of each item as they 
completed the questionnaire, as well as being interviewed after completing the 
questionnaire. This exposed the researcher to the "conversational processes"429 
involved in answering each item and ensured that the items did not have 
unintended interpretations. 410425 
Minor changes were made to the pre-test versions of the CROQ-CABG and 
CROQ-PTCA to develop the preliminary field test versions. Table 4.3 presents the 
phrasing of each of the CROQ items in the three stages of questionnaire 
development - pre-test, preliminary and final field test versions. Several CABG 
patients needed clarification of the meaning of four items (chest pain, chest 
tightness, discomfort in the chest, and radiating pain). Patients were confused as 
to whether the questions were referring to angina pain or to current pain sensations 
that were the result of the operation. For this reason "due to angina" was added to 
each of these items to make it clear that the question was asking about angina 
pain, not pain associated with the CABG operation which appear later in the 
questionnaire. 
The pre-test version of the cognitive functioning domain asked about the frequency 
of cognitive problems, but did not ask whether these problems were a result of the 
patient's heart condition. Several patients answered this question in the "general 
sense" and stated that they experienced these problems because of age. For this 
reason the transition statement" The next questions ask about problems related to 
your heart condition" was added. 
Minor changes were made to the items addreSSing complications. Two CROQ-
CABG items were subdivided into six items as they combined several symptoms, 
which were not necessarily related, in a single item. The order of items in the 
CROQ-CABG was changed Slightly to group all chest-related items together. The 
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wording of two CROQ-CABG items was slightly changed to make them more 
specific to the problem. One item in the CROQ-PTCA about infection, oozing or 
tenderness in the groin wound was split into three separate items, as these were 
considered too different to be grouped together. The CROQ-PTCA item about 
concern over the appearance of the scar was considered inappropriate and 
eliminated, as patients do not tend to scar after PTCA. This item was replaced 
with a new item (problems in the groin where the catheter was inserted) which 
covered the problems described in the patient interviews concerning lumps and 
problems in the groin wound. 
All patients except one indicated that the questionnaires covered the relevant 
domains and that there was "nothing missing". An additional item was added to the 
psychological functioning domain about difficulty in planning ahead (e.g. vacations 
and social events), which one patient described had been a significant problem for 
him and his wife. 
Some of the long questions in the pre-test versions of the CROQ were split over 
two pages. This caused difficulties for some patients when completing the 
questionnaires as they felt important issues had been missed out of these sections. 
Some felt frustrated when they discovered that the question continued over the 
page and changed their earlier responses in the light of the content of the next 
page. This was a particular problem for the items addressing complications in the 
CROQ-CABG. To resolve these problems, the question order was changed slightly 
for the CROQ to avoid splitting questions between pages.427 
Minor changes were made to the pre-test questionnaire format. The grid lines 
were removed from the questions to make them clearer and replaced by light 
shading of alternate items to help the patients focus on the correct line and related 
response category. 
The health services researchers who reviewed the questionnaires felt that the 
questionnaire would accomplish the study objectives.427 A few minor grammatical 
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changes were made to the items. The experts in health measurement were 
satisfied by the format and style of the questionnaire, item sequence, questionnaire 
content and instructions.· The CROQ was deemed ready for field testing in large 
samples. 
The preliminary field test versions of the post-revascularisation CROQ-CABG 
(Appendix 4.7) and CROQ-PTCA (Appendix 4.8) contain 83 and 75 items, 
respectively. The 53-item pre-revascularisation preliminary field test versions of 
the CROQ-CABG (Appendix 4.9) and CROQ-PTCA (Appendix 4.10) are identical 
in item content. 
4.5 Summary 
This chapter described the development and pre-testing of the CROQ-CABG and 
CROQ-PTCA questionnaires. Subsequent chapters describe the methods and 
results of the preliminary and final field tests undertaken to evaluate the 
psychometric properties of the CROQ in large samples of patients. 
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CHAPTER 5 
PSYCHOMETRIC EVALUATION OF THE CROQ: METHODS 
The psychometric evaluation of the CROa was carried out in three stages in two 
independent field tests: item reduction and preliminary psychometric evaluation 
(preliminary field test) and final psychometric evaluation (final field test). This 
chapter describes: i) data collection and management; ii) methods used for item 
reduction; and iii) methods used to evaluate the psychometric properties of the 
CROa. 
5.1 Data collection and management 
This section describes the methods of data collection and management, including 
sampling frame and recruitment, inclusion and exclusion criteria, and questionnaire . 
administration used in both the preliminary and final field tests. 
5. 1. 1 Sampling frame and recruitment 
Patients were recruited from three hospitals in the UK, the Royal Brompton and 
Harefield Trust Hospitals in London and the Wythenshawe Hospital in Manchester. 
All three hospitals perform a high number of CABG and PTCA procedures 
annually. 
All patients who were expected to undergo coronary revascularisation in the study 
period were eligible to participate in the study. Patients were concurrently recruited 
from the three sites after they were given a date for CABG or PTCA, or from CABG 
waiting lists, where available. Patients were recruited between February 1999 and 
May 1999 for the preliminary field test and between November 1999 and May 2000 
in the final field test. In order to identify patients scheduled for CABG and PTCA, 
waiting list administrators, Cardiology Facilitators, and Consultants' secretaries 
were contacted twice-weekly. In addition, ward and catheterisation laboratory 
diaries were checked where possible. 
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In all three hospitals, patients are given very short notice of the date for 
revascularisation. In many cases, patients are telephoned just a few days prior to 
admission as soon as a slot becomes available. Operations are frequently 
cancelled and rescheduled. Elective patients can be assigned a theatre slot a few 
days in advance, but if emergency cases are admitted, the elective patient moves 
down the list. 
To avoid sending questionnaires to patients at a time so close to major surgery, 
CABG waiting lists were used to recruit patients where possible. Patients at the 
Royal Brompton Hospital were recruited if they had been on the central waiting list 
for over 40 weeks, or if they had been assigned a high urgency score category. 
The aim was ta, recruit patients on the waiting list who were most likely to undergo 
CABG in the following 2 to 3 months. This waiting list is clearly categorised and 
updated on a weekly basis. The Harefield Hospital does not routinely use urgency , 
ratings and the central waiting list is not managed on a weekly basis. Consultants' 
secretaries at the Harefield were telephoned on a twice-weekly basis for patient 
details. It was not necessary to use the Wythenshawe Hospital waiting list, as a 
Waiting List Co-ordinator was able to provide information on a weekly basis. 
Surgeons and cardiologists at the Wythenshawe Hospital confirm CABG and 
PTCA lists toward the end of the week preceding the surgery date. The proposed 
theatre schedules were faxed to the Project Co-ordinator on a weekly basis, 
generally on a Friday morning. In an attempt to increase sample size, patients 
scheduled for CABG/PTCA on a Monday were sent the questionnaire as late as 
the previous Friday morning. This may have reduced the overall response rate, as 
some patients may not have received the pre-revascularisation questionnaire 
before they were admitted for revascularisation. Recruitment at all three sites 
~ continued until at least 100 CABG and 100 PTCA baseline questionnaires, from 
patients who had actually undergone the procedure, had been returned. 
Procedure lists were produced at each hospital, confirming which patients had 
undergone CABG and PTCA and the date. All patients who underwent CABG or 
PTCA during the recruitment period were sent a 3-month post-revascularisation 
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questionnaire, even if they had not been sent a baseline questionnaire before 
revascularisation. This was done to maximise the sample size for the 
psychometric analyses of post-revascularisation data, and to ensure that the 
samples used for the psychometric analyses were representative samples of all 
patients undergoing CABG and PTCA at the three hospitals. 
Patients who returned both the pre- and post-revascularisation versions of the 
CROa comprised the responsiveness subsample. A random sample of CABG and 
PTCA patients in the 3-month post-revascularisation sample formed the test-retest 
subsample. Patients in this sample were sent two copies of the 3-month post- ' 
revascularisation CROa and were asked to complete and return the second 
questionnaire 2 weeks after completing the first. 
5.1.1.1 Inclusion and exclusion criteria 
No age limits were applied as coronary revascularisation is increasingly being 
offered to elderly patients with CHD. Patients who had coronary stents implanted 
during PTCA were also included to ensure a representative sample of patients who 
had undergone routine coronary revascularisation. 
The following patients were excluded from the study: private patients, non-UK 
residents, patients participating in another trial involving completion of 
questionnaires, and patients undergoing CABG combined with another procedure, 
such as valve replacement. In addition, patients were excluded from the pre-
revascularisation sample if the Project Co-ordinator was not informed that they 
were scheduled for surgery at least 2 days before the procedure date. 
5. 1.2 Questionnaire administration 
Both prelim inary and final field tests were conducted by postal survey to patients' 
home addresses. All patients who met the inclusion criteria were invited to 
participate. Patients completed the preliminary field test version of the CROa at 
two assessment pOints: pre-revascularisation and at 3-months post-
revascularisation. Patients completed the final field test version of the CROa at 
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three assessment points: pre-revascularisation, and at 3- and 9-months post-
revascularisation. 
Prior to revascularisation, patients were sent a package that included a letter of 
invitation from their Consultant (Appendix 5.1 or 5.2), a patient information sheet 
describing the study and introducing the research team (Appendix 5.3 or 5.4), a 
consent form (Appendix 5.5), a stamped addressed envelope and the pre-
revascularisation version of the CROQ-CABG (Appendix 4.9 or 5.6) or CROQ-
PTCA (Appendix 4.10 or 5.7). 
A few days before the target assessment point of 3- and 9-months post-
revascularisation, patients who had undergone revascularisation were sent the 
post-revascularisation package which contained a cover letter from the Project Co-
ordinator (Appendix 5.8, 5.9 or 5.10), the post-revascularisation CROQ-CABG 
(Appendix 4.7 or 5.11) or CROQ-PTCA (Appendix 4.8 or 5.12), a patient 
information sheet (Appendix 5.13, 5.14 or 5.15), and a stamped addressed 
envelope. The 3-month post-revascularisation package sent to patients who had 
not completed the pre-revascularisation version of the CROQ contained a letter of 
invitation from their Consultant (Appendix 5.16), a patient information sheet 
(Appendix 5.17), a consent form (Appendix 5.18) and the post-revascularisation 
CROQ-CABG (Appendix 4.7 or 5.11) or CROQ-PTCA (Appendix 4.8 or 5.12). To 
avoid unnecessarily upsetting family members if a patient had died, the Project Co-
ordinator confirmed whether the patient was still alive immediately before sending 
out all post-revascularisation questionnaires. This was done by either checking the 
hospital's Patient Administration System or by telephoning the patient's GP 
surgery. 
All patients in the final field test (except patients in the test-retest subsample) were 
sent a booklet containing the CROQ and one of the following questionnaires: the 
Short-Form 36 (SF-36), 87 the Seattle Angina Questionnaire (SAQ),325 the Quality of 
Life After Myocardial Infarction Questionnaire (QLMI-2)348 or the Minnesota Living 
with Heart Failure Questionnaire (L1hFE).419 The purpose of administering two 
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questionnaires to each patient at each time point was to gather data to evaluate 
the external construct validity of the CROO and to assess the comparative 
responsiveness of the different HROoL instruments. The SF-36 was selected as it 
is the most commonly used generic HROoL questionnaire and is well validated. 
The SAO, OLMI-2 and LlhFE were selected as they are the most psychometrically 
sound cardiac-specific questionnaires and include some sim ilar content domains. 
Standard techniques425 436 were used to ensure a high response rate, including 
personalised letters, standardised instructions, follow-up reminder letters and 
stamped addressed return envelopes. The cover letter inviting patients to take part . 
in the study included the purpose of the study, what was required of participants 
and a statement informing patients about confidentia lity. 427 In the post-
revascularisation sample, reminder letters were sent at 3 and 5 weeks after the 
original mailing date to patients who did not return a completed questionnaire. The . 
3-week reminder contained a cover letter (Appendix 5.19) and another copy of the 
CROO, whereas the 5-week reminder consisted only of the cover letter (Appendix 
5.20). Patients who did not return the questionnaire after ~o reminders were 
considered non-responders. Reminders were not ·sent to patients in the pre-
revascularisation sample, as the interval between notification and the date of the 
procedure was too short. 
5.2 Item reduction 
The purpose of the preliminary field test was to select items to be retained for use 
in the final field test versions of the questionnaires (item reduction) and to carry out 
a preliminary psychometric evaluation of the item-reduced CROO. This section 
describes the methods of analyses for item reduction of the CROO. 
5.2. 1 Item reduction strategy 
A detailed analysis plan, with three main phases of item reduction, was drawn up 
to incorporate the pre- and post-revascularisation assessment pOints. The item 
reduction analysis plan was based on earlier research incorporating a variety of 
methods,371 372 but was modified for use with a pre-I post-intervention design. 
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The pre-revascularisation CROQ data were used as the starting pOint of the 
analyses due to the nature of the questionnaire~ Common criteria for item 
reduction analysis include analyses of maximum and aggregate adjacent 
endorsement frequencies. However, one would expect ceiling effects in the post-
revascularisation data as the procedures are known to be effective at alleviating 
problems associated with CHD, such as symptoms and accompanying limitations 
in physical and mental functioning. If the post-revascularisation data were used as 
the starting pOint and maximum endorsement frequency criteria applied, important 
items might have been eliminated. Analyses were, therefore, based on pre-
revascularisation data and further tested in the post-revascularisation samples to ' 
confirm findings. 
Phase One: Item reduction analyses were firstly carried out on the 52 items in the 
core domains that were common to both the pre- and post-revascularisation . 
versions of the CROQ-CABG and CROQ-PTCA (Symptoms, Physical! 
Psychological! Social! and Cognitivel Functioning). As all patients about to 
undergo both CABG and PTCA have CHD, pre-revascularisation data for both 
procedures were pooled to increase the sample size enabling rigorous tests of 
scaling assumptions. Preliminary scales identified from analysis of the pooled pre-
revascularisation data were then tested in the independent pre- and post-
revascularisation samples (CABG only and PTCA only) to evaluate their 
robustness. 
Phase Two: Item reduction analyses were then conducted on the set of 10 
common items included in the post-revascularisation versions of both the CROQ-
CABG and CROQ-PTCA. Data obtained from the CABG and PTCA post-
revascularisation samples were pooled and used for these analyses. These 
analyses were then repeated in each of the post-revascularisation samples 
independently (CABG only and PTCA only) to check that similar items would have 
been eliminated if the questionnaires had been item-reduced independently without 
pooling the data. 
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Phase Three: Item reduction analyses were finally performed on the 19 CABG and 
11 PTCA post-revascularisation complication items in each of the post-
revascularisation samples independently (CABG only and PTCA only). This was 
done because the complication items differ in content for the CROa-CABG and 
CROa-PTCA. 
The purpose of item reduction analyses is to determine the subset of items that are 
the most robust when evaluated rigorously using standard psychometric methods. 
Items with the weakest measurement properties that failed specified criteria were 
eliminated from the CROa initial item pool (item elimination). The item-reduced 
questionnaire was then scaled and the scale properties evaluated (tests of scaling 
assumptions). Additional items were eliminated on the basis of further 
psychometric tests until all pre-specified criteria were satisfied. 
5.2.2 Item elimination 
Items were eliminated from the CROa mainly on the, basis of quantitative 
{psychometric)64 90 366 369 411 437 criteria, but qualitative {clinimetric)65 74 criteria were 
also considered for a few items. Item reduction involves many of the same tests 
described in Chapter 2, but these tests are applied at the item rather than scale 
level. Table 5.1 presents the psychometric criteria used to evaluate the CROa at 
both the item and scale level. For some tests, the criteria for items are more 
stringent than for scales. 
Standard psychometric methods for item reduction were applied including: item-
total correlations, item redundancy, missing data, maximum and aggregate 
adjacent endorsement frequencies, item responsiveness, and item test-retest 
reliability. Criteria applied during item reduction that differed from those described 
in Chapter 2 are described below. In order to ensure that items of clinical 
Significance were retained, qualitative criteria took precedence over psychometric 
criteria only for a very small number of items for which it was agreed that the item 
should be retained for clinical or conceptual reasons. 
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Item-total correlations: The criterion used to eliminate items in the CRDa was an 
item-total correlation less than .30.366 Criteria cited in the literature range from 
strict (.40) to liberal (.20). With no consensus as to which criterion to use, the 
value in the middle of the range (.30) was chosen. 
Item redundancy: Values of greater than. 70438 and. 75439 have been suggested as 
criteria for item redundancy. The criterion used to eliminate items in the CROa 
was an inter-item correlation greater than or equal to .75. The item in the pair with 
the poorest psychometric properties as judged by other criteria (e.g. missing data, 
maximum endorsement frequencies and aggregate adjacent endorsement' 
frequencies) was eliminated. In the case where two items were psychometrically 
equivalent, a decision was made by consensus with another psychometrician, 
based on other characteristics of the item (e.g. relevance, clarity, item length). If 
one or both items was considered clinically important, the item was retained. 
Highly correlated items of similar content were considered for combining into one 
item, and highly correlated items that appeared to measure distinct aspects were 
considered for retention. 
Missing data: A more stringent criterion (greater than 5%) than applied at the scale 
level was used to eliminate items in the CRDa. 
Maximum endorsement frequencies: Values for item floor/ceiling effects of greater 
than 90%,440 85%,26 80%,441 and 70%439 have been applied in the literature. The 
criterion used to eliminate items in the CRDa was maximum endorsement 
frequency (MEF) greater than or equal to 75%. This value was chosen for two 
reasons: it was within the range of values reported in the literature and, empirically 
did not lead to excessive item elimination. No criteria are specified in the literature 
for minimum endorsement frequencies so this was not used to eliminate items from 
the CROa. The MEF criterion was applied with caution, as there are no guidelines 
for evaluating both pre- and post-intervention versions of a scale. In the case of 
coronary revascularisation, one would expect high endorsement frequencies for 
response alternatives that reflect poor health before surgery and improvement after 
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surgery. Furthermore, in some cases a symmetrical distribution of responses 
should not be expected,374 as for example with items related to uncommon states 
such as severe depression. Items were, therefore, not eliminated on the basis of 
endorsement frequencies from the post-revascularisation CROa. 
Aggregate adjacent endorsement frequencies: An additional criterion is to eliminate 
items in which the aggregate endorsement frequency for two or more adjacent 
response categories is less than or equal to 10%.437 This criterion was also 
applied in the analysis of the pre-revascularisation version of the CROa, in which 
items are expected to be better distributed across response categories, but not in ' 
the post-revascularisation version, where data are expected to be skewed towards 
better outcomes. 
Item responsiveness: Responsiveness is generally assessed for scales rather than , 
for items. However, in order to retain only the most robust items, responsiveness 
was also assessed at the item level in the item reduction stage. Items which did 
not show significant change (p<.OS) between the pre-revascularisation and 3-
month post-revascularisation assessments were considered unresponsive and 
eliminated. This criterion was used in the item reduction stage of the core domains 
of the pre- and post-revascularisation versions of the CROa (Symptoms, Physicall, 
Psychosociall, and Cognitive Functioning). 
Item test-retest reliability: Test-retest reliability is also generally assessed for scales 
rather than for items, but was also assessed at the item level in order to retain only 
the most robust items. As there is no established criterion for item test-retest, a 
value of greater than .40 was used as this is well below the scale test-retest 
criterion of greater than or equal to .70.90 Items with a test-retest correlation less 
than .40 were eliminated. As test-retest was only evaluated at 3-months post-
revascularisation, this criterion was used only for item elimination in the post-
revascularisation version of the CROa. 
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5.2.3 Tests of scaling assumptions 
After initial item elimination, preliminary subscales were created on the basis of both 
a priori conceptualisations of which items would be expected to be grouped together 
(i.e. separate scales for Symptoms, Physical! Psychological! Social! and Cognitive 
Functioning, Satisfaction, and Complications) and empirical criteria (factor analysis 
and Cronbach's alpha). Scales were summed to create summary scores and the 
psychometric properties evaluated. Standard tests of scaling assumptions64 369 374 383 
411 were performed to confirm that items were correctly grouped together, that items 
in the same scale measured the same construct, and that items in different scales 
measured different aspects of outcome. Tests of scaling assumptions were carried . 
out through exploratory factor analysis, internal consistency, and an examination of 
item convergent and discriminant correlations (multi-trait scaling techniques369374). 
Factor analysis was used to empirically derive scales after item elimination; it was 
used only as an exploratory technique to generate hypotheses about the structure of 
the data.385 No items were eliminated based on factor analyses but "rogue" items 
that failed to load on a factor were identified. Unrotated Principal Components 
factor analysis was used as the starting point to check that all items loaded on the 
first factor (criterion: greater than or equal to .30) and that all items were measuring 
the same underlying construct. Cronbach's alpha and item-total correlations were 
used to confirm the internal consistency of scales. Item convergent and 
discriminant validity correlations were used to evaluate each item in relation to its 
hypotheSised scale as well as in relation to other scales. Ware et al. 's374 definitions 
of scaling successes and failures were used (see Chapter 2), but the more 
stringent criterion of only allowing definite scaling successes (SS) was applied in 
the initial stages of item elimination to ensure that only items with the most robust 
measurement properties were retained. Qualitative (clinimetric) criteria took 
precedence over psychometric criteria only if it was agreed that the item should be 
retained on clinical grounds. Further items were eliminated as they failed 
psychometric cr~teria and analyses were repeated until a" criteria were satisfied. 
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5.3 Preliminary and final field tests 
After tests' of scaling assumptions were carried out to confirm the psychometric 
adequacy of the item~reduced scales, the acceptability, reliability, validity and 
responsiveness of the scales were evaluated using standard psychometric 
techniques (see Chapter 2).64 366 411 442 The psychometric evaluation was carried 
out in two stages: the preliminary psychometric evaluation was carried out using 
data from the preliminary field test and the final psychometric evaluation was 
carried out using data from the final field test. Analyses were conducted separately 
for both the pre- and post-revascularisation versions of the CROQ-CABG and 
CROQ-PTCA, using data obtained from the pre- and post-revascularisation patient 
samples. 
The purpose of the final field test was to evaluate the psychometric properties of 
the item-reduced questionnaires in independent samples. It was necessary to , 
confirm that the psychometric properties were maintained in an independent 
sample of patients who completed only the item-reduced versions of the CROQ. 
The methods for the preliminary and final psychometric evaluations were identical, 
but the final evaluation involved more extensive testing of external construct 
validity and responsiveness. The methods of the preliminary and final 
psychometric evaluations are described below; the criteria applied are described in 
Chapter 2. 
5.3. 1 Acceptability 
Response rates in the pre- and post-revascularisation samples were calculated to 
establish overall acceptability to patients. Acceptability was also assessed on the 
basis of percentage of missing data for items and scales, floor and ceiling effects, 
and skewness of score distributions. 
5.3.2 Internal consistency and test-retest reliability 
Cronbach's alpha was calculated to assess internal consistency. Intraclass 
correlation coefficients were calculated between the two administrations of the 
post-revascularisation versions of the CROQ to determine test-retest reliability. 
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5.3.3 Calculation of summary scores 
To test the assumption that items could be summed to form scales without 
standardisation or weights, several criteria were evaluated: symmetry of item-
-
response distributions, equivalence of item means and standard deviations, and 
roughly equivalent item-total correlations408 (see Chapter 2). 
For subscales in which all items were measured on the same response scale (i.e. 
Physical! Cognitive! Psychosocial! Functioning and Complications), items were 
summed to create a total score and then transformed to a 0-100 scale,57 with 100 
representing the best possible outcome. For subscales in which items were 
measured on response scales with a different number of categories (i.e. Symptoms 
and Satisfaction), items were re-calibrated to the response format held by the majority 
of items as follows: 
Scale (item) 
Symptoms (Q2) 
Satisfaction (Q12) 
Satisfaction (Q13) 
Satisfaction (Q14) 
Recoding for re-calibration 
. (1=1) (2=1.66) (3=2.50) (4=3.33) (5=4.16) (6=5) 
(1 =1) (2=1.75) (3=2.50) (4=3.25) (5=4) 
(4=missing) (1 =1) (2=2.5) (3=4) 
(1 =1) (2=2.5) (3=4) 
One item (Q2) in the Symptoms scale is scored on a 6-point scale and the remaining 
six items on a 5-point scale. This item was re-calibrated to a 5-point scale. Three of 
the six items in the Satisfaction scale are measured on a 4-point scale (Q11a-c), two 
on a 3-point scale (Q13, Q14), and one on a 5-point scale (Q12). Items in the 
Satisfaction scale were re-calibrated to a 4-point scale. After re-calibration, items 
were summed to create a total score and then transformed to a 0-100 scale 
consistent with the other scales. Appendix 5.21 summarises these scoring 
procedures. 
Missing data were imputed according to the algorithm recommended for scoring the 
SF-36.5766 If at least 50% of items in a scale were completed, a person-specific 
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estimate (mean of the non-missing items) was substituted for the missing items. A 
missing scale score was assigned if over 50% of the items in a scale were missing. 
To calculate a total score (Core Total) for the core pre- I post-revascularisation 
domains (Symptoms, PhysicaII, Psychosociall and Cognitivel Functioning) which are 
measured on response scales with a varying number of categories, it was necessary . 
to standardise the scores rather than re-calibrate. Raw scores were transformed to 
z-score equivalents54 371 372 before being summed to form total scores. In order to 
minimise the effect of missing data, mean z-scores rather than total z-scores were 
used. This is based on the sum of the z-score transformations of each item divided 
by the number of items in the scale. The program for calculating summary scale 
scores, based on the mean of the z-scores for items in the summary scale, allows 
inclusion of a questionnaire with 50% or less of missing data. Z-scores were 
transformed to T-scores based on a mean of 50 and a standard deviation of 10 for 
reporting purposes.54371 372 To calculate a total score (Total Outcome) for the post-
revascularisation domains (Adverse effects and Satisfaction) the same scoring 
procedure was followed. 
5.3.4 Tests of scaling assumptions 
Item convergent and discriminant correlations were calculated for each scale to 
test scaling assumptions. Correlations between each item to its own scale and to 
each of the other scales were examined. Scaling assumptions were tested by 
examining item convergent and discriminant correlations.374 
5.3.5 Validity 
5.3.5.1 Content validity 
Content validity was evaluated in two different ways: firstly, during development of 
the CROa through expert clinical opinion, a comprehensive literature review, and 
comparison with existing measures; and secondly, responses to an open-ended 
question asking the patient "Is there anything else you would like to tell us about 
your heart condition or heart operation that is not covered in this questionnaire?" 
were examined to identify additional content not covered. 
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5.3.5.2 Construct validity: within-scale analyses 
Four types of analyses were undertaken to evaluate the internal construct validity 
of the CROQ: internal consistency, intercorrelations between scales, factor 
analysis, and known group differences I hypothesis testing. 
5.3.5.2.1 Internal consistency. Cronbach's alpha was calculated to measure 
internal consistency, the degree of support for the construct validity of the scales. 
5.3.5.2.2 Intercorrelations between scales. Intercorrelations between scales were 
calculated to determine the extent to which the scales measure separate but 
related constructs; the objective was to evaluate unique reliable variance. The 
Symptoms and Physical Functioning scales were expected to be moderately to 
highly correlated, as cardiac symptoms tend to be induced on exertion. Scales 
measuring physical health (Symptoms and Physical Functioning) were expected to 
be correlated more highly with each other than with scales measuring mental 
aspects of health (Psychosocial and Cognitive Functioning). Similarly, scales 
measuring mental health (Psychosocial and Cognitive Functioning) were expected 
to be moderately correlated with each other and to be correlated more highly with 
each other than with scales measuring physical aspects of health (Symptoms and 
Physical Functioning). Low correlations were expected between Complications 
and all other scales, as this measures a different aspect of HRQoL. 
5.3.5.2.3 Factor analysis. Factor analysis was performed on the pre- and post-
revascularisation items in both pre- and post-revascularisation samples to confirm 
the assignment of items to the scales identified from item reduction analyses. It 
was also performed on the post-revascularisation items in both the CABG and 
PTCA post-revascularisation samples. Principal Axis Factoring with Varimax 
rotation, modelling the number of factors to be extracted based on the scales 
identified from the item reduction analyses, was performed. For the analysis of the 
32 core pre-I post-revascularisation items, four factors were extracted to evaluate 
support for the four core scales identified from the item reduction analyses 
(Symptoms, Physicall, Psychosocial/, and Cognitive Functioning). For the 
137 
analyses of the post-revascularisation items, a two-factor solution was modelled to 
evaluate support for the assignment of items into the two procedural-specific 
outcome scales (Satisfaction and Complications). The number of cross loadings 
(items loading on more than one factor greater than or equal to .35) was examined. 
5.3.5.2.4 Known groups I hypothesis testing (within scale analyses). T-tests were 
used to test a series of hypotheses about expected differences between known 
groups: 
• Patients who report global improvement after revascularisation will show 
significantly higher CROQ scores (better health outcomes) than those who 
report their condition as being the same or worse. Mean CROQ scores for 
patients categorised as improved (scored 4 "a little better", or 5 "much better" 
on Q12) and unimproved (scored 1 "much worse", 2 "a little worse", or 3 "about 
the same" on Q12), were compared. 
• Patients who report being bothered by chest pain due to angina after 
revascularisation will show significantly lower CROQ scores (poorer health 
outcomes) than those who report they are not bothered. Mean CROQ scores 
for patients categorised as bothered (scored 1 "a lot", 2 "quite a bit", 3 
"moderately", or 4 "a little" on Q1a) and not bothered (scored 5 "not at all" on 
Q1a) by chest pain, were compared. 
5.3.5.3 Construct validity: comparison with external criteria 
The external construct validity of the CROQ was not evaluated in the preliminary 
field test, which was primarily undertaken for purposes of item reduction analyses. 
In the final field test, the CROQ was compared against existing generic and 
disease-specific HRQoL questionnaires (SF-36, SAQ, QLMI-2, LlhFE), 
demographic and clinical variables. 
5.3.5.3.1 Convergent and discriminant validity. Convergent and discriminant 
correlations between the CROQ and scales of other HRQoL questionnaires were 
examined to test hypothesised relationships. For example, the CROQ Physical 
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Functioning scale was expected to be more highly correlated with the Physical 
Component Score (PCS) than to the Mental Component Summary Score (MCS) of 
the SF-36. To further evaluate discriminant validity, CROQ scales were correlated 
with demographic variables (age, sex and social class); hypothesised low 
correlations with these variables demonstrate that scores on the CROQ are not 
biased by these demographic factors. 
For CABG, some clinical variables are routinely collected in hospitals for purposes 
of clinical audit. Where possible this information was obtained. Clinical pre-
revascularisation data available for a subsample of CABG patients included: 
Canadian Cardiovascular Society Classifications of angina (CCS76), New York 
Heart Association classifications of dyspnoea (NYHA75), and ejection fractions. 
Correlations between pre-revascularisation CCS and NYHA classifications and the 
CROQ-CABG Symptoms scale and symptom items (chest pain, chest discomfort, 
radiating pain, and nitro frequency) were examined. As few data are routinely 
collected for PTCA, the CROQ-PTCA could not be evaluated against clinical data. 
5.3.5.3.2 Known groups I hypothesis testing (analyses against external criteria). 
One-way ANOVA was used to test differences in mean pre-revascularisation 
CROQ-CABG symptom scores for patients who differed in the severity of angina 
as measured by the CCS, dyspnoea as measured by the NYHA, and heart function 
as measured by ejection fraction. It was hypothesised that CROQ-CABG symptom 
scores would decrease with increasing severity of angina, dyspnoea and heart 
function. Ejection fraction was defined as either good (>50%), fair (30-50%) or 
poor «30%).171 
5.3.6 Responsiveness 
T-statistics, effect sizes389390 and standardised response means391 were calculated 
for all CROQ (and SF-36, SAQ, QLMI-2, LlhFE in the final field test) scales across 
time (pre- and 3-months post-revascularisation). In the final field test, these 
statistics were also calculated between pre- and 9-month post-revascularisation. 
The ability of scales to detect continuing change over time (longitudinal change) 
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was also evaluated between the 3- and 9-month post-revascularisation time 
periods. 
5.4 Summary 
This chapter presented the methods of analyses for the three stages of 
psychometric evaluation of the CROa questionnaires: item reduction, preliminary 
psychometric evaluation and final psychometric evaluation. Chapter 6 presents the 
results of these analyses. 
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CHAPTER 6 
PSYCHOMETRIC EVALUATION OF THE CROQ: RESULTS 
The psychometric properties of the CRDa were evaluated in two field tests: the 
preliminary and final field tests. This chapter presents the results from these two 
field tests. The preliminary field test was undertaken for the purpose of item 
reduction and to perform a preliminary psychometric evaluation. The final field test 
was undertaken to perform a full psychometric evaluation of the CRDa in an 
independent sample, using the same methodology as the preliminary psychometric 
evaluation, but with more extensive testing of extemal construct validity and 
responsiveness. As the results of analyses in the preliminary psychometric 
evaluation are very similar to those of the final psychometric evaluation, this 
chapter reports only results for the final psychometric evaluation, results of the 
preliminary psychometric evaluation are presented in Appendices 6.1 to 6.18. 
6.1 Preliminary field test 
6. 1. 1 Respondent characteristics 
Respondents in the pre-revascularisation CABG sample (N=146) ranged in age 
from 34 to 82 (mean age 63.3 ± 8.7) years, with 22% of the sample 70 years of age 
or over and 74% male (Table 6.1 a). Respondents in the post-revascularisation 
CABG sample (N=289) ranged in age from 35 to 82 (mean age 63.7 ± 9.0) years, 
with 24% of the sample 70 years of age or over and 75% male. Respondents in 
the responsiveness subsample (N=128) had similar demographic characteristics to 
those in the pre- and post-revascularisation samples. The majority of patients in 
each CABG sample were white, retired, males, living with their partner. In each 
sample, patients were recruited from all three hospitals. A large proportion of 
patients reported that they got angina on exertion or at rest at pre-revascularisation 
and these figures fell at 3-months post-revascularisation. 20% of patients reported 
that they had been re-admitted to hospital for reasons to do with their heart 
condition. 
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Respondents in the pre-revascularisation PTCA sample (N=128) ranged in age 
from 36 to 88 (mean age 62.1 ± 9.7) years, with 21 % of the sample 70 years of age 
or over and 67% male (Table 6.1 b). Respondents in the post-revascularisation 
PTCA sample (N=280) ranged in age from 35 to 88 (mean age 62.3 ± 9.8) years, 
with 23% of the sample 70 years of age or over and 69% male. Respondents in 
the responsiveness subsample (N=114) had similar demographic characteristics to 
those in the pre- and post-revascularisation samples. The majority of patients in 
each PTCA sample were white, retired, males, living with their partner. In each 
sample, patients were recruited from all three hospitals. A large proportion of 
patients reported that they got angina on exertion or at rest at pre-revascularisation 
and these figures fell at 3-months post-revascularisation. 19% of patients reported 
that they had been re-adm itted to hospital for reasons to do with their heart 
condition. 
6. 1.2 Response rates 
Questionnaires were considered ineligible if the patient reported that the procedure 
had not been carried out. A few patients reported that their PTCA had been 
started, but not completed due to the nature of the blockage in the arteries. These 
patients were scheduled for PTCA and consequently appear on the procedure lists. 
The validity of these patient reports were not confirmed by checking the patients' 
medical records. 
6.1.2.1 Pre-revascularisation samples 
A total of 257 questionnaires were posted to patients awaiting CABG (Table 6.2). 
Of these, 192 (75%) were returned. Of the 257 questionnaires sent, 186 were 
considered eligible for inclusion; 71 did not actually undergo CABG in the study 
period and so were not considered eligible. Of the 186 eligible patients, 146 
completed and returned questionnaires. The response rate for the CABG pre-
revascularisation sample was thus 78% (146/186). 
A total of 272 questionnaires were posted to patients awaiting PTCA (Table 6.2). 
Of these, 186 (68%) were returned. Of the 272 questionnaires sent, 183 were 
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considered eligible for inclusion; 89 did not actually undergo PTCA in the study 
period and so were not considered eligible. Of the 183 eligible patients, 128 
completed and retumed questionnaires. The response rate for the PTCA pre-
revascularisation sample was thus 70% (128/183). 
6.1.2.2 Post-revascularisation samples 
A total of 358 3-months post-revascularisation questionnaires were sent to patients 
who had undergone CABG (Table 6.3). Of these, 289 (81 %) were retumed. 
Included in this sample of 289 patients were 103 patients who were only sent the 
3-month post-revascularisation CROQ-CABG, 58 patients in the test-retest 
subsample, and 128 patients in the responsiveness sample (see below). 
A total of 341 3-months post-revascularisation questionnaires were sent to patients 
who had undergone PTCA (Table 6.3). Three of these patients were later 
considered ineligible for this study (procedure abandoned. due to nature of 
blockage). Of the 338 eligible patients sent a questionnaire, 280 (83%) retumed it. 
Included in this sample of 280 patients were 109 patients who were only sent the 
3-month post-revascularisation CROQ-PTCA, 57 patients in the test-retest 
subsample, and 114 patients in the responsiveness sample (see below). 
Post-revascularisation only subsamples: A subsample of 122 CABG patients were 
sent a questionnaire only at 3-months post-revascularisation. Of these 122 
patients, 103 (84%) returned the questionnaire. A subsample of 123 PTCA 
patients were sent a questionnaire only at 3-months post-revascularisation. Of 
these 123 patients, 109 (89%) retumed the questionnaire. 
Test-retest subsamples: A subsample of 90 CABG and 90 PTCA patients were 
sent two questionnaires at 3-months post-revascularisation to complete within a 2-
week interval to provide data for test-retest analyses. Of the 90 CABG patients, 58 
(64%) returned both questionnaires. Of the 90 PTCA patients, 57 (63%) retumed 
both questionnaires. 
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Responsiveness samples: Patients who completed both the pre- and post-
revascularisation versions of the CROQ are referred to as the responsiveness 
sample. The 146 CABG patients who completed the pre-revascularisation 
questionnaire were sent a 3-nionth post-revascularisation questionnaire. Of the 
146 patients, 128 (88%) returned it (Table 6.3). This sample of 128 patients is 
referred to as the CABG responsiveness sample. Five of the 146 patients had died 
and three were too sick to complete the questionnaire according to relatives. 
The 128 PTCA patients who completed the pre-revascularisation questionnaire 
were sent a 3-month post-revascularisation questionnaire. Three of these patients 
were later considered ineligible as they notified the Project Co-ordinator that the 
operation had been started but abandoned due to the nature of the blockage in the 
arteries. (Table 6.3) Of the 125 eligible patients in the sample, 114 (91%) returned 
the 3-months post-revascularisation questionnaire and are referred to as the PTCA 
responsiveness sample. 
6. 1.3 Item reduction 
During the item reduction analyses, the pre-revascularisation CROQ was reduced 
from 52 to 32 evaluative items, the post-revascularisation CROQ-CABG from 81 to 
50 evaluative items, and the CROQ-PTCA from 73 to 45 evaluative items. Table 
6.4 summarises the results of the item reduction analyses, showing items that were 
eliminated at each stage of the analysis. 
6.1.3.1 Phase one: item reduction of core pre-I post-revascularisation items 
A total of 20 items were eliminated from the 52 core pre- I post-revascularisation 
evaluative items, leaving a total of 32 evaluative items covering four domains 
(Symptoms - 7 items, Physical Functioning - 8 items, Psychosocial Functioning -
14 items, Cognitive Functioning - 3 items) and one descriptive item (symptoms on 
exertion). Sixteen items were eliminated for failing the following criteria: inter-item 
correlations <.75 (9 items), missing data <5% (1 item), maximum endorsement 
frequencies <75% (4 items), and aggregate adjacent endorsement frequencies 
>10% (2 items). This left a reduced item pool of 36 items. A further four items 
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were eliminated in the two stages of tests of scaling assumptions, leaving a final 
item pool of 32 core pre- I post-revascularisation evaluative items and one 
descriptive item in the CROQ. 
6.1.3.2 Phase two: item reduction of common post-revascularisation only items 
Three of the ten common evaluative items included in both post-revascularisation 
versions of the CROQ were eliminated for failing the following criteria: item-total 
correlations ~.30 (1 item), and inter-item correlations <.75 (2 items). This left a 
reduced item pool of seven evaluative·items (six items in the Satisfaction domain 
and one item about fear of symptoms returning) and one descriptive item (re-
admission to hospital). The item about fear of symptoms returning failed the tests 
of scaling assumptions and so was excluded from the scale. However, this item 
was retained in the CROQ as it was considered important based on the findings of 
the patient interviews. 
6.1.3.3 Phase three: item reduction of procedure-specific complication items 
A total of 8 items were eliminated from the 19 CROQ-CABG complication items. 
Three of the 19 complication items were eliminated for failing the inter-item 
correlations criterion of <.75, leaving a reduced item pool of 16 items. A further five 
items were eliminated when scaling assumptions were tested, leaving an 11-item 
Complications scale in the CROQ-CABG. 
Five items were eliminated from the 11 CROQ-PTCA complication items, leaving a 
6-item Complications scale. Three of the 11 complication items were eliminated for 
failing the following criteria: inter-item correlations <.75 (1 item), and item test-
retest >.40 (2 items), leaving a reduced item pool of 8 items. Two items bruised 
thigh and bruised groin area were inter-correlated .75, just failing the inter-item 
correlation criterion of <.75. Bruised thigh was eliminated from further analyses. 
but it was decided on clinimetric grounds to combine the two items in the final field 
test version. In the qualitative interviews, patients reported the content of both 
items to be problems, and both items had similar psychometric properties with 
neither appearing to be 'better' than the other. A further two items were eliminated 
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when scaling assumptions were tested, leaving a final item pool of six complication 
items in the CROa-PTCA. 
6. 1.4 CROQ (final version) 
Figure 6.1 presents the conceptual model for the final version of the CROa. As a 
result of item reduction analyses the final version of the CROa includes four core 
pre- ,I post-revascularisation scales (Symptoms, Physical Functioning, 
Psychosocial Functioning, Cognitive Functioning) and two post-revascularisation 
scales (Complications, Satisfaction). Analyses did not support the division of items 
into separate scales for psychological and social functioning; empirical evidence 
supported a single scale, Psychosocial Functioning for these items. The evaluative 
item addressing fear of symptoms returning which did not 'fit' in the subscales was 
retained in the CROa and included in the Total Outcome score. The descriptive 
item addressing symptoms on exertion was retained in the Symptoms domain, but 
not scored in the Symptoms scale. The descriptive item addressing readmission to 
hospital was retained in the Adverse effects content domain, but not scored. 
6.1.5 Preliminary psychometric evaluation 
The results of the preliminary psychometric evaluation are similar to those of the 
final psychometric evaluation so results are presented in Appendices 6.1 to 6.18. 
6.2 Final field test 
As there were no major differences in the findings of the preliminary and final 
psychometric evaluations, only the results of the final field test are presented. 
Where minor differences did occur between the findings of the preliminary and final 
psychometric evaluations, these differences are noted. Response frequencies for 
each question on the CROa-CABG and CROa-PTCA at pre-, 3-, and 9-months 
post-revascularisation are presented in Appendices 6.19a to 6.21 b. Values are the 
percent endorsed and not valid percent so not all numbers add up to exactly 100% 
due to missing data and rounding error. 
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6.2. 1 Respondent characteristics 
Respondents in the pre-revascularisation CABG sample (N=281) ranged in age 
from 35 to 85 (mean age 63.6 ± 9.2) years, with 26% of the sample 70 years of age 
or over and 85% male (Table 6.5a). Respondents in the post-revascularisation 
CABG sample (N=415) ranged in age from 37 to 94 (mean age 65.0 ± 8.9) years, 
with 33% of the sample 70 years of age or over and 83% male. Respondents in 
the responsiveness subsample (N=198) had similar demographic characteristics to 
those in the pre- and 3-month post-revascularisation samples. The majority of 
patients in each CABG sample were white, retired, males, living with their partner. 
In each sample, patients were recruited from all three hospitals. The majority of 
patients completed the SF-36 or SAQ as the second questionnaire, with fewer 
completing the QLMI-2 or the LlhFE. Based on occupation, each social class was 
represented in all CABG samples. A large proportion of patients reported that they 
got angina only on exertion or at rest and on exertion at pre-revascularisation and 
these figures fell at 3-months post-revascularisation. 16% of patients reported that 
they had been re-admitted to hospital for reasons to do with their heart condition. 
Respondents in the pre-revascularisation PTCA sample (N=159) ranged in age 
from 38 to 89 (mean age 60.6 ± 9.7) years, with 18% of the sample 70 years of age 
or over and 75% male (Table 6.5b). Respondents in the post-revascularisation 
PTCA sample (N=345) ranged in age from 36 to 84 (mean age 62.3 ± 10.2) years, 
with 25% of the sample 70 years of age or over and 73% male. Respondents in 
the responsiveness subsample (N=107) had similar demographic characteristics to 
those in the pre- and 3-month post-revascularisation samples. The majority of 
patients in each CABG sample were white, retired, males, living with their partner. 
In each sample, patients were recruited from all three hospitals. The majority of 
patients completed the SF-36 or SAQ as the second questionnaire, with fewer 
completing the QLMI-2 or the LlhFE. Based on occupation, all social classes 
except social class V were represented in all PTCA samples. A large proportion of 
patients reported that they got angina only on exertion or at rest and on exertion at 
pre-revascularisation and these figures fell at 3-months post-revascularisation. 
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17% of patients reported that they had been re-adm itted to hospital for reasons to 
do with their heart condition. 
6.2.2 Acceptability 
6.2.2.1 Response rates 
6.2.2.1.1 Pre-revascularisation samples. A total of 408 questionnaires were 
posted to patients awaiting CABG (Table 6.6). Of the 408 questionnaires sent, 407 
were considered eligible for inclusion; one patient reported that they had already 
undergone CABG in another hospital and so were not considered eligible. Of the 
407 eligible patients, 281 completed and returned the questionnaire. The response 
rate for the CABG pre-revascularisation sample was thus 69% (281/407). 
A total of 274 questionnaires were posted to patients awaiting PTCA (Table 6.6). 
Of the 274 questionnaires sent, 270 were considered eligible for inclusion; four 
patients reported that they were only undergoing investigation, not PTCA, and later 
did not appear on the PTCA procedure lists for the date their 'operation' had been 
scheduled. Of the 270 eligible patients, 159 completed and returned the 
questionnaire. The response rate for the PTCA pre-revascularisation sample was 
thus 59% (159/270). 
6.2.2.1.2 Post-revascularisation samples. A total of 509 3-months post-
revascularisation questionnaires were sent to patients who had undergone CABG 
(Table 6.7). Of these. 415 (82%) were returned. Included in this sample of 415 
patients were 167 patients who were only sent the 3-months post-revascularisation 
CROQ-CABG. 50 patients in the test-retest subsample. and 198 patients in the 
responsiveness sample (see below). 
A total of 468 3-months post-revascularisation questionnaires were sent to patients 
who had undergone PTCA (Table 6.7). Four of these patients were later 
considered ineligible for this study (procedure abandoned due to nature of 
blockage). Of the 464 eligible patients sent a questionnaire, 345 (74%) returned it. 
Included in this sample of 345 patients were 190 patients who were only sent the 
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3-months post-revascularisation questionnaire, 48 patients in the test-retest 
subsample, and 107 patients in the responsiveness sample (see below). 
Post-revascularisation only subsamples: A subsample of 223 CABG patients were 
sent a questionnaire only at 3-months post-revascularisation. Of these 223 CABG 
patients, 167 (75%) returned the questionnaire. A subsample of 279 PTCA 
patients were sent a questionnaire only at 3-months post-revascularisation. Four 
of these 279 PTCA patients were subsequently considered ineligible as they 
reported that the procedure had not been completed due the nature of the 
blockage in the arteries. Of the 275 eligible patients, 190 (69%) returned the 
questionnaire. 
Test-retest subsamples: A subsample of 70 CABG and 70 PTCA patients were 
sent two questionnaires at 3-months post-revascularisation to complete within a 2-
. week interval to provide data for test-retest analyses. Of the 70 CABG patients, 50 
(78%) returned both questionnaires. Of the 70 PTCA patients, 48 (69%) returned 
both questionnaires. 
Responsiveness samples: 216 of the 281 patients who completed and returned 
the pre-revascularisation version of the CROa underwent CABG in the study 
period and were sent a 3-months post-revascularisation questionnaire. Of the 216 
patients, 198 (92%) returned the questionnaire (Table 6.7). This sample of 198 
patients is referred to as the CABG responsiveness sample. Two of the 281 
patients had died and one was too sick to complete the questionnaire according to 
relatives. 
119 of the 159 patients who completed and returned the pre-revascularisation 
version of the CROa underwent PTCA in the study period were sent a 3-months 
post-revascularisation questionnaire. Of the 119 patients, 107 (90%) returned the 
questionnaire (Table 6.7). This sample of 107 patients is referred to as the PTCA 
responsiveness sample. 
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6.2.2.2 Item and scale non-response 
As shown in Tables 6.8a-6.9b, the proportion of missing data for each item is low, 
ranging from 0 - 7.1 % in the pre- and post-revascularisation versions of the 
CROa. In the preliminary field test, the proportion of missing data was less than 
5% for all items. Scale non-response was also low in both pre- and post-
revascularisation samples (Table 6.10 and 6.11); scale scores could be calculated 
for 95-100% of patients. 
6.2.2.3 Item floor and ceiling effects 
Analysis of item endorsement frequencies for the pre- and post-revascularisation 
versions of the CROa (Table 6.8a to 6.9b) show responses to be well distributed 
across response categories, with all response categories used. There were no 
marked floor or ceiling effects in the pre-revascularisation samples. However, as 
expected, there were noticeable ceiling effects in the post-revascularisation 
sample, i.e. higher endorsement frequencies for the response categories 
representing more favourable health states. 
6.2.2.4 Scale floor and ceiling effects 
Table 6.10 presents descriptive statistics for CROa pre-revascularisation scale 
scores. The full range of the score distribution was observed for all scales in the 
CABG and PTCA samples. All scale scores showed substantial variability 
suggesting that they cover all important levels of the constructs they measure. 
There were no large scale floor or ceiling effects, as only a small percentage of 
respondents endorsed the bottom (zero) and top (100) of the scale score ranges. 
The only exception was the Cognitive Functioning scale where the top of the scale 
was endorsed by 18% of CABG patients and 21 % of PTCA patients. This result 
was consistent with that of the preliminary field test and is not surprising, as not all 
patients report cognitive problems. Pre-revascularisation scale scores were not 
heavily skewed, with all skew values falling in the range +1 to -1. 
Table 6.11 presents descriptive statistics for the CROa post-revascularisation 
scale scores. The full range of the score distribution was observed for two of the 
150 
six scales of the CROQ-CABG (Physical! and Cognitive Functioning) and for five of 
the six CROQ-PTCA scales (Symptoms, Physicall and Cognitive/ Functioning, 
Satisfaction and Complications). All scale scores showed substantial variability 
suggesting that they cover all the important levels of the constructs they measure. 
There were no scale floor effects in either of the post-revascularisation samples. 
No criteria were set for scale ceiling effects in the post-revascularisation samples 
as ceiling effects were expected after revascularisation. There were moderate 
scale ceiling effects for the Symptoms (21% and 13%), Physical Functioning (28% 
and 24%), Cognitive Functioning (5% and 30%) and Satisfaction (1% and 21%) 
scales in the CROQ-CABG and CROQ-PTCA respectively, reflecting good 
outcomes in these domains at 3-months post-revascularisation. There was a very 
large ceiling effect for the Complications scale in the PTCA sample (62%). This 
ceiling effect was expected at 3-months after PTCA, as complications are short-
lasting in comparison to those of CABG where there was a very small ceiling effect 
(4%). These results are consistent with the findings in the preliminary field test. 
Table 6.11 also shows that all the scales were heavily negatively skewed in the 
CABG sample indicating more respondents scoring more favourable outcomes 
after coronary revascularisation. In the PTCA sample, the scale scores were less 
heavily skewed with the exception of the Complications scale. For both the CABG 
and PTCA samples, mean post-revascularisation scores for the four core pre- / 
post-revascularisation scales (Symptoms, Physicall, Psychosociall, and Cognitive 
Functioning) were higher than they were at pre-revascularisation (Tables 6.10 and 
6.11 ), suggesting improvement in these domains after treatment for both 
procedures. 
6.2.3 Reliability 
6.2.3.1 Internal consistency 
Cronbach's alpha coefficients for all pre- and post-revascularisation scales of the 
CROQ exceeded the criterion of >.70 (Tables 6.12 and 6.13). All coefficients are 
>.80 in all samples indicating excellent internal consistency. 
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The homogeneity of the CROQ was evaluated on the basis of item-total 
correlations. Item-total correlations within each scale of the CROQ were similar 
(Tables 6.8 and 6.9), indicating that each item was contributing equally to the scale 
construct. Tables 6.12 and 6.13 present the range and mean of the item-total 
correlations within each scale of the pre- and post-revascularisation versions of the 
CROQ. The range of item-total correlations within each scale is small and the 
mean item-total correlations are moderate to high. All item-total correlations are 
above the criterion of ~.30, except infection in the chest wound. The item-total 
correlation for this item was .25 in the CROQ-CABG Complications scale and .19 
in the Total Outcome score. One possible reason for this is that only a few patients 
reported that they were bothered by infection in the chest wound, whereas reports 
of the other complications were more common. This item passed the criterion of 
.30 in the preliminary field test. The item was retained on grounds of clinical 
importance. 
Tables 6.12 and 6.13 also present the range and mean inter-item correlations for 
each scale in the pre- and post-revascularisation samples. In the pre-
revascularisation samples, mean inter-item correlations for the scales range from 
.39 to .78 for the CROQ-CABG .47 to .79 for the CROQ-PTCA. In the post-
revascularisation samples, mean inter-item correlations for the scales range from 
.28 to .73 for the CROQ-CABG .33 to .80 for the CROQ-PTCA. 
6.2.3.2 Test-retest reliability 
Intraclass correlation coefficients were greater than the criterion of >.70 for all 
scales of the CROQ, indicating excellent test-retest reliability (Table 6.13). The 
CROQ-CABG Complications scale just failed the criterion of >.70 in the preliminary 
psychometric evaluation (ICC=.68), but demonstrated excellent reproducibility in 
the final field test (ICC=.83). It is possible that some CABG patients in the 
preliminary field test sample were still experiencing change in the bothersomeness 
of complications at 3-months after CABG. 
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6.2.4 Tests of assumptions for summated-rating 
The item-response distributions for all items within each scale in the pre- and post-
revascularisation samples are presented in Tables 6.8a-6.9b. Item response 
distributions are similar for all ite'ms within each scale for each of the pre- and post-
revascularisation samples. Item means and standard deviations within each scale 
were similar; for example means range between 1.54 to 2.52 for the Physical 
Functioning scale in the CABG pre-revascularisation sample (Table 6.8a). For the 
great majority of items, the values of the standard deviations fell within two tenths 
of a unit with only a few discrepancies. Tables 6.8a-6.9b also present item-total 
correlations for each of the scales. With the exception of the Symptoms and 
Complications scales, the item-total correlations within each scale were "roughly 
equal" indicating that they are all contributing to the underlying construct and that 
equal weights can be applied to all items within the scale when scoring. These data 
support the assumption that items can be summed to form scales without 
standardisation or weights. Item-total correlations in the Symptoms and 
Complications scales demonstrated a slightly wider range of values. 
Six scales were calculated (Symptoms, Physicall, Psychosocial/, and Cognitive 
Functioning, Satisfaction and Complications). Two total scores were also 
calculated: the Core Total which is comprised of the 32 core pre- I post-
revascularisation items, and the Total Outcome score which is comprised of the 
post-revascularisation Satisfaction and Complication items plus one additional item 
which is not included in the subscales (symptoms return). 
6.2.5 Tests of scaling assumptions 
Tables 6.14a - 6.15b present item convergent and discriminant correlations for the 
CROQ in the pre- and post-revascularisation samples. These data were used to 
test scaling assumptions and to confirm the robustness of the scales identified from 
item reduction analyses. In all samples, the great majority of items were definite 
scaling successes, a few were probable scaling successes and very few were 
probable scaling failures; none of the items were definite scaling failures. A 
consistent finding across most samples was that shortness of breath was more 
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highly correlated with the Physical Functioning scale than to the Symptoms scale. 
This is probably because shortness of breath is induced on physical exertion. It 
was decided to retain this item in the Symptoms scale for clinimetric reasons. 
In general, there were slightly more definite scaling successes in each of the 
samples in the preliminary field test. In the CABG pre-revascularisation samples, 
28 and 22 items were definite scaling successes in the preliminary and final field 
tests, respectively. In the PTCA pre-revascularisation samples, 24 and 19 items 
were definite scaling successes in the preliminary and final field tests, respectively. 
In the CABG post-revascularisation samples, 44 and 40 items were definite scaling 
successes in the preliminary and final field tests, respectively. In the PTCA post-
revascularisation samples, 39 and 40 items were definite scaling successes in the 
preliminary and final field tests, respectively. 
6.2.5.1 Pre-revascularisation 
Table 6.14a presents the item convergent and discriminant correlations for the 32 
core evaluative items in the pre-revascularisation CABG sample. 21 of the 32 
items were definite scaling successes, 10 were probable scaling successes, and 1 
was a probable scaling failure (shortness of breath). The Cognitive Functioning 
scale achieved a scaling success rate of 100%. Shortness of breath was also a 
probable scaling failure in the preliminary field test. 
Table 6.14b presents the item convergent and discriminant correlations for the 32 
core evaluative items in the pre-revascularisation PTCA sample. 19 of the 32 
items were definite scaling successes, 11 were probable scaling successes and 2 
were probable scaling failures (shortness of breath and palpitations). It is possible 
that the small sample size (N=159) contributed to this pattern. Palpitations and 
shortness of breath were retained in the Symptoms scale for clinimetric reasons; 
these two items were probable scaling successes in the preliminary field test. The 
Cognitive Functioning scale achieved a scaling success rate of 100%. 
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6.2.5.2 Post-revascularisation 
Table 6.15a presents item convergent and discriminant correlations for all CROO-
CABG evaluative items in the post-revascularisation sample. 40 of the 49 items 
were definite scaling successes, 8 were probable scaling successes and 1 was a 
probable scaling failure (shortness of breath). The Physical Functioning scale 
achieved a scaling success rate of 100%. In the preliminary field test shortness of 
breath was a probable scaling success and overall was a probable scaling failure. 
The item, overall, is a global item, which one would expect to be correlated with 
other domains. 
Table 6.15b presents item convergent and discriminant correlations for all CROO· 
PTCA evaluative items in the post-revascularisation sample. 40 of the 44 items 
were definite scaling successes, 3 were probable scaling successes and 1 was a 
probable scaling failure (shortness of breath). The Physical Functioning, Cognitive 
Functioning and Complications scales achieved a scaling success rate of 100%. In 
the preliminary field test shortness of breath was a probable scaling success. 
6.2.6 Validity 
i 6.2.6.1 Content validity 
The content validity of the CROO was confirmed during the development of the 
questionnaires through expert opinion from clinicians, interviews with patients, a 
comprehensive literature review, and comparison with existing measures. 
Inspection of the responses made to the open-ended question in the preliminary 
field test, ("ls there anything else you would like to tell us about your heart 
condition or heart operation that is not covered in this questionna;re?'~ confirmed 
that no important issues had been excluded. The most common responses 
concerned the long wait prior to revascularisation and the associated anxiety, 
details of medication and medical history, and appreciation for care received. 
None of these issues addressed missing content from the questionnaires indicating 
that the content validity of the CROO is acceptable from the patient's perspective. 
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No comments were made about the impact of CHD or CABG/PTCA on sexual 
functioning thus confirming the decision to exclude this domain from the CROQ. 
6.2.6.2 Construct validity: within scale analyses 
6.2.6.2.1 Internal consistency. Evidence of excellent internal consistency for all 
scales supports the construct validity of the CROQ. Moderately high item-total 
correlations and high Cronbach's alpha coefficients (Tables 6.12 and 6.13) indicate 
that a single construct is being measured and that the items can be combined into· 
scales. 
6.2.6.2.2 Intercorrelations between scales. Tables 6.16 and 6.17 present 
intercorrelations between CROQ scales and total scores for the pre- and post-
revascularisation samples, respectively. 
Pre-revascu/arisation: In both pre-revascularisation samples, each of the four 
CROQ core scales were moderately to highly correlated with the Core Total score 
(Table 6.16). The Cognitive Functioning scale was least highly correlated with the 
Core Total score; this was expected as this scale has only 3 items. In both 
samples, the correlations between the scales and the Core Total score were higher 
than the inter-scale correlations, supporting the convergent validity of all the 
scales. 
Table 6.16 shows moderate correlations between each of the scales in the pre-
revascularisation samples (ranging from .41 to .71 and .51 to .74 in the CROQ-
CABG and CROQ-PTCA, respectively). These values indicate that the scales are 
measuring different, but related constructs. There was also evidence of unique 
reliable variance indicated by ·reliability coefficients for each scale being greater 
than each of the inter-scale correlations. In both pre-revascularisation samples, the 
highest inter-scale correlation was between Physical Functioning and Symptoms 
(.71 and .74 for the CROQ-CABG and CROQ-PTCA, respectively) and the lowest 
inter-scale correlation was between Symptoms and Cognitive Functioning (.41 and 
.51 for the CROQ-CABG and CROQ-PTCA, respectively). These results support 
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the division of items into scales as one would expect scales measuring related 
health constructs to be moderately correlated and scales measuring different 
constructs to be less highly correlated. 
Post-revascularisation: In the post-revascularisation samples, each of the four 
CROO core scales was highly correlated with the Core Total score, and each of the 
post-revascularisation only scales {Satisfaction and Complications} was highly 
correlated with the Total Outcome score {Table 6.17}. Each scale was more highly 
correlated with its own total score than to the other scales, supporting the 
convergent validity of the scales. 
Table 6.17 shows moderate correlations between each of the scales in the post-
revascularisation samples {ranging from .28 to .69 and .23 to .71 in the CROO-
CABG and CROO-PTCA, respectively}. These scales are clearly measuring 
different, but related constructs. There was also evidence of unique reliable 
variance indicated by reliability coefficients for each scale being greater than each 
of the inter-scale correlations. 
if In the CABG post-revascularisation sample, the highest inter-scale correlations 
were between Cognitive Functioning and Psychosocial Functioning {.69}, Physical 
Functioning and Symptoms {.63} and Psychosocial Functioning and Physical 
Functioning (.63). The lowest inter-scale correlations were between Cognitive 
Functioning and Satisfaction (.28), Complications and Satisfaction (.43), and 
Cognitive Functioning and Complications (.44). In the PTCA post-revascularisation 
sample, the highest inter-scale correlations were between Physical Functioning 
and Symptoms {.71}, Psychosocial Functioning and Physical Functioning {.67}, and 
Psychosocial Functioning and Cognitive Functioning (.64). The lowest inter-scale 
correlations were between, Complications and Physical Functioning (.23), 
Complications and Satisfaction (.28), Complications and Symptoms (.31), and 
Cognitive Functioning and Satisfaction (.31). These correlations followed the 
expected pattem with the exception of the moderately high correlation between 
Physical Functioning and Psychosocial Functioning {.63 and .67 in the CROO-
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CABG and CROQ-PTCA, respectively). This finding was consistent with the 
findings in the preliminary psychometric evaluation of the post-revascularisation 
CROQ-PTCA. 
6.2.6.2.3 Factor analysis. Principal axis factor analysis with Varimax rotation was 
performed on the 32 core pre- I post-revascularisation evaluative items of the 
CROQ, both at pre- and post-revascularisation in the CABG and PTCA samples 
(Tables 6.18a to 6.19b). Separate factor analyses were carried out on the post-
revascularisation only items (Tables 6.20a and b). The principal axis factoring was 
modelled on four factors for the core 32-item pool and modelled on two factors for 
the post-revascularisation only items (18-item CABG pool and 13-item PTCA pool). 
Findings supported the CROQ's scale structure. A consistent finding throughout 
the factor analyses was that Psychologicall and Social Functioning were not 
separate constructs as originally proposed; items in these two domains loaded on 
to just one factor, the Psychosocial Functioning factor. 
Pre-revascularisation: The principal axis factor analysis of the 32 core items in the 
CABG pre-revascularisation sample produced four clear factors:' Symptoms, 
Physical Functioning, Cognitive Functioning, and Psychosocial Functioning (Table 
6.18a). Tests of sampling adequacy (Kaiser-Meyer-Olkin =.95) and sphericity 
(Bartlett's test of sphericity =.000) were acceptable. The four-factor solution 
accounted for 59% of the variance. Six items cross loaded onto another factor with 
a difference <.20, but five of these loaded higher on their 'hypothesised factor'. 
Shortness of breath loaded higher on the Physical Functioning factor than 
Symptoms, as it did in the preliminary field test. 
The principal axis factor analysis of the 32 core items in the PTCA pre-
revascularisation sample also produced four clear factors: Symptoms, Physical 
Functioning, Cognitive Functioning, and Psychosocial Functioning (Table 6.18b). 
Tests of sampling adequacy (Kaiser-Meyer-Olkin =.94) and sphericity (Bartlett's 
test of sphericity =.000) were acceptable. The four-factor solution accounted for 
61 % of the variance. Six items cross loaded onto another factor with a difference 
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<.20, but five of these were more highly correlated with their 'hypothesised' factor. 
Shortness of breath loaded higher on the Physical Functioning factor than 
Symptoms; this did not occur in the preliminary field test. 
Post-revascularisation: The principal axis factor analysis of the 32 core items in, 
the CABG post-revascularisation sample produced four clear factors: Symptoms, 
Physical Functioning, Cognitive Functioning, and Psychosocial Functioning (Table 
6.19a). Tests of sampling adequacy (Kaiser-Meyer-Olkin =.95) and sphericity 
(Bartlett's test of sphericity =.000) were acceptable. The four-factor solution 
accounted for 58% of the variance. Four items cross loaded onto another factor 
with a difference <.20, three items loaded higher on the 'wrong' factor (shortness of 
breath, trouble, restricteci) , and overprotective did not load on a factor >.35. The 
factor solution in the final field test was considerably clearer than in the prelim inary 
field test. In the preliminary field test, only two clear factors were identified 
(Symptoms and Physical Functioning) with some overlap between the Cognitive 
Functioning and Psychosocial Functioning items (Appendix 6.12a). ' This finding 
questioned the construct validity of the Psychosocial Functioning and Cognitive 
Functioning scales, but evidence from further psychometric testing provided 
I. evidence that these scales do measure separate constructs. 
The prinCipal axis factor analysis of the 32 core items in the PTCA post-
revascularisation sample produced four clear factors: Symptoms, Physical 
Functioning, Cognitive Functioning, and Psychosocial Functioning (Table 6.19b). 
Tests of sampling adequacy (Kaiser-Meyer-Olkin =.96) and sphericity (Bartlett's 
test of sphericity =.000) were acceptable. The four-factor solution accounted for 
65% of the variance. Four items cross loaded onto another factor with a difference 
<.20, but three of these were more highly correlated with their 'hypothesised' 
factor. Shortness of breath loaded higher on the Physical Functioning factor than 
Symptoms. In the preliminary field test, palpitations did not load on a factor >.35, 
but was retained in the Symptoms scale for clinimetric reasons; in the final field test 
palpitations did load on the Symptoms factor. 
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The principal axis factor analysis of the 18 CABG post-revascularisation only items 
produced two clear factors (Satisfaction and Complications) with no items cross 
loading (Table 6.20a). Tests of sampling adequacy (Kaiser-Meyer-Olkin =.85) and 
sphericity (Bartlett's test of sphericity =.000) were acceptable. The two-factor 
solution accounted for 36% of the variance. Infection in the chest wound did not 
load on a factor >.35 in the final field test, but did in the preliminary field test. As 
previously described, few patients reported bothersomeness from this 
complication. 
The principal axis factor analysiS of the 13 PTCA post-revascularisation items 
produced two clear factors (Satisfaction and Complications) with no items cross 
loading on more than one factor (Table 6.20b). Tests of sampling adequacy 
(Kaiser-Meyer-Olkin =.82) and sphericity (Bartlett's test of sphericity =.000) were 
acceptable. The two-factor solution accounted for 47% of the variance. In the 
preliminary field test, concern over bruises did not load on a factor >.35, but was 
retained in the Complications scale; in the final field test it loaded .61 on the 
Complications factor. 
;, The item symptoms return inconsistently loaded on either the Complications scale, 
the Satisfaction scale, or both across all the samples and was therefore excluded 
from the subscales, but it was included in the Total Outcome score as it was 
considered an important item. 
6.2.6.2.4 Known group differences I hypothesis testing (within scale analyses). 
Evidence in support of the construct validity of the CROO was demonstrated 
through tests of hypotheses for known groups. 
Table 6.21 presents mean scores for patients who reported global improvement in 
their heart condition at 3-months post-revascularisation compared with those who 
reported no improvement. As hypothesised, those who reported global 
improvement scored higher (better health outcomes) on all eROa scales than 
those who reported no improvement. These scores were Significantly higher 
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(p<.05) for all except the Cognitive Functioning (p=.251) and Complications 
(p=.057) scales in the CROQ-CABG, and for all scales in the CROQ-PTCA. These 
findings were supported in the preliminary field test; all scales (except the CROQ-
CABG Complications scale, p=.338) demonstrated significant differences between 
these two groups for the CABG and PTCA samples. 
Table 6.22 presents mean post-revascularisation scores for patients who reported 
being bothered by chest pain due to angina at 3-months post-revascularisation, 
versus those not at all bothered. As hypothesised, all CROQ scores were 
significantly lower (p<.05) for patients who reported that they were bothered by 
chest pain at 3-months post-revascularisation. 
6.2.6.3 Construct validity: comparison with extemal criteria 
Tables 6.23 to 6.31 present the comparison of the CROQ against external criteria: 
HRQoL questionnaires (SF-36, SAQ, QLMI-2, LlhFE), demographics (age, sex, 
social class), and clinical variables (CCS, NYHA, and ejection fraction). 
6.2.6.3.1 Convergent and discriminant validity (pre-revascularisation). Tables 
:' 6.23 and 6.24 present convergent and discriminant correlations between the 
CROQ and the SF-36, SAQ, QLMI-2 and the LlhFE in the CABG and PTCA pre-
revascularisation samples. The CROQ demonstrated the expected relationship 
with the SF-36 Summary Component Scores at pre-revascularisation (Table 6.23). 
The convergent and discriminant validity of the CROQ were demonstrated by 
Symptoms (.71 and .66) and Physical Functioning (.75 and .81) being more highly 
correlated than Psychosocial Functioning (.38 and .53) and Cognitive Functioning 
(.29 and .35) with the SF-36 Physical Component Summary Score (PCS) in both 
the CABG and PTCA pre-revascularisation samples, respectively. Similarly, 
Psychosocial Functioning (.70 and .60) and Cognitive Functioning (.58 and .57) 
were more highly correlated than Symptoms (.34 and .31) and Physical 
Functioning (.22 and .31) with the SF-36 Mental Component Summary Score 
(MCS) in both the CABG and PTCA pre-revascularisation samples, respectively. 
The CROQ Core Total score was moderately correlated with the PCS and MCS in 
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both the CABG and PTCA samples, reflecting its physical and mental health 
components. Correlations between the CROQ and the SF-36 Summary 
Component Scores are moderate as one would expect between generic and 
disease-specific questionnaires. 
Table 6.24 presents correlations between the CROQ and each of the eight SF-36 
dimension scores. This table presents additional data in support of the construct 
validity of the CROQ at pre-revascularisation. The Symptoms and Physical 
Functioning scales of the CROQ were more highly correlated with the SF-36 
dimension scores measuring physical aspects of health (convergent validity) than 
to the dimensions measuring mental aspects of health (discriminant validity). 
Similarly, the Psychosocial Functioning and Cognitive Functioning scales were 
more highly correlated with the SF-36 dimension scores measuring mental rather 
than physical aspects of health. 
Table 6.23 presents further evidence supporting the construct validity of the CROQ 
at pre-revascularisation through its relationship with other disease-specific 
questionnaires. The Physical Functioning scale of the CROQ-CABG and CROQ-
~ PTCA was highly correlated with the SAQ Exertional Capacity scale (.90) 
supporting the construct validity of this scale. These scales are similar in content 
so one would expect them to be highly correlated .. The CROQ Symptoms scale 
was moderately to highly correlated with the SAQ Anginal Frequency scale (.78) 
supporting the construct validity of this scale. As these scales have slightly 
different content (frequency of chest pain and bothersomeness of cardiac 
symptoms), they were not expected to be too highly correlated. The Core Total 
score of the CROQ-CABG and CROQ-PTCA was very highly correlated with the 
QLMI-2 Global (.82 and .90) and LlhFE Total (-.94 and -.93) scores, suggesting 
that the CROQ is measuring the overall impact of heart disease including both 
mental and physical components. As some of the items in the CROQ were derived 
from the QLMI-2, high correlations were expected. 
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Table 6.25 presents correlations between the CROa and age, sex and social class 
in the pre-revascularisation samples. All coefficients were low (less than the 
criterion of .40) indicating good discriminant validity. Responses to the CROa 
were not strongly influenced by age, sex or social class at pre-revascularisation. 
Table 6.26 presents further evidence of the convergent validity of the CROa-CABG 
at pre-revascularisation through correlations between pre-revascularisation CROa-
CABG item and scale scores and the CCS and NYHA classifications of angina and 
dyspnoea. CROa-CABG item and scale scores were only moderately correlated 
with these clinical classifications of disease severity «.40). Correlations of this 
magnitude between clinician and patient reports of symptom severity are common. 
6.2.6.3.2 Convergent and discriminant validity (post-revascularisation). Tables 
6.27 and 6.28 present convergent and discriminant correlations between the 
CROa and the SF-36, SAa, aLMI-2 and LlhFE in the CABG and PTCA post-
revascularisation samples. The CROa demonstrated the expected relationship 
with the SF-36 Summary Component Sccires at post-revascularisation (Table 6.27). 
The convergent and discriminant validity of the CROa were demonstrated by 
i Symptoms (.60 and .68) and Physical Functioning (.75 and .75) being more highly 
correlated than Psychosocial Functioning (.59 and .49) and Cognitive Functioning 
(.46 and .49) with the SF-36 PCS in both the CABG and PTCA pre-
revascularisation samples, respectively. Similarly, Psychosocial Functioning (.64 
and .73) and Cognitive Functioning (.46 and .49) were more highly correlated than 
Symptoms (.36 and .32) and Physical Functioning (.36 and .37) with the SF-36 
MCS in both the CABG and PTCA pre-revascularisation samples, respectively. 
The CROa Core Total score was moderately correlated with the PCS and MCS in 
both the CABG and PTCA samples, reflecting its physical and mental health 
components. Again, correlations between the CROa and the SF-36 Summary 
Component Scores were moderate as expected. 
Table 6.28 presents correlations between the CROa and each of the eight SF-36 
dimension scores at post-revascularisation and provides additional data in support 
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of the construct validity of the CROQ. As in the pre-revascularisation samples, the 
Symptoms and Physical Functioning scales of the CROQ were more highly 
correlated with the SF-36 dimension scores measuring physical aspects of health 
(convergent validity) than with the dimensions measuring mental aspects of health 
(discriminant validity). Similarly, the Psychosocial Functioning and Cognitive 
Functioning scales were more highly correlated with the SF-36 dimension scores 
measuring mental rather than physical aspects of health. 
Table 6.27 presents further evidence supporting the construct validity of the CROQ 
at post-revascularisation through its relationship with other disease-specific 
questionnaires. The Physical Functioning scale of the CROQ-PTCA was highly 
correlated with the SAQ Exertional Capacity scale (.90) supporting the construct 
validity of this scale. The correlation was noticeably smaller with the CROQ-CABG 
. . 
(.67), a relationship which was not observed at pre-revascularisation. The CROQ 
Symptoms scale was moderately to highly correlated with the SAQ Anginal 
Frequency scale supporting the construct validity of this scale (.74 and .86 for the 
CABG and PTCA samples, respectively). The CROQ's Satisfaction scale was 
moderately to highly correlated with the SAQ's Treatment Satisfaction scale (.65 
: and. 72) in the CABG and PTCA samples, respectively. High correlations between 
these scales were not expected as the CROQ measures satisfaction with the 
outcome of revascularisation and information received and the SAQ measures 
satisfaction with care and treatment. The Core Total score of the CROQ-CABG 
and CROQ-PTCA was highly correlated with the QLMI-2 Global (.92 and .89) and 
LlhFE Total (-.87 and -.74) scores, once again suggesting that the CROQ is 
measuring the overall impact of heart disease including both mental and phYSical 
components. 
Tables 6.29 presents correlations between the CROQ and age, sex and social 
class in the post-revascularisation samples. All coefficients were low (less than the 
criterion of .40) indicating good discriminant validity. Responses to the CROQ 
were not strongly influenced by age, sex or social class at post-revascularisation. 
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6.2.6.3.3 Known groups I hypothesis testing (analyses against external criteria). 
Table 6.30 presents mean pre-revascularisation CROQ-CABG symptom scores for 
each grade of angina (CCS), dyspnoea (NYHA), and ejection fraction. As 
hypothesised, mean CROQ-CABG symptom scores were significantly lower 
(reflecting poor health outcomes) for patients with more severe angina (p<.005) 
and dyspnoea (p<.033). Although, CROQ-CABG symptom scores were lower for 
patients with poor ejection fraction, this difference was not significant. 
6.2.7 Responsiveness 
Effect sizes and standardised response means are presented for all 
responsiveness analyses, but to summarise the results, this section focuses on the 
effect sizes and describes any noticeable differences when standardised response 
means are used. Table 6.31 presents mean pre- and 3-months post-
revascularisation scores for the CROQ. All CROQ scales showed significant 
change between pre- and 3-months post-revascularisation (p<.05). Large effect 
sizes were observed for CROQ-CABG Symptoms (2.83), Physical Functioning 
(1.47) and Psychosocial Functioning (1.53), but only a moderate effect size for 
Cognitive Functioning (0.67). A large effect size was observed for CROQ-PTCA 
Symptoms (0.99), moderate effect sizes for Physical Functioning (0.66) and 
Psychosocial Functioning (0.67), and a small effect size" for Cognitive Functioning 
(0.24). The standardised response means showed a similar pattern in both" 
samples. Figures 6.2 and 6.3 are graphical presentations of pre- and post-
revascularisation CROQ-CABG and CROQ-PTCA scores for the responsiveness 
subsamples. 
Effect sizes reflect both the responsiveness of the CROQ and the effectiveness of 
treatment i.e. CABG or PTCA. As some patients did not report global improvement 
and coronary revascularisation is not always successful in alleviating symptoms 
and problems associated with CHD, the responsiveness analyses were repeated 
on a subsample of patients who reported global improvement to determine the 
responsiveness of the CROQ (Table 6.32). As expected, effect sizes for the 
CROQ-PTCA increased after excluding 22% of the sample who did not report 
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global improvement after PTCA; large effect sizes were observed for three of the 
four core scales. However, the expected pattern was not observed for the CROQ-
CABG when just 8% of the sample who did not report global improvement were 
excluded. Effect sizes for the CROQ-CABG were lower for this subsample than for 
the whole responsiveness CABG sample, but were of the same magnitude, i.e. 
moderate or large. There is no obvious reason for these unexpected results. 
Standardised response means did however increase in value (but not magnitude) 
when those who did not report global improvement were excluded (i.e. followed the 
expected pattern). In the preliminary field test, all effect sizes and standardised 
response means increased in value when performed on the CABG and PTCA 
subsamples who reported global improvement. 
Table 6.33 presents mean pre- and 9-months post-revascularisation scores for the 
CROQ. All CROQ scales showed significant change between pre and 9-months 
post-revascularisation (p<.05). Large effect sizes were observed for all CROQ-
o '. • ' 
CABG scales: Symptoms (1.87), Physical Functioning (1.61), Psychosocial 
Functioning (1.43), and Cognitive Functioning (0.81). A similar pattern was 
observed for the standardised response means, but Cognitive Functioning 
"demonstrated only a moderate effect (0.66). Large effect sizes were observed for 
CROQ-PTCA Symptoms (0.95), moderate for Physical Functioning (0.63) and 
Psychosocial Functioning (0.64), and small for Cognitive Functioning (0.33). 
Standardised response means were of the same magnitude. Effect sizes and 
standardised response means between pre- and 9-months post-revascularisation 
are of the same magnitude as observed at 3-months post-revascularisation for 
each scale, except Cognitive Functioning in the CROQ-CABG. Cognitive 
Functioning demonstrated a large effect size (0.81) at 9-months post-
revascularisation and only a moderate effect size (0.67) at 3-months post-
revascularisation, in the CABG sample indicating that cognitive functioning 
improved between 3- and 9-months post-revascularisation. There was a 
noticeably smaller effect size for CROQ-CABG Symptoms between pre- and 9-
months post-revascularisation (1.87) than between pre- and 3-months post-
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revascularisation (2.83), but this difference is less dramatic using the standardised 
response means (1.39 and 1.56). 
Table 6.34 presents mean CROO change scores for patients who reported global 
improvement in their heart condition after revascularisation compared with those 
who did not report improvement. As expected, CROO mean change scores were 
significantly higher (p<.05) for those who reported that their heart condition was 
better overall 3-months post-revascularisation than for those who did not report 
improvement for the CABG and PTCA samples. The same pattern was observed 
at 9-months post-revascularisation. Some caution should be paid in interpreting 
these results as sample sizes are small for the unimproved groups. 
Table 6.35 presents longitudinal change in CROO scores over time between 3- and 
9-months post-revascularisation. Only very small effect sizes were observed for all 
CROO scales between 3- and 9-months post-revascularisation, except for CROO-
CABG Complications. This indicates that there was little change (improvement or 
deterioration) in these domains between 3- and 9-months post-revascularisation. 
However, CROO-CABG Complications demonstrated Significant change (p<.05) 
··reflected in a moderate effect size (0.53); CABG patients continued to be bothered 
by complications between 3- and 9-months post-revascularisation reflecting the 
length of time these problems can persist. Satisfaction scores remained stable 
over this period, with almost no differences between scores at these two time 
pOints. 
6.2.7.1 Relative responsiveness 
Tables 6.37 to 6.39 present the relative responsiveness of the CROO, SF-36, and 
SAO. This section describes differences in effect sizes for the CROO, SF-36 and 
SAO for scales measuring similar constructs. Table 6.36 shows larger effect sizes 
for the Symptoms (2.50 and 0.97) and Physical Functioning (1.19 and 0.73) scales 
of the CROO than for the SF-36 PCS (0.85 and 0.56) in the CABG and PTCA 
samples, respectively. The standardised response means showed a similar 
pattern with the exception of the CROO-PTCA Physical Functioning scale (0.70) 
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which is of similar magnitude to the SF-36 PCS (0.75). Similarly, a larger effect 
size and standardised response mean was demonstrated for the Psychosocial 
Functioning scale of the CROQ (1.52 and 0.64) than for the SF-36 MCS (0.67 and 
, 
0.07), in the CABG and PTCA samples, respectively. These data demonstrate the 
superior responsiveness of the disease-specific CROQ compared with the generic 
SF-36 in the CABG (n=72) and PTCA (n=38) samples, who completed both . 
questionnaires at pre- and 3-months post-revascularisation. 
Table 6.37 presents effect sizes and standardised response means for each of the 
eight SF-36 dimension scores. Large effect sizes were observed in the CABG 
sample for the Physical Functioning (1.14), Vitality (0.89), and Social Functioning 
(0.83) scales, but in the PTCA sample these scales only demonstrated small to 
moderate effect sizes (0.42, 0.56, 0.27, respectively). Very small effect sizes were 
observed for the Role-Emotional (0.14) and Mental Health (0.13) dimensions in the 
PTCA sample, contrasting greatly with the effect size of 0.64 observed for the 
CROQ Psychosocial Functioning scale in the PTCA sample. 
Table 6.38 presents the relative responsiveness of the CROQ and the SAQ. Large 
effect sizes and standardised response means of similar magnitude were observed 
for both the CROQ Physical Functioning scale (1.74) and the SAQ Exertional 
Capacity scale (1.56) in the CABG sample. However, the SAQ Exertional Capacity 
scale (0.84) demonstrated greater responsiveness than the CROQ Physical 
Functioning scale (0.67), in the PTCA sample. Large effect sizes of similar 
magnitude were observed for the CROQ Symptoms scale (2.74 and 1.09) and the 
SAQ Anginal Frequency (2.59 and 0.80) and Anginal Stability (2.57 and 0.91) 
scales in the CABG and PTCA samples, respectively. The CROQ appears to be 
as responsive as the SAQ. 
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CHAPTER 7 
DISCUSSION 
This chapter begins with a brief summary of results. Subsequent sections include 
a discussion of study strengths and limitations, and of methodological and practical 
issues. Implications of the study findings and areas for future research are then 
discussed. 
7.1 Summary of results 
This study reports on the development and rigorous psychometric evaluation of the 
CROO. Results demonstrate that it is possible to develop an acceptable, reliable, 
valid and responsive disease-specific questionnaire to evaluate patient-based 
outcomes before and after two types of coronary revascularisation, CABG and 
PTCA. 
Evidence from two independent field tests demonstrated that the CROO is 
acceptable, reliable, valid and responsive. The acceptability of the CROO was 
indicated by high response rates, a low proportion of missing data, well distributed 
endorsement frequencies (in the pre-revascularisation versions) and acceptable 
floor and ceiling effects. Good internal consistency and reproducibility provided 
strong evidence for the reliability of the CROO. Tests of scaling assumptions and 
factor analysis confirmed the grouping of items into scales. The content validity of 
the CROO was confirmed during development of the questionnaires. Support for 
the construct validity of all versions of the CROO was demonstrated by high 
correlations between scale and total scores, moderate correlations between 
scales, and convergent and discriminant correlations with other HROoL 
instruments (SF-36, SAO, OLMI-2, and LlhFE). The CROO was also able to 
detect differences between groups of patients who reported varying levels of global 
improvement, and between patients with different levels of disease severity as 
measured by the CCS and the NYHA. The CROa demonstrated responsiveness 
through its ability to detect significant improvements after CABG and PTCA. A 
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comparison of relative responsiveness demonstrated that the CROe was more 
responsive to change than the generic SF-36, and at least as responsive as the 
disease-specific SAe in both the CABG and PTCA samples. 
As the CROe has been validated against rigorous scientific criteria and on large 
samples of patients from three different clinical sites, the psychometric evidence is 
robust. The CROe far exceeded the criterion set for each psychometric test. The 
psychometric properties of the CROe are strong and were replicated in two studies 
with few differences between the two. The CROe is now ready for use in other 
studies where further tests of its validity can be evaluated. In terms of 
Erickson's396 life cycle model of a health status instrument, the CROe has passed 
stage one (concept formation, draft instrument, pilot testing), stage two (test of 
measurement properties, use by developers) and is now ready for stage three (use 
by others for the same purpose of study) and stage four (widespread use including 
different types of studies and different populations). 
7.2 Study strengths 
This study used state-of-the-art methods for instrument development and 
validation, including the involvement of patients in instrument development, 
extensive two-stage field testing in large samples, item reduction analyses using 
explicit criteria and responsiveness analyses. As elderly people and women have 
been largely underrepresented in the development of existing cardiac-specific 
questionnaires, the inclusion of these groups in this study is an important feature of 
study design. 
7.2. 1 Patient involvement in instrument development 
Patient involvement in instrument development is a necessary step to ensure that 
the core "critical components" are included425 and that the questionnaire is 
acceptable to patients. However, it is often overlooked and instruments are often 
developed without interviewing patients about their experience of living with a 
condition or undergoing a specific treatment.44 There is currently a paucity of 
research exploring patients' perspectives of cardiac conditions.426 . Incorporating 
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patients' views in health care evaluation helps to ensure that factors which may 
influence health outcomes are known and understood. The CROa was developed 
using content identified from 20 patient interviews, expert opinion, the literature and 
existing instruments. Where possible the "language" patients used was 
incorporated into the items. These steps are important as familiar language and 
relevant issues should increase response rate and the accuracy of responses.430 
It was the interviews with patients that revealed the importance of measuring 
physical and psychological complications after coronary revascularisation. 
Patients described a range of treatment-specific complications that persisted for 
some time after coronary revascularisation, such as post-procedural pain, wound 
healing problems, bruising and swelling. Whilst these problems associated with 
treatment have been described in the literature, they tend to be viewed as relatively 
minor problems. However, the interviews with patients revealed the impact that 
these complications have on patients' day-to-day lives, sometimes for many 
months after revascularisation. There have been no attempts to routinely quantify 
and monitor these complications using a validated instrument. The CROa is the 
first validated instrument to assess these complications; results show that these 
questions form a reliable and valid scale that is sensitive to change over time. The 
findings of the qualitative interviews were confirmed by the data collected using the 
CROa; many patients reported that they were bothered by complications at least 3 
months after revascularisation, and some still reported bothersomeness at 9 
months after revascularisation. 
In addition to involving patients in helping to generate the content of the CROa, 
patients also participated in pre-testing the instrument. Although pre-testing is of 
crucial importance in instrument development to determine the acceptability of the 
questionnaire in terms of content and phrasing, many instrument developers do not 
include this stage or do not report their findings. Instrument developers for the 
majority of cardiac-specific measures do not report results from pre-testing. 
Excluding this stage of instrument development could result in questionnaires with 
unintended meaning. Pre-testing of the CROa with CABG patients revealed the 
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necessity of very clear definitions between chest pain due to angina and chest pain 
due to the operation . . Careless use of existing measures in post-CABG samples 
might result in patients reporting chest pain (from angina) when in fact it is post-
operative pain that they are experiencing. This could lead to an interpretation of 
reduced effectiveness of the procedure. 
7.2.2 Extensive two-stage field testing 
The CRDa was subjected to a rigorous two-stage validation process: a preliminary 
field test for item reduction and preliminary psychometric evaluation, and a final 
field test for extended psychometric validation of the item-reduced questionnaires 
in independent samples. The majority of patient-based, CHD-specific 
questionnaires have not undergone this two-stage psychometric validation, a 
methodological weakness that is not limited to instrument development in CHD. 
Whilst some cardiac-specific instrument developers have performed item reduction 
analyses, it is less common for the item-reduced questionnaire to be further tested 
in an independent sample before publication, as was done in the evaluation of the 
CRDa. For scientific integrity, when items are removed from an instrument the 
psychometric properties of the new item-reduced instrument must be tested again 
in an independent sample. All changes made to an instrument need to be 
validated to ensure that the instrument retains its psychometric properties. 
By conducting extensive two-stage field testing in independent samples, important 
additional information about the generalisability of the results and the robustness of 
the psychometric properties is generated. As instrument developers tend to be 
over optimistic about a measure's validitY,368 there is the danger that other 
researchers take these properties as established and use the measure without 
confirming the psychometric properties in their own sample. Whilst publication is 
an important method of disseminating information on newly available instruments, 
journal editors and peer reviewers need to be encouraged to be more familiar with 
the necessary steps in instrument development and evaluation before accepting 
papers for publication. In this way, the publication of measures in their infancy will 
be avoided. The problem is confounded by authors frequently famng to report 
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details about instrument format, such as mode of administration and modification to 
the original instrument.396 Results generated from modified instruments are not 
directly comparable to results generated from the source instrumenP67 396 With 
more attention to these apparently minor details, greater confidence can be placed 
in the results from studies using these instruments and further data can be 
accumulated in support of the validity of the instrument. 
7.2.3 Large samples 
The CROQ was field tested in large samples of patients to increase the 
generalisability of results. It is not uncommon for disease-specific instruments to 
be developed and validated on small samples of patients, and cardiac-specific 
measures are no exception. Appendix 3.1 describes the samples in which existing 
cardiac-specific measures were developed. Many of these measures were 
originally validated in small samples, but some have since undergone 
psychometric testing in independent samples in other studies. However, it is 
interesting to note that the majority of these questionnaires were published before 
being tested on large samples. Instruments developed on small samples, which 
are not tested further in other samples, have only preliminary evidence of scientific 
credibility. As guidelines for sample sizes are poorly defined for psychometric 
testing, guidance is needed on the size of sample needed for the testing of each 
psychometric property (reliability, validity and responsiveness). However, the 
smaller the sample, the less confidence can be placed in the results. Juniper et 
a/.443 recommend a sample of at least 100 subjects for item reduction analyses, 
and Ware et a/.374 recommend at least 300 for tests of item convergent and 
discriminant validity. As the CROQ was developed using large numbers of patients 
in excess of 300, it is very likely that the results are generalisable and that they can 
be replicated in further studies using independent samples. However, this 
assumption needs to be tested. 
7.2.4 . Tests of scaling assumptions 
Large sample sizes in this study also permitted tests of scaling assumptions to be 
performed using item convergent and discriminant correlations. Only one289 of the 
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reliable and valid cardiac-specific measures identified in Chapter 3 applied tests of 
scaling assumptions in the validation phase. Scaling tests helped to confirm the 
construct validity of the CROa and were essential for item reduction. The CROa 
demonstrated excellent construct validity when scaling assumptions were tested 
using strict criteria, with some scales achieving a scaling success rate of 100%. 
Tests of scaling assumptions should be performed for existing cardiac-specific 
questionnaires to further evaluate their construct validity. The aLMI-2, for 
example, has several items that are scored in more than one scale, suggesting that 
these questions might have poor item discriminant validity. 
7.2.5 Item reduction analyses using explicit criteria 
The item reduction phase in instrument development is often omitted, or poorly 
documented. For example, only a small proportion of existing cardiac-specific 
questionnaires included an item reduction stage in instrument development (see 
Appendix 3.1). The methods and results of these analyses are also poorly 
documented. This study used explicit and clearly defined criteria in item reduction 
analyses and reported which individual items were eliminated. There is a need for 
more research into the consequences of taking different approaches,444 as different 
methods and criteria can produce scales with different content. 65 445 446 Some 
criteria for item reduction, such as item floor and ceiling effects are very poorly 
reported in the health measurement literature; instrument developers need to 
specify all criteria used. In this study, methods and criteria for item reduction used 
by other researchers were reviewed and then combined into a single item 
reduction strategy for the CROa with explicit criteria. This strategy was then 
tested in the pre- and post-revascularisation CABG and PTCA samples to ensure 
that only the strongest items were retained. 
During item reduction, items were eliminated from the CROa primarily on the basis 
of explicit psychometric criteria.54 90 366 369 411 437 However, qualitative (clinimetric) 
criteria65 74 were also considered for some items; the balance between these two 
approaches is rarely described. Items were eliminated if they did not meet explicit 
psychometric criteria, but representative coverage of a priori content domains and 
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the retention of items of clinical significance were also ensured. Qualitative criteria 
took precedence over psychometric criteria on the rare occasion when it was 
agreed that the item could be retained on clinical grounds or for conceptual 
reasons, as in the case of global items. However, these items were only retained if 
the psychometric properties of the scale were not weakened by their inclusion. For 
example, the item shortness of breath repeatedly failed the tests of scaling 
assumptions and did not load highest on its hypothesised factor during factor 
analysis. Elimination of this item, which is an important symptom of CHD, might 
have limited the clinical usefulness of the scale and the CROQ might be viewed as 
having poor content validity. This item was retained in the Symptoms scale, as 
retaining it did not weaken the already strong psychometric properties of this scale .. 
A similar situation occurred with palpitations. Excessive adherence to strictly 
psychometric criteria could result in scales with poor content validity; instrument 
developers need to give specific reasons for retaining or discarding items from a 
scale. 
7.2.6 Responsiveness analyses 
Many instrument developers do not evaluate the responsiveness of their 
instrument. Only about half of the existing reliable and valid cardiac-specific 
questionnaires reviewed in Chapter 3 have demonstrated the ability to detect 
change over time. It is essential for evaluative instruments used in clinical trials to 
have demonstrated the ability to measure change. Highly responsive scales are 
preferred because they allow clinical trials to be performed with smaller samples.97 
The CROQ demonstrated the ability to detect change over time between pre-
revascularisation and 3-/9-months post-revascularisation; some very large effect 
sizes and standardised response means were demonstrated. The Complications 
scale of the CROQ-CABG also demonstrated evidence of the ability to detect long-
term change over time between 3- and 9-months post-revascularisation. 
Further research into the relationship between different methods of evaluating 
responsiveness is needed.382 396 447 Wright and Young97 compared the 
responsiveness of a series of instruments using different. indices of 
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responsiveness. They found that the rank order of responsiveness of the 
instruments changed when different indices were used. In this study, the 
magnitude of responsiveness (i.e. small, moderate or large) was only slightly 
different when the standardised response means391 were used instead of the 
standard effect size.389 390 Husted et al., 388 in their review of methods of assessing 
responsiveness, concluded that if there are different aspects of responsiveness 
that are of interest, more than one statistic can be reported. 
7.2.7 Inclusion of specific patient groups 
A feature of this study is the inclusion of women and the elderly, both of whom 
have been largely underrepresented in the development of many of the existing 
cardiac-specific questionnaires. 
7.2.7.1 Women 
Women have been largely under-represented in HRQoL studies in cardiac 
populations.260 448 With an increasing number of women undergoing CABG and 
PTCA in the UK each year, the measurement of health outcomes in this group is 
becoming increasingly pertinent. As described in Chapter 3, the majority of 
cardiac-specific measures have been developed exclusively with male populations. 
The CROQ is different in that it was developed and validated on samples of 
patients including both men and women. Further validation in larger samples of 
women, or in a purely female sample, is recommended before promoting the use of 
this measure for women. However, as women were included in the patient 
interviews used to generate the CROQ and in the samples used for psychometric 
evaluation, there is preliminary evidence that the CROQ is appropriate for 
measuring disease-specific outcomes in both men and women undergoing CABG 
and PTCA. 
There is currently a paucity of research into gender comparisons of HRQoL 
following coronary revascularisation.26o The availability of a questionnaire 
appropriate for use with women might encourage more extensive gender 
comparison studies in the future. Gender comparisons are all the· more important 
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with recent studies suggesting that women with CHD may experience a different 
pattern of symptoms to men, with women reporting more pain in the neck, back 
and jaw.136-139 449 The CROO is the first validated CHD-specific questionnaire to 
include an item about radiating pain to other parts of the body (e.g. arms, 
shoulders, hands, neck, throat, jaw, back). Future studies using the CROO will be 
able to compare symptom patterns for men and women. As existing CHD-specific 
measures have included definitions of angina that were developed when CHD was 
considered to be a male disease, they may not be sensitive enough to detect 
different patterns of cardiac symptoms experienced by women. Women have 
reported worse HROoL after CABG and PTCA than men,450 451 but it is possible 
that the use of a more appropriate outcome measure, such as the CROO, will 
produce different findings after adjustment for age and disease severity. There is 
also evidence that women have different problems from men during recovery;452 
more research is needed to determine whether men and women report different 
patterns of concerns and experiences.178 
7.2.7.2 Elderly people 
Many existing cardiac-specific questionnaires have been developed with patients 
under 75 years of age. The CROO-CABG was validated in a sample of patients 
ranging in age from 36 to 94 years, with 33% of the sample aged 70 years of age 
or over. The CROO-PTCA was validated in a sample of patients ranging in age 
from 36 to 84 years, with 25% 70 years of age or over. As the CROO was 
developed on patients with a wide age range and with no age exclusions, it should 
be appropriate for measuring disease-specific outcomes in all age groups. 
However, the CROO needs to be further evaluated in a sample of purely elderly 
and very elderly patients to check that its strong measurement properties are 
maintained in these subsamples. This is planned as a future research project. 
As health care resources are scarce and coronary revascularisation expensive, 
providers of health care may have to prioritise patients for surgery. Decisions 
should be based on need, but need is a very vague and imprecise concept. The 
best definition of need is the 'ability to benefit'. VVhilst different mechanisms for 
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prioritising patients are used, the underlying theory is that patients who can 
'benefit' most in terms of extended life expectancy or improvement in HRQoL 
should be prioritised for treatment. In an equitable system there would be equal 
access for equal need, but other factors such as age may be factored into the 
decision process; higher rates of intervention occur among younger people than 
among older people, despite the considerably higher prevalence of CHD in older 
people.453 Some patients may be being denied treatment due to their increasing 
age. The use of age as a criterion for rationing is defended on the grounds that 
older people have had their "fair innings" and that younger people can benefit 
more.454 One counter argument is that age as a criterion per se should be rejected 
on the basis that risk should be individually assessed based on physiological 
condition and the ability to benefit.455 Justification for performing coronary 
revascularisation in the elderly has been a contentious issue due to the high costs 
involved.456 However, whilst a higher proportion of older patients have 
complications leading to death and disability after coronary revascularisation 
compared with younger patients, it is proving to be effective in terms of both 
survival and improvement in HRQoL in this group.322 365 456-460 With coronary 
revascularisation being ~ffered increasingly to elderly patients, it is important to 
have an instrument to measure health outcomes and HRQoL in this group. A 
sensitive disease-specific instrument, appropriate for use with elderly people, offers 
the optimal method for detecting actual improvements in HRQoL and should 
provide important information relevant to decisions on treatment prioritisation. 
7.3 Study limitations 
Results of this study should be interpreted in the light of limitations in both the 
qualitative and quantitative stages of the study. These limitations are described in 
terms of two general classes of systematic error: selection bias and observation 
(information) bias.461 Selection bias refers to error due to systematic differences in 
characteristics between those who are selected for study and those who are not. 462 
463 Observation bias includes any systematic error in the measurement of 
information on outcome.461 
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7.3. 1 Selection bias 
A possible limitation in the qualitative and quantitative stages of the study is the 
degree to which findings are biased as a result of the sampling strategy and 
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sampling frame. In the qualitative stage, patients were selected for interview in 
Outpatient clinics using an opportunistic rather than random sampling strategy. 
This method of sampling limits the generalisability of findings to the group studied, 
as the experiences of patients excluded by the sampling strategy are not known. 
The patients who were not interviewed might have had different experiences and 
characteristics than those who were interviewed. This method of sampling was 
adopted as it gave the researcher immediate access to patients. To overcome the 
possible effects of this bias, a more systematic sampling strategy was used to 
identify patients to be invited for interview in their own homes. 
A potential for selection bias in the quantitative stage of the study occurred due to 
difficulties in recruiting consecutive patients prior to revascularisation; not all 
patients scheduled for CABG and PTCA could be included in the pre-
revascularisation samples. This problem was a direct result of the system of 
providing patients with a date for revascularisation with very short notice. This 
prevented the researcher from sending questionnaires to all elective patients 
scheduled for surgery. In addition, due to the use of a postal survey to patients' 
homes, it was not possible to include patients admitted as emergency cases or as 
transfers from other hospitals. The pre-revascularisation samples may not be 
entirely representative of all patients who undergo these procedures at these 
hospitals. To minimise the problem, the researcher kept in close contact with 
Consultants' secretaries, waiting list administrators, and Cardiology Facilitators to 
take note of any changes in theatre schedules. Some patients were also recruited 
from the waiting list. 
To minimise the potential for selection bias in the post-revascularisation samples, 
consecutive patients who had undergone coronary revascularisation at the three 
study hospitals (in the same time period that patients were recruited in the pre-
revascularisation sample) were invited to take part in the study. Hence, all patients 
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who were not invited to participate at pre-revascularisation (emergency cases and 
those given short notice of the procedure) were invited to take part at 3-months 
post-revascularisation. This consecutive recruitment of patients removed the 
possibility of selection bias due to selective recruiting . 
. Non-response bias is another possible study limitation. The sample may not be 
representative of the larger population as non-respondents may differ from 
respondents in some important and/or systematic way.464 It is possible that 
patients who did not respond by completing the CROO were different in some way 
to those who did respond. For example, they might have been less satisfied with 
treatment or may have been sicker or have been re-hospitalised. To overcome the 
potential problem of non-response bias, steps were taken to increase the response 
rate to the survey through the use of personalised letters, emphasis on 
confidentiality, stamped addressed return envelopes and postal reminders.436 The 
high response rates achieved in this study suggest that a high degree of 
confidence can be placed in the results. Response rates in each part of the study 
(with the exception of the 59% response rate for the pre-revascularisation CROO-
PTCA in the final field test) were in excess of the figure of 68% cited by Asch et 
al.37o as the mean response rate to postal surveys published in medical journals. 
The high response rates will have partly offset the potential for non-response bias. 
Ideally, non-respondents should be compared with respondents in terms of 
demographic and disease-severity variables, but this is not always possible. In 
future studies using the CROO, effort should be made to determine reasons for 
non-response, and non-responders should be compared with responders in terms 
of characteristics such as disease severity, age, sex, and social class.-
Withdrawal bias arises when patients who withdraw from a study differ 
systematically from those who remain. 462 It is unlikely that withdrawal bias was a 
significant limitation in this study as very few patients who completed the baseline 
(pre-revascularisation) questionnaire failed to return the follow-up post-
revascularisation questionnaire. However, it is possible that the few patients who 
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withdrew were less satisfied or had poorer health outcomes than those who 
responded. 
7.3.2 Observation (information) bias 
Further limitations of this study are described below in terms of observation 
(information) bias. This type of bias results from systematic differences in the way 
outcome data are obtained.461 
Interviewer bias refers to systematic differences in soliciting, recording, or 
interpreting information from subjects.461 Interviewer bias was a potential source of 
bias in the qualitative stage of development of the CROa. It is possible that the' 
personal characteristics of the interviewer, such as gender and age, influenced 
patients' willingness to disclose information.466 To minimise the effect of 
interviewer bias, the researcher tried to develop a rapport with participants to make 
them feel more relaxed and able to speak freely. Chapter 4 describes the interview 
techniques used to gather information in an unbiased manner. To avoid inter-
interviewer bias, one researcher conducted all interviews. It is possible that field 
notes might have been unintentionally recorded in a biased manner. As the 
researcher can never be totally free from preconceptions, expectation bias, i.e. the 
systematic error of measuring and recording observations so that they concur with 
prior expectations,461 may have occurred. The interviewer tried to keep an open, 
reflective mind whilst gathering the data and recorded patients' stories as they 
were reported. The purpose of the interviews was to gather information about the 
experiences of patients who have undergone coronary revascularisation; the 
researcher took a non-directive approach in order to generate spontaneous 
responses,425 and tried not to be judgmental. 
Another potential source of information bias in the quantitative stage of the study 
was the tim ing of questionnaire adm inistration in the pre-revascularisation 
samples. Before coronary revascularisation, patients may be anxious about the 
procedure they are about to undergo.160 168 Ideally, the pre-revascularisation 
questionnaire should be administered before pre-operative emotional responses 
181 
confound patients' responses.260 However, due to the short notice given to patients 
about when the procedure would take place, some patients completed the CROa 
very close to their operation date. Whilst all responses to the pre-revascularisation 
CROa might be confounded by emotional state, this problem may have been more 
salient for those patients who completed the CROO very close to their operation 
date. To counterbalance this potential problem, some patients in the pre-
revascularisation samples were recruited from the waiting lists. 
Two further types of information bias, social desirability bias and (faking good', 
might have influenced the study findings in both the qualitative and quantitative 
stages of the study. Social desirability bias concerns the unintentional tendency to 
report positive answers, and 'faking good' concerns the intentional creation of a 
false positive impression.64 During the qualitative stage of instrument 
development, it is possible that patients {intentionally or unintentionally} focused on 
the positive aspects of the care as they were grateful for the life-saving treatment 
they had received. Several patients were 'full of praise' for the treatment they had 
received. To minimise the potential effect of this bias, attempts were made by the 
researcher to encourage patients to talk freely and confidentially about their 
experiences. A few patients did criticise some aspects of the care they received, 
for example inadequate follow-up after hospital discharge, hospital food and the 
long wait for their operation. The fact that patients were negative about some 
aspects of care suggests that social desirability bias and faking good had only a 
limited impact on the content of the interviews. All patients invited to participate in 
the interviews agreed. It could be argued that some patients agreed to take part in 
the interviews as they did not want to appear ungrateful for their treatment in the 
presence of their doctor. However, the enthusiasm and complete acceptance of 
those invited to be interviewed at home by an unknown researcher cannot be 
dism issed. The researcher was welcomed into each of the patients' homes, and 
several patients even organised their working day around the visit. Patients' 
sincerity in wanting to help with the research project was also reflected in their 
comments to the open-ended item in the CROO; many patients offered to be of 
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more help and provided contact telephone numbers. The willingness to participate 
suggests that information provided was of good quality and not intentionally biased. 
Social desirability bias and faking good are also possible sources of bias in the 
quantitative stage of the study. To minimise the potential for this bias, the 
questionnaire was phrased carefully to avoid biased and I or leading questions.427 
429 In order to encourage honest responses, effort was also made to inform 
patients that the study was confidential and would not affect the care they received 
at the hospital. A standard method for measuring the extent to which an 
instrument is effected by social desirability is the simultaneous administration of a 
scale such as the Crowne-Marlowe scale of social desirability.467 Social desirability 
bias was not formally evaluated in this study due to the already large number of 
questionnaires administered, but this was identified as an important area for future 
research. 
7.3.3 Generalisability 
This section discusses the extent to which patients recruited in this study are 
representative of patients undergoing coronary revascularisation in the UK, and 
consequently the extent to which results are generalisable. Where available, the 
demographics (Le. age, gender, ethnicity and social class) of patients in this study 
are compared with national figures171 and data from three large UK clinical trials 
(BARI,468 CABRI.242 RITA244) to evaluate the effectiveness of coronary 
revascularisation (see Table 7.1). 
Patients in this study were recruited from three hospitals in the UK. The extent to 
which patients treated at these hospitals are representative of all patients 
undergoing CABG and PTCA in the UK needs to be addressed. Two of the 
hospitals in this study (Royal Brompton and Harefield Trust Hospitals) are tertiary 
referral centres and are generally considered to be national centres of excellence. 
It is possible that they treat patients with a different case-mix severity than other 
hospitals, and hence the patients treated might not be representative of patients 
treated elsewhere. To overcome this potential bias, a third hospital (the 
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Wythenshawe, a District General hospital in Manchester) was selected to 
complement these two centres by providing patients with a potentially different 
case-mix. The purpose of this study was to develop a questionnaire appropriate 
for use with patients with all levels of disease-severity. It was, therefore, necessary 
to include patients with severe disease to gather the spectrum of problems. 
The average age of patients undergoing CABG in the UK has risen steadily from 
60.5 years in 1993 to 62.7 years in 1998.171 The mean age of CABG patients in 
the pre-revascularisation sample of this study is similar to the average age of all 
patients undergoing CABG in the UK, although the post-revascularisation sample 
was on average 2.3 years older (see Table 7.1). National figures for PTCA were 
not available. In comparison to the age composition of patients recruited in three 
large clinical trials conducted in the UK,242 244 468 the PTCA samples in the CROQ 
validation study are representative of patients undergoing coronary 
revascularisation in the UK. Again, the CABG post-revascularisation sample was 
approximately 4 years older. 
In terms of gender composition, the proportion of women in the PTCA samples in 
this study, was generally similar to the other studies reported in Table 7.1. There 
was a 7-9% smaller proportion of women in this study compared with the UK 
CABG national figures. 
South Asians (Indians, Bangladeshis, and Sri Lankans) living in the UK have 
particularly high rates of CHD,124 but this group was largely underrepresented in 
this study, as in other UK studies (see Table 7.1). About 7-12% of patients in this 
study were from ethnic minorities. This might in part be due to the geographical 
catchment areas for these hospitals. The ethnicity composition· of samples 
undergoing coronary revascularisation in the UK is poorly documented in the 
literature. Only one of the clinical trials (BARI) presented in Table 7.1 presented 
the proportion of patients who were white.468 The proportion of white patients in the 
CROa validation study was similar to that reported in the BARI study. 
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In this study, approximately half of the patients in the samples were from manual 
and half from non-manual social classes. Two of the hospitals in this study are 
based in the greater London area with catchment areas largely covering the south 
of England. The south of England is generally considered to be more affluent than 
the north.469 It is therefore possible that the Brompton and Harefield hospitals treat 
patients with a different social class composition than hospitals in other areas of 
the UK, and are hence unrepresentative of the UK as a whole. The Wythenshawe 
Hospital was included in this study to minimise the potential for this bias by 
increasing the catchment area of this study to include areas in the north west of 
England. CHD is more prevalent in manual than non-manual workers in the UK.124 
126128 In this study, patients from each social class were represented. None of the 
large studies reporting outcomes in CABG and PTCA have described social class 
distributions of their sample, thus precluding comparisons with this study. By using 
patients treated at all three hospitals in the quantitative stages of the study, bias as 
a result of hospital geographical location and social class should have been 
reduced. 
7.3.3.1 Comparison with other studies using the SF-36 
The extent of the generalisability of the findings of this study to the wider 
population can be assessed by comparison with results of other studies using the 
SF-36. Tables 7.2 and 7.3 show SF-36 scores CABG and PTCA patients in this 
study, compared with three sets of US norms and with CABG and PTCA patients in 
other studies reported in the literature.. Independent t-tests were used to test 
differences between SF-36 PCS/MCS summary scores for CABG and PTCA 
patients in this study, compared with normative data and with scores for CABG and 
PTCA patients in other studies. Some studies reported in Tables 7.2 and 7.3 did 
not report PCS and MCS scores and these studies are included in the tables for 
information purposes only. 
7.3.3.1.1 Pre-revascularisation. As expected, SF-36 PCS/MCS scores for 
CABG patients in this study are significantly lower than US norms for the general 
population (p=.OOO / p=.OOO), for people in the general population with angina 
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(p=.015 I p=.002) and for MOS participants with angina (p=.OOO I p=.OOO), but 
similar (p=.913 I p=.325) to scores reported in another study of CABG patients.47o 
Results are similar for PTCA. SF-36 PCS/MCS scores for PTCA patients in this 
study are significantly lower than US norms for the general population (p=.OOO I 
p=.006) and for MOS participants with angina (p=.OOO I p=.004), but not 
significantly lower compared with people in the general population with angina 
(p=.055 I p=.329). It was not possible to test the differences between scores in this 
study and those reported by Nash et al.302 and Seto et al.305 as mean scores and 
standard deviations were not available for these studies. 
7.3.3.1.2 Post-revascularisation. 
SF-36 PCS scores for CABG patients at 3-months post-revascularisation in this 
study are significantly lower than US norms for the general population (p=.OOO), but 
are significantly higher than the norms for people in the general population with 
angina (p=.OOO) and for MOS participants with angina (p=.007). However, MCS 
scores at 3-months post-CABG are not significantly different from the US norms for 
the general population (p=.588), for people in the general population with angina 
(p=.092) and for MOS participants with angina (p=.926). The same pattern in PCS 
and MCS scores is found at 9-months post-CABG. 
SF-36 PCS scores for PTCA patients at 3-months post-revascularisation in this 
study are significantly lower than US norms for the general population (p=.OOO), but 
not significantly different from the norms for people in the general population with 
angina (p=.058) and MOS partiCipants with angina (p=.429). SF-36 MCS scores 
for PTCA patients at 3-months post-revascularisation in this study are significantly 
lower than US norms for the general population (p=.005), and the norms for MOS 
participants with angina (p=.006), but not significantly different from the norms for 
people in the general population with angina (p=.528). 
SF-36 PCS scores for PTCA patients at 9-months post-revascularisation in this 
study are Significantly lower than US norms for the general population (p=.OOO), but 
not significantly different from the norms for people in the general population with 
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angina (p=.375) and MOS participants with angina (p=.999). SF-36 MCS scores 
for PTCA patients at 9-months post-revascularisation in this study are not 
significantly different from the US norms for the general population (p=.544), the 
norms for people in the general population with angina (p=.723) and for MOS 
participants with angina (p=.433). 
7.4 Methodological issues 
This study presented some challenging methodological issues: scoring 
questionnaires with varying numbers of response categories, the appropriateness 
of treating ordinal-level data as interval, and what item reduction strategy to adopt 
in developing a questionnaire to be used both pre- and post-intervention. 
7.4. 1 Scoring questionnaires with varying numbers of response categories 
This study raised important methodological questions about combining items to 
form scales. In questionnaires with items that are all measured on the same 
response scale, i.e. scales with the same number of response categories, items 
can be summed to form scale scores. Although many HRQoL and other outcome 
questionnaires do indeed contain items that are all measured on the same scale, it 
is not always possible or appropriate to use the same response scale for all items. 
For example, it might be most appropriate to use dichotomous items to indicate the 
presence or absence of symptoms and graded Likert-type scales to measure the 
frequency or severity of emotional responses, all in the same questionnaire. 
Sometimes it is difficult to put all items on the same response scale without 
appearing to force the items to fit. In this study, where items were borrowed from 
several different questionnaires, it was not possible to force all items to the same 
metric. This raised the issue of how to scale and score the CROQ items. 
There is relatively little guidance in the HRQoL literature about strategies for 
constructing summated rating scales and the relative advantages and 
disadvantages of the different methods:407 This is because most scales are based 
on items with the same number of response categories. However, after a review of 
established instruments and methods of combining items to form scales, several 
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methods were identified. The SF-36 Bodily Pain. scale contains two items 
measured on different response scales; one item is measured on a 6-point scale 
and the other on a 5-point scale. One assumption of summated rating is that items 
should have equal variance. Recognising that items measured on different 
response scales do not satisfy this criterion, Ware et al.87 developed a scoring 
algorithm to recalibrate the 5-point item to the same 6-point response scale of the 
other item (1 =6.0) (2=4.75) (3=3.5) (4=2.25) (5=1.0). After recalibration, items are 
summed before being transformed to a 0-100 point scale with scores between zero 
and 100 representing the percentage of the total possible score achieved. This 
same method of recalibrating items and transforming scales to 0-100 scores was 
followed for scoring the subscales of the CROO. 
However, whilst this method of scoring has been adopted frequently in the 
literature, it is not strictly the most psychometrically appropriate method. 64 371 372 407 
To facilitate interpretation between scores on different scales and instruments, it is 
common practice in many of the most frequently used psychological measures to 
standardise scores before summing items to form scales, (i.e. raw scores are 
transformed to z-score equivalents64 before being summed to form total scores). 
Because transforming raw scores to z-scores generates negative scores which are 
not easily interpretable, z-scores are often transformed to T-scores for reporting 
purposes.64 T-scores are based on a mean of 50 and a standard deviation of 10 to 
give an easily understood range of scores. One advantage of using standardised 
scores such as z- and T-scores is that similar to percentiles, they enable 
comparisons about where one respondent stands in relation to all other 
respondents.64 Whilst these scoring methods are common in psychometrics, they 
are generally unfamiliar to developers and users of health outcome instruments. 
One criticism of T-scores is that they may be difficult to understand, which is why 
0-100 point scales are so popular in HROoL measurement.S7 
As items in the CROO are measured on scales with a varying number of response 
categories, it is difficult to compare scores on one scale with scores on another. T-
scores were, therefore, considered as a possible solution. T-scores were used to 
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create CROa total scores (Total Core and Total Outcome), but not for any of the 
subscale scores. This is because all subscales except two (Symptoms and 
Satisfaction) are measured on the same response scale. For the Symptoms and 
Satisfaction subscales, items were re-calibrated to the same response scale and 
then summed and transformed to a 0-100 scale using the method of the SF-36. 
The decision to alter the scores through re-calibration was weighed up against the 
strong advantage of not having to use standardised T-scores for individual 
subscales. Whilst T-scores may not be familiar to some users of the CROa, failure 
to standardise the items in the total scores before summing would have been 
methodologically unacceptable. 
One limitation of T-scores is that as they are sample dependent, the interpretation 
of scores is limited to comparisons within the sample from which T-scores were 
derived. To make cross-sample comparisons, it is necessary to undertake 
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normative studies with large numbers of subjects to generate population T-scores 
and norms. Population norms provide a standard against which scores from other 
studies can be compared and are essential for the interpretation of a scale's scores 
in a particular study. The use of a normative sample allows a population rather 
than sample mean and standard deviation to be used to evaluate T-scores. In this 
way, T-scores are no longer sample dependent. 
It is interesting that recent improvements in the SF-3689 have taken into account 
the methodological superiority of scoring using standardised scores (z- and T-
scores) over the earlier approach87 of transforming scores to a 0-100 point scale. 
That is, whereas in version 1 of the SF-36 the eight dimension scores were 
calculated using the 0-100 point transformation (although pes and MCS scores 
use the T-score method), version 2 has adopted the T-score method for the 
scoring of the eight dimension scores. This method is viewed as preferable as the 
general population norm is built into the scoring algorithm, thus all scores above or 
below 50 can be interpreted as above or below the general population norm. By 
developing this scoring method for all the scales, comparisons in scores can be 
made across the scales and pes and MeS summary scores directly. 
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7.4.2 Treating ordinal-level data as interval 
Related to methodological issues about scoring is the debate about the 
appropriateness of applying interval-level statistics to ordinal-level data. For some 
years407 there has been considerable debate as to whether it is acceptable to treat 
. ordinal data generated from Likert scales as interval-level data.405 406 Stevens471 
proposed that the level of measurement dictates the choice of statistical method, 
i.e. parametriC statistics for interval data and non-parametric statistics for ordinal 
data. His view has been ferociously challenged for many years,405 472 but not 
without rejoinder.406 As recent as 1997, there was a resurgence of the old debate 
with an entire issue of the British Journal of Psychology dedicated to this 
debate.473-479 It is now generally accepted by many methodologists that data from 
rating scales can be analysed as if they were interval without introducing severe 
bias if the distribution of scores is not severely skewed.64 87 366 The treatment of 
ordinal data as interval does not lead to a great loss in accuracy and the advantage 
is that the results from parametric tests are more easily interpreted. 
In this study, as the CROa items were not severely skewed, it was appropriate to 
treat the data as interval. The assumption that items could be summed to form 
scales without standardisation or weights was evaluated using several criteria: 
symmetry of item-response distributions, equivalence of item means and standard 
deviations, and 'roughly equivalent' item-total correlations.369 408 
7.4.3 Item reduction strategy for a pre- and post-intervention instrument 
Whilst item reduction techniques are now quite widely used in developing health 
measurement questionnaires, methods and techniques of item reduction analyses 
are poorly documented in the HRaoL Iiterature.444 In measuring outcomes before 
and after an intervention such as coronary revascularisation, the same instrument 
is usually administered at both assessment pOints. However, the CROa is slightly 
different in that it has a core set of 33 items that are administered both before and 
after coronary revascularisation, as well as some additional items in the post-
revascularisation version that are specific to the procedure and are therefore only 
asked after the procedure. The pre- and post-revascularisation versions of the 
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CRDQ are thus very similar, but different. During item reduction analyses, the 
question arose as to whether to treat these two different versions as entirely 
different questionnaires and to validate them separately, or to item-reduce one 
version and then model it on the second to verify the item reduction strategy. It 
was clearly not appropriate to consider the questionnaires as entirely separate and 
to item reduce each one separately, as doing two separate item reductions could 
result in different content for the two versions without a common core. The lack of 
a common core would make comparisons of before and after revascularisation 
difficult. There were no precedents in the literature to resolve this issue. 
A decision had to be made, therefore, about which questionnaire version (pre-
revascularisation or post-revascularisation) to use for item reduction analyses. The 
pre-revascularisation version was selected for initial item reduction analyses as 
standard item reduction techniques include an analysis of item endorsement 
frequencies, which one would expect to be skewed after coronary revascularisation 
reflecting significant health improvements. If the post-revascularisation version 
had been used as the starting pOint, some items of key importance at pre-
revascularisation might have been eliminated. The elimination of items from item 
pools at one point in time based on inter-item correlations (item redundancy) can 
be risky as their relationship at another point in time might be different.443 For this 
reason, reduced item pools developed from the pre-revascularisation version of 
the questionnaire were modelled in each post-revascularisation sample to test the 
robustness of the scales identified at pre-revascularisation and to verify the core 
set of items in the pre-revascularisation version. The clear presentation of the 
methods and criteria used to eliminate items from the CRDQ both at pre- and post-
revascularisation should help guide other methodologists who need to develop 
both pre- and post-intervention versions of an outcome instrument. 
As dramatic changes in health status and HRQoL are observed after coronary 
revascularisation, it is important to ensure that an instrument used before treatment 
retains its psychometric properties when used to assess outcome after 
revascularisation. Domains of interest can vary with the stage or severity of illness; 
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issues that are pertinent to CHD patients before revascularisation might not remain 
relevant after treatment and this could alter the psychometric properties of an 
instrument. 
7.5 Practical issues in developing the CROQ 
A number of practical challenges were encountered in implementing a systematic 
sampling strategy, verifying that patients are alive, and being a researcher in the 
clinical context. 
7.5. 1 Implementing a systematic sampling strategy 
The implementation of a systematic recruitment strategy before revascularisation 
proved to be impossible, as the identification of patients scheduled for coronary 
revascularisation was surprisingly difficult. The ideal of recruiting consecutive 
patients as they were given a date for revascularisation seemed feasible in 
hospitals with central waiting lists and a system of informing patients of their date 
for CABG or PTCA by letter. However, the vast majority of cases were actually 
given very short notice of the date for revascularisation .. Some patients, for whom 
there was insufficient time to send a letter, were telephoned by the Consultant's 
secretary or Cardiology Facilitator and asked to come to the hospital within the 
next couple of days. Within each hospital, each Consultant had a different system 
for scheduling patients in theatre slots. It took some time to determine how these 
systems actually worked in practice. 
Several of the cardiac surgeons did not have a regular system for deciding which 
patients would be called in for CABG for the next week, whilst others did. 
Sometimes theatre schedules were decided on a Friday afternoon, including the 
slot for the following Monday's procedures. This gave the researcher very short 
notice to try to recruit the patient into the study, with the result that not all eligible 
patients could be recruited; several patients reported that they had received the 
questionnaire too late. Whilst one hospital had a detailed central waiting list 
specifying the urgency of cases for CABG using a 3-point scoring system, 
scheduling appeared to go on at a series of different levels. Some Consultants' 
192 
secretaries held files of patients categorised as 'urgent', 'previous cancellations', 
and 'long waiters' who were priority cases. These files were inspected on a regular 
basis by the researcher in an attempt to identify those most likely to b~ admitted for 
CABG over the com ing weeks. All secretaries were visited or telephoned on a 
twice-weekly basis to request information on patients scheduled or likely to be 
scheduled for CABG. It soon became obvious that a mUlti-level approach needed 
to be taken in each hospital to gather the necessary information. Hospital ward 
admission diaries were inspected in one nearby hospital on a twice-weekly basis to 
identify patients who had been missed by the other methods. Sole reliance on 
busy medical secretaries for information about which patients were scheduled for 
surgery proved to be unfeasible. The Wythenshawe Hospital appeared to have the 
optimal system; each Friday, the Waiting List Administrator provided the 
researcher with a list of patients scheduled for surgery for the following week. 
Recruitment of patients prior to PTCA also proved to be difficult. In all three 
hospitals, patients were scheduled for PTCA by a Cardiology Facilitator. However, 
these records were sometimes inaccurate. In one hospital, the name of patients 
scheduled for PTCA were entered in a catheter ·Iaboratory diary held by the 
Cardiology Facilitator, but were identified only by name (not hospital number). The 
researcher took note of patients' names and the date they were scheduled for 
PTCA, then proceeded to identify addresses and hospital numbers from the 
computerised patient administration system (PAS). As hospital numbers are the 
unique identifier for patients, this information was essential to correctly identify 
patients. On entering the names into the PAS, difficulties were encountered, 
particularly with patients with common surnames who could not be easily identified 
out of a large bank of possible patients. Some patients' names had been spelt 
incorrectly in the diary and were consequently difficult to identify on the PAS. 
These problems aside, on several occasions, patients returned blank· eROa 
questionnaires to the Project Co-ordinator with a note saying that they were not 
due to have PTCA as they had already had it done elsewhere or had already had it 
done in this same hospital. The researcher was later informed that one Consultant 
in particular might schedule a patient for investigation only (i.e. not for intervention), 
193 
but then on discovering that the patient needed PTCA, would perform it at the 
same time rather than scheduling the patient at a later date. This caused problems 
in the scheduling of procedures as the Cardiology Facilitator was not always 
informed that the patient had undergone PTCA. 
It was easier to implement a systematic sampling strategy for the post-
revascularisation sample as patients were easily identified according to procedure 
lists generated by Information Departments. However, some problems were also 
encountered at this stage. A few patients notified the Project Co-ordinator that 
they had not undergone PTCA, despite being on the procedure list indicating that 
they had undergone the procedure. These patients reported they had only 
undergone invasive investigation (not intervention), as the cardiologist had found 
that the PTCA was anatomically impossible to perform. As these patients should 
not strictly have been on the PTCA list, they were considered ineligible for 
purposes of this study. 
Response rates were lower in the pre-revascularisation than post-revascularisation 
samples. This might partly be explained by the fact that patients were frequently 
sent the pre-revascularisation CROa too close to the date of their operation to 
permit completion before the procedure. Some patients who felt unwell or anxious 
prior to their operation and did not want to complete the questionnaire might also 
explain the lower response rate. Another reason might be the inability to send 
patients reminders due to the short time period between the date of the notification 
of revascularisation and the actual date of the procedure. These problems with 
recruitment at pre-revascularisation are common to other surgical procedures 
where short notice is given for procedure dates, and are difficult to overcome. 
Researchers should be aware of the potential difficulties in recruiting patients prior 
to surgery using a postal survey and allow sufficient time and resources to recruit 
the necessary sample. 
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7.5.2 Verifying that patients are alive 
To avoid unnecessarily upsetting families and friends by sending a deceased 
person a questionnaire, the local ethics committees advised that hospital records 
were checked before sending out post-revascularisation questionnaires. However, 
hospital records are notoriously out of date for registering deceased patients. 
Hospitals are often not informed that a patient has died after leaving the hospital, 
as they are reliant on GPs and relatives to contact them with this information. In 
this study, despite routinely checking hospital records, several patients who were 
deceased were unknowingly sent questionnaires. This caused unnecessary upset 
for families and friends. The hospital records were subsequently amended to avoid 
upsetting the families again. The use of the national system of data flagging was 
considered as a method of gaining more reliable data, but these records are 
several months out of date and current information was essential. As the Project 
Co-ordinator was unable for practical reasons to check all three hospitals' 
computerised hospital records, the GP practice at which the patient was registered 
was telephoned to obtain this information. This proved to b~ a more reliable 
method of gathering this sensitive information. However, as this information is 
confidential, receptionists should not, according to a Data Protection Act, divulge 
this information without a formal request in writing, a process that can take some 
time. The majority of practices contacted did verify whether the patient was alive 
over the telephone, but this was in fact a breach of patient confidentiality. 
7.5.3 Being a researcher in a clinical context 
This study highlighted some of the problems of being a researcher in a clinical 
context, for example dealing with sensitive issues, requests for clinical advice and 
"cries for help". 
During the qualitative interviews with patients, some sensitive issues were raised. 
Several patients recounted very distressing stories about their experiences of 
having a chronic disease and of life-threatening events. Repeated references were 
made to death and fear of dying and experiences were discussed which some 
patients might have wanted to forget. It is essential that researchers interviewing 
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patients with chronic diseases have experience in dealing with sensitive issues and 
that they show compassion to patients rather than treating them as a source of 
information for their study. Before interviewing patients with chronic diseases for 
research purposes, it is advisable to have a list of relevant specialist contacts 
within the hospital to whom patients can be referred. Where several interviewers 
are involved in data collection, ground rules should be established before 
interviewing, e.g. agreeing follow-up mechanisms such as informing liaison or 
community nurses with the patient's permission, informing patients of self-help 
groups, not leaving distressed interviewees alone after the interview where 
possible, etc. Interviewers should also debrief with colleagues after interviewing so 
that they are not burdened by the problems described in the interviews. During the 
patient interviews in this study, several patients requested technical information 
and advice about their clinical condition. The researcher referred these patients to 
qualified health care professionals who were able to answer these questions 
accurately. 
Inspection of responses to the open-ended item in the eROa also revealed some 
"cries for help". On several occasions patients attached letters describing their 
current c6ncems~ medication problems,~~6r~lackof follow-up from~ the hospital and 
several patients wrote questions in the hope of getting a response. Once again, 
this raises the question of how researchers should deal with these Ireal' problems. 
The ethics of research practice dictates that the information obtained in a research 
study should be kept confidential; contacting hospital staff without the consent of 
the patient is considered to be a breach of patient confidentiality. However, at 
times it can appear to be equally unethical to ignore a "cry for help". The most 
appropriate method is to ask the patient if they would like you to put them in touch 
with someone who can help. Unfortunately, in this study it was only on entering 
the data that these comments were read in detail and in most occasions this was 
too late as it was several weeks after the data was collected. Researchers 
gathering this type of information should read all comments made by respondents 
immediately on receiving the questionnaires in case there are any cries for help 
which need urgent attention. 
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7.6 Study implications 
This section discusses the potential contribution of the CROQ to research and 
clinical audit I quality improvement. 
7.6. 1 Research 
In order to evaluate the effectiveness of treatments, the choice of outcome 
measure is of paramount importance. For some time the lack of an appropriate 
disease-specific instrument for coronary revascularisation has been noted.26o 262 287 
480 Researchers have had to choose from a range of disease-specific measures 
which are either conceptually inappropriate or which have unknown psychometric 
properties when used with coronary revascularisation patients. Alternately, 
researchers have used a battery of measures in an attempt to cover all of the 
important content domains. The CROQ is the only psychometrically sound 
disease-specific questionnaire that is conceptually appropriate for the 
comprehensive assessment of HRQol and health outcomes both before and after 
coronary revascularisation. Its potential uses are therefore numerous. 
In clinical studies of effectiveness, researchers are often trying to detect small and 
sensitive-lreatmerir-effecfs~-whTch-s6metimi:)s-ca-nnof be--measurecf -by-cllnlcal-
measures alone. HRQol questionnaires are now frequently used in many areas of 
medicine and surgery to detect these sometimes subtle changes. As a validated 
instrument tested against rigorous scientific standards, the CROe can be used 
with confidence in research. Generic measures such as the NHp225 241 and SF-
36226 have mainly been used in cardiovascular clinical trials, possibly because 
there is more evidence of their robustness to measure patient-based outcomes in a 
variety of patient groups and the ability to compare results across trials. The 
CROQ has demonstrated evidence of responsiveness that exceeds that of the 
generic SF-36. 
In recent years, a few clinical trials have used disease-specific questionnaires, for 
example the international trial of PTCA with stenting versus CABG, the Stent or 
Surgery (50S) trial. 481). However, instruments such as these, originally developed 
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for patients maintained on medical therapy, need to be further validated for use 
with CABG and PTCA patients. As the CROQ has been validated scientifically for 
use in CHD patients before and after CABG and PTCA, confidence can be placed 
in its measurement properties. The inappropriate use of HRQoL instruments that 
have not been validated in the target population can lead to confusing or 
inconsistent results. All modifications to an instrument need to be validated, 
including its use in different patient groups from those in whom it was initially 
validated. It is not just psychometric equivalence that can change but also 
conceptual relevance. These rules and violations have not been made clear to 
potential users of HRQoL questionnaires and need to be made more accessible. 
Recognising the need to measure a diverse range of outcomes after CABG and 
PTCA, some clinical trial investigators have administered a battery of HRQoL 
measures (with each instrument measuring one or two domains). In the SOS 
trial,481 for example, patients complete a combination of five generic and disease-
specific questionnaires (Seattle Angina Questionnaire, Cardiac Health Profile, SF-
36, EuroQol, and the Zung Self-Rating Depression Scale). The result is that 
patients have a number of lengthy questionnaires to complete. The CROQ has 
several advantages over this battery approach. As a single comprehensive 
measure covering all the important domains, it avoids the need for using more than 
one instrument. This reduces the burden placed on the patient in terms of the 
reduced time taken to complete the CROQ compared with a battery of measures. 
The use of a single measure also avoids the situation where the patient perceives 
a great deal of repetition across the different questionnaires. 
Another advantage of the CROQ over the battery approach is its simple scoring 
system. By using a battery of measures, researchers have to score each 
instrument separately, some of which have complex scoring mechanisms, thus 
creating a greater burden. The use of a battery also creates a number of 
dependent variables, making analysis and interpretation more cumbersome. The 
CROQ has a further advantage in that the four core pre- I post-revascularisation 
scales (Symptoms, PhYSical Functioning, Psychosocial Functioning and Cognitive 
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Functioning) can be summed to create an overall core functioning scale (Core 
Total). Although it is not valid to simply form a summated total score from a battery 
of individual measures,83 factor analysis can be used to derive a composite score 
for use in analysis. The availability of a reliable and valid summary score will 
enable researchers to measure the impact of several key domains in a single 
score. This will make it easier to compare health outcomes between groups of 
patients as it measures overall impact as opposed to individual components. It is 
sometimes difficult to determine whether one procedure should be described as 
more effective than another if one results, for example, in improvement in 
symptoms and another results in improvement in psychosocial functioning. The 
reliability and validity of the Core Total score has been demonstrated and it can be 
used with confidence with patients both before and after CABG and PTCA. 
7.6.2 Clinical audit / quality improvement 
The CROQ is a potentially useful tool for clinical audit and quality improvement at 
both the national and local level. The National Service Framework (NSF) that has 
recently been published for CHD11 to define standards for service provision in an 
attempt to tackle unacceptable variations in quality across the country, includes 
. suggesfions~ of inaicators-anddh,fcalaiJdifcriterfa fhafcan-be-·used··loassess-ti,e 
quality of treatment. These criteria are currently based on clinical parameters, 
such as risk-adjusted number and percent of patients dying after CABG before 
discharge from hospital, by surgeon and centre. It is feasible that the CROQ could 
be used to provide information on health outcomes and service quality that is not 
measured by these clinical outcomes and that scores could be compared across 
Trusts after adjusting for case-mix severity. The CROQ could also be used to 
measure the impact on the patient of policy changes described in the NSF e.g. 
reduced waiting times for CABG and PTCA patients. 
The CROQ could also be used by hospitals as a local indicator of quality. It could 
be used as a quality improvement tool to provide information about the impact of 
care from the patient's perspective; gaps in care could be identified and local 
standards could be set. If, for example, a large percentage of patients reported that 
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they were not satisfied with the information they received about their heart 
operation, action could be taken to "improve the quality of information provided to 
patients whilst in hospital. Improvements in patient education an~ information 
dissemination might result in improved outcomes.172 Information generated from 
the open-ended item in the eROO could also be used to identify areas for 
improvement in care. These areas could then be further explored through other 
methods such as qualitative interviews to further understand the nature of the 
problems and ways to overcome them. 
Findings from this study suggest that the eROO can be successfully implemented 
as an audit tool. Successful implementation was demonstrated by the support the 
study received at the three hospitals by surgeons and cardiologists, the ease with 
which the eROO was administered and the high response rates from patients in 
each of the three hospitals. Surgeons and cardiologists at participating hospitals 
were enthusiastic and supportive in providing the researcher with access to patient 
information. Once details of patients scheduled for surgery are known, the eROO 
can be administered easily, as demonstrated by one researcher's ability to recruit 
large numbers of patients simultaneously from three different clinical sites across 
the UK. On-site clinical audit assistants should be able to administer the eROO 
more easily, as they have access to the relevant information and can regularly 
check for scheduled procedures. A scoring manual and scoring programme are 
soon to be developed for the eROO, which will help users score their data. The 
eROO could be implemented in other UK hospitals and become a nationally 
recognised audit tool. 
The eROO provides information about a range of procedure-specific adverse 
effects. As these adverse effects can negatively affect HRQoL, they need to be 
monitored.175 Little previous research has attempted to quantify the impact of 
adverse effects from the patient's perspective after CABG and PTeA. Studies 
which have evaluated these outcomes have either been qualitative studies172 173 332 
482 or have used instruments with unknown psychometric properties.176 482 There 
have been no attempts to routinely monitor these important aspects of outcome 
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from the patient's perspective using a validated instrument. Providers of care 
generally do not know the proportion of patients who experience these adverse 
effects following CABG and PTCA. The CROQ will be a useful tool fO.r health care 
providers for routine monitoring of the bothersomeness and persistence of these 
outcomes. 
Information generated through use of the CROQ could also potentially help 
improve health outcomes. Studies suggest that patient expectations can influence 
outcome;118 beliefs and expectations have been shown to playa role in recovery 
from CABG.483 Data generated from the CROQ could be used to provide health 
care professionals with more information about the changes patients should expect 
when they have CABG or PTCA, enabling them to provide patients with more 
accurate information about how other patients have felt at specific points in time 
after CABG and PTCA. The provision of information to patients about what they 
should expect when undergoing procedures and recovery might lead to improved 
health outcomes.482 If patients expect specific problems after revascularisation, 
they might experience less anxiety and improved outcome. Better provision of 
information about the course of recovery before revascularisation and before 
leaving hospital might help patients be more realistic about expected recovery 
time. 
The potential for the use of the CROQ in clinical audit is illustrated in the next 
section. The data collected as part of this psychometric study will feed directly into 
the clinical audit departments at the Royal Brompton, Harefield and Wythenshawe 
Hospitals. A full report for clinical audit is currently being prepared; the following 
section illustrates the type of descriptive information about outcome that can be fed 
into the audit process. 
7.6.2.1 Patient-based outcomes in coronary revascularisation as measured by 
the CROQ 
This section reports on some of the descriptive findings and changes that occurred 
between pre- and post-revascularisation for CABG and PTCA patients in this study, 
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as measured by the CROQ. It provides descriptive information about the 
experience of CABG and PTCA from the patient's perspective. It does not address 
the comparative effectiveness of CABG and PTCA procedures as it is a 
psychometric study that was not designed to evaluate -effectiveness. However, it 
does consider, at a strictly exploratory level, some of the descriptive findings in 
CABG versus PTCA. Appendices 6.19a-6.21 b present frequencies of responses 
to each item in the pre- and post-revascularisation versions of the CROQ-CABG 
and CROQ-PTCA in the final field test. 
Consistent with the findings of numerous other studies, this study demonstrated 
that patients report dramatic improvements in several dimensions of HRQol after 
both CABG and PTCA. Previous research using generic HRQol questionnaires 
has shown that CABG and PTCA generally result in improvements in symptoms, 
functional capacity, emotional and social functioning.162176179 181 271 300310320325326 
This study also demonstrated statistically significant changes in symptoms, 
physical!, psychosocial! and cognitive functioning for CABG and PTCA patients 
between pre- and 3- I 9-months post-revascularisation, as measured by the 
CROQ. 
In terms of symptom relief, CABG patients reported a dramatic improvement in 
symptoms. At pre-revascularisation, only 12% of patients reported that they were 
"not at all" bothered by chest pain, 12% by discomfort in the chest, 15% by 
shortness of breath, 25% by radiating pain and 41 % by palpitations. At 3-months 
post-revascularisation these figures increased dramatically, with 82% of patients 
reporting that they were "not at all" bothered by chest pain, 78% by discomfort in 
the chest, 34% by shortness of breath, 75% by radiating pain, and 58% by 
palpitations. At 9-months post-revascularisation, scores remained high, but some 
values were lower than at 3-months post-revascularisation. Before CABG, 20% of 
the sample reported that they had taken no nitroglycerin over the past 4 weeks and 
8% reported that their heart condition had caused them no trouble. At 3-months 
post-revascularisation, these figures rose to 89% and 57%, respectively. There 
was little change in these figures between 3- and 9-months post-revascularisation. 
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PTCA patients also reported a dramatic improvement in symptoms. At pre-
revascularisation, only 16% of patients reported that they were "not at all" bothered 
by chest pain, 8% by discomfort in the chest, 11 % by shortness of breath, 23% by 
radiating pain and 35% by palpitations. At 3-months post-revascularisation these 
figures increased dramatically, with 52% of patients reporting that they were "not at 
all" bothered by chest pain, 42% by discomfort in the chest, 26% by shortness of 
breath, 54% by radiating pain, and 57% by palpitations. However, by 9-months 
post-revascularisation, all of these figures had fallen; improvement reported at 3-
months post-PTCA was not maintained at 9-months post-PTCA, suggesting that 
some patients experienced recurrent angina. Before PTCA, 26% of the sample 
reported that they had taken no nitroglycerin over the past 4 weeks and 6% 
reported that their heart condition had caused them no trouble over the past 4 
weeks. At 3-months post-revascularisation, these figures rose to 55% and 39%, 
respectively. There was little change in these figures between 3- and 9-months 
post-revascularisation. 
At pre-revascularisation, CABG and PTCA patients reported similar levels of the 
bothersomeness of symptoms, but at post-revascularisation there was a very 
different pattern, with PTCA patients showing less symptom improvement than 
CABG patients. On average, CABG and PTCA patients in the responsiveness 
subsample reported 39- and 23-point score improvements on the Symptoms scale 
between pre- and 3-months post-revascularisation, respectively. Symptom relief 
was accompanied by dramatic improvements in physical functioning for CABG and 
PTCA patients between pre- and 3-months post-revascularisation. On average, 
CABG and PTCA patients in the responsiveness subsamples reported 32- and 18-
point score improvements on the Physical Functioning scale between pre- and 3-
months post-revascularisation, respectively. CABG patients reported continued 
improvement in physical functioning between 3- and 9-months post-
revascularisation, but PTCA patients did not. 
CABG and PTCA patients reported improvements in social functioning between 
pre- and 3-months post-revascularisation and continued improvement between 3-
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and 9-months post-revascularisation, but these changes were less dramatic than 
improvements in psychological functioning. CABG and PTCA patients reported 
improvement in all items measuring psychological functioning between pre- and 
post-revascularisation and most, but not all, items demonstrated continued 
improvement between 3- and 9-months post-revascularisation. A surprising finding 
was that CABG and PTCA patients reported similar levels of feeling depressed at 
pre- and 3-months post-revascularisation, with approximately 30% reporting 
depression "none of the time" at both assessment points. However, at 9-months 
post-revascularisation 64% of CABG and 53% of PTCA patients reported feeling 
depressed "none of the time", suggesting that 36-47% of patients continue to feel 
depressed for some time after revascularisation. On average, CABG and PTCA 
patients in the responsiveness subsamples reported 30- and 17 -point score 
improvements on the Psychosocial Functioning scale between pre- and 3-months 
post-revascularisation, respectively. 
little change was observed in cognitive functioning between pre- and post-
revascularisation for CABG and PTCA patients. On average, CABG and PTCA 
patients in the responsiveness subsamples reported 15- and 7 -point score 
improvements on the Cognitive Functioning scale between pre- and 3-months 
post-revascularisation, respectively. At 9-months post-revascularisation many 
CABG and PTCA patients still reported problems with cognitive functioning 
(reasoning, memory and concentration). There were no obvious differences 
between CABG and PTCA patients. 
At 3-months post-revascularisation, 16% of CABG and 17% of PTCA patients 
reported that they had been re-adm itted to hospital since revascularisation for an 
overnight stay for reasons to do with their heart condition or heart operation. At 9-
months post-revascularisation, these figures rose to 21 % for CABG and 28% for 
PTCA patients. Few studies in the literature have evaluated complications after 
coronary revascularisation from the patient's perspective. However, studies that 
have described these complications report very similar results to this study, in 
terms of the type of problems and the length of time these problems can persist.176 
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206482 The most bothersome complications 3 months after CABG in this study were 
tenderness around the chest wound, numbness in the leg or arm as a result of 
having the vein removed for use as grafts, numbness around the chest wound, and 
swollen feet or ankles. Skaggs and Yates reported swollen ankles as the most 
common complication reported by patients 3 months after CABG.482 
Many patients reported that they were bothered by complications at 3-months post-
CABG and a number still reported bother from complications at 9-months post-
CABG. At 3-months post-CABG, many patients reported that they were at least 
"moderately" bothered by chest wound pain (23%), tenderness around the chest 
wound (30%), numbness or tingling around the chest wound (28%), pain in the leg 
or arm wound (23%), numbness or tingling in the leg or arm due to the operation 
(34%) and swollen feet or ankles (29%). At 9-months post-CABG these figures 
had fallen, but continued to be at least "moderately" bothersome for some patients; 
the CROQ was able to detect long-term changes in these complications. Longer-
term follow-up might have determined the point in time at which these 
complications disappear for the subgroup of patients still reporting them at 9-
months post-CABG. Other studies have reported that these types of problems can 
persist for as long as 12 months after CABG.175176 Caine et a/.176 found that 28% 
and 26% of patients continued to report chest or leg pain at 3- and 12-months post-
CABG, respectively. Caine et aI's. findings are consistent with the findings in this 
study at 3-months post-CABG, but higher than the values reported at 9-months 
post-CABG. One possible reason for this difference is that the CROQ asks about 
bothersomeness of the problem rather than simply whether it exists. 
There is very little discussion about minor complications with PTCA in the 
literature. However, patients interviewed in developing the content of the CROQ-
PTCA did identify some complications that they had experienced, some of which 
caused them considerable bother in the first few weeks of recovery. Due to the 
relatively less invasive nature of PTCA over CABG, researchers have paid little 
attention to these complications which are often short-lived. Skaggs and Yates482 
did, however, report that the most common complication post-PTCA in their study 
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was bleeding or haematoma at the catheter insertion site. In the interviews for this 
study, problems at the catheter insertion site were also reported to be bothersome 
by patients. However, bruising around the groin wound or thigh was the most 
commonly reported complication in the CROQ-PTCA. 
Whilst studies in the literature do not report minor complications post-PTCA, this 
study found that a small proportion of PTCA patients do report bother from 
complications for as long as 3-months after PTCA. For example, patients reported 
that they were at least "moderately" bothered by pain in the groin wound (6%), 
tenderness around the groin wound (7%), numbness or tingling in the groin area 
(4%), and bruising around the groin wound or thigh (10%). At 9-months post-
PTCA, patients continued to report that they were bothered by some of these 
complications. It is likely that patients might report more bothersomeness of the 
complication items in the CROQ-PTCA if the assessment point was closer to the 
date of PTCA, e.g. 1-month post-PTCA, as the problems are usually short-lasting. 
However, the 3-month assessment point was selected as it is generally considered 
to be a time when patients have recovered from coronary revascularisation or are 
showing signs of recurring angina.482 
A more serious and common problem after PTCA is recurrent angina,204 but 
insufficient~ research has been carried out to examine the psychosocial impact of 
recurring angina in patients who have undergone PTCA. White and Frasure-
Smith206 reported that 1- and 3-months post-revascularisation, PTCA patients were 
more uncertain about their illness than patients who had undergone CABG. They 
proposed that this increased uncertainty is the result of being informed about high 
rates of restenosis. Similarly, in this study, PTCA patients were more worried that 
their symptoms might return than CABG patients; at 3-months post-
revascularisation, 36% of CABG and 58% of PTCA patients reported that they 
were worried at least "a little of the time" that their symptoms might return. At 9-
months post-revascularisation, these figures rose for CABG (53%) and PTCA 
(76%) patients; patients were more concerned that their symptoms might return at 
9-months than at 3-months post-revascularisation. 
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CABG and PTCA patients reported being very satisfied with the results of their 
operation and care received, although CABG patients generally reported more 
favourable outcomes. A total of 81 % of CABG and 64% of PTCA patients reported 
that they were "much better" overall compared with before their operation and 
almost half of both samples reported that the results from their operation were 
"better than expected". A total of 83% of CABG and 65% of PTCA patients 
reported that they were very satisfied with the results of their operation. More 
CABG patients (70%) reported to be very satisfied with the information they 
received about how they might feel while recovering from their operation than 
PTCA patients (57%). Little change in satisfaction was reported between 3- and 9-
months post-revascularisation by CABG or PTCA patients. 
7.7 Future research 
Several areas for future research are discussed in this section, including: further 
validation in different samples and specific patient groups; the development of 
norms; the measurement of long-term outcomes; the prediction of health 
outcomes; the development of methods for the interpretation of scores; the use of 
self-report to evaluate adverse effects; and the development of language 
adaptations. 
7.7. 1 Further validation of the CROQ 
In terms of Erickson's396 life cycle model of a health status instrument, the CROa 
is ready for stage three (use by others for the same purpose of study) to further 
evaluate its validity, before stage four (widespread use including different types of 
studies and different populations). The most important proposal for future research 
is for further studies to confirm the validity of the CROa. 
Whilst this study demonstrated that the CROa has excellent psychometric 
properties, further studies are needed to investigate the measurement properties of 
the CROa in different samples to help further confirm its validity as an outcome 
measure. The CROa has currently only been used in limited samples; findings 
need to be replicated in other samples, with patients from different hospitals in 
207 
different geographical locations, possibly with a different gender, ethnic and social 
class composition, to ensure greater generalisability. These studies will help 
accumulate important confirmatory evidence that is necessary before the CROQ 
can be fully recommended as a reliable, valid and responsive tool for all patients 
undergoing CABG and PTCA in the UK. Further confirmation of its psychometric 
properties in independent samples will lend weight to its suitability as a national 
audit tool. 
Whilst the CROQ was tested in representative samples 'of coronary 
revascularisation patients, it is possible that some groups were less well 
represented than others. For example, whilst the CROQ was validated in samples 
that included elderly patients and women, further studies are required in these 
specific groups. As previously discussed in Section 7.2.7.2, the CROQ should be 
validated in samples of patients comprised only of elderly and only of women to 
further confirm the validity in these specific groups. Future research with the 
CROQ should also focus on the inclusion of ethnic minority groups. For example, 
South East Asians who comprise a significant proportion of patients with CHD in 
the UK.124 were poorly represented in this and most national studies. 
Further research should evaluate the appropriateness of the CROQ as an outcome 
measure for different types of treatment for CHD, such as for minimally invasive 
bypass surgery and for the evaluation of cardiac rehabilitation programmes. 
Recent technical advances in coronary revascularisation have resulted in the 
development of some novel procedures, including surgery directly on the beating 
heart and minimally invasive CABG surgery. The effectiveness of these 
procedures is currently being evaluated. It is possible that the CROQ could be a 
useful tool in evaluating these procedures from the patient's perspective. Future 
research needs to be directed at assessing the appropriateness of using the 
CROQ to evaluate outcomes for each new procedure. The CROQ is currently 
being used in a randomised controlled trial of coronary revascularisation with or 
without cardiopulmonary bypass (B Reeves, personal communication, 20 February, 
2001). It is also currently being used to evaluate patient-based outcomes in a 
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clinical trial (AMIST) of coronary angioplasty with stenting versus minimally 
invasive CABG for patients with single vessel disease of the left anterior 
descending coronary artery.484 Both these clinical trials are in progress and results 
are not yet available. The psychometric properties of the CROQ will need to be 
evaluated in the minimally invasive surgery sample to establish its acceptability, 
reliability, validity and responsiveness in this group, as it was not originally intended 
for use with these patients. It is possible that some items might not be appropriate 
for patients treated with minimally invasive surgery; some items may need to be 
eliminated and new ones created to address the different complications associated 
with treatment. A new Complications scale could be developed; the psychometric 
properties of the 'new' instrument would then need to be fully validated. 
Further research should evaluate the appropriateness of the CROQ as an outcome 
measure for CABG and PTCA patients undergoing cardiac rehabilitation 
programmes. The aim of cardiac rehabilitation programmes is to improve health 
outcomes and HRQoL for patients who have experienced a cardiac event such as 
myocardial infarction, CABG or PTCA. McGee et 8/.281 undertook a systematic 
review of psychosocial outcome assessment in cardiac rehabilitation and reported 
that there is widespread use of instruments with poor psychometric justification for 
their use. They found that there is currently not a single instrument that is user-
friendly, reliable, valid and responsive. The reliability, validity and responsiveness 
of the CROQ have been demonstrated in this study for use with patients before 
and 3-months after revascularisation. The CROQ proved to be very responsive to 
treatment changes after CABG and PTCA in this study and it is possible that it is 
responsive enough to detect smaller changes in health status that occur as a result 
of cardiac rehabilitation. 
7.7.2 Deve/oping norms 
The development of population norms for the CROQ has been identified as an 
important area for future research. Population norms provide expected and typical 
scores, i.e. they provide a standard against which results from other studies can be 
compared. To enable accurate comparisons, normative data can be reported for 
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different age and gender distributions. As the collection of data to create norms 
involves very large samples, most published HRQoL instruments are initially 
validated in the study sample and in many cases the instrument is further tested in 
several other studies. However, with the exception of some of the gold-standard 
generic measures such as the SF-36, few measures get to the point of generating 
normative data. In psychological measurement, a gold-standard instrument is 
considered completed only when normative data for the instrument has been 
generated. For example, most measures of intelligence and personality provide 
normative data for comparative purposes. This can be a time-consuming and 
expensive process. To encourage widespread use of the CROQ, the development 
of normative data should become a priority. The availability of population 
normative data for the CROQ will enable users to compare their scores with 
expected values from a larger reference population i.e., it would resolve the current 
problem of the sample dependency of T-scores. Norms could be developed for 
different age, gender and disease-severity groups at different assessment points, 
such as before revascularisation, 3, 6, 9 months and 1, 3 and 5 years after 
revascularisation. Researchers and health care providers could then identify 
. differences in scores and investigate the reasons for these differences. 
7.7.3 Long-term outcomes 
This study measured health outcomes at 3- and 9-months after CABG and PTCA. 
Small differences in outcome were observed between 3 and 9 months post-
revascularisation, suggesting that longer-term follow-up to at least 1-year post-
revascularisation is needed to provide information on the pattern of responses over 
time. Future studies using the CROQ should measure outcomes additionally at 1 
and 5 years after CABG and PTCA. It is not uncommon for researchers using 
HRQoL instruments to measure only short- and medium-term outcomes in cardiac 
populations. However, in order to compare lasting differences between treatments, 
longer-term follow up is essential. The measurement of long-term outcomes would 
also provide additional data to assess the responsiveness of the CROQ. 
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7.7.4 Prediction of health outcomes 
As discussed in Chapter 1, psychosocial factors have been shown to predict 
clinical outcomes and survival in CHD. Future research should evaluate the ability 
of the CROQ to predict patients at high risk of adverse events after coronary 
revascularisation (such as recurrent angina, repeat revascularisation, MI and 
death). Rumsfeld et al.47o propose that self-report may be a valuable tool for risk 
stratification before CABG, as they found that pre-revascularisation SF-36 PCS 
scores independently predicted mortality at 6 months after adjusting for known 
clinical risk factors. Herlitz et al.485 reported that pre-operative HRQoL (measured 
by the NHP, PGWB and PAS) was a strong independent predictor for impaired 
HRQoL 5 years after CABG. The collection of clinical data for individual patients in 
conjunction with CROQ data will provide information to test the ability of the CROQ 
to detect adverse events after revascularisation. After adjusting for clinical and 
sociodemographic variables, the ability of the CROQ to independently predict long-
term HRQoL could also be evaluated. 
7.7.5 Developing methods for the interpretation of scores 
One problem faced by all HRQoL instrument developers is that whilst scores on an 
instrument may be useful in research, their meaning in the clinical setting is less 
obvious. Interpretability is defined as the degree to which one can assign 
qualitative meaning to the quantitative scores of an instrument.eD Many instrument 
developers inadequately explore this attribute. Many instruments have 
demonstrated the ability to detect change, but the clinical meaningfulness of these 
changes is rarely established - statistical significance does not imply clinical 
significance.27 It is only with increased use and familiarity with specific instruments 
that we can begin to appreciate Clinically meaningful differences.395 397 The 
understanding of the clinical significance of objective measures has been based on 
experience with a large number of patients over time; the same is true of HRQoL 
measurement.486 
A variety of methods have been proposed to interpret scores.395 397 398 487 488 A 
recent expert panel symposium organised by the Agency for Healthcare Research 
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and Quality (AHRQ) to address advances in the measurement of health status and 
HRQoL focused on methods to facilitate the interpretation of HRQoL scores.447 
Some leading health outcomes methodologists propose the use of clinical data to 
help calibrate HRQoL instruments and facilitate interpretation.393 394 There is some 
consensus that changes in HRQoL should be "anchored" to other clinical changes 
or results.395 For example, a 10-point change in a HRQoL instrument might be 
shown to demonstrate a change in functional ability from grade 4 to grade 3 as 
measured by the CCS.76 It is also important to note that minimal important 
differences487 can have different meanings for different users. For the patient this 
might be the increment in health status that is "noticeable" as improvement or 
worsening, whereas for the clinician this might be the amount of change in HRQoL 
that would warrant a change in treatment plan.393 Methods of score interpretation 
are attracting increasing attention in the HRQoL literature as it is of crucial 
importance for widespread adoption of these instruments into clinical practice.89397 
447 
Although the CROQ has demonstrated the ability to detect change, the clinical 
meaningfulness of these changes is yet to be established. The collection of CROa 
data alongside clinical variables will facilitate the interpretation of the meaning of 
scores. Methods could be developed to calibrate the meaning of changes in the 
CROQ in relation to other clinical parameters to provide meaningful information to 
clinicians, and consequently to patients. This important area for future research 
needs to be investigated using methods proposed by the leading experts who 
recognise that clinical significance of scores will evolve over time, as is the case for 
biochemical and other clinical measures.395 486 The collection of CROQ data 
alongside other HRQoL instruments will provide information to help evaluate the 
external responsiveness of the CROQ.388 The extent to which CROQ scores relate 
to corresponding changes in a 'reference' instrument should help interpretation of 
the meaning of scores. This was not evaluated in this study, but was identified as 
an area for future research. It is not uncommon for instrument developers to 
exclude this type of analysis from the initial validation study. With increased use of 
the CROQ in several studies, data will be generated to permit these analyses. 
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The issue of clinical interpretation is even more pertinent with the application of 
measures into clinical practice for use at the individual-patient level. There is 
increasing interest in using HRQoL instruments for individual assessment and 
treatment monitoring. As is the case with the majority of health outcome 
instruments, the CROa was developed as a tool for group-level application, not for 
individual clinical assessment. Measures that are used to make treatment 
decisions for individual patients need to be evaluated using different criteria to 
those used in this study. It is possible that the CROa could be used for individual-
patient level assessments, but research needs to be conducted to assess whether 
it meets the appropriate measurement standards.26 
7.7.6 Using self-report to evaluate adverse effects 
After a patient has been discharged from hospital it is notoriously difficult to gather 
information about adverse effects, such as re-admissions to other hospitals and 
complications. One method of gathering this information is to ask the patient about 
subsequent events after leaving hospital. However, it is essential that such self-
reported information be validated. 
In this study, information about adverse effects including re-admission to hospital 
was collected through patient self-report. The CROa includes an item about re-
admissions to hospital for cardiac-related problems since revascularisation. Whilst 
this question appears to have been answered 'well', its reliability and validity are 
unknown, and hence it is not scored with the evaluative items in the questionnaire. 
This single descriptive item may be useful to hospitals performing CABG and 
PTCA, as after discharge patients do not necessarily return for follow-up, making it 
difficult to assess the proportion who experience problems during recovery (such 
as recurrent chest pain, wound infections, arrhythm ias, stroke, repeat 
revascularisation). To place confidence in the information reported by patients in 
the CROa, medical case notes at various hospitals (or GP records) would need to 
be inspected for evidence to support or refute the information given by patients. 
This was not done as part of this study due to time and resource constraints. It is, 
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however, a necessary step that patients' self-reports of reasons for re-admissions 
to hospital be validated against clinical data. 
Whilst this study has demonstrated that it is possible to develop a reliable, valid 
and responsive Complications scale for coronary revascularisation, the validity of 
the information at the item level needs to be further evaluated. We currently do not 
know, for example, whether patients' descriptions of wound 'infections' reflect 
actual infections as described by health professionals. Further research is needed 
to validate patient self-report and clinical evidence of infections. Health 
professionals sometimes use a telephone follow-up service to collect information 
about complications after discharge from hospital. Gathering this type of 
information by telephone can be time consuming and expensive. This study is the 
first to have developed a standardised method for collecting information about 
complications after coronary revascularisation. 
7.7.7 Cultural and language adaptations 
An important area of future research is the development and validation of different 
language and cultural adaptations of the CROQ, using standardised scientific 
methods for translating and evaluating instruments for use in different cultural and 
language groups. 399-404 
CHD affects large numbers of ethnic minorities living in the UK who do not speak 
English. For example, South East Asians living in the U.K are at particularly high 
risk of developing CHD124 and not all are able to speak or read English. The 
inclusion of patients from ethnic minority communities who do not speak English 
can cause some practical problems in HRQoL research as interpreters and trained 
interviewers are needed. However, it is feasible to develop and validate patient-
based measures of outcome for patients from minority ethnic groups.399489490 
The measurement of HRQoL before and after coronary revascularisation has 
attracted great international interest. With an increasing number of international 
clinical trials to evaluate the effectiveness of coronary revascularisation, there is an 
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increasing need for a patient-based instrument that can be administered in various 
languages. Future research should be directed at developing different language 
versions of the CROQ to facilitate comparison of disease-specific HRQoL and 
health outcomes between different countries. All cultural and language 
adaptations of the CROQ should be carried out using accepted methods to ensure 
conceptual and linguistic equivalence.399-403 A full psychometric evaluation of the 
properties of e~ch cultural and or language adaptation should be undertaken.404 
Work is currently in progress to develop and validate an Italian version of the 
CROQ.491 The CROQ has been translated into Italian using standard methods of 
forward-backward translation.402 403 Firstly, two expert bilingual translators 
independently translated the CROQ from English to Italian. Two different expert 
translators, blind to the original version, then independently back-translated the 
Italian version into English. The Italian questionnaires have been pre-tested with a 
focus group of Italian patients to evaluate the clarity of wording and 
appropriateness of phrasing. The questionnaires are currently undergoing field 
testing with 100 CABG and 100 PTCA patients before and 3-months post-
revascularisation. This field study will provide data for the preliminary 
psychometric evaluation of the Italian version of the CROQ. The Italian version will 
be evaluated according to the same psychometric criteria as those described for 
this study. 
7.8 Conclusions 
The measurement of HRQoL after coronary revascularisation has attracted 
considerable research. Measures of morbidity and mortality provide a limited 
evaluation of the impact of coronary revascularisation, as CABG and PTCA are 
usually directed toward improving HRQoL and symptom relief rather than cure. 
Numerous disease-specific HRQoL questionnaires have been developed for CHD, 
but most have not been developed and validated against rigorous scientific 
standards. Those with established psychometric properties have largely been 
developed for use with medically not surgically treated patients; and are 
conceptually inappropriate for the comprehensive measurement of the impact of 
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coronary revascularisation. Due to the lack of an available validated and 
conceptually appropriate patient-based measure of outcome for coronary 
revascularisation, a new instrument was developed. The Coronary 
Revascularisation Outcome Questionnaire is an acceptable, reliable, valid and 
responsive measure of patient-based outcomes in CABG and PTCA. The CROa 
has many potential uses, including research on the appropriateness and 
effectiveness of coronary revascularisation in different patient groups and use as a 
routine clinical audit tool for providers of CABG and PTCA in the UK. 
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TABLE 1.1 Mortality Rates for Coronary Heart Disease in England and Wales by Age (1999) 
All ages England &Wales 
5-14 years 
15-24 years 
25-34 years 
35-44 years 
45-54 years 
55-64 years 
65-74 years 
75-84 years 
85 years and over 
Mortality rate per 1,000,000 1 
Males 
2,297 
1 
1 
24 
208 
927 
3,046 
8,780 
20,311 
37,256 
Females 
1,880 
1 
2 
7 
46 
194 
883 
3,725 
11,371 
26,252 
1 The 'All ages England & Wales' rates are age-standardised. The rates for the other rows are not age-
standardised i.e. they are age-specific only. 
Source: National Statistics. Mortality statistics cause. Review of the Registrar General on deaths by cause, sex 
and age, in England and Wales, 1999. London: The Stationery Office, 2000. 
TABLE 1.2 Mortality Rates for Coronary Heart Disease in the UK by Country, Region, and Sex (1991-97) 
Mortality rates per 100,000 I 
Overall 15-44yrs 45-64 yrs 65+ yrs 
Males 
United Kingdom 268 10 260 1,805 
England -261 10 -248 -1,765 
North East *315 *13 *323 *2,079 
North West *302 *13 *305 *2,000 
Yorkshire and the Humber *287 11 *280 *1,932 
East Midlands -262 10 -248 -1,776 
West Midlands *276 11 *269 *1,854 
East -232 -8 -202 -1,620 
London -246 10 -243 -1,647 
South East -226 -8 -198 -1,568 
South West -238 -8 -210 -1,655 
Wales *285 11 *281 *1,907 
Scotland *321 *13 *342 *2,093 
Northern Ireland *303 10 *308 *2,016 
Females 
United Kingdom 127 2 72 984 
England -123 2 -67 -955 
North East *159 *3 *101 *1,203 
North West *147 *3 *90 *1,122 
Yorkshire and the Humber *138 2 *80 *1,068 
East Midlands -124 2 70 -963 
West Midlands *130 2 74 *1,002 
East -108 -1 -49 -866 
London -112 -2 -64 -868 
South East -103 -1 -47 -828 
South West -106 -2 -50 -844 
Wales *134 2 *80 *1,024 
Scotland *161 *3 *108 *1,205 
Northern Ireland *149 2 *93 *1,135 , 
Mortality rates are age-standardised. 
* Significantly higher than the United Kingdom rate. .... Significantly lower than the United Kingdom rate 
Source: National Statistics. Geographic variations in health. London: The Stationery Office, 2001. 
~ 
Data are aggregated over the 5 calendar years. Cases in each calendar year were defined as patients who had a diagnosis of CHD ever-recorded and 
treatment with asprin, or drugs in BNF chapter 2, during that year. 
2 Age-standardised to the European population. 
3 Number of cases derived from a sample of 211 general practices, with 1,388,000 patients, 684,000 males and 704,000 females. 
Source: National Statistics. United Kingdom Health Statistics. London: The Stationery Office, 2001. 
TABLE 1.3b Prevalence Rates of Treated Coronary Heart Disease in Scotland by Age and Sex (1998) 
All ages 1 
Rates per 1 ,000 patients 
0-34yrs 35-44 yrs 45-54 yrs 55-64 yrs 65-74 yrs 75-84 yrs 85 yrs and over 
Males 
Scotland 3 24.3 0.4 4.9 26.2 79.0 102.4 104.0 78.9 
Females 
Scotland 3 14.3 0.2 2.8 14.1 43.7 63.5 68.2 55.5 
1 Age standardised to the European population. . 
2 Number of cases derived from 40 general practices with a combined practice population of 110,729 males and 114,007 females. 
3 Cases were defined as patients who had a CHD diagnosis recorded during 1998. 
Source: National Statistics. United Kingdom Health Statistics. London: The Stationery Office, 2001. 
I\) 
m 
Number of cases 
(all ages) 3 
2,795 
2,090 
TABLE 1.4 UK Trends in Coronary Artery Bypass Graft Surgery 
Isolated CABGs 
Year 
1977 
1978 
1979 
1980 
1981 
1982 
1983 
1984 
1985 
1986 
1987 
1988 
1989 
1990 
1991 
1992 
1993 
1994 
1995 
199617 
1997/8 
n 
2,297 
2,653 
2,918 
4,057 
5,130 
6,008 
8,332 
9,433 
10,667 
10,767 
11,521 
11,113 
12,648 
14,431 
15,659 
19,241 
21,031 
22,056 
22,475 
22,160 
25,639 
Source: Society of Cardiothoracic Surgeons' National 
Adult Cardiac Surgical Database Report, 1998. 
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TABLE 1.5 UK Percutaneous Coronary Intervention Procedures 
Year 
1991 
1992 
1993 
1994 
1995 
1996 
1997 
1998 
1999 
Number of 
intervention 
centres 
52 
52 
53 
54 
54 
53 
58 
61 
63 
Total angioplasty and 
other coronary 
intervention 
procedures 1 
9,933 
11,575 
12,937 
14,624 
17,344 
20,511 
22,902 
24,899 
28,133 
Rate 
per 
million 
174 
203 
227 
256 
304 
359 
402 
437 
494 
Increase 
(%) 
16.5 
11.8 
13.0 
18.6 
18.1 
11.7 
8.7 
13.0 
Source: British Cardiovascular Intervention Society (1999) (htpp:/twww.bcis.org.uklaudit). 
1 Including PTCA, atherectomy, excimer laser, rotablator and stents. 
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TABLE 1.6 Content Domains Included In Conceptual Models of HRQoL in Coronary Revascularisation 
m m ~ ~ .:::t:. 0. m G> '-:::J 0 0 c _0 0 .- 0 0 .- 0 '-0 c °c c Oc E G>O o ;: '- 0.- 0·- oc 0 ~.§ 'c .- 0 -c 10C 0 
- '0> E-
-
00 
-0 o.s::::;.Q 
- 6 0 c G> 
·in ts .s::::;.- m·- 0. -0.0 0 00 ·-0 '-00 E o..!.. .- c: '-Study '- ~c >'c °c :::J >. C 0- 00:::J ~ fI):::J o :::J G>fI):::J >. :2~ ou-0-.2 0-_ en_ z 0._ en enG>~ 
Jenkins & Stanton, 1984 286 CABG&Valve • • • • • • 
Working Group for CABG, 1984 287 CABG • • • • • • • 
Mayou & Bryant, 1987 179 CABG • • • • 
Cleary et al., 1991 289 PTCA • • • • • • 
Walter, 1992 285 Cardiac surgery • • • • 
Bliley & Ferrans, 1993 290 PTCA • • • • 
Papadantonaki et al., 1994 284 CABG& PTCA • • • • • 
Cornell et al., 1996 260 CABG& PTCA • • • • • • 
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TABLE 1.7 Selected Examples of Change in HRQoL After Coronary Revascularisation 
Instrument and study 
Short Form 36 (SF-36) 87 
MacDonald et al. (1998) 301 
Bamason et al. (2000) 303 
Lindsay et al. (2000) 304 
Krumholz et al. (1996) 271 
Seta et al. (2000) 305 
Nash et al. (1999) 302 
I'V 
-..J 
W 
Procedure 
CABG 
CABG 
CABG 
PTCA 
PTCA 
PTCA 
Assessment point 
Pre and 3-months post 
Pre and 3, 6, & 1.2 months 
post 
Pre and 12 months post 
Pre and 6-months post 
Pre and 6-months, 1 yr post 
Pre- and 6-months post 
Results 
Improvement in all 8 dimensions 3m post-revascularisation, but improvements not 
statistically Significant in General Health Perceptions, Mental Health, and Role-
Emotional. Largest improvements observed in Role-Physical and Physical 
Functioning. 
Baseline scores on 7 ofthe 8 dimensions were significantly lower than at 3, 6, and 
12 m after CABG. Role-Emotional baseline scores were not Significantly lower than 
at 3m post CABG, but were significantly lower than 6 and 12m post CABG scores. 
3m dimension scores were also significantly lower than 6 and 12m scores except 
for Social Functioning and General Health Perceptions. 
Significant improvement in all 8 dimensions at 12m post. pts with lower pre-
operative SF-36 scores were less likely to gain improvement in SF-36 scores post 
CABG. 
Before PTCA, many pts reported substantial disability. Pre-operative scores for all 
dimensions (except General Health Perceptions) were well below values for the US 
norm. There were significant changes in all dimensions 6m post PTCA except for 
General Health Perceptions. 6m post-operative scores were very close to values 
for the US norm. Role-Physical was most responsive to changes after PTCA 
followed by Physical Functioning. 
Pre-revascularisation, both elderly and non-elderly pts had substantial impairments 
in PCS and modest impairments in MCS compared to the normative data for the US 
population. At 6m post PTCA, PCS and MCS improved substantially in both groups 
and these improvements were sustained at 1 yr post PTCA. 
Mean PCS increased significantly from 36.6 before PTCA to 43.4 at 6m post PTCA. 
Mean MCS increased significantly from 48.5 before PTCA to 50.5 at 6m post PTCA. 
Instrument and study Procedure 
Nottingham Health Profile (NHP) 306 
Caine et al. (1991) 176 I CABG 
Caine et al. (1999) 307 
Pocock et al. (1996) 225 
Wahrborg for CABRI 
(1999) 308 
CABG& 
PTCA 
CABG& 
PTCA 
General Health Questionnaire (GHQ) 309 
McKenna et al. (1992) 310 I PTCA 
Assessment point 
Pre, and 3-months, 
1 yr and 5yrs post 
Pre, 1 m, 6m and 12m post 
Pre and 1 yr post 
Pre, 2- and 10-months post 
Results 
Significant improvement in NHP scores between pre and 3m post CABG indicating 
an appreciable improvement in general health state. At 1 yr scores compared 
favourably with those from a normal male population. 
Between 1 and 5yrs post CABG, slight improvements were seen in NHP 
dimensions of pain, sleep, social isolation, and emotional reactions, whereas signs 
of deterioration were noted in the physical mobility and energy scores. 
CABG & PTCA produced marked improvement in all dimensions (energy, pain, 
emotional reactions, sleep, social isolation, and mobility) and seven aspects of daily 
living (Part 2 of NHP). pts with angina at 2 yrs scored lower than angina-free pts , 
whose perceived health was similar to population norms. PTCA pts reported 
slightly greater impairment on NHP compared with CABG pts post-
revascularisation. 
Marked improvements in QOL total score and 6 dimensions of the NHP Part 1 for 
both CABG & PTCA compared to baseline. The change in score was not significant 
for the sleep dimension in the PTCA group or for social isolation for the CABG 
group. Marked improvement in QOL in NHP Part 2. The improvement concerning 
family, social ad sexual life was not significant in either group. For both groups, 
scores at 1 yr were similar to NHP scores in a normal age-matched group. 
Highly significant changes on GHQ between pre- and 2m post PTCA. No further 
significant changes occurred between 2 and 10m indicating that the initial 
improvement was sustained over this period. 
. Functional Status Questionnaire (FSQ) . 
Allen et al. (1990) 205 I CABG & 
I\) 
--.J 
.::.. 
PTCA 
1, 6 and 12 months post CABG pts: significant improvements of functional status on every subscale (physical 
activity, social activity, work performance, mental health, quality of interaction) over 
the 1 yr follow-up. PTCA pts: significant improvements in all dimensions except for 
the quality of interaction at 1yr compared with baseline. 
Instrument and study I Procedure Assessment point 
Psychosocial Adjustment to Illness Scale (PAIS) 
Langeluddecke et al. CABG 
(1989) 159 
Folks et at. (1986) 315 CABG 
Raft et at. (1985) 314 CABG& 
PTCA 
Profile of Moods State (POMS) •• " 
Papadantonaki at al. 
(1994) 284 
~---.-
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0'1 
CABG& 
PTCA 
Pre, 8 and 12 months post 
Pre and 6-months post 
8 and 15 months post 
Pre and 3 weeks post 
Results 
Psychological morbidity prior to surgery was high, with one-third having clinically 
significant levels of depression and/or anxiety symptoms. Scores on the PAIS 
indicated a generally high level of psychosocial impairment pre-operatively, with 
vocational and domestic functioning being most severely affected, social and sexual 
functioning being less impaired, and extended family relationships being largely 
unaffected. In general, there was a significant reduction in psychological morbidity 
and an improvement in psychosocial functioning at 8m, which remained at 12m. 
Vocational and domestic functioning showed the greatest improvement. Sexual and 
social functioning showed modest improvements overall, with significant numbers 
reporting residual impairment due to their heart disease. 
Significant improvement on 4 of the 7 subscales (sexual function, vocational status, 
domestic environment, social activities). No significant changes were observed in 
patient relationships to their extended families or with psychologic distress 
displayed by the patient population as a whole. The only significant decline with 
respect to post-operative psychosocial adjustment was observed on the subscale 
examining health concems. 
Overall PAIS scores were Significantly better for pts who had undergone PTCA than 
the scores for those who had undergone CABG after 8m, and this superior 
functioning continued after 15m. After 8m pts who had undergone PTCA functioned 
Significantly better at work, in sexual performance and with their families. The 
significant improvement in work functioning continued at 15m, but the differences in 
sexual and family domains became non-significant. 
No difference in overall POMS or individual subscales between CABG and PTCA 
pts before revascularisation. Overall mood state improved for pts in both CABG 
and PTCA groups after the procedure compared with their scores before the 
procedure. However, there was a significantly greater improvement in mood for the 
PTCA than the CABG group. Improved mood for both groups was significant for all 
subscales except vigor. 
- -----
Instrument and study Procedure Assessment point 
Spielberger's State-Trait Anxiety Inventory (STAI) 317 
Pinna Pintor et al. CABG Pre and post-op 
(1992) 166 
Faris & Stotts (1990) 255 PTCA Pre and 6 weeks post 
Zung Depression Scale 318 
Pinna Pintor et al. CABG Pre and post-op 
(1992) 166 
Psychological General Well-being Index (PGWB) 311 
Her1itz et al. (2000) 312 CABG Pre and 5yrs post 
Social Activities Questionnaire 
Lindsay et al. (2000) 304 CABG Pre and 12 months post 
Key: 
Pts: Patients 
PCS: Physical Component Summary Score of the SF-36 
MCS: Mental Component Summary Score of the SF-36 
I\.) 
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Results 
No change in trait anxiety, but improvement in state anxiety after CABG. Pts who 
experienced cardiac events were characterised by significantly higher levels of state 
anxiety at the pre and post-operative evaluations than those who did not experience 
cardiac events. 
No change in trait anxiety scores, but significant decrease in state anxiety scores 
afterPTCA 
Depression scores were significantly worse than before surgery 
I 
Significant improvement in all six dimensions (anxiety, depression, well-being, self-
control, health, vitality) 
A higher social network score and higher pre-operative heath status were 
associated with improved health status. High levels of social support were 
associated with improved health status post operatively. 
I\.) 
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TABLE 3.1 Search Strategy for Computerised Bibliographic Databases 
Medline I Health Star Psych Lit 
Thesaurus terms 
Heart diseasel all subheadings 
Myocardial ischaemia! all subheadings 
Coronary artery bypassl all subheadings 
Angioplasty-transluminal percutaneous coronaryl all subheadings 
Text words 
Quality of life Heart disease 
Questionnaire* Heart surgery 
Interview* Cardiac 
Health status Quality of life 
Disease-specific* Questionnaire 
Disease specific* Psychometric 
Outcome measure 
Outcome assessment 
Patient-based 
Self-assessment 
Self-administered 
Self-report 
Psychometric 
Patient satisfaction 
Expectation* 
Well-being 
-
-_._---
* indicates that the text word can be followed by any letter, for example questionnaire* is used to identify 
articles containing the words questionnaire and questionnaires. 
TABLE 3.2 Cardiac-Specific Patient-Based Questionnaires: Psychometric Properties 
Question naire 
•• Cleary et a/.'s 
Battery: Cleary et I scales 
al (1991) 
Coronary Health 
Profile: Karlsson 
1999 
Modified Physical 
Functioning 
Questionnaire: 
Faris & Stotts 
(1990) & 
Papadantonaki 
I\.) 
'-l 
OJ 
Total (0.82): 
[Papadantonakll 
Reliability Content 
validity 
existing 
measures 
Confirmed 
by 
clinicians, 
nurses & 
Based on 
existing 
measures 
Criterion-related 
validity 
Concurrent 
Construct validity 
Convergent (r) 
Moderate inter-
scale scaling 
correlations. assump-
Large battery of tions 
existing scales 
Responsiveness 
significant change 
after 1 month. 
Most responsive: 
dyspnoea, angina, 
emotional 
Scores showed 
improvement over 
time for CABG & 
PTCA 
Questionnaire 
. - Perception of 
the Waiting 
Period 
QUestionnaire: 
Pieper at al. (1985) 
Problems of 
cardiac patients 
in early recovery 
questionnaire: 
Jaarsma et aI. 
(1995) 
Prospective study 
of QOl before & . 
after CABG: Caine 
at a/. (1991) 
Quality of life 
during 
rehabilitation 
afterCABG: 
Engbolm at aI. 
(1992) 
I\) 
~ (0 
Internal 
consistency (a) 
Life effect (0.70), 
Life rating (0.70), 
Relationship 
effect (0.87), 
Relationship 
rating (0.57) 
-
-
-
Reliability Content 
validity 
Test-retest Inter-
(rnCC) rater (k) 
- -
Confirmed 
by nurses 
- -
Confirmed 
by panel of 
experts 
- - -
- - -
Criterion-related Construct validity Responsiveness 
validity 
Concurrent Predic- Convergent (r) Discrimi- Known Factor 
tive nant (r) groups analysis 
- -
T otallife-effect - The greater - -
score correlated the concern 
significantly with about 
the tension- surgery, the 
anxiety, greater was 
depression- the 
dejection, perceived 
fatigue-inertia effect of 
scales of POMS waiting on 
life & 
relationship 
with partner 
- - -
- - - -
- - -
- - - -
- - - - -
- -
Reliability Content Criterion-related Construct validity Responsiveness 
validity validity 
Questionnaire Internal Test-retest Inter- Concurrent Predic- Convergent (r) Discrimi- Known Factor 
consistency (a) (rnCC) rater (k) tive nant (r) groups analysis 
** Quality of Life 
-
(0.74) Total Confirmed - - Highly correlated - - - Sensitive to 
Index - Novl Sad [2-3 wk variance by to Parsonnet change between 
(QOLi-NS): Potic interval] explain- clinicians, pre-operative risk pre-surgery and 6, 
at a/. (1999) ed pts, scores (0.99) 12 and 24 month 
99.1% literature follow-up 
review, & 
existing 
measures 
Self-report of 
- - - - - - - - - -
-
recovery 
questionnaire: 
Gartner at 81. 
(1994) 
Symptoms of Total (0.84) 
- -
Based on 
- - -
Not - YES -
Illness Factor existing correlated 
Score: Jenkins at measures with neuro-
81. (1994) psycholo-
gical 
function, 
personal 
relps, or 
economic 
variables 
Waiting List 
- - -
Confirmed 
- - - -
-
-
-
Impact by pts 
Questionnaire 
(WUQ): Teo et 81. 
cl!!98L_ _ _ _ _ ___ __ ,-
I\) 
~ 
QUestionnaire 
Wythenshawe 
Hospital 
Cardiothoracic 
Outcomes Study : 
Bridgewater et al. 
(unpublished) 
Zyzanski's 
Behavioural 
Change Scales: 
Zyzanski at al. 
(1981 ) 
Angina Impact 
Questionnaire 
(AIQ): Wilson at al. 
(1991 ) 
Angina Pectoris 
Quality of life 
Questionnaire 
(APQLQ): Wiklund 
et al. (1991) 
Swedish Version 1 
'" ()) 
-" 
Reliability 
Internal 
Problematic due 
to high % of 
missing data 
Mean item-total 
correlations range 
between 0.50-
0.79 for the 4 
scales 
Total (0.85) 
Test-retest I Inter-
rater (k) 
Confirmed 
by 
clinician.s 
review 
r.rit .. rinn_r .. lated 
Concurrent Predic- I Convergent (r) 
tive 
Total exercise 
time related to 
physical 
dimension 
Construct validity 
Discrimi-
nant (r) 
Responsiveness 
YES 
Reliability Content Criterion-related Construct validity Responsiveness 
validity validity 
Questionnaire Internal Test-retest Inter- Concurrent Predic- Convergent (r) Discrimi- Known Factor 
consistency (a.) (rnCC) rater (k) tive nant (r) groups analysis 
** French version Global (0.95), 
- - - - -
High level inter- Item Asymptom- YES Physical activity 
Angina Pectoris Physical (0.82), scale convergent atic pts had scale responsive 
Quality of Life Symptoms (0.87), correlatiQns & discrim- better aOL. afterCABG 
Questionnaire Emotional (0.90), (>0.60) suggests inant aOL 
(APQLQ): Marquis Life Satisfaction one global validity reduced 
at aI. (1995) (0.87) concept. (84-91% with 
Expected success increasing 
correlations with rate) angina pain. 
SF-36, eg Discrimin-
physical activity ated betw 
scale & SF-36 symptom-
Physical atic & 
Functioning asymptom-
(0.76) atic pts 
(except 
Emotional) 
** Angina-Related Total (0.97) 
- -
Confirmed 
- -
Degree of work Not - - -
Limitations at by patient limitation correlated 
Work focus correlated with 
Questionnaire: group significantly with gender, 
Lerner at aI. (1998) SF-36 & with self age, 
reports of angina education 
symptoms or income 
Angina TyPE 
- - - - - - -
- - - -
Specification 
Form: Health 
Outcomes Institute 
Database (1997) 
N 
~ 
Questionnaire 
- Quality of Life 
Questionnaire for 
Angina Pectoris: 
Marquis (1995) 
RAND Chest Pain 
(Angina) Battery: 
Berman at a/. 
(1981) 
Rose 
Questionnaire 
(London School 
of Hygiene Chest 
Pain I 
Cardiovascular 
Questionnaire): 
Rose et aI. (19n) 
Rose (London 
School of Hygiene 
Dyspnoea) 
Questionnaire: 
Rose et aI. (1982) 
N Q) 
U) 
Internal 
consistency (a) 
SF-36 (0.80-
0.95), APQLQ 
(0.95), 3 single 
item scales. 
Patient's 
complaint module 
not evaluated 
-
-
-
Reliability Content 
validity 
Test-retest Inter-
(rIlCC) rater (k) 
- -
Confirmed 
by 
clinicians, 
pts, 
literature 
review . 
. 
Composed 
ofSF-36. 
APQLQ3 
new items 
& 9-item 
patient's 
complaints 
module 
- -
Based on 
Rose 
Questionn-
aire 
- - -
- - -
Criterion-related Construct validity Responsiveness 
validity 
Concurrent Predic- Convergent (r) Discrlmi- Known Factor 
tive nant (r) groups analysis 
- - - -
Asymptom-
- -
atic pts had 
better QOL. 
pts with 
lowest 
number of 
attacks 
reported 
best QOL. 
QOL 
decreased 
with 
increasing 
chest pain 
- - -
- Distinguish- - -
ed subjects 
who had 
angina 
- Predict Validated against - - - -
or of clinician 
CHD diagnosis of 
mortal- angina 
ity, 
ECG 
abnorm 
-ality 
- - -
- - -
-
-Reliability Content Criterion-related Construct validity Responsiveness 
validity validity : 
Questionnaire Internal Test-retest Inter- Concurrent Predic- Convergent (r) Discrimi- Known Factor i 
consistency (a.) (rIlCC) rater (k) tive nant (r) groups analysis 
- Seattle Angina Physical (0.89), Physical 
- Confirmed - - All 5 scales - No signif - 4 of the 5 SAQ 
Questionnaire Anginal (0.83), by correlated changes scales responsive 
(SAQ): Spertus et Frequency (0.87), Anginal clinicians significantly with amongst 3m after PTCA 
a/. (1995) Treatment Stability other measures stable pts More responsive 
Satisfaction (0.24), of diagnosis and after 3m. than SF-36 
(0.77), Disease Anginal patient function. Unstable 
Perception (0.66) Frequency E.g. Physical & pts scored 
(Dougherty et a/. (0.76), treadmill lower on 
1998) Treatment performance, Anginal 
Satisfaction Disease stability. 
(0.81), Perception & SF- Signif. 
Disease 36GHP scale Difference 
Perception (0.60), treatment in scores 
(0.78). Satisfaction & between 
Analyses external measure CCS grades 
performed in (0.67) 
stable pts 
baseline and 
3m later 
-
I\) 
~ 
Questionnaire 
** Summary Index 
(51) for the 
assessment of 
quality of life in 
angina pectoris: 
Wilson at al.(1991) 
Questionnaire: 
Wiklund at al. 
(1992) 
** Heart Patients 
Psychological 
Questionnaire: 
Erdman (1982) 
N 
ex> 
01 
I 
I Int~rnal 
Total (0.94), 
Impact (0.95), 
Physical (0.96), 
Vitality (0.98), 
Alertness (0.98), 
Self-control 
(0.98), Emotional 
(0.91 ) 
Symptoms (0.77), 
Mental (0.85), 
Physical (0.78), 
Social functioning 
(0.60), Social 
integration 
(0.10), Life Events 
(0.44) 
ity Content 
validity 
I T ~st-retest Inter-
rllCC) rater (k) 
Total (0.84), - Confirmed 
Impact by 
(0.77), clinicians & 
Physical literature 
(0.84), review 
Vitality 
(0.76), 
Alertness 
(0.69), Self-
control 
(0.77), 
Emotional 
(0.83) 
[4wk 
interva 
Based on 
existing 
measures 
Well-being 
(0.73), 
Disability 
(0.85), 
Displeasure 
(0.80), Social 
Criterion-related Construct validity I Responsiveness 
validity 
Concurrent Predic- Convergent (r) Discrimi- Known Factor 
tive nant (r) groups analysis 
- - Overall index - - YES Detected more 
correlated with change at 3m than 
symptom scores 6wks. All 
& negatively categories showed 
correlated to >30/0 improvement. 
frequency of More responsive 
attacks. Majority than PGWB. 
of inter-scale But pts had been 
correlations were on treatment 
moderate . before they 
entered the study 
Inter-scale Symptom-
correlat- atic pts had 
ions worse 
generally HRQoL 
moderate 
to low 
«0.50) 
Low to moderate Low 
intercorrelations. correlat-
Moderate ions with 
correlations with age, sex 
external criteria 
Questionnaire 
- Quality of Ute 
after acute MI 
(QLMI): Oldridge et 
al (1991), 
Hillers et a/. (1994) 
- Modified 
Quality of Ufe 
after acute MI 
(QlMI-1): Um et 
aJ. (1993) 
- Modified 
Quality of Ute 
after acute MI 
(QLMI-2): Valenti 
at aJ. (1996) 
I\) 
(X) 
m 
Reliability 
Internal Test-retest 
consistency (a) (rnCC) 
Symptoms (0.59), Symptoms 
Restrictions (0.83), 
(0.73), Restrictions 
Confidence (0.75), 
(0.50), Self- Confidence 
esteem (0.78), (0.87), Self-
Emotion (0.83) esteem 
(0.85), 
Emotion 
(0.86) & 
Total (0.86). 
[8-12m 
interval] 
Emotional (0.94), No values, 
Physical (0.89), but based on 
Social (0.84) QlMlwhich 
is 
reproducible 
Emotional (0.95), 
-
Physical (0.93), 
Social (0.95) 
Content 
validity 
Inter-
rater (k) 
- Confirmed 
by 
clinicians, 
pts, 
literature 
review, & 
existing 
measures 
-
Confirmed 
by 
clinicians, 
pts, 
literature 
review, & 
existing 
measures 
- Confirmed 
by 
clinicians, 
pts, 
literature 
review, & 
existing 
measures 
Criterion-related Construct validity Responsiveness 
validity 
Concurrent Predic- Convergent (r) Discrimi- Known Factor 
tive nant (r) groups analysis 
- -
Highly correlated 
- Oistinguishe YES Responsive over 
to emotional d between 12 months. 
function. treatment & Emotional 
Moderately control dimension more 
correlated to groups responsive than 
utility measures. existing measures. 
QWB, BOI, 12 month effect 
POMS, Katz sizes: Total (1.22), 
instrument of Restrictions (1.34), 
social function Confidence (1.43) 
- -
No details, but 
-
Previous MI YES Responsive to 
claim "good & differences 
construct validity" rehospitalis between treatment ) 
ed pts groups 
scored 
lower, as 
expected 
- -
Similar scores as 
-
QOLhigher YES 
-
previous study of for pts with 
QlMI-1 no previous 
MI and no 
hospital re-
admittance 
Questionnaire 
WHO 
Rehabilitation 
Failure 
Questionnaire 
(CHQ): Guyatt et 
al. (1989) 
Disease Specific 
Questionnaire for 
Severe Heart 
Failure: Cowley et 
al. 
Heart Failure 
Functional Status 
Inventory: Dracup 
et al (1992) 
Walden et a/. 
(1989, 1994) 
I\.) 
CD 
-....J 
Reliability 
Internal Test-retest 
with 25 pts 
- -
Content Criterion-related 
validity validity 
Concurrent Predic-
tive 
by 
clinicians, 
pts, & 
literature 
review 
YES Based on - -
existing 
measures 
Construct validity I Responsiveness 
Convergent (r) Discrimi- Known Factor 
nant (r) groups analysis I Sensitive to 
improvement at 6 
& 12 months 
::::::;:::: ::::::::;.:- '-"'-';r~~;~;~f?r? 
Six min walking Distinguished pts 
test (0.60), who improved & 
NYHA (0.42). those who didn't. 
Moderate Correlations 
correlations with between CHQ & 
pts' global pts global ratings 
ratings of of change in 
dyspnoea, dyspnoea, change 
fatigue, & in walking test 
emotional score & change in 
heart failure 
classification I (C 
Discriminat-
ed between change in 
treatment treatment group vs 
and placebo placebo group 
PAIS Total score Not 
(0.31). Ejection correlated 
fraction & 6 min with age, 
walk results & sex, 
self-reported marital 
activity level are status 
correlated 
Questionnaire 
- Kansas City 
Heart Failure 
Questionnaire 
(KCHFQ): Green 
et a/. (2000) 
- Left Ventricular 
Dysfunction 
Questionnaire 
(LVD-36): O'Leary 
& Jones (2000) 
I\) 
Q) 
Q) 
Reliability 
Internal Test-retest 
consistency (a) (rftCC) 
Physical limitation No Significant 
(0.90), Symptoms change in 
(0.88), Quality of scores for 
life (0.78), Social clinically 
limitation (.86), stable pts 
Self-efficacy between 
(0.62), KCCQ baseline and 
functional status 3 months 
(O.93), KCCQ 
clinical summary 
(0.95) 
Kuder- 0.95 
Richardson's [1-3wks 
coefficient interval1 
(0.95) 
Content Criterion-related 
validity validity 
Inter- Concurrent Predic-
rater (k) tive 
-
Confirmed 
- -
by 
clinicians, 
pts, 
literature 
review, & 
existing 
measures 
-
Confirmed 
- -
by 
clinicians, 
pts, 
literature 
review, & 
existing 
measures 
Construct validity Responsiveness 
Convergent (r) Discrimi- Known Factor 
nant (r) groups analysis 
Physical 
- Statistical - Very sensitive to 
limitations with difference changes in 
NYHA (0.65), between cardiomyopathy 
SF-36 Physical mean status (3 months 
limitations (0.84), symptom apart). 
QOL domain and scores and Responsiveness 
SF-36 GHP mean statistics range 
(0.45), LlhFE Functional between 0.62 -
(0.62), Social status 3.19. More 
domain and SF- scores for responsive than 
36 Social (0.62), NYHA the SF-36 and the 
Functional status classes LlhFE 
and NYHA 
(0.55), clinical 
summary score 
and NYHA (.55) 
More correlated Not - YES Responsive 
to physical health correlated between baseline 
of SF-36 than to age, &6 months. 
psychological. gender or Change in LVD-36 
Weak correlation aetiology was strongly 
between LVD-36 related to a 
& ECG, but transition question 
sign if. correlation measuring global 
with exercise test change 
Questionnaire 
- Kansas City 
Heart Failure 
Questionnaire 
(KCHFQ): Green 
et aI. (2000) 
- Left Ventricular 
Dysfunction 
Questionnaire 
(LVD-36): O'Leary 
& Jones (2000) 
I\) 
(X) 
CD 
Reliability 
Internal Test-retest 
consistency (a) (rftCC) 
Physical limitation No significant 
(0.90), Symptoms change in 
(0.88), Quality of scores for 
life (0.78), Social clinically 
limitation (.86), stable pts 
Self-efficacy between 
(0.62), KCCQ baseline and 
functional status 3 months 
(0.93), KCCQ 
clinical summary 
(0.95) 
Kuder- 0.95 
Richardson's [1-3wks 
coefficient intervaij 
(0.95) 
Content Criterion-related 
validity validity 
Inter- Concurrent Predic-
rater (k) tive 
- Confirmed - -
by 
clinicians, 
pts, 
literature 
review, & 
existing 
measures 
-
Confirmed 
- -
by 
clinicians, 
pts, 
literature 
review, & 
existing 
measures 
Construct validity Responsiveness 
Convergent (r) Discrimi- Known Factor 
nant (r) groups analysis 
Physical 
- Statistical - Very sensitive to 
limitations with difference changes in 
NYHA (0.65), between cardiomyopathy 
SF-36 Physical mean status (3 months 
limitations (0.84), symptom apart). 
QOL domain and scores and Responsiveness 
SF-36 GHP mean statistics range 
(0.45), LlhFE Functional between 0.62 -
(0.62), Social status 3.19. More 
domain and SF- scores for responsive than 
36 Social (0.62), NYHA the SF-36 and the 
Functional status classes LlhFE i 
and NYHA 
(0.55), clinical 
summary score 
and NYHA (.55) 
More correlated Not 
-
YES Responsive 
to physical health correlated between baseline 
of SF-36 than to age, &6 months. 
psychological. gender or Change in LVO-36 
Weak correlation aetiology was strongly 
between LVD-36 related to a 
& ECG, but transition question 
signif. correlation measuring global 
with exercise test change 
Questionnaire 
-Self 
Assessment of 
quality of life in 
severe heart 
failure (QLQ-
SHF): 
Wiklund at at. 
(1987) 
Self-Management 
of Heart Failure: 
Riegel at at. (2000) 
Cardiac 
Adjustment Scale: 
Rumbaugh (1965) 
I'V 
CD 
o 
Reliability 
Internal 
consistencl 
Total (0.88) Total (0.82), 
Somatic 
(0.82), Life 
Satisfaction 
(0.75), 
Psycholog-
ical (0.79), 
Physical 
(0.8 
Alpha ranged 
between 0.79 and 
0.92 for all 6 
subscales 
authors 
judgement 
& patient 
complaints 
Confirmed 
by experts, 
pts, & 
literature 
Concurrent 
tive 
Convergent (r) 
Somatic with 
physical (0.33). 
Correlations with 
SIP, Mood 
Adjective 
Checklist NYHA 
(0.42-0.72) 
Construct validity 
nant 
Psycholog-
ical with 
physical 
(0.36) 
Known 
groups 
Conflicting 
results of its 
ability to 
discriminate 
between 
active 
treatments 
and placebo 
Factor 
analysis 
YES 
Responsiveness 
Moderately 
sensitive to small 
changes in HRQoL 
Questionnaire 
** Cardiac Denial 
of Impact Scale: 
Fowers (1992) 
** Cardiac 
Depression Scale: 
Hare & Davis 
(1995) 
** cardiac Health. 
Profile (CHP): 
Wahrborg& 
Emanuelsson 
(1996) 
I\.) 
<0 
~ 
Internal 
consistency (a) 
Total (0.72) 
Total (0.90) 
Total (0.89) 
Reliability 
Test-retest 
(rnCC) 
(0.71) 
[3 wi< 
interval] 
-
Results 4 
weeks prior 
to 
angiography 
compared 
with before 
catheteris-
ation (0.93) 
Content Criterion-related 
validity validity 
Inter- Concurrent Predic-
rater (k) tive 
-
Based on 
- -
existing 
measures 
- Confirmed Beck -
by health Depression 
profession- Scale (0.73) & 
als clinical ratings 
of depression 
(0.67) 
-
Confirmed 
- -
by 
clinicians & 
pts 
Construct validity Responsiveness 
Convergent (r) Discrimi- Known Factor 
nant (r) groups analysis 
Supported by its Not 
- . -
-
pattern of correlated 
correlations with with age, 
M ultidirnensional ethnicity, 
Health Locus of gender, 
Control Scale & number of 
Marlowe Crowne cardiac 
Scale. events 
Negatively 
related to 
measures of 
both physical & 
psychological 
distress (various 
instruments) 
-
Not - YES -
correlated 
with age 
CHP outcome - Significant YES Compared before 
score & global difference angiography (29.1) 
NHP score (0.75) between & afierCABG 
mean (23.2) scores. 
scores for No PTCA scores 
angina pts reported I 
(35.7) & 
control 
(22.5) pts 
Questionnaire 
- Duke Activity 
status Index 
(DASI): Hlatky, et 
aI. (1989) 
Expectations and 
Satisfaction 
Questionnaire: 
Staniszewska & 
Ahmed (2000) 
-Ferrans& 
Powers Quality of 
Life Index: (QLI-
Cardiac Version 
III): Ferrans & 
Powers (1985) 
{Faris & Stotts, 
1990J 
(Papadantonaki, 
1994) 
- Global Moods 
Scale (GMS): 
Denollet (1993) 
"-> 
«) 
"-> 
Internal 
consistency (a) 
-
-
Overall (0.98), 
Functioning 
(0.90), 
Socio-economic 
(0.89), 
Psychological 
(0.90), Family 
(0.79) 
[Papadantonaki, 
1994J 
Negative Affect 
(0.66) 
Positive Affect 
(0.57) 
Reliability Content 
validity 
Test-retest Inter-
(rIlCC) rater (k) 
- -
Confirmed 
by 
clinicians 
- -
Confirmed 
by pts 
(0.87) 
-
Based on 
[2wk Ferrans & 
intervaq Powers' 
(Faris & generic 
Stotts, 1990J aLI 
measure 
(0.55) 
-
Devised to 
[3rn intervaq reflect two-
dimension-
al model of 
mood 
Criterion-related Construct validity Responsiveness 
validity 
Concurrent Predic- Convergent (r) Discrimi- Known Factor 
tive nant (r) groups analysis 
- -
Peak O2 uptake - - - -
(0.58) 
- - - - - - -
- -
Correlations Moderate No signif. 
-
Only overall aOL 
between Total correlat- differences & Functioning 
score and ions with in aLI scale improved in 
subscales external scores both gps over 
o.n -0.90 measures between time. 
{Faris & Stotts, CCS grades Psychological 
1990J [Dougherty scale not as 
et at. 1998] sensitive as 
POMS 
[Papadantonaki, 
1994J 
- -
A series of Consistent - YES Rehab pts 
hypothesised pattern of reported sign if. 
correlations with convergent increase in 
the subscales of & positive affect & 
the POMS & discrirnin- decrease in 
STAI ant validity negative affect 
after 3m 
---
_ .. _ ... _-
-
Questionnaire 
** Health 
Complaints Scale 
(HCS): Denollet 
(1994) 
** 
Multidimensional 
IndexofUfe 
Quality (MLlQ): 
Avis et aI. (1996) 
** Cardiac Quality 
of Life Index 
(CQLI): Rukholm 
et aI. (1998) 
"-> CO 
W 
Reliability 
Internal T est-retest 
consistency (a.) (rnCC) 
All scales ~ 0.89 All scales ~ 
0.69 
[3m interval] 
All above 0.76 (0.62 to 
except Social 0.84) 
Functioning 
(0.62) [10-21 day 
interva~ 
Total (0.87) Total (0.81) 
Content Criterion-related 
validity validity 
Inter- Concurrent Predic-
rater (k) tive 
- Based on 
- -
existing 
measures 
-
Confirmed 
- -
by 
clinicians, 
pts, 
literature 
review, & 
existing 
measures 
- Based on - -
Padilla & 
Granfs 
Quality of 
Life Index 
& expert 
opinion 
Construct validity Responsiveness 
Convergent (r) Discrimi- Known Factor 
nant (r) groups analysis 
Correlated to Not 
-
YES Rehab subjects 
STAI, Symptom correlated but not controls 
Checklist-90 & to reported signif. 
Heart Patients measures decrease in 
Psychological of self- somatic & 
Questionnaire deception cognitive health 
& social complaints after 
inhibition 3m 
PhYSical Health Physical & 
- - -
& Physical Mental 
Functioning Health 
(0.68). scales 
Correlations with correlated 
criterion 0.57 
measures 
ranged 0.51 to 
0.78 (exceeded 
0.70 for 4 
domains). 
Used several 
I QOL measures 
Positively - Discrimin- YES -
correlated to ated healthy 
Spitzer's global pts from 
measure of QOL those with 
(0.67) cardiac 
illness 
Reliability Content Criterion-refated Construct validity Responsiveness 
validity validity 
Questionnaire Internal Test-retest Inter- Concurrent Predic- Convergent (r) Discrimi- Known Factor 
consistency (a) (rIlCC) rater (k) tive nant (r) groups analysis 
- Reduced Duke Ranged between 46 stable pts 
-
Confirmed CCS (-0.51), 
- -
- Stable pts - Effect size after 
Activity Status 0.81-0.89 [2wk by exercise test scored PTCA = 0.75, for 
Index: Alonso at interval] clinicians (0.45) higher than stable pts =0.22 
aI.(1997) those 
undergoing 
PTCA 
Soderlind et ai's 
- - - - - - - - -
- -
Quality of Life 
Questionnaire: 
Soderlind et aI. 
(1997) 
Specific Activity 
- - - - - -
Significantly - - - -
Questionnaire: correlated to 
Rankin at aI. (1996) measured peak 
V02 (0.57) 
Symptom Scale: Total (0.92), 
- -
Confirmed 
- -
Stable - - - -
Keresztes et aI. Angina (0.87), by correlations in 
(1993) Shortness of clinicians & the expected 
Breath (0.86), literature direction 
Fatigue (0.85) review between all 
instruments with 
the MET level 
achieved on the 
treadmill 
_ ... 
. ... 
I\) 
f. 
-Questionnaire 
- Utility Based 
Quality of Ute-
Heart 
Questionnaire: 
Martin at aI. (1999) 
Veterans Specific 
Activity 
Questionnaire: 
Myers at aI. (1994) 
KEY 
-
Pts 
YES 
ICC 
MET 
PGC-MAI 
PGWB 
Reliability Content Criterion-related Construct validity 
validity validity 
Internal Test-retest Inter- Concurrent Predic- Convergent (r) Discrirni- Known 
consistency (a) (rIlCC) rater (k) tive nant (r) groups 
Psychological Psycholog-
- - - -
Correlations with - pts with 
distress (0.91), ical distress otherQOL sign if. 
Self-care (0.79), (0.81), Self- questionnaires anginal 
Social activities care (0.65), (GHQ & Life dyspnoea 
(0.85), Physical Social Satisfaction A) scored 
ability (0.80) activities followed the signif. 
(0.71), expected pattern worse than 
Physical other pts 
ability (0.76) 
- - - - - - - - -
, 
Details not found. Instruments with testing ongoing are included in table, but assigned • _. where the results are not yet given 
Questionnaire met minimum reliability and validity criteria. 
Patients. 
Responsiveness 
Factor 
analysis 
-
Detected changes 
in clinical status 
for who 
experienced 
adverse event 
- -
Authors claim the measure satisfies criteria, but values not given in instrument development paper, or too much information to summarise 
Intra class correlation coefficient. 
Metabolic equivalents. 
Philadelphia Geriatric Centre Multilevel Assessment Instrument. 
Psychological General Well-Being Index. 
1 The paper describing the psychometric properties of this questionnaire is published in Swedish restricting the critique of the psychometriC properties. 
I\.) 
(0 
01 
TABLE 3.3 Selected Reliable and Valid Cardiac-Specific Patient-Based Questionnaires: Item Reduction, Responsiveness and 
Validated language Versions 
Questionnaires 
Perception of the Waiting Period Questionnaire 
Quality of Life Index - Novi Sad (QOLi-NS) 
i.!m~IIIIIIIIHt:I:M:II:m::fI:r:::fI:rI:::l:I::r:II::::II:tIIM::r::r::rmI:r 
Angina Pectoris Quality of Life Questionnaire 
: French version 
Angina-Related Limitations at Work 
Questionnaire 
Quality of Life Questionnaire for Angina 
Pectoris 
Seattle Angina Questionnaire (SAQ) 
Summary Index for QOL in angina (SI) 
t\) 
<0 
0) 
Patient group 
CHD: Pre-CABG 
only 
CHD: CABG only 
CHD: Angina only 
CHD: Angina only 
CHD: Angina only 
CHD: Angina only 
I CHD: Angina only I 
Included item Responsiveness Validated language versions (country) 
evaluated 
,/ English (USA) 
English (USA) 
,/ ,/ Serbo-Croatian (yugoslavia) 
English (USA) 
French (France) 
,/ English (UK, USA, Australia, New Zealand & 
Canada) , Italian (Italy), Spanish (Spain), Norwegian 
(Norway), Dutch (Belgium & The Netherlands), 
Danish (Denmark), German (Germany), Swedish 
French (France, Belgium & Can 
,/ ,/ Finnish (Finland) 
Questionnaires 
Mi§iif.4fAlIhit.tai.iijlffi:itI:::i:tiIII'::i:fffflffi?fiIItm:tII 
Heart Patients Psychological Questionnaire 
Quality of life after Acute MI (QlMI) 
Quality of Life after Acute MI (QlMI-1) 
Quality of life after Acute MI (QlMI-2) 
naire 
lar Dysfunction Questionnaire 
Minnesota Living with Heart Failure 
Questionnaire (LlhFE) 
Self Assessment of Quality of Life in severe 
Heart Failure Questionnaire 
I\) 
<0 
........ 
Patient group 
CHD: MI only 
CHD: MI only 
CHD: MI only 
Heart failure 
Heart failure 
Heart failure 
Heart failure 
Heart failure 
Included item Validated language versions (country) 
./ ./ English (Canada) 
./ ./ English (Australia) 
./ ./ 
./ English (USA) 
./ ./ English (UK) 
./ English (USA. Canada & UK. Australia) . French 
(France. Canada. Switzerland & Belgium). 
Portuguese (Portugal. Brazil) . German (Germany) . 
Norwegian (Norway). Swedish (Sweden) . Dutch 
(The Netherlands & Belgium). Hebrew (Israel). 
Polish (Poland) . Italian (Italy) . Danish (Denmark) . 
Finnish 
./ Swedish (Sweden) 
Questionnaires 
Cardiac Depression Scale 
Cardiac Health Profile (CHP) 
uke Activity Status Index (DASI) 
of Life Index: (QLI-
Health Complaints Scale (HCS) 
Multidimensional Index of Life Quality (MLlQ) 
Cardiac Quality of Life Index (CQLI) 
Reduced Duke Activity Status Index 
Utility Based Quality of Life-Heart 
Questionnaire 
I\) 
<0 
CD 
Patient group 
Cardiac: General 
CHD: General 
Cardiac: General 
CHD: General 
CHD: General 
CHD: General 
Cardiac: General 
Cardiac: General 
CHD: General 
Cardiac: General 
Included item Validated language versions (country) 
./ 
-
English (Australia) 
./ ./ Swedish (Sweden) 
- -
English (USA) 
- -
English (USA), Spanish (Spain), Norwegian 
./ ./ 
./ ./ Dutch (Belgium) 
./ 
-
English (USA) 
- -
English (Canada) 
./ ./ Spanish (Spain) 
-
./ English (Australia) 
TABLE 3.4 Content Domains Included in Reliable and Valid Cardiac-Specific Patient-Based Questionnaires 
Satisfaction 
Questionnaires Cardiac Physical Psychological Social General Adverse with Expectations 
symptoms well-being effects treatment 
]§§rgB'::@!!@.§imii@li.§i.:I:f::;::::!:::::::::::;'tIII?IImm?fff???:I;:':t;:t:::ff?:::?f;t;f:::t:::;?::tI::::': i:iWfi{i,::;i::it::::::::.:::::::t::'::ri,{"'::::::::::::::i:t:,:}{:::::::i::,:/::::::::::'::::i::::::::::;;:;:;:\t:},t:,::::: !t::'::::::::}\'/?':·1:::::::!:!:::::,:'::'::t:,::::.::&::::;::::;; ·:;;),:,i:}::: .. }":':, :::::I::::::{m::::::::::::::::::::{:::::::!::f'!:::II:::::::::!:!::I:!::::!J!1 
Cleary et ai's Battery •••••
Perception of the Waiting Period Questionnaire 
Quality of Life Index - Novi Sad 
(QOLi-NS) 
Angina Pectoris Quality of Life Questionnaire 
(APQLQ): French version 
Angina-Related Limitations at Work 
Questionnaire 
Quality of Life Questionnaire for Angina Pectoris 
Seattle Angina Questionnaire (SAQ) 
Summary Index for QOL in angina (SI) 
Heart Patients Psychological Questionnaire 
Quality of life after Acute MI (QLMI) 
Modified Quality of Life after Acute MI (QLMI-1) 
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Questionnaires Cardiac Physical Psychological Social General 
symptoms well-being 
Modified Quality of Life after Acute MI (QLMI-2) • • • • • 
Riin:t ... ti::::::::i::i::::::::::::::::::'::I:::::::::::::tt::::::::::::t:::::::::::i::II:::::::::i::::::i::::::::::::I:I:Im:::::::I:::~ 
Chronic Heart Failure Questionnaire (CHQ) • • • 
Kansas City Heart Failure Questionnaire • • • • • 
(KCHFQ) 
Left Ventricular Dysfunction Questionnaire • • • • 
(LVD-36) 
Min~esota Living with Heart Failure •• • • 
Questionnaire (LlhFE) 
Self Assessment of Quality of Life in severe • •• • 
Cardiac Denial of Impact Scale (CD IS) • 
Cardiac Depression Scale 
Cardiac Health Profile (CHP) 
Duke Activity Status Index (DASI) 
Ferrans & Powers Quality of Life Index: (QLI-
Cardiac Version III) 
Global Moods Scale (GMS) 
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Satisfaction 
Adverse with Expectations 
effects treatment 
• • 
• 
• 
Questionnaires 
Health Complaints Scale (HCS) 
Multidimensional Index of life Quality (MLlQ) 
Cardiac Quality of Life Index (CQLI) 
Reduced Duke Activity status Index 
Utility Based Quality of Ufe-Heart Questionnaire 
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Satisfaction 
Psychological Social General Adverse with Expectations 
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I-- Content domain I 
Symptoms 
(pre- and post-revascularisation) 
Medication 
(pre- and post-revascularisation) 
limitations in daily activities 
(pre- and post-revascularisation) 
Psychological functioning 
(pre- and post-revascularisation) 
Cognitive functioning 
(pre- and post-revascularisation) 
Social functioning 
(pre- and post-revascularisation) 
TABLE 4.1 Qualitative Interview Topic list 
Topics 
Type of symptoms 
Severity I intensity of symptoms I bothersome ness 
Which activities I situations induce the symptoms 
Frequency & bothersomeness of taking medication 
Interference with employment 
Interference with activities which are physically demanding (shopping I 
housework I gardening) 
Disturbance of other activities (lifting light objects, walking, stairs) 
Disturbance of self-care (dressing, bathing) 
Interference with recreational activities 
Interference with social activities 
Disturbance of sleep (restless, early wakening. discomfort, anxiety) 
Feelings about coronary heart disease (anxiety, depression, frustration) 
Feelings I fears about CABG I PTCA 
Fear of death I heart attacks 
Coping 
Trouble keeping attention and concentrating 
Memory problems 
Difficulties reasoning I making decisions 
Speed of reactions 
Any changes from pre- to post-revascularisation 
Impact on friends and family before and after operation (anxiety) 
Too much I not enough attention and worry 
Impact on personal relationships 
Social support 
Independence I feeling a burden on family & friends 
w 
o 
w 
Content domain 
Complications 
(physical and psychological) 
Psychological functioning 
(post-revascularisation) 
Satisfaction 
(post-revascularisation) 
Information 
(post-revascularisation) 
Pre-I post-surgical perceptions 
Topics 
Re-admission to hospital- reason? Repeat revascularisation? 
Complications 
Wound infection - where, when? 
New feelings of pain 1 numbness- where, when? 
Weakness 1 lethargy 
Eating problems 1 loss of appetite 1 nausea 
Concern over appearance of scars 1 bruising 
Feelings immediately post-surgery 
Unresolved anxiety & concerns post-operatively 
Feelings whilst recovering - progress made, frustration 
Need for reassurance about heart condition 1 progress 
Post surgery depression 1 mood 
Attitude towards surgery 
Fear of symptoms returning 
Concern about needing another heart operation in the future 
Impact of surgery on day-to-day life 
Satisfaction with outcome of surgery 
Satisfied with progress made (immediate and long term) 
Satisfaction with care received 
How can care be improved? 
Knowledge of own condition and operation 
About recovering from operation 
Quality of information given 
Quantity of information given 
Timing of information given 
What did you hope would be different after surgery? 
What were your concerns about the surgery? 
Reflections about spe~ of reC()very 
TABLE 4.2 Selected Excerpts From Patient Interviews Grouped by Content Domain 
Content domain Sample statements from patient interviews [procedure] 
Pre-revascularisation "Sometimes it was like a lancing pain, others just pain". She would not describe this as a discomfort but "just pain 
symptoms really". [CASG] 
He described one of his attacks of chest pain: "I held my head in my hands on the steering wheel and experienced 
excruciating pain", "it was so bad I just wanted to die there and then". "It is like a paralysing weakness and sort of went 
down my ann". [PTCA] 
"I got a feeling, ... not pain, ... sort of a discomfort, a soreness in my chest when walking up hill, or doing DIY like sawing 
or gardening" [CABG] 
She described her angina as "a pain ..... nottightnessl". I had "awful ann pain (she grabbed her ann) .... A constant pain 
like having a blood pressure band tightened around the ann". It was very painful and she was "frightened". [CABG] 
"I started to notice a pain in my anns which was quite minute at the time I suppose" ... "it was a tightness across the 
chest". [PTCA) 
Limitations in daily activities "I get sick if I walk too far". "I have good days and bad days, but if I do too much like walk to the shops (under half a 
mile) I feel terrible ... I don't like to go too far from home". She has been like this for a "good couple of months now". Her 
husband drives her everywhere so that she doesn't have to walk. She said she couldn't survive without him - he does so 
much. She says she is fine as long as she sits dOing nothing but that is boring and she gets frustrated and "it isn't a life 
really". "I can't go out as the chest pain comes on .... I can't remember the last time I went out SOCially!" [CABG1 
"I cant lift heavy things which is annoying" [CASG] 
'" got short of breath when walking up hilts, ..... on the staircase, .... and walking the dog" [CASG] 
Psychological functioning He "packed up the business" (owned his own). He "feared that it would all happen again" and "found it hard to live with". 
It "protruded all my thoughts", "There is always the doubt in the back of your mind that it can all go wrong again .... The 
family all live in fear that It will happen again. It is hard to be positive". [PTCA] 
"I was afraid of doing too much, but I pushed myself on". [PTCA] 
His wife described him as becoming very selfish after the operation. She had to put up with the situation too. She used 
to worry a lot. He would go off on cycle rides and she wouldn't know where he was gOing or when he would be back. 
He would be adamant that there was nothing wrong with him and just say: "I'm doing it for me!.... There is nothing wrong 
with mel" [PTCA] 
'" get very frustrated because I am not used to being inactive". [PTCA] 
- .. --~-
--
, Her husfland said that "she has 1'1(}_quali!yof I~- there is no 1~1'1 in ~_,feelin9Iike tI'l~s_"~ __ ~ ___ ~ ________ 
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Content domain 
Social functioning 
Cognitive functioning 
Complications 
Sample statements from patient interviews [procedure] 
Didn't tell his wife about the chest pains and heart attacks he was having even when she was there when they 
happened. "I used to pretend it was something else". He usually felt better fairly quickly and didn't want to worry his 
wife. [PTCA] 
"I spent 2 weeks with my son in the country, but I felt a burden .... I found it depressing and embarrassing .... I wanted to 
go home to my own bed, ... own privacy". "I wanted my independence". [CABG] 
"I don't have the confidence to go too far which is annoying". [CABG] 
"Memory problems are frustrating". My memory was immediately affected and still is. "I used to do six crosswords a 
day, but I find them difficult even now, ... the words just don't come to me any longer, and I forget names". On several 
occasions he forgot the word he wanted to use such as "sternum" and got frustrated, but is obviously used to it. 
[3 months post CABG- believed these problems were related to the operation] 
I have a "tight pain" across my chest like I am "strapped in and need to be released". "It feels like something needs to be 
taken out or taken off' ... "it is horrible". It causes her a lot of worry and she doesn't know what it is or why it happens. 
This pain was there straight after the operation and 3 months later it has not gone. [CABG] 
"The muscular pains are fading gradually" .... "I am still sore from where they opened the chest" (4 months post CABG) 
She has a swollen leg which causes her to worry a lot. She doesn't understand why it hurts so much. "It is a burning 
pain" ..... It hurts a lot when I sit still for a long time or stand on it for a long time". [CABG] 
"For the first 4-6 weeks my leg wound hurt .... the area between the thigh to the knee hurt most" .... "My lower leg still 
feels numb (3 months post CABG), but this will get better in time" .... "1t was only really the leg pain that bothered me" .... 
"the wound dragged me down a bit". [CABG] 
"My leg is numb and it hurts when you touch it" ... "I have been very worried about it" .... "I don't know whether it is 
normal?" [3 months post CABG) 
"I felt nauseous about eating immediately after surgery and this still affects me a bit (4 months post surgery) .... it's a 
horrible experience". (CABG) 
"I had a weepy leg and chest wound". [CABG) 
He has a chest wound infection ("hospital acquired infection") which he regards as a "nuisance" even though it has been 
·seeping for weeks" and he has to have his dreSSing changed twice a week. (4 months post CABG) 
"My sternum used to click from where they sewed me up". [CABG] 
He noticed that he had a "strong heart beat.. .. A real thump, not rapid though". He described how you do not usually 
feel your heart beat, but he "could certainly feel this one!" [CABG1 
Content domain Sample statements from patient interviews [procedurel 
Satisfaction "Six months he said •..... if it hadn't been for the Brompton I would be dead" (CABG] 
". would have died if I hadn't had the operation" (CABG] 
"Very satisfied with the surgery as long as it has worked this time!" [PTCA] 
"Can't complain about anything really" [CABGl 
"It completely changed my life - it is wonderful! ...... "Absolutely 100% satisfied" [pTCA1 
"Not impressed ..... (by PTeA) ... "it has failed 3 times and I don't want another!" 
"I got better much faster than I thought I would! [PTCA] 
"I can only say nice things about the experience ........ , can't criticise anything in any way" [pTCA1 
She thought that all her heart disease symptoms would go - that she would no longer have pain etc. She never 
imagined that she would have "a different sort of chest pain. which is as horrible as this". She never thought she would 
have leg pain. The doctors might have told her but it was all too much to take in and she was too worried. She said she 
was not scared of having the surgery she just wanted to have it done to get better. She said that she is "not happy now· 
as she feels so unwell and she "had hoped to be feeling much better". [CABGI 
&1 
Vigorous actlvntes 
Moderate activities 
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TABLE 4.3 Phrasing of CROQ Items For The Three Phases of Questionnaire Development 
- t"".""" ""'T ... "''''''wo, on average, 
many times have you taken nitros 
(nitroglycerin tablets or spray) for your 
chest oain. chest tightness or angina? 
During the past 4 weeks, how much 
trouble has your heart condition caused 
of preliminary field test 
.... r ... inn of CROQ items 
Phrasing of final field test version of 
CROQitems 
During the past 4 weeks, on average, how 
many times have you taken nitros 
(nitroglycerin tablets or spray) for your 
chest pain, chest tiahtness or an 
Moderate activities, such as moving a 
table, pushing a vacuum cleaner, bowling, 
CROQ item 
Climbing one flight of 
stairs 
Bending, keeling, 
stooping 
Walk> 1 mile 
Walk half a mile 
Walk 100 yards 
Bathing or dressing 
Time spent 
Accomplish 
Kind of work 
Performing 
Worry heart condition 
Over-doing it 
Heart attack 
. Symptoms return 
Another operation 
Frightened by pain 
Out of control 
Uncertain 
(..) 
o 
00 
Phrasing of pre-test Phrasing of preliminary field test Phrasing of final field test version of 
version of CROQ items version of CROQ items CROQ items 
Climbing one flight of stairs Climbing one flight of stairs Climbing one flight of stairs 
Bending, keeling, stooping Bending, keeling , stooping Bending, kneeling or stooping 
Walking more than a mile Walking more than a mile -
Walking half a mile Walking half a mile Walking half a mile 
Walking one hundred yards Walking one hundred yards Walking one hundred yards 
Bathing or dressing yourself Bathing or dressing yourself Bathing or dressing yourself 
During the past 4 weeks, have you had any of the following problems with your work or -
other regular daily activities as a result of your heart condition? 
Cut down the amount of time spent on Cut down the amount of time spent on -
work or other activities work or other activities 
Accomplished less than you would like Accomplished less than you would like 
-
Were limited in the kind of work or other Were limited in the kind of work or other -
activities activities 
Had difficulty performing the work or Had difficulty performing the work or -
other activities (for example, it took extra other activities (for example, it took extra 
effort) effort) 
The next questions ask about your feelings about your heart condition. During the past 4 weeks , how often have you felt: 
Worried about your heart condition? Worried about your heart condition? Worried about your heart condition? 
Worried about doing too much or over- Worried about doing too much or over- Worried about doing too much or over-
doing it? doing it? doing it? 
Worried that you might have a heart attack Worried that you might have a heart attack Worried that you might have a heart attack 
or die suddenly? or die suddenly? or die suddenly? 
Worried that your symptoms might return? Worried that your symptoms might return? Worried that your symptoms might return? 
Worried that you might need another heart Worried that you might need another heart -
operation in the future? operation in the future? 
Frightened by the pain or discomfort of Frightened by the pain or discomfort of Frightened by the pain or discomfort of 
your heart condition? your heart condition? your heart condition? 
Out of control of your life? Out of control of your life? -
Uncertain about the future? Uncertain about the future? Uncertain about the future? 
--------
CROQitem 
Unsure 
Low morale 
Depressed 
Frustrated 
Irritated 
Avoid activities 
Interfered with enjoyment 
Positive outlook 
Difficult to plan 
Reason 
Forget 
Attention 
Concentration 
Confusion 
React slowly 
(..) 
o 
co 
Phrasing of pre-test 
version of CROQ items 
Unsure of yourself or lacking in self-
confidence? 
Low in morale? 
Depressed? 
Frustrated or impatient? 
Irritated? 
That you had to avoid certain activities 
because of your heart condition? 
That your heart condition interfered with 
your enjoyment of life? 
That it was difficult to keep a positive 
outlook about your health? 
-
During the past 4 weeks, how much of the 
time did you: 
Have difficulty reasoning and solving 
problems, for example making plans, 
making decisions, learning new things? 
Forget, for example things that happened 
recently, where you put things or 
appointments? 
Have trouble keeping your attention on 
any activity for long? 
Have difficulty doing activities involving 
concentration and thinking? 
Become confused and start several 
actions at a time? 
React slowly to things that were done or 
said? 
--
Phrasing of preliminary field test Phrasing of final field test version of 
version of CROQ items CROQitems 
Unsure of yourself or lacking in self- -
confidence? 
Low in morale? -
Depressed? Depressed? 
Frustrated or impatient? Frustrated or impatient? 
Irritated? -
That you had to avoid certain activities -
because of your heart condition? 
That your heart condition interfered with That your heart condition interfered with 
your enjoyment of life? your enjoyment of life? 
That it was difficult to keep a positive That it was difficult to keep a positive 
outlook about your health? outlook about your health? 
That it was difficult to plan ahead (eg That it was difficult to plan ahead (eg 
vacations , social events, etc.)? vacations, social events, etc.)? 
The next questions ask about problems related to your heart condition. During the 
past 4 weeks, how much of the time did you: 
Have difficulty reasoning and solving Have difficulty reasoning and solving 
problems, for example making plans, problems, for example making plans, 
making decisions, learning new things? making decisions, leaming new things? 
Forget, for example things that happened Forget, for example things that happened 
recently, where you put things or recently, where you put things or 
appointments? appointments? 
Have trouble keeping your attention on -
any activity for long? 
Have difficulty doing activities involving Have difficulty doing activities involving 
concentration and thinking? concentration and thinking? 
Become confused and start several -
actions at a time? 
React slowly to things that were done or -
said? 
Phrasing of pre-test Phrasing of preliminary field test Phrasing of final field test version of 
CROQ item version of CROQ items version of CROQ items CROQitems 
Not complete Not complete things or activities you Not complete things or activities you -
started? started? 
This question is about the impact of your heart condition on your family and friends and the extent to which it has interfered with your 
social activities. During the 12ast 4 weeks, how often have you experienced the following as a result of your heart condition: 
Personal relationships Difficulties with your personal Difficulties with your personal -
relationships? relationships? 
Family overprotective Family or friends being overprotective Family or friends being overprotective Family or friends being overprotective 
toward you? toward you? toward you? 
Feeling a burden Feeling like you are a burden on others? Feeling like you are a burden on others? Feeling like you are a burden on others? 
Restricted in social Feeling restricted in your social activities Feeling restricted in your social activities Feeling restricted in your social activities 
activities (like visiting with friends, relatives, etc) (like visiting with friends, relatives, etc)? (like visiting with friends, relatives, etc)? 
Feeling excluded Feeling excluded from doing things with Feeling excluded from doing things with -
other people? other people? 
Too far from home Feeling worried about going too far from Feeling worried about going too far from Feeling worried about going too far from I 
home? home? home? 
The next question asks about how The next question asks about how The next question asks about how 
satisfied you are with your heart satisfied you are with your heart satisfied you are with your heart 
operation. How satisfied are you with the: operation. How satisfied are you with the: operation. How satisfied are you with the: 
Satisfied with progress Progress you have made since your heart Progress you have made since your heart -
operation? operation? 
Satisfied with results Results of your heart operation? Results of your heart operation? Results of your heart operation? 
Satisfied with info about Infonnation you were given about your Infonnation you were given about your Information you were given about your 
op heart operation? heart operation? heart operation? 
Satisfied with recovery Infonnation you were given about how you Information you were given about how you Information you were given about how you 
info might feel while recovering from your heart might feel while recovering from your heart might feel while recovering from your heart 
operation? operation? operation? 
Info at the right time Were you given the information about your Were you given the information about your -
heart operation at the right time? heart operation at the time you needed 
it? 
Overall compared to Overall , how would you describe your Overall, how would you describe your Overall , how would you describe your 
before op heart condition now com12ared to before heart condition now coml2ared to before heart condition now com12ared to before 
your heart operation? you had your heart operation? you had your heart operation? 
w 
~ 
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Phrasing of pre-test Phrasing of preliminary field test Phrasing of final field test version of 
CROQitem version of CROQ items version of CROQ items CROQ items 
Speed of recovery Has your recovery from your heart I Has your recovery from your heart I Has your recovery from your heart 
operation so far been: operation so far been: operation so far been: 
Expectation . of r~sults . . . I ~r~ .. t~e re.s.~lts .from y?~ .. r. heart .. o.p'~rati.on: I .p..re the results from your heartoperation I Are the results from y~ur heart operation: • .,.! 
f: •. CR.gQW.ABG .. c.omP~n· ltena.: ···!:.·.·:·.:·: ··· :·: ···:·:.:·.:·.:···::r:::·:·:··.··:::·:· ... . :.: .• :.:-:-;.:: •. : •. : ............. : ...•.•. :.: ............ : .. : ..... :.: ... : ...... . ..... .. :..... . ... ::. ....... . .: ..........• : ..... :"> .... :: .... :. : .......... : .......... . 
Pain in chest wound 
Pain in chest area 
Infection in chest wound 
Oozing chest wound 
Tender chest wound 
Numb chest wound 
Pain leg wound 
Other pain in leg 
Infection in leg wound 
Oozing leg wound 
Tender leg wound 
Numb leg 
Bruising on chest 
Bruising on leg 
Swollen feet 
Weakness 
Nausea 
Loss of appetite 
to) 
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j The next section asks about problems you might have had since your heart operation. 
you bothered by the following problems? 
Pain in your chest wound 
Any other pain in your chest or neck due 
to your operation 
Infection, oozing or tenderness in your 
chest wound 
Numbness or tingling in your chest 
Pain in your leg or ann wound 
Any other pain in your leg or ann due to 
your operation 
Infection, oozing or tenderness in your leg 
or ann wound 
Numbness or tingling in your leg or ann 
Bruising on your chest 
BruiSing on your leg or arm where a vein 
was removed 
Swollen feet or ankles 
Weakness or lethargy 
Nausea 
Loss of appetite 
Pain in your chest wound 
Any other pain in your chest or neck area 
due to your operation 
Infection in your chest wound 
Oozing from your chest wound 
Tenderness around your chest wound 
Numbness or tingling around your chest 
wound 
Pain in your leg or ann wound 
Any other pain in your leg or ann due to 
your operation 
Infection in your leg or ann wound 
Oozing from your leg or ann wound 
Tenderness around your leg or ann 
wound 
Numbness or tingling in your leg or ann 
due to your operation 
Bruising on your chest 
Bruising on your leg or ann where a vein 
was removed 
Swollen feet or ankles 
Weakness or lethargy 
Nausea 
Loss of appetite 
During the past 4 weeks, how much were 
Pain in your chest wound 
Infection in your chest wound 
Tenderness around your chest wound 
Numbness or tingling around your chest 
wound 
Pain in your leg or ann wound 
Any other pain in your leg or ann due to 
your operation 
Infection in your leg or ann wound 
Numbness or tingling in your leg or ann 
due to your operation 
Bruising on your chest 
Bruising on your leg or ann where a vein 
was removed 
Swollen feet or ankles 
CROQitem 
over scars 
w 
~ 
I\) 
version 
Concern over the appearance of your 
surgical scars 
e past 4 weeks, have you 
chest pain, chest tightness or angina: 
• At rest? 
• Only on exertion? 
• Not at all? 
in your groin where 
was inserted 
over the appearance of your 
the past 4 weeks, have you 
chest pain, chest tightness or angina: 
• At rest? 
• Only on exertion? 
• Not at all? 
CROQitems 
Problems in your groin where the catheter 
was inserted 
Concern over the appearance of your 
bruises 
During the past 4 weeks, have you had 
chest pain, chest tightness or angina: 
• At rest? 
• On exertion? 
• At rest and on exertion? 
• Not at all? 
Phrasing of pre-test Phrasing of preliminary field test Phrasing of final field test version of 
CROQitem version of CROQ items version of CROQ items CROQitems 
Readmission to hospital Since ~our heart ooeration, have you been Since ~our heart oQeration, have you been Since ~our heart ooeration, have you been 
re-admitted to hospital (for an overnight re-admitted to hospital for an overnight re-admitted to hospital for an overnight 
stay) for any reason to do with your heart stay for any reason to do with your heart stay for any reason to do with your heart 
condition or your heart operation? condition or heart operation? Please condition or heart operation? Please 
Please give as many details as you can give as many details as you can below. give as many details as you can below. 
below. 
CII) 
....a. 
CII) 
TABLE 5.1 Criteria Used in the Psychometric Evaluation of the CROQ 
Criterion: item Criterion: scale 
Psychometric test level analyses level analyses 
!:::muti!!:!p.i!!II!!:iJ:!J.D!!jJ.lm::D!:::!I@!!t!!~I!::::::::':!::::::':'!!!':::::!!::!!!:!:!!!:!!:!::!:::::::::!::::!::::::::::::!::,!!!!::::::::::::::::::::::!:::::::::::!::::::!::::::::;!:;:::::!:::;:;:::::;::::::;::;!::::::;:::':!::!!W:'/::::::::::':::':';:::;::';::.;~;:::: 
Acceptability 
Missing data 
Floor/ceiling effects 
Skewness 
Reliability 
Internal consistency 
Cronbach's alpha 
Item-total correlation 
Test-retest 
Intraclass I Pearson correlation Coefficient 
Validity 
Construct 
Internal consistency 
Inter-scale correlations 
Convergent correlations 
Discriminant correlations 
Factor analysis 
Responsiveness 
Effect size I standardised response mean 
<S% 
NA 
+1 to - 1 a 
NA 
.30 
.40 
NA 
NA 
NA 
NA 
NA 
NA 
<10% 
<7S% a 
+1 to - 1 
.70 
.30 
.70 
>.70 
Moderate 
>.40 
<.40 
Factor loadings 
~. 3S . 
Cross loadings b 
with a difference 
of at least .20 
Small (.20 ), 
moderate (.SO), 
;,::miiJ.$:::@p.p.nil:::inJ.Y::::in::':itim:::~@iiUin@J.¥§g::::::':;:::::::::::::::::::::::::::::,!::::::!:::::::::::;'::::::::::::::::;,:!:::::::!::::::::::::::::::::::::::::::::::::::::::::;::::::!:!:!::!:::!I!~:0i:;!::::~!:"0:0:~:,:'::!:::::';;!:'::':::!:: 
Item redundancy (correlation) ~. 7S NA 
Maximum endorsement frequency ~. 7S% NA 
Aggregate endorsement frequency <10% NA 
Item responsiveness p<.OS C NA 
Item convergent I discriminant correlations Items must be NA 
SS or PSS d 
Key: 
NA 
a 
b 
c 
d 
Not applicable. 
Pre-revascularisation version of the CROa only. 
Items which cross load onto another factor should have a difference of at least .20. 
T-tests between pre- and 3-months post-revascularisation. 
SS = scaling success, PSS = probable scaling success. 
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TABLE 6.1a Respondent Characteristics: CROQ-CABG (Preliminary Field Test) 
Pre CABG (N=146) " 3m post CABG (N=289) ;} CABG Responsiveness (N=12SflJ 
Gender 
Male 108 (74) 1 216 (75) 95 (74) 
Female 38 (26) 73 (25) 33 (26) 
Age (years) 
Mean (SO) 63.3 (8.7) 63.7 (9.0) 63.6 (8.4) 
Range 34-82 35-82 34-82 
~ 70 years 32 (22) 69 (24) 25 (20) 
Clinical site 
Brompton 65 (44) 88 (31) 52 (40) 
Harefield 32 (22) 82 (28) 29 (23) 
Wythenshawe 49 (34) 119(41) 47 (37) 
Ethnicity 
White 137 (94) 267 (92) 121 (94) 
Black/Caribbean 1(1) 1(1) 1 (1) 
Indian 3 (2) 9 (3) 2 (2) 
Pakistani 0(0) 2 (1) 0(0) 
Other 5 (3) 10 (3) 4 (3) 
Missing 0(0) 0(0) 0(0) 
Employment status 
Employed full-time 31 (21) 47 (16) 28 (22) 
Employed part-time 7(5) 17 (6) 7 (5) 
Voluntary work 1 (1) 2 (1) 1 (1) 
Homemaker 7 (5) 5 (2) 4 (3) 
Retired 81 (55) 165 (57) 72 (56) 
Unable to work I disabled! unemployed 16 (11) 50 (17) 13 (10) 
Other 2 (1) 0(0) 2 (2) 
Missing 1 (1) 3 (1) 1 (1) 
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Pre CABG (N=146) ~-. 3m post CABG (N=289)" CABG Responsiveness (N=128) 4 
Uving situation 
Alone 24 (16) 44 (15) 22 (17) 
Only with partner 72 (49) 137 (47) 66 (52) 
With other family members 31 (22) 52 (18) 26 (20) 
Other 0(0) 1 (1) 0(0) 
Missing 19 (13) 55 (19) 14(11) 
Symptoms on exertion? 
At rest (44) (10) 
Only on exertion (47) (30) 
At rest and on exertion 
Not at all (8) (60) 
Missing (1) (0) 
Readmitted to hospital after CABG? 
No (80) 
Yes (20) 
Missing (0) 
1 Numbers in brackets are percents, unless specified otherwise. 
2 All patients who completed pre-revascularisation CROQ, and actually had CABG in study period. 
3 All patients who completed 3-month posl-revascularisation CROQ, including those not sent a pre-revascularisation questionnaire and the 
Test-retest subsample. 
4 All patients who completed both the pre- and 3-month post-revascularisation CROQ-CABG. 
TABLE 6.1b Respondent Characteristics: CROQ-PTCA (Preliminary Field Test) 
Pre PTCA (N=128) z 3m post PTCA (N=280)" PTCA Responsiveness (N=114) 4 
Gender 
Male 86 (67) 1 192 (69) 75 (66) 
Female 42 (33) 88 (31) 39 (34) 
Age (years) 
Mean (SO) 62.1 (9.7) 62.3 (9.8) 62.8 (9.7) 
Range 36-88 35-88 35-88 
~ 70 years 27 (21) 64 (23) 29 (25) 
Clinical site 
Brompton 48 (38) 88 (32) 43 (38) 
Harefield 49 (38) 107 (38) 44 (39) 
Wythenshawe 31 (24) 85 (30) 27 (23) 
Ethnicity 
White 118 (92) 250 (89) 104 (91) 
Black/Caribbean 1 (1) 1 (1) 1 (1) 
Indian 5 (4) 13 (4) 5 (4) 
Pakistani 2 (2) 7 (2) 2 (2) 
Other 2 (1) 4 (2) 2 (2) 
Missing 0(0) 5 (2) 0(0) 
Employment status 
Employed full-time 34 (27) 61 (22) 29 (25) 
Employed part-time 10 (8) 12 (4) 10 (9) 
Voluntary work 0(0) 3 (1) 0(0) 
Homemaker 5 (4) 10 (4) 4 (4) 
Retired 58 (45) 136 (48) 53 (46) 
Unabte to work I disabled! unemployed 20 (15) 55 (20) 17 (15) 
Other 1 (1) 0(0) 1 (1) 
Missing 0(0) 3 (1) 0(0) 
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Pre PTeA (N=128):l;- 3m poSt PTeA (N=280) 4 -PTeA ResPonsiveness (1\1=114) 4 
Living situation 
Alone 23 (18) 46 (16) 21 (18) 
Only with partner 59 (46) 142 (51) 54 (47) 
With other family members 26 (20) 57 (20) 21 (18) 
Other 1 (1) 1 (1) 1 (1) 
Missing 19 (15) 34 (12) 17 (14) 
Symptoms on exertion? 
At rest (41) (24) 
Only on exertion (49) (38) 
At rest and on exertion 
Not at all (9) (38) 
Missing (1) (0) 
Readmitted to hospital after PTeA? 
No (80) 
Yes (19) 
Missing (1) 
1 Numbers in brackets are percents, unless specified othelWise. 
2 All patients who completed pre-revascularisation CROa, and actually had PTCA in study period. 
3 All patients who completed 3-month post-revascularisation CROa, including those not sent a pre-revascularisation questionnaire 
and the Test-retest subsample. . 
4 All patients who completed both the pre- and 3-rnonth post-revascularisation CROa-PTCA. 
TABLE 6.2 Response Rates: CROQ Pre-Revascularisation (Preliminary Field Test) 
CROQ-CABG CROQ-PTCA 
Total number questionnaires sent 257 272 
Total number ineligible questionnaires 71 89 
Number did not have CABG/PTCA in study period 71 89 
Total number eligible questionnaires sent 186 183 
Total number eligible questionnaires received 146 186 
Number returned blank - no reason given 0 0 
Non-responders Number returned blank - received too late 0 0 
Number too sick to complete 0 0 
Response rate: number questionnaires completed 1 number eligible questionnaires 146/186 = 78% 128/183 = 70% 
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TABLE 6.3 Response Rates: CROQ Post-Revascularisation (Preliminary Field Test) 
CABG-CABG 3m CROQ-PTCA 3m 
Total number questionnaires sent 358 341 
Total number of ineligible patients I 0 3 
Total number eligible questionnaires received 289 280 
Overall response rate 289/358 = 81% 280 1 338= 83% 
Responsiveness sample 
Number sent 146 128 
Number ineligible 0 3 
Number eligible questionnaires received 128 114 
Response rate 128/146 = 88% 114 1125 = 91 % 
Patients sent 3-month post questionnaire only 
Number sent 122 123 
Number ineligible 0 0 
Number eligible questionnaires received 103 109 
Response rate 103/122 = 84% 109/123 = 89% 
Test-retest sample 
Number sent 90 90 
Number ineligible 0 0 
Number eligible questionnaires received 58 57 
Response rate 58/90 = 64% 57/90=63% 
Questionnaires were considered ineligible if the patient reported that the procedure was not carried out, e.g. due to the nature 
of the blockage in the arteries. 
TABLE 6.4 Item Reduction Analyses 
TestTCriterion) I Result Items eliminated 
o; pt1aseOne~,Itetrr'R8ductiOn ofCoril Pr"'l~PoSt-RevasctJlarisatiorrJt:8ms'-Usina PooltKl Pre;.ReVascuiarisatiOn-Sample IN=27#·}'iF'%fh:.., " ;~~t? _ -.j. ,;i" .. ,- f-::' , '''." " ,; '::'~ 
52-item pool 
Item-total correlations (~.30) No item-total correlations <.30 None 
Inter-item correlations « .7S) Inter-item correlations ~.7S : 9 items eliminated: 
• attention & concentration (.86) • attention 
• low morale & depressed (.83) • low morale 
• frustrated & irritated (.83) • irritated 
• avoid activities & interfered with enjoyment (.82) • avoid activities 
• chest tightness & chest discomfort (.81) • chest tightness 
• walk> 1 mile & walk half a mile (.81) • walk> 1 mile 
• restricted in social activities & feefing excluded (.79) • feeling excluded 
• confusion & react slowly (.78) • react slowly 
• concentration & react slowly (.77) • out of control 
• out of control & uncertain (.77) 
• attention & react slowly (. 7S) 
Missing data «S%) Missing data ~S%: 1 item eliminated: 
• vigorous actMties (7%) • vigorous activities 
• walk> 1 mile (7%) 
Maximum endorsement frequency « 7S%) Maximum endorsement frequencies ~7S%: 4 items eliminated: 
• accomplish (8S%) • accomplish 
• time spent (7S%) • time spent 
• kind ofworlc (81%) • kindofworlc 
• ueftvr ing (78%) • performing 
Aggregate adjacent endorsement frequency (>10%) 2 or more adjacent response categories endorsed s10%: 2 items eliminated: 
• confusion (6.2%) • confusion 
• attention (7.6%) • not complete 
• react slowly (7.6%) 
• not complete (8.4%) 
Item responsiveness (items must be responsive p <.OS All items responsive between pre- and 3 months post-revascularisation (p <.OS) None 
between pre- and 3 months post-revascularisation) 16 items eliminated 
~ 
~ 
Test \_; ..... ;.,..., Result Items eliminated . 
38-item DOOI 
Factor analysis (principal components factoring) No items loaded on the first factor <.30 None 
unrotated for 36 items No -rogue- items identified 
(eigen values >1, factor loadings ~.3O) 
Factor analysis (principal axis factoring) with Varimax Produced 5 factors accounting for 58.9% variance, with all items loading on a None 
rotation for 36 items factor. Some items crossloaded on more than one factor. Social Functioning did 
(eigen values >1, factor loadings ~35, cross loadings not form a separate scale as hypothesised, but loaded on same factor as 
~2 difference) Psychological Functioning 
Factor analysis (principal axis factoring) with Varimax Factors conceptually measuring Psychosocial Functioning, Cognitive Functioning, None 
rotation for 36 items Symptoms, & Physical Functioning 
(modelling 4 factors: factor loadings ~35, cross loadings 
~2 difference) 
Factor analysis (principal axis factoring) with Varimax Too many factors and crossloading items None 
rotation for 36 items 
(modelling 6 factors: factor loadings ~.35, cross loadings 
~2 difference) 
Cronbach's alpha using scales identified by factor Cronbach's alpha: None 
analysis (alpha ~.70; deletion of items should not Symptoms (9 items) = .89 
'substantially increase' value of alpha) Physical (8 items) = .91 
PsychosocIal (16 items) = 95 
Cognitive (3 items) = .88 
Core Total = (36 items).96 
AlPha would not substantiallY increase If any items were deleted in any scale 
ltem-total correlations ~3O) No item-totaI correlations <.30 None 
Tests of scaling assumptions (item convergent and AI items were more highly correlated to their own scale than to other scales by at 3 items eliminated: 
discriminant correlations). Items should be more highly least 2 SEs except: • low energy 
correlated to their own scale by ~ 2 standard errors • shottneaa of breath (PSS): Retained for clinical reasons • sleep (scaling success). Probable scaling success (PSS) • ' steep (PSS) • unsure 
allowed only if item can be retained on clinical or • low energy (PSS) 
conceptual grounds • unsure cPSS) 
3 items eliminated 
- ---
~ 
Test,_ . Result Items eliminated 
33-item pool 
Factor analysis (principal axis factoring) with Varimax Produced 5 factors conceptualy measwing Psychosocial Functioning, Cognitive None 
rotation for 33 items Functioning, Symptoms, & Physical Functioning. 
I (eigen values >1, factor Ioaclngs ~.35, cross loadings Every item loaded on a factor, but too many factors. 3 cross loadings <2 
I ~.2 difference) (shortness Ofbreath, intetfered with ertoyment, difficult to plan). 
Factor analysis (principal axis factoring) with Varimax Factors identified: Psychosocial Functioning, Cognitive Functioning, Symptoms, & None 
rotation for 33 items Physical Functioning. 3 Items cross loaded <.2 difference (shottness of bteath, 
(modelling 4 factors, factor loadings ~.35, cross loadings tmuble, feeling restricted) 
~2 difference) 
Cronbach's alpha using scales identified by factor Cronbach's alpha: None 
analysis (alpha ~.70; deletion of Items should not Symptoms (7 items) = .87 
'substantially increase' value of alpha) Physical (8 items) = .91 
Psychosocial (15 Items) = 94. 
Cognitive (3 Items) = .88 
Core Total (33 items) = .96 
Alpha would not substantiallY increase if items were deleted in any scales 
Item-totaI correlations (~.3O) No item-totaI correlations <.30 None 
Tests of scaling assumptions (Item convergent and AI items were more highly correlated to their own scale than to other scales by at 1 item eliminated: 
discriminant correlations). Items should be more highly least 2 SEs except • personal relationships 
correlated to their own scale by ~ 2 standard errors • shottness of breath (PSS) 
(scaling success). Probable scaling success (PSS) • paIpItatfons (PSS) 
allowed only if item can be retained on clinical or • personal relationships (PSS) 
conceptual grounds shortness of breath & • ns were retained for clinical reasons 
1 item eliminated 
32-itempool 
Factor analysis (principal axis factoring) with Varimax Produced 5 factors conceptually measuring Psychosocial Functioning, Cognitive None 
rotation for 32 items Functioning, Symptoms, & Physical Functioning. Every item loaded on a factor, 
(eigen values >1, factor loadings ~35. cross loadings but too many factors. 2 items cross loaded <.2 difference (intetfeted with 
~2 difference) enjoyment, difficult to plan) 
Factor anatysis (principal axis factoring) wiIh Varimax Factors identified: Psychosocial Functioning, Cognitive Functioning, Symptoms & None 
rotation for 32 items Physical Functioning. 1 item cross loaded with a difference <.2 (trouble). 
(modeling 4 factors: factor loadings ~35. cross loadings TmubIe is a global item which one would expect to be correlated to several 
~2 difference) factors 
~ 
c-l 
Test (Criterion) Result Items eliminated 
Cronbach's alpha using scales identified by factor Cronbach's alpha: None 
analysis (alpha ~.70; deletion of items should not Symptoms [l items) = .88 
'substantially increase' value of alpha) Physical (8 items) = .91 
Psychosocial (14 items) = 94 
Cognitive (3 items) = .88 
Core Total (32 items)= .95 
Alpha would not substantialJv increase if any items were deleted in any scale 
Item-total correlations (>.30) No item-total correlations <.30 None 
Tests of scaling assumptions (item convergent and An items were more highly correlated to their own scale than to the other scales None 
discriminant correlations). Items should be more highly by at least 2 SEs except: 
correlated to their own scale by ~ 2 standard errors • shortness of breath (PSS) (scaling success). Probable scaling success (PSS) • palp;tations (PSS) 
allowed only if item can be retained on clinical or shortness of breath & palpitations were retained for clinical reasons 
conceptual grounds 
No items eliminated. Final item pool: 32 items 
"p~two:~  Reduction Of1.f(:omriiQn-p~t-Reyas¢Qlari$atiOrt OPlv ttems\lsiridP~ PCJ~~ev.,.scularisatioil Sample (N=569 "'i", ',( ,,",6 '~ -" ',;;~ ~ - >:'~ 
10-item pool 
Factor analysis (principal components factoring) An items loaded on first factor> .30 except: None 
unrotated for 10 items • timing of infonnation 
(eigen values >1, factor loadings ~.30) timina of infonnation identified as "rogueW item 
Item-total correlations (~.30) Item-total correlations <.30: 1 item eliminated: 
• timing of Infonnation (.18) • timino of infonnation 
Inter-item correlations «.75) Inter-item correlations ~.75: 2 items eliminated: 
• satisfied with progress & satisfied with results (.83) • satisfied with progress 
• sym"toms retum & anotherooeration (.80) • another operation 
Missing data «5%) No items with missing data >5% None 
Item test-retest (> .40) No correlation coefficients ~.40 None 
3 items eliminated 
7-item pool 
Cronbach's alpha for 7-item common post scale (~.70, Cronbach's alpha = .83 None 
deletion of items should not 'substantially increase' (alpha would not substantially increase if any items were deleted from scale) 
value of alpha) 
~ 
~ 
Test (Criterion) 
Tests of scaling assumptions (item convergent and 
discriminant correlations). Items should be more highly 
correlated to their own scale by ~ 2 standard errors 
(scaling success). Probable scaling success (PSS) 
allowed only if item can be retained on clinical or 
conceptual grounds 
~e"Jhree: ftem ~udion:of Pl'oced~ ~. 
CRoa..cABG Complications (N=289) 
19-item pool 
Factor analysis (principal components factoring) 
unrotated for 19 items 
(eigen values >1, factor loadings ~.30) 
Factor analysis (principal axis factoring) with Varimax 
rotation for 19 items 
(eigen values >1, factor loadings ~.35, cross loadings 
~.2 difference) 
Item-total correlations (~.30) 
Inter-item correlations «.75) 
Missing data «5%) 
Item test-retest (~.40) 
w 
f\) 
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Result Items eliminated 
All items were more highly correlated to their own scale by at least 2 SEs except: None 
• overall (PSF) 
• symptoms retum (SF) 
Overall was retained as it was correlated to scales that fit conceptually for a 
global item. Symptoms retum was excluded from Satisfaction scale as it was a 
scaling failure, but was retained in the CROQ (in Total Outcomes scale) 
Final item pool: 7 items 
compticaliQh.u.ems.!i! " "')K¥P\rt"" i!,~.,""hl' W{;; ,~.''.'i~';f;7S~'~;., . 'fk'i'V'hi,,;~".:<:>i.t4j1i~';"""".~"}' t'1f:-.iio ';i;~'~>\'1;.:.:, '0 •• ~".. \ 
No items loaded on the first factor <.30. None 
No "rogue" items identified 
Produced 5 factors, but too many factors and too many cross loading items. None 
2 items did not load on any of the factors (Appetfte and Scar appearance) 
No item-total correlations <.30 None 
Inter-item correlations ~.75: 3 items eliminated: 
• infectjon leg/arm wound & oozing Jeg/arm wound (.90) • oozing from chest wound 
• oozing from chest wound & infection chest wound (.85) • oozing leg/arm wound 
• pain in leg/arm wound & tendemess around leg/arm wound (.78) • tendemess around leg/arm wound 
No items with missina data ~% None 
Item test-retest correlation coefficients <.40: None - items already 
• oozing from chest wound (.24) eliminated 
• oozing /eg/arm wound (-.06) 
3 items eliminated 
--
Test (Criterion, 
16.ftem pool 
ltem-total correlations ~.30) 
Tests of scaling assumptions (item convergent and 
discriminant correlations). Items should be more highly 
correlated to their own scale by ~ 2 standard errors 
(scalng success) 
12-item pool 
Item-total correlations{~3O) 
Tests of scaling assumptions (Item convergent and 
discriminant correlations). Items should be more highly 
correlated to their own scale by ~ 2 standard errors 
-<scaling success) 
11-item pool 
Item-totat correlations (~.3O) 
Tests of scaling assumptions (item convergent and 
discriminant correlations). Items should be more highly 
correlated to their own scale by ~ 2 standard errors 
(scaling success) 
CROQ.PTCA . 
11-item pOOl 
Factor analysis (principal components factoring) 
unrotated for 11 items 
(eigen values >1 t factor loadings ~30) 
Factor analysis (principal axis factoring) with Varimax 
rotation for 11 items 
(eigen values >1 J factor loadings ~35J cross loadings 
~.2 differencel 
ltem-total correlations R.3O) 
w 
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Result Items eliminated 
No item-totat correlations <.30 None 
AI items were more highly correlated to their own scale than to the other scales 4 Items eliminated: 
by at least 2 SEs except • pain In the chest area 
• pain in the chest area (PSS) • weakness 
• weakness (pSF) • appetite 
• appetite (PSSJ • scar appearance 
• scar appearance (PSS) 
AI these items were also correlated to at least 2 other scales and were eliminated 
No item-totat correlations <.30 None 
AI items were more highly correlated to their own scale than to other scales by at 1 item eliminated: 
least 2 SEs except • nausea 
• nausea (PSS) 
Nausea was also correlated to at least 2 other scales I 
No item-totat correlations <.30 None 
PJ items were more highly correlated to their own scale than to other scales by at None 
least 2 Ses 
8 items efllllinated. Final item pool: 11 items 
No items loaded on the first factor <.30. None 
No "rogue- items identified 
Produced 3 factors, but too many factors and too many aossloading items None 
No items loaded on a factor <.35 
No item-total correlations <.30 None 
------
------
Test (Criterion) Result Items eliminated 
Inter-item oorrelations «.75) Inter-item correlations ~ .75: 1 item eiminated: 
• bruised gTOin wound & bnJised thigh (.75) • bruised thigh 
but this item Is joined with 
bruised groin wound in final 
field test version to create a 
new item (btuising around your 
groin wound or thigh) 
MIssing data «5%) No items with missi!lQ_ data ~% None 
Item test-retest (2.40) Item test-retest correlation coefficients <.40: 2 items eiminated: 
• infection in groin wound (can't compute as gnot at all- for all but one pt) • infection in groin wound 
• oozing groin wound {-.1 ~ • oozing groin wound 
3 items eliminated. Pool reduced to 8 items 
8-itempool 
Item-total corre1ations (~.3O) No item-total correlations <.30 None 
Tests of scaling assumptions (item convergent and AI items were more tighly correlated to their own scale than to other scales by at 2 items eliminated: 
discriminant correlations). Items should be more highly least 2 SEs except • discomfott in chest from 
correlated to their own scale by ~ 2 standard errors • discomfort in chest from op (PSF) op 
,_mill success) • swollen feet (pSF) • swollen feet 
6-item pool 
ltem-total correlations (~.3O) No item-totaf correlations <.30 None 
Tests of scal"mg assumptions (Item convergent and AI items were more highly correlated to their own scale than to other scales by at None 
discriminant correlations). Items should be more highly Ieast2 SEs 
correlated to their own scale by ~ 2 standard errors 
(scaling success) 
L---- ___ ~ ________ ~ ___ ~ ________ 
- - -
-- ,-
_ _ _ _ ______ ~ __ ~~ eliminated and 1 pair of items combined. Final item pool: 6 items 
Key: 
SE: Standard error. SS: Scaling success. PSS: Probable scaling success. PSF: Probable scaling failure. SF: Scaling failure. 
~ 
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TABLE 6.5a Respondent Characteristics: CROQ-CABG (Final Field Test) 
Pre CABG (N=281)z 3m Post CABG (N=415)" CABG Responsiveness (1\1=198)4 
Gender 
Male 
Female 
Age (years) 
Mean (SO) 
Range 
~ 70 years 
Clinical site 
Brompton 
Harefield 
Wythenshawe 
Ethnicity 
White 
Indian 
Pakistani 
Other 
Missing 
Employment status 
Employed fuM-time 
Employed part-time 
Voluntary work 
Homemaker 
Retired 
Unable to work I disabled! unemployed 
Other 
Missing 
Living situation 
Alone 
Only with partner 
With other family members 
Other 
Missing 
238 (85) 1 
43 (15) 
63.6 (9.2) 
35-85 
72 (26) 
101 (34) 
63 (22) 
117 (42) 
261 (93) 
12 (4) 
3 (1) 
5 (2) 
53 (19) 
9 (3) 
1 (1) 
6 (2) 
147 (52) 
49 (17) 
15 (5) 
1 (1) 
39 (14) 
188 (67) 
51 (18) 
3 (1) 
343 (83) 166 (84) 
72 (17) 32 (16) 
65.0 (8.9) 64.31 (8.8) 
37-94 36-84 
139 (33) 59 (30) 
131 (32) 53 (27) 
125 (30) 46 (23) 
159 (38) 99 (50) 
369 (89) 183 (92) 
20 (5) 9 (5) 
8 (2) 1 (1) 
12 (3) 5 (2) 
6 (1) 
65 (16) 33 (17) 
19 (5) 7 (3) 
0(0) 0(0) 
12 (3) 4 (2) 
239 (58) 109 (55) 
54 (12) 32 (16) 
23 (5) 12 (6) 
3 (1) 1 (1) 
66 (16) 23 (12) 
272 (66) 142 (71) 
70 (17) 31 (16) 
4 (1) 2 (1) . 
3 (1) 0(0) 
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Pre CABG (N=281)" 3m Post CABG (N=415)" CABG Responsiveness (N=198)" 
2nd Questionnaire 
SF-36 
SAQ 
QLMI-2 
LlhFE 
Test-Retest 
Social class 5 
Class I 
Class" 
Class III N 
Class III M 
Class IV 
Class V 
Missing 
Symptoms on exertion? 
At rest 
Only on exertion 
At rest and on exertion 
Not at all 
Missing 
Readmitted to hospital after CABG? 
No 
Yes 
Missing 
101 (36) 
85 (30) 
48 (17) 
47 (17) 
25 (9) 
77 (27) 
30 (11) 
93 (33) 
29 (10) 
13 (5) 
14 (5) 
(9) 
(39) 
(40) 
(11) 
(1) 
1 Numbers in brackets are percents, unless specified otherwise. 
123 (30) 
102 (25) 
71 (17) 
69 (17) 
50 (12) 
35 (8) 
107 (26) 
43 (10) 
131 (32) 
48 (12) 
20 (5) 
31 (7) 
(5) 
(11) 
(15) 
(66) 
(3) 
(82) 
(16) 
(2) 
73 (37) 
56 (28) 
35 (18) 
34 (17) 
14 (7) 
55 (27) 
19 (10) 
71 (36) 
22 (11) 
11 (6) 
5 (3) 
2 All patients who completed pre-revascularisation CROQ, and actually had CABG in study period. 
3 All patients who completed 3-month post-revascularisation CROQ, including those not sent a pre-revascularisation questionnaire and the Test-retest subsample. 
4 All patients who completed both the pre- and 3-month post-revascularisation CROQ-CABG. 
5 Coded according to occupation using the classifications described by the Office of Population Censuses and Surveys (Standard occupational classification vol 3: 
social classifications and coding methodology. London: HMSO, 1991). Categorised as: I) Professional, etc. occupations; II) Managerial and Technical 
occupations; JIIN); Skilled occupations (non-manual); 111M) Skilled occupations (manual); IV) Partly skilled occupations; V) Unskilled occupations. 
TABLE 6.5b Respondent Characteristics: CROQ-PTCA (Final Field Test) 
Gender 
Male 
Female 
Age (years) 
Mean (SO) 
Range 
~ 70 years 
Clinical site 
Brompton 
Harefield 
Wythenshawe 
Ethnicity 
White 
Indian 
Pakistani 
Other 
Missing 
Employment Status 
Employed full-time 
Employed part-time 
Voluntary work 
Homemaker 
Retired 
Unable to work I disabled! unemployed 
Other 
CAl 
CAl 
o 
Missing 
Uving situation 
Alone 
Only with partner 
With other family members 
Other 
Missing 
Pre PTCA (N=1S9) z 3m Post PTCA (N=345) os PTCA Responsiveness (N=1 07) 4 
120 (75) 1 251 (73) 80 (75) 
39 (25) 94 (27) 27 (25) 
60.6 (9.7) 62.3 (10.2) 60.92 (9.8) 
38-89 36-84 39-80 
29 (18) 86 (25) 23 (21) 
28 (18) 73 (21) 21 (20) 
40 (25) 92 (27) 20 (19) 
91 (57) 180 (52) 66 (62) 
144 (91) 303 (88) 96 (89) 
4 (2) 14 (4) 3 (3) 
1 (1) 8 (2) 1 (1) 
8 (5) 13 (4) 5 (5) 
2 (1) 7 (2) 2 (2) 
39 (25) 83 (24) 28 (26) 
11 (7) 15 (4) 8 (7) 
2 (1) 0(0) 
7 (4) 10 (3) 4 (4) 
63 (40) 152 (44) 40 (37) 
26 (16) 52 (15) 20 (19) 
13 (8) 24 (7) 7(7) 
7 (2) 0(0) 
21 (13) 54 (16) 17 (16) 
98 (61) 191 (55) 65 (61) 
38 (24) 93 (27) 25 (23) 
1 (1) 2 (1) 0(0) 
1 (1) 5 (1) 0(0) 
Pre PTCA (N=159)"--3m Post PTCA (N=345)" PTCA Responsiveness (N=107) 4 
2nd Questionnaire 
SF-36 48 (30) 84 (24) 38 (35) 
SAa 53 (33) 90 (26) 34 (32) 
QLMI-2 32 (20) 66 (19) 22 (21) 
LlhFE 26 (17) 57 (17) 13 (12) 
Test-Retest 48 (14) 
Social class 5 
Class I 7 (4) 19 (6) 5 (4) 
Class II 42 (26) 97 (28) 31 (29) 
Class III N 22 (14) 42 (12) 19 (19) 
Class III M 52 (33) 109 (32) 32 (30) 
Class IV 24 (15) 43 (12) 12 (11) 
Class V 0(0) 7 (2) 0(0) 
Missing 12 (8) 28 (8) 8(7) 
Symptoms on exertion? 
At rest (13) (7) 
Only on exertion (32) (26) 
At rest and on exertion (45) (22) 
Not at all (8) (42) 
Missing (12) (3) 
Readmitted to hospital after PTCA? 
No (80) 
Yes (17) 
Missing (3) 
1 Numbers in brackets are percents, unless specified otherwise. 
2 All patients who completed pre-revascularisation CROa, and actually had PTCA in study period. 
3 All patients who completed 3-month post-revascularisation CROQ, including those not sent a pre-revascularisation questionnaire and the Test-retest subsample. 
4 All patients who completed both the pre- and 3-month post-revascularisation CROQ-PTCA. 
5 Coded according to occupation using the classiftcations described by the Office of Population Censuses and Surveys (Standard occupational classification vol 3: 
social classifications and coding methodology. London: HMSO, 1991). Categorised as: I) Professional, etc. occupations; II) Managerial and Technical 
occupations; !liN); Skilled occupations (non-manuaQ; 111M) Skilled occupations (manuaQ; IV) Partly skilled occupations; V) Unskilled occupations. 
w 
W 
-0. 
--.. ~ 
w 
w 
f\) 
TABLE 6.6 Response Rates: CROQ Pre-Revascularisation (Final Field Test) 
~ -
CROQ-CABG 
Total number questionnaires sent 408 
Total number ineligible questionnaires 1 
Number not having operation or already had operation 1 
Total number eligible questionnaires sent 407 
Total number eligible questionnaires received 281 
Number returned blank - no reason given 2 
Non-responders Number returned blank - received too late 5 
Number too sick to complete 1 
Number not known at this address 1 
J~esponse rate: number questionnaires completed 1 number of eligible questionnaires 281/407= 69% 
CROQ-PTCA I 
274 ! 
4 ! 
4 
270 
159 
0 
2 
1 
0 
159/270= 59% 
w 
w 
w 
TABLE 6.7 Response Rates: CROQ Post-Revascularisation (Final Field Test) 
CROQ-CABG 3m CROQ-PTCA 3m 
Total number questionnaires sent 509 468 
Total number of ineligible patients 1 0 4 
Total number eligible questionnaires received 415 345 
Overall response rate 415/509 = 82% 345/464 = 74% 
Responsiveness sample 
Number sent 216 119 
Number ineligible 0 0 
Number eligible questionnaires received 198 107 
Response rate 198/216 = 92% 107/119 =90% 
Patients sent 3-month post questionnaire only 
Number sent 223 279 
Number ineligible 0 4 
Number eligible questionnaires received 167 190 
Response rate 167 1223 =75% 190/275 = 69% 
Test-retest sample 
Number sent 70 70 
Number ineligible 0 0 
Number eligible questionnaires received 50 48 
Re~ponse rate 50/70 =71% 48/70 = 69% 
- -------_ ... _----
1 Questionnaires were considered ineligibfe if the patient reported that the procedure was not carried out, e.g. due to the nature 
of the blockage in the arteries. 
TABLE 6.8a Item Descriptive Statistics: CROQ-CABG Pre-Revascularisation (Final Field Test) 
% missing Endorsement frequencies by response category (%) Item-total correlation 
Item data 1 2 3 4 5 6 Mean (SD) n r 
Chest pain 2.5 14.9 23.8 23.8 22.8 12.1 2.93 (1.3) 279 .83 
Chest discomfort 3.2 14.2 27.4 24.2 19.2 11.7 2.86 (1.2) 279 .82 
Shortness of breath 0.7 17.4 25.6 20.3 21.4 14.6 2.90 (1.3) 279 .55 
Radiating pain 1.1 14.6 21.4 18.1 19.9 24.9 3.19 (1.4) 279 .64 
Palpitations 2.5 4.3 11.4 14.2 27.0 40.6 3.91 (1.2) 279 .46 
Nitroglycerin 0.0 13.5 26.0 18.9 13.9 7.5 20.3 3.37 (1.7) 279 .63 
Trouble 1.1 16.4 28.1 29.5 17.1 7.8 2.72 (1.2) 279 .77 
Moderate activities 3.2 34.9 40.9 21.0 1.86 (.75) 275 .69 
Ufting & carrying 2.8 30.6 45.2 21.4 1.90 (.73) 275 .69 
Climbing flights of stairs 7.1 53.0 29.2 10.7 1.54 (.69) 275 .73 
Climbing one flight of stairs 3.9 15.3 45.6 35.2 2.21 (.70) 275 .75 
Bending, keeling, stooping 2.8 15.3 43.4 38.4 2.24 (.71) 275 .57 
Walk half a mile 3.2 46.3 34.5 16.0 1.69 (.74) 275 .67 
Walk 100 yards 2.8 15.7 43.1 38.4 2.23 (.71) 275 .68 
Bathing or dressing 2.5 6.0 34.9 56.6 2.52 (.61) 275 .62 
Reason 0.0 6.8 9.6 10.7 23.8 17.4 31.7 4.31 (1.6) 281 .81 
Forget 0.4 6.8 11.7 12.1 24.9 17.8 26.3 4.15(1.6) 281 .81 
Concentration 0.0 6.4 10.7 11.4 20.6 19.6 31.3 4.30 (1.6) 281 .86 
Worry heart condition 1.4 20.3 23.8 28.8 19.2 6.4 2.67 (1.2) 279 .81 
Over-doing it 1.4 13.9 27.8 29.5 18.5 8.9 2.81 (1.2) 279 .78 
Heart attack 1.1 12.8 11.7 25.3 24.6 24.6 3.37 (1.3) 279 .72 
Frightened by pain 0.4 10.0 13.5 35.6 19.6 21.0 3.28 (1.2) 279 .78 
Uncertain 1.4 19.2 16.7 25.3 24.9 12.5 2.95 (1.3) 279 .73 
Depressed 1.1 8.9 8.9 26.7 24.9 29.5 3.58 (1.3) 279 .66 
Frustrated 1.4 15.3 . 25.3 25.6 20.3 12.1 2.88 (1.3) 279 .71 
Interfered with enjoyment 0.7 23.8 28.1 23.5 17.1 6.8 2.54 (1.2) 279 .78 
Positive ou1look 1.1 11.7 23.5 27.4 22.8 13.5 3.03 (1.2) 279 .76 
Difficult to plan 0.7 34.2 29.5 15.3 13.5 6.8 2.29 (1.3) 279 .65 
Family overprotective 1.1 12.5 20.3 21.0 22.8 12.5 3.03 (1.2) 279 .54 
Feeling a burden 1.1 11.7 .11.0 25.6 21.4 29.2 3.46 (1.3) 279 .70 
Restricted in social activities 1.1 142 18.9 27.4 13.5 24.9 3.16(1.4) 279 .75 ' 
Too far from home 0.7 16.7 19.2 20.3 14.9 28.1 3.19(1.5) 279 .76 
w 
~ 
TABLE6.8b Item Descriptive Statistics: CROQ-PTCA Pre-Revascularisation (Final Field Test) 
% missing Endorsement frequencies by response category (%) Item-total correlation 
Item data 1 2 3 4 5 6 Mean (SO) n r 
Chest pain 3.8 15.1 20.8 23.9 20.1 16.4 3.02 (1.3) 159 .79 
Chest discomfort 1.9 17.0 28.3 21.4 23.3 8.2 2.77 (1.2) 159 .83 
Shortness of breath 1.3 18.2 28.3 19.5 21.4 11.3 2.79 (1.3) 159 .54 
Radiating pain 3.1 13.8 21.4 21.4 17.0 23.3 3.15 (1.4) 159 .74 
Palpitations 4.4 4.4 13.2 17.6 25.2 35.2 3.77 (1.2) 159 .50 
Nitroglycerin 0.0 7.5 19.5 24.5 11.3 10.7 26.4 3.77 (1.7) 159 .61 
Trouble 1.3 14.5 25.8 35.8 16.4 6.3 2.50(1.1) 159 .82 
Moderate activities 2.5 37.1 35.8 24.5 2.74 (0.8) 156 .74 
Ufting & canying 5.0 30.8 40.9 23.3 1.87 (0.8) 156 .78 
Climbing flights of stairs 3.8 55.3 30.2 10.7 1.92 (0.7) 156 .68 
Climbing one flight of stairs 3.1 21.4 40.9 34.6 1.54 (0.8) 156 .75 
Bending, keeling, stooping 3.1 17.6 37.7 41.5 2.14 (0.7) 156 .64 
Walk half a mile 3.1 47.2 34.6 15.1 2.25 (0.7) 156 .72 
Walk 100 yards 5.0 13.2 41.5 40.3 1.67 (0.7) 156 .69 
Bathing or dressing 3.1 4.4 25.8 66.7 2.28 (0.6) 156 .63 
Reason 1.9 8.2 11.9 10.7 11.3 182 37.7 4.35 (1.7) 159 .81 
Forget 0.0 5.7 10.7 15.1 20.1 14.5 34.0 4.29 (1.6) 159 .81 
Concentration 0.0 6.3 13.2 9.4 17.6 17.0 36.5 4.35 (1.7) 159 .87 
Worry heart condition 1.9 18.9 22.0 28.9 20.1 8.2 2.76 (12) 157 .78 
Over-doing it 0.6 18.9 23.9 30.8 16.4 9.4 2.73 (1.2) 157 .79 
Heart attack 1.3 13.8 10.1 30.2 18.2 26.4 3.34 (1.4) 157 .68 
Frightened by pain 1.3 14.5 17.0 27.7 19.5 20.1 3.14 (1.3) 157 .79 
Uncertain 1.9 27.0 17.6 20.8 17.0 15.7 2.76 (1.4) 157 .78 
Depressed 1.3 7.5 11.9 27.0 22.0 30.2 3.56 (1.3) 157 .72 
Frustrated 1.3 14.5 22.0 31.4 20.1 10.7 2.90 (1.2) 157 .65 
Interfered with enjoyment 1.3 28.9 20.8 22.6 16.4 10.1 2.57 (1.3) 157 .78 
Positive outlook 1.3 18.9 12.6 28.9 17.6 20.8 3.09 (1.4) 157 .81 
Difficult to plan 1.3 30.2 17.6 19.5 13.8 17.6 2.71 (1.5) 157 .78 
Family overprotective 1.3 10.1 20.8 23.9 23.3 20.8 3.24 (1.3) 157 .62 
Feeling a burden 2.5 8.8 10.7 23.3 182 36.5 3.65 (1.3) 157 .70 
Restricted in social activities 0.6 17.0 15.7 23.3 14.5 28.9 3.23 (1.5) 157 .74 
Too far from horne 0.6 19.5 12.6 18.9 15.7 32.7 3.30 (1.5) 157 .78 
c..> 
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TABLE 6.9a Item Descriptive Statistics: CROQ-CABG Post-Revascularisation (Final Field Test) 
% missing Endorsement frequencies by response category % Item-total correlation 
Item data 1 2 3 4 5 6 Mean (SO) n r 
Chest pain 2.7 0.5 1.4 2.7 10.8 81.9 4.77 (0.6) 410 .69 
Chest discomfort 2.4 0.5 2.9 3.4 13.0 77.8 4.69 (0.7) 410 .71 
Shortness of breath 1.7 4.1 9.2 12.8 38.1 34.2 3.91 (1.1) 410 .53 
Radiating pain 3.1 1.7 3.6 3.6 13.5 74.5 4.60 (0.9) 410 .67 
Palpitations 2.7 1.4 3.9 9.2 24.8 58.1 4.38 (0.9) 410 .38 
Nitroglycerin 1.0 1.0 1.4 0.7 1.4 5.1 89.4 5.79 (0.8) 410 .57 
Trouble 1.7 1.9 3.4 6.5 29.9 56.6 4.38 (0.9) 410 .69 
Moderate activities 3.1 10.4 33.0 53.5 2.45 (0.7) 406 .64 
Ufting & canying 4.3 10.1 37.1 48.4 2.40 (0.7) 406 .68 
Climbing flights of stairs 6.7 11.3 35.4 46.5 2.38 (0.7) 406 .72 
Climbing one flight of stairs 4.3 3.1 15.2 77.3 2.78 (0.5) 406 .76 
Bending, keeling, stooping 3.4 7.0 27.5 62.2 2.57 (0.6) 406 .66 
Walk half a mile 4.1 8.0 17.1 70.8 2.66 (0.6) 406 .72 
Walk 100 yards 3.4 3.6 10.4 82.7 2.82 (0.5) 406 .64 
Bathing or dressing 2.4 2.9 10.6 84.1 2.93 (0.5) 406 .64 
Reason 0.7 1.9 4.1 6.0 14.2 24.1 48.9 5.03 (1.3) 413 .74 
Forget 0.2 1.9 4.8 8.7 18.6 28.4 37.3 4.79 (1.3) 413 .78 
Concentration 0.7 1.9 4.3 5.5 16.9 29.6 41.0 4.92 (1.2) 413 .83 
Worry heart condition 1.7 2.9 5.5 14.5 31.5 44.1 4.10(1.0) 410 .77 
Over-doing it 1.4 3.1 7.7 18.6 42.2 27.0 3.93 (1.0) 410 .74 
Heart attack 1.2 2.7 1.9 10.1 14.2 69.9 4.49 (1.0) 410 .70 
Frightened by pain 1.7 2.9 3.1 9.9 18.1 64.3 4.40 (1.0) 410 .78 
Uncertain 2.4 4.8 4.6 13.0 25.3 49.9 4.14(1.1) 410 .77 
Depressed 1.9 2.9 3.4 14.2 21.0 56.6 4.28 (1.0) 410 .71 
Frustrated 2.9 2.9 9.2 21.2 29.9 34.0 3.85 (1.1) 410 .69 
Interfered with enjoyment 1.4 5.5 7.0 13.5 27.7 44.8 4.01 (1.2) 410 .80 
Positive ouUook 1.7 2.7 7.7 9.4 25.3 53.3 4.21 (1.1) 410 .84 
Difficult to plan 1.7 7.0 7.2 14.7 20.2 49.2 3.99 (1.3) 410 .81 
. Family overprotective 2.2 1.7 10.8 24.8 38.8 21.7 3.69 (1.0) 410 .49 
Feeling a burden 2.2 3.4 5.5 13.7 17.1 58.1 4.24(1.1) 410 .72 
Restricted in social activities 1.9 4.1 5.3 11.8 14.7 62.2 4.28 (1.1) 410 .75 
Too far from home 1.7 4.1 5.5 9.6 18.1 61.0 4.28(1.1) 410 .74 
~ 
~ 
CAl 
CAl 
...... 
Item 
Pain in chest wound 
Infection in chest wound 
Tender chest wound 
Numb chest wound 
Bruising on chest 
Pain leg wound 
Other pain in leg 
Infection in leg wound 
Numb leg . 
Bruising on leg 
Swollen feet 
Satisfied with results 
Satisfied with info about op 
Satisfied with recovery info 
Overall compared to before op 
Speed of recovery 
Expectation of results 
Symptoms return 
% missing 
data 
0.7 
12 
1.9 
22 
2.7 
2.9 
3.6 
2.9 
1.7 
2.9 
1.0 
0.5 
0.7 
0.5 
0.5 
0.0 
1.4 
1.4 
Endorsement frequencies by response category % 
1 2 3 4 5 6 
4.1 8.9 9.9 29.2 47.2 
2.4 1.0 0.7 5.8 88.9 
5.5 8.9 15.4 43.6 24.6 
6.5 9.9 11.3 32.3 37.8 
1.4 1.0 5.5 8.0 81.4 
5.1 7.2 11.1 25.5 48.2 
4.3 6.0 6.0 12.8 67.2 
3.9 4.1 1.7 7.2 80.2 
8.7 10.1 14.7 30.1 34.7 
2.7 3.4 5.3 14.7 71.1 
8.9 8.9 11.1 26.7 43.4 
1.7 1.7 13.3 82.9 
1.7 4.3 15.4 77.8 
2.2 7.7 19.5 70.1 
0.7 1.4 5.1 11.1 81.2 
17.3 28.4 32.0 22.2 
7.0 41.9 49.6 
4.1 2.2 18.6 29.2 44.6 
Item-total correlation 
Mean (SO) n r 
4.07(1.1) 411 .60 
4.80 (0.7) 411 .25 
3.74(1.1) 411 .56 
3.87 (1.2) 411 .47 
4.72 (0.8) 411 .53 
4.08 (1.2) 411 .71 
4.38 (1.1) 411 .67 
4.61 (1.0) 411 .41 
3.73 (1.3) 411 .58 
4.53 (1.0) 411 .53 
3.88 (1.3) 411 .46 
3.78 (0.6) 414 .60 
3.71 (0.6) 414 .52 
3.58 (0.7) 414 .57 
4.71 (0.7) 414 .48 
2.59 (1.0) 414 .60 
2.43 (0.6) 414 .60 
4.10(1.1) 
TABLE 6.9b Item Descriptive Statistics: CROQ-PTCA Post-Revascularisation (Final Field Test) 
% missing Endorsem~t frequencies by response category % Item-total correlation 
Item data 1 2 3 4 5 6 Mean (SO) n r 
Chest pain 4.1 3.2 7.2 9.3 24.3 51.9 4.19 (1.1) 340 .86 
Chest discomfort 4.3 2.9 9.9 9.9 30.7 42.3 4.04 (1.1) 340 .84 
Shortness of breath 2.9 7.2 12.2 16.5 35.1 26.1 3.62 (1.2) 340 .63 
Radiating pain 4.1 3.2 7.0 10.1 21.4 54.2 4.21 (1.1) 340 .72 
Palpitations 3.2 1.7 5.2 5.5 27.5 56.8 4.37 (0.9) 340 .51 
Nitroglycerin 1.7 0.9 7.5 10.1 5.8 19.4 54.5 5.02 (1.4) 340 . .74 
Trouble 2.3 32 52 17.4 32.8 39.1 4.02 (1.0) 340 .82 
Moderate activities 5.8 14.8 34.5 44.9 2.32 (0.7) 327 .80 
Ufting & canying 7.0 15.7 33.0 44.3 2.31 (0.7) 327 .77 
Climbing flights of stairs 7.0 26.1 34.8 32.2 2.07 (0.8) 327 .78 
Climbing one flight of stairs 6.4 6.7 29.0 58.0 2.55 (0.6) 327 .79 
Bending, keeling, stooping 4.9 10.7 29.6 54.8 2.46 (0.7) 327 .68 
Walk half a mile 5.2 18.6 28.7 47.5 2.31 (0.8) 327 .79 
Walk 100 yards 6.7 7.8 18.6 67.0 2.63 (0.6) 327 .73 
Bathing or dressing 4.6 3.2 18.8 73.3 2.74 (0.5) 327 .68 
Reason 3.2 3.8 6.1 8.1 11.9 15.9 51.0 4.89 (1.5) 336 .81 
Forget 2.3 4.9 6.1 9.6 13.9 24.3 38.8 4.67 (1.5) 336 .84 
Concentration 2.3 4.6 5.5 8.1 13.6 18.3 47.5 4.82 (1.5) 336 .89 
Worry heart condition 3.2 7.5 10.1 25.2 33.6 20.3 3.51 (1.2) 333 .81 
Over-doing it 3.5 5.8 13.0 24.9 26.1 26.7 3.57 (1.2) 333 .78 
Heart attack 3.5 6.4 7.2 22.6 19.1 41.2 3.84 (1.2) 333 .74 
Frightened by pain 3.8 8.1 7.5 15.1 23.5 42.0 3.87 (1.3) 333 .81 
Uncertain 3.2 11.9 12.5 17.4 27.0 28.1 3.49 (1.4) 333 .84 
Depressed 3.5 4.6 6.1 18.3 22.3 45.2 4.01 (1.2) 333 .71 
Frustrated 4.3 9.0 9.9 22.0 21.4 33.3 3.63 (1.3) 333 .77 
Interfered with enjoyment 3.8 10.1 11.9 20.6 22.3 31.3 3.55 (1.3) 333 .83 
Positive outlook 3.8 5.8 12.2 21.4 24.1 32.8 3.68 (1.2) 333 .83 
Difficult to plan 2.9 8.7 16.2 13.6 19.1 39.4 3.66 (1.4) 333 .83 
Family overprotective 4.1 5.8 8.1 26.1 27.2 28.7 3.68 (1.2) 333 .56 
Feeling a burden 3.5 3.5 4.6 13.9 18.0 56.5 4.24 (1.1) 333 .68 
Restricted in social activities 4.3 4.6 5.5 15.7 16.2 53.6 4.13(1.2) 333 .78 
Too far from home 3.5 7.2 8.7 12.2 22.9 45.5 3.94 (1.3) 333 .76 
w 
w 
ClD 
w 
w 
CD 
Item 
Pain in groin wound 
Tender groin wound 
Numb groin 
Bruised groin wound 
Problems from catheter 
Concern over bruises 
Satisfied with results 
Satisfied with info about op 
Satisfied with recovery info 
OVerall compared to before op 
Speed of recovery 
Expectation of results 
Symptoms return 
% missing 
data 
3.5 
4.3 
4.6 
4.9 
4.9 
3.8 
2.0 
2.9 
2.6 
2.0 
3.2 
3.2 
3.8 
Endorsement frequencies by response category % 
1 2 3 4 5 6 
1.2 1.7 3.5 10.4 79.7 
1.2 2.0 4.1 12.8 75.7 
2.0 0.9 1.2 6.1 85.2 
2.9 2.9 4.3 11.0 73.9 
1.4 1.4 1.7 52 85.2 
1.2 0.6 0.3 3.8 90.4 
5.2 7.8 20.0 64.9 
2.3 7.8 14.2 72.8 
4.9 12.5 22.6 57.4 
2.9 4.1 12.5 14.8 63.8 
13.9 24.9 20.9 37.1 
15.4 39.7 41.7 
9.6 13.0 26.1 30.7 16.8 
Item-total correlation 
Mean (SD) n r 
4.72 (0.7) 330 .76 
4.67 (0.8) 330 .78 
4.80 (0.7) 330 .59 
4.58 (0.9) 330 .54 
4.800.70 330 .71 
4.89 (0.5) 330 .61 
3.48 (0.9) 340 .70 
3.62 (0.7) 340 .54 
3.36 (0.9) 340 .53 
4.35 (1.0) 340 .58 
2.84 (1.1) 340 .62 
2.27 (0.7) 340 .62 
3.33 (1.2) 
w 
~ 
o 
TABLE 6.10 Scale Descriptive Statistics: CROQ Pre-Revascularisation (Final Field Test) 
Range of scores 
CROQ scale % missing Scale Sample Mean SO Skewness % floor % ceiling 
Symptoms 1 0-100 0-100 51 .14 24.6 .088 1 4 
Physical Functioning 2 0-100 0-100 51.55 26.7 .133 3 5 
Psychosocial Functioning 1 0-100 0-100 50.52 24.3 -.010 1 1 
Cognitive Functioning 0 0-100 0-100 65.08 28.9 -.525 2 18 
Core Total 1 35-65 50.00 6.6 -.008 1 1 
Symptoms 0 0-100 0-100 51 .34 24.7 .046 1 2 
Physical Functioning 2 0-100 0-100 51.48 28.0 .075 3 7 
Psychosocial Functioning 1 0-100 0-100 51.78 26.3 -.037 1 1 
Cognitive Functioning 0 0-100 0-100 66.33 30.7 -.597 3 21 
Core Total 1 37-63 49.92 7.0 -.025 1 1 
w 
~ 
~ 
TABLE 6.11 Scale Descriptive Statistics: CROQ Post-Revascularisation (Final Field Test) 
Range of scores 
CROQ Scale % missing Scale Sample Mean SO Skewness % floor % ceiling 
Symptoms 1 0-100 9-100 87.57 14.9 -2.16 0 21 
Physical Functioning 2 0-100 0-100 80.27 22.7 -1.53 1 28 
Psychosocial Functioning 1 0-100 1-100 78.14 21 .0 -1.45 0 28 
Cognitive Functioning 1 0-100 0-100 78.27 22.6 -1.23 1 5 
Core Total 1 21-57 49.95 6.6 -1 .63 1 29 
Complications 1 0-100 4-100 80.36 16.9 -1.46 0 4 
Satisfaction 1 0-100 11-100 83.12 18.0 -1 .33 0 1 
Total Outcome 1 25-57 49.98 5.5 -1 .58 1 1 
Symptoms 1 0-100 0-100 77.02 22.1 -1.17 1 13 
Physical Functioning 5 0-100 0-100 71 .22 28.1 -0.75 1 24 
Psychosocial Functioning 4 0-100 1-100 69.24 24.9 -0.71 0 7 
Cognitive Functioning 3 0-100 0-100 75.91 27.6 -1 .18 2 30 
Core Total 3 29-59 49.98 7.03 -0.83 1 1 
Complications 
Satisfaction 
Total Outcome 
4 
1 
2 
0-100 
0-100 
0-100 
0-100 
13-56 
93.54 
76.77 
49.97 
14.08 -3.49 
21 .99 -1 .02 
5.92 -2.38 
1 
1 
1 
62 
21 
3 

w 
~ 
w 
TABLE 6.13 Reliability: eROQ Post-Revascularisation (Final Field Test) 
Internal consistency Test-retest sample 
Item-total Inter-item 
eROQ Scale correlation correlation Cronbach's 
range (mean) range (mean) N alpha N ICC 1 
Symptoms (7 items) .38-.71 (.61) .19-.84 (.45) 410 .85 50 .90 
Physical Functioning (8 items) .64-.76 (.68) .38-.70 (.53) 406 .90 49 .93 
Psychosocial Functioning (14 items) .49-.84 (.74) .32-.79 (.57) 410 .95 49 .92 
Cognitive Functioning (3 items) .74-.83 (.78) .67-.79 (.73) 413 .89 49 .80 
Core Total (32 items) .41-.78 (.63) .13-.84 (.41) 333 .96 49 .95 
Complications (11 items) .25-.71 (.52) .05-.75 (.33) 411 .84 50 .83 
Satisfaction (6 items) .48-.60(.56) .19-.69(.41) 414 .81 50 .90 
Total Outcome (18 items) .1 9-.64(.49) .01-.75(.28) 288 .88 50 .90 
Physical Functioning (8 items) .68-.80 (.75) .48-.74 (.62) 327 .93 42 .91 
Psychosocial Functioning (14 items) .56-.84 (.77) .33-.80 (.61) 333 .96 44 .93 
Cognitive Functioning (3 items) .81-.89 (.84) .74-.85 (.80) 336 .92 47 .86 
Core Total (32 items) .47-.81 (.69) .22-.87 (.48) 260 .97 44 .93 
Complications (6 items) .54-.78 (.66) .31-.80 (.52) 330 .87 46 .86 
Satisfaction (6 items) .53-.70 (.60) .23-.73 (.45) 340 .83 47 .91 
Total Outcome (13 items) .36-.63 (.53) .02-.76 (.33) 184 .86 46 .93 
1 ICC: Intraclass correlation coefficient. 
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TABLE 6.14a Item Convergent and Discriminant Correlations: CROQ-CABG Pre-Revascularisation (Final Field Test) 
CROQ-CABG scale 
Symptoms 
Physical Functioning 
Psychosocial 
Functioning 
Cognitive Functioning 
CROQ-CABG scale 
CROQ-CABG item Symptoms Ph}'!t_ic:al Fu~ctioning Ps~osocial Functioning 
Chest pain .83.56 .48 
Chest discomfort .82 .59 .50 
Shortness of breath .55 .592 .44 
Radiating pain .64 .541 .47 
Palpitations .46 .35 .41 
Nitroglycerin .63 .47 .35 
Trouble .77 .68 .57 
Moderate activities .58 .69 .54 
Lifting & carrying .57 .69 .47 
Climbing flights of stairs .56 .73 .46 
Climbing one flight of stairs .55 .75 .45 
Bending, keeling, stooping .43 .57 .46 
Walk half a mile .58 .67 .50 
Walk 100 yards .53 .68 .49 
Bathing or dressing .54 .62 .49 
Worry heart condition .48 .45 .81 
Over-doing it .50 .53 .78 
Heart attack .41 .35 .72 
Frightened by pain .57 .56 .78 
Uncertain .34 .32 .73 
Depressed .39 .33 .66 
Frustrated .46 .49 .71 
Interfered with enjoyment .51 .54 .78 
Positive ouUook .42 .41 .76 
Difficult to plan .37 .42 .65 
Family overprotective .43 .49 .54 
Feeling a burden .50 .60 .70 
Restricted in social activities.54 .63 .75 
Too far from home .52 .59 .76 
Reason .39 .42 .61 
Forget .40 .41 .49 
Concentration .34 .39 .53 
I Values in bold indicate probable scaling successes. :l Values in bold and underlined indicate probable scaling failures. 
Cognitive Functioning 
.30 
.33 
.39 
.31 
.29 
.17 
.39 
.35 
.32 
.35 
.33 
.30 
.36 
.31 
.35 
.41 
.40 
.38 
.44 
.45 
.55 
.47 
.50 
.52 
.44 
.39 
.45 
.45 
.43 
.81 
.81 
.86 
~ 
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TABLE 6.14b Item Convergent and Discriminant Correlations: CROQ-PTCA Pre-Revascularisation (Final Field Test) 
CROQ-PTCA scale 
CROQ-PTCA scale CROQ-PTCA item Symptoms Physical Functioning Psychosocial Functioning 
Symptoms Chest pain .79 .56 .51 
Chest discomfort .83 .60 .58 
Shortness of breath .54 .622 .SO 
Radiating pain .74 .59 .54 
Palpitations .50 .481 .51 
Nitroglycerin .61 .48 .45 
Trouble .82 .72 .65 
Physical Functioning Moderate activities .63 .74 .62 
Psychosocial 
Functioning 
Cognitive 
Functioning 
Ufting & canying .62 .78 .65 
Climbing ftights of stairs .64 .68 .55 
Climbing one ftight of stairs .59 .75 .57 
Bending, keeling, stooping .44 .64 .48 
Walk half a mile .59 .72 .56 
Walk 100 yards .58 .69 .55 
Bathing or dressing .54 .63 .58 
Worry heart condition .54 .54 .78 
Over-doing it .58 .59 .79 
Heart attack .50 '.46 .68 
Frightened by pain .66 .59 .79 
Uncertain .51 .52 .78 
Depressed .50 .55 .72 
Frustrated .45 .51 .65 
Interfered with enjoyment .54 .62 .78 
Positive outlook .52 .62 .81 
Difficult to plan .53 .61 .78 
Family overprotective .42 .46 .62 
Feeling a burden .56 .59 .70 
Restricted in social activities .62 .71 .74 
Too far from home .59 .63 .78 
Reason .49 .47 .62 
Forget .46 .50 .54 
Concentration .47 .47 .58 
Values in bold indicate probable scaling successes. " Values in bOkfand undel1ined indicate probable scaling failures. 
Cognitive Functioning 
.42 
.45 
.36 
.45 
.40 
.30 
.41 
.43 
.44 
.36 
.47 
.40 
.38 
.40 
.39 
.51 
.48 
.44 
.54 
.49 
.57 
.46 
.51 
.57 
.57 
.37 
.44 
.48 
.47 
.81 
.81 
.87 
CROQ-CABG 
scale 
Symptoms 
Physical 
Functioning 
Psychosocial 
Functioning 
Cognitive 
Functioning 
~ 
TABLE 6.15a Item Convergent and Discriminant Correlations: CROQ-CABG Post-Revascularisation (Final Field Test) 
CROQ-CABG item 
Chest pain 
Chest discomfort 
Shortness of breath 
Radiating pain 
Palpitations 
Nitroglycerin 
Trouble 
Moderate activities 
Ufting & carrying 
Climbing fligh1s of stairs 
Climbing one flight of stairs 
Bending, keeling, stooping 
Walk half a mile 
Walk 100 yards 
Bathing or dressing 
Worry heart condition 
Over-doing it 
Heart attack 
Frightened by pain 
Uncertain 
Depressed 
Frustrated 
Interfered with enjoyment 
Positive outlook 
Difficult to plan 
Family overprotective 
Feeling a burden 
Restricted in social activities 
Too far from home 
Reason 
Forget 
Concentration 
Symptoms 
.69 
.71 
.53 
.67 
.38 
.57 
.69 
.51 
.45 
.51 
.49 
.50 
.51 
.44 
.46 
.52 
.47 
.45 
.58 
.42 
.39 
.45 
.54 
.53 
.51 
.28 
.49 
.55 
.54 
.42 
.36 
.42 
Physical Functioning 
.38 
.42 
.58 2 
.47 
.30 
.38 
.60 
.64 
.68 
.72 
.76 
.66 
.72 
.64 
.64 
.45 
.47 
.36 
.49 
.40 
.47 
.45 
.53 
.48 
.53 
.36 
.55 
.65 
.64 
.42 
.39 
.45 
CROQ-CABG scale 
Psychosocial Functioning Cognitive Functioning 
.42 .32 
.45 .35 
.47 1 .35 
.44 .28 
.35 .24 
.34 .28 
.62 .38 
.54 .34 
.50 .33 
.48 .34 
.50 .37 
.45 .37 
.50 .37 
.42 .31 
.46 .38 
.77 .50 
.74 .52 
.70 .52 
.78 .51 
.77 .54 
.71 .53 
.69 .54 
.80 .56 
.84 .60 
.81 .57 
.49 .44 
.72 .54 
.75 .55 
.74 .52 
.66 .74 
.54 .78 
.67 .83 
Complications 
.36 
.38 
.41 
.38 
.33 
.26 
.50 
.41 
.35 
.39 
.32 
.41 
.43 
.36 
.37 
.47 
.44 
.40 
.52 
.42 
.45 
.48 
.55 
.55 
.54 
.33 
.45 
.50 
.46 
.37 
.40 J 
.44 
Satisfaction 
.30 
.33 
.43 
.33 
.29 
.26 
.54 
.42 
.35 
.39 
.30 
.37 
.40 
.28 
.33 
.43 
.37 
.30 
.47 
.35 
.38 
.44 
.51 
.46 
.48 
.15 
.38 
.45 
.39 
.31 
.18 
.28 
CROQ-CABG CROQ.CABG scale 
scale CROQ..CABG it~ ___ . Syrnploms.PllysicalFunctioning Psychosocial Functioning . Cognitive Fun.ctioning __ Gom~licatlons 
Complications Pain in chest wound .44 .37 .53 .36 .58 
Infection in chest wound .21 .22 .22 .25 .25 
Tender chest wound .41 .35 .49 .38 .56 
Numb chest wound .32 .23 .38 .29 .47 
Bruising on chest .37 .30 .40 .32 .53 
Pain leg wound .39 .42 .47 .32 .71 
Other pain in leg .39 .39 .48 .36 .67 
Infection in leg wound .22 .23 .21 .14 .41 
Numb leg .32 .37 .44 .28 .58 
Bruising on leg .31 .33 .32 .24 .53 
Swollen feet .23 .25 .24 .16 .56 
Satisfaction Satisfied with results .47 .42 .44 .21 .36 
Satisfied with info about op .21 .26 .33 .19 .27 
Satisfied with recovery info .21 .28 .34 .15 .25 
OVerall .46.34 .33 .19 .25 
Speed of recovery .40 .40 .41 .26 .37 
Expectation of results .42 .34 .36 .20 .31 
1 Values in bold indicate probable scaling successes. 2 Values in bold and underlined indicate probable scaling failures. 
~ 
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Satisfaction 
.34 
.10 
.33 
.17 
.30 
.34 
.36 
.22 
.30 
.30 
.21 
.60 
.52 
.57 
.48 
.60 
.60 
TABLE 6.1Sb Item Convergent and Discriminant Correlations: CROQ-PTCA Post-Revascularisation (Final Field Test) 
CROQ.pTCA CROQ.pTCA scale 
scale CROQ.pTCA item Symptoms Physical Functioning Psychosocial Functioning Cognitive Functioning Complications Satisfaction 
Symptoms Chest pain .86 .59 .56 .41 .25 .49 
Chest discomfort .84 .55 .52 .36 .24 .52 
Shortness of breath .63 .65 2 .48 .36 .25 .38 
Radiating pain .72 .52 .51 .37 .29 .45 
Palpitations .51 .41 1 .40 .26 .24 .28 
Nitroglycerin .74 .54 .47 .33 .20 .40 
Trouble .82 .68 .63 .43 .28 .57 
Physical Moderate activities .64 .80 .62 .43 .18 .36 
Functioning Ufting & carrying .61 .77 .61 .42 .20 .36 
Climbing fligh1s of stairs .55 .78 .55 .44 .15 .34 
Climbing one flight of stairs .57 .79 .55 .39 .13 .30 
Bending, keeling, stooping .51 .68 .50 .42 .27 .33 
Walk half a mOe .64 .79 .54 .37 .18 .37 
Walk 100 yards .56 .73 .51 .35 .15 .34 
Bathing or dressing .51 .68 .51 .31 .22 .29 
Psychosocial Worry heart condition .54 .51 .81 .49 .26 .39 
Functioning Over-doing it .51 .53 .78 .49 .24 .32 
Heart attack .44 .41 .74 .46 .22 .32 
Frightened by pain .61 .59 .81 .53 .27 .45 
Uncertain .51 .47 .84 .50 .29 .38 
Depressed .41 .42 .71 .52 .19 .38 
Frustrated .53 .57 .77 .56 . 29 .37 . 
Interfered with enjoyment .59 .62 .83 .61 .32 .47 
Positive ouUook .53 .55 .83 .56 .30 .43 
Difficult to plan .53 .60 .83 .60 .31 .39 
Family overprotective .36 .45 .56 .33 .25 .29 
Feeling a burden .46 .54 .68 .42 .23 .34 
Restricted in social activities .58 .68 .78 .54 .31 .46 
Too far from home .51 .63 .76 .57 .35 .37 
Cognitive Reason .43 .45 .66 .81 .34 .32 
Functioning Forget .39 .42 .52 .84 .36 .25 
Concentration .43 .47 .61 .89 .34 .30 
~ 
Q) 
CROQ-PTCA CROQ-PTCA scale 
scale CROQ-PTCA item Symptoms Physical Functioning Psychosocial Functioning Cognitive Functioning Complications Satisfaction 
Complications Pain in groin wound 24 .19 28 .30 .76 .18 
Tender groin wound .31 .21 .32 .31 .78 .24 
Numb groin .32 .22 .34 .31 .59 .28 
Bruised groin wound .17 .12 .20 .29 .54 .17 
Problems from catheter .17 .14 .19 .23 .71 .19 
Concem over bruises .25 .15 .28 .30 .61 .25 
Satisfaction Satisfied with results .58 .41 .41 .29 .25 .70 
Satisfied with info about op .21 .22 .27 .14 .17 .54 
Satisfied with recovery info .17 .13 .26 .11 .19 .53 
Overall .57 .37 .40 .25 .25 .58 
Speed of recovery .40 .29 .34 .25 .21 .62 
Expectation of results .49 .43 .43 .31 .18 .62 
Values in bold indicate probable scaling successes. 1 Values in bold and underlined indicate probable scaling failures. 
~ 
<0 
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TABLE 6.16 Intercorrelations Between Scales: CROQ Pre-Revascularisation (Final Field Test) 
CROQscaie 
CROQscaie Symptoms Physical Psychosocial Cognitive 
Functioning Functioning Functioning 
:::::mllltWllm:::lNffig!j:]:::I::::::::::::::::::::::::::::::::::::::::::I::::::::::I:::::::::::::::::::::::::::::::::::::::::::::: :::::::;:",,::;;::;::,,::::::::":':':::::::::::':,:;:::,::::'::::::':"":::;::,:::::r:::;'2::,:::::::,::::::::::}:::;::::::;:, ,::::':::::':::::::::::i ,:mm:::: 
Symptoms (.88)1 
Physical Functioning .71 
Psychosocial Functioning .60 
Cognitive Functioning .41 
Core Total .81 
(.90) 
.63 
.44 
.84 
(.95) 
.59 
.92 
(.91 ) 
.67 
;:::ellmijliml::f lffii :g§ll :':,:::::,I:::::::::::::::':::::::::::::::::::':.:':::::::::::::':':"::::::::,,,::::.::::,:::::::·:::':::·::':·::,·:·:::::::,:::I':·:':::::::::·::::::I.:·:·::::::::':':':::::·::',:"":::;;","",,;,;;::':t::;::::::;::::::::;::::I:i:::,::::":.:::':::::.::::!:::::::::::j::::::' ...... ,;:::::::;.:.":';:::::::::':'::::::i\:::r:: 
Symptoms (.89) 
Physical Functioning .74 
Psychosocial Functioning .69 
Cognitive Functioning .51 
Core Total .85 
(.91 ) 
.73 
.52 
.88 
1 Values in brackets indicate Cronbach's alpha coefficient. 
(.95) 
.63 
.94 
(.92) 
.70 
TABLE 6.17 Intercorrelations Between Scales: CROQ Post-Revascularisation (Final Field Test) 
CROQscaie Physical Psychosocial 
Symptoms Functioning Functioning 
Symptoms (.85) 
Physical Functioning .63 (.90) 
Psychosocial Functioning .62 .63 (.95) 
CROQscaie 
Cognitive 
Functioning 
Cognitive Functioning .44 .46 .69 (.89) 
Core Total 
Core Total .79 .82 .94 .73 (.96) 
Satisfaction 
Satisfaction .50.47 .51 .28 .55 (.81) 
Complications .52 .50 .61 .44 .63 .43 
Total Outcome .63 .58 .71 .48 .74 .74 
Symptoms (.91) 
Physical Functioning .71 
Psychosocial Functioning .63 
Cognitive Functioning .45 
Core Total .82 
Satisfaction 
Complications 
Total Outcome 
.55 
.31 
.56 
(.93) 
.67 
.48 
.86 
.42 
.23 
.45 
1 Values in brackets indicate Cronbach's alpha coefficient. 
v.> 
U1 
...... 
(.96) 
.64 
.93 
.48 
.34 
.60 
(.92) 
.69 
.31 
.37 
.47 
(.97) 
.53 (.83) 
.36 .28 
.63 .77 
Complications 
(.84) 
.91 
(.87) 
.82 
w 
~ 
TABLE 6.18a Principal Axis Factor Analysis: CROQ-CABG Core Items Pre-Revascularisation (Final Field Test) 
Factor 
CROQ~ABG item 1 2 3 4 
Chest pain .19 28 .89 .08 
Chest discomfort .20 .33 .81 .11 
Shortness of breath 1 .15 .48 .34 .25 
Radiating pain .23 .37 2 .50 .13 
Palpitations .27 .21 .29 .16 
Nitroglycerin .15 .28 .63 -.01 
Trouble .26 .49 .60 .16 
Moderate activities 25 .67 23 .12 
Ufting & carrying .16 .68 .24 .09 
Climbing flights of stairs .13.72 .24 .13 
Climbing one flight of stairs .13.73 .22 .11 
Bending, keeling, stooping .24 .57 .10 .10 
Walk half a mile .22 .59 .33 .15 
Walk 100 yards .22 .62 .26 .08 
Bathing or dressing .24.54 .27 .14 
Reason .40 .20 .11 .73 
Forget .23 .21 .17 .76 
Concentration .26 .21 .04 .89 
Wony heart condition .82 .18 .21 .06 
Over-doing it .72 .31 .23 .05 
Heart attack .77 .08 .22 .06 
Frightened by pain .70 .31 .28 .12 
Uncertain .79 .05 .09 .18 
Depressed .62 .10 .10 .38 
Frustrated .59 .31 .14 .24 
Interfered with enjoyment .67 .35 .17 .22 
Positive outlook .73 .16 .12 .28 
Difficult to plan .56 .28 .07 .23 
Family overprotective 1 .38.40 .14 .19 
Feeling a burden .52.51 .09 .22 
Restricted in social activities .56 .52 .15 .16 
Too far from home .63.44.17 .11 
1 Item loads higher on the 'wrong factor'. 2 Values in bold indicate items crossloading on more than one factor with a difference <.20. 
W 
0'1 
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TABLE 6.18b Principal Axis Factor Analysis: CROQ-PTCA Core Items Pre-Revascularisation (Final Field Test) 
Factor 
CROQ-PTCA item 1 2 3 4 
Chest pain-- - .20 ----:20 - .85 .16 
Chest discomfort .26.34.72 .17 
Shortness of breath 1 .21 .53 .32 .15 
Radiating pain .23 .34 .60 .21 
Palpitations , .34 .27 .32 .18 
Nitroglycerin .21.22 .63 .05 
Trouble .32 .48 2 .67 .08 
Moderate activities .28.69 .27 .14 
Ufting & carrying .33 .69 .26 .14 
Climbing flights of stairs .23 .59 .38 .09 
Climbing one flight of stairs .25 .63 .28 .22 
Bending, keeling, stooping .17 .65 .08 .22 
Walk haifa mile .25 .57 .37 .10 
Walk 100 yards .27 .52 .36 .14 
Bathing or dressing .35.48 .25 .14 
Reason .40 .17 .20 .72 
Forget .24 .. 28 .15 .77 
Concentration .30 .19 .17 .85 
Worry heart condition .74 .18 .27 .18 
Over-doing it .73 .24 .32 .12 
Heart attack .69 .08 .29 .15 
Frightened by pain .71 .20 .40 .20 
Uncertain .73 .22 .19 .20 
Depressed .59 .33 .09 .34 
Frustrated .53 .30 .13 .24 
Interfered with enjoyment .62.43 .16 .21 
Positive outlook .71 .33 .13 .28 
Difficult to plan .62 .42 .12 .28 
Family overprotective .52 .31 .16 .08 
Feeling a burden .53.46 .20 .12 
Restricted in social activities 1 .49 .62 .19 .14 
Too far from home .64.44 .21 .10 
1 Item loads higher on the 'wrong factor'. 2 Values in bold indicate items crossloading on more than one factor with a difference <.20. 
TABLE 6.19a Principal Axis Factor Analysis: CROQ-CABG Core Items Post-Revascularisation (Final Field Test) 
Factor 
CROQ-CABG item 1 2 3 4 
Chest pain .17 .16 .85 .12 
Chest discomfort .22 .19 .83 .12 
Shortness of breath 1 .29 .50 .27 .09 
Radiating pain .19 .30 .67 .07 
Palpitations .33 .19 .20 .02 
Nitroglycerin .14 .24 .59 1.0 
Trouble 1 .SO 2 .42 .43 .02 
Moderate activities .37.56 .19 .04 
Ufting & carrying .30 .63 .09 .03 
Climbing flights of stairs .20.71 .15 .09 
Climbing one flight of stairs .14.79 .11 .18 
Bending, keeling, stooping .16 .64 .19 .16 
Walk half a mile .21 .70 .18 .14 
Walk 100 yards .13 .63 .18 .14 
Bathing or dressing .13 .64 .16 .21 
Reason .43 .21 .15 .64 
Forget .29 .17 .13 .73 
Concentration .40.22 .12 .77 
Worry heart condition . 79 .17 .19 .12 
Over-doing it .69 22 .15 .19 
Heart attack .70 .08 .18 .20 
Frightened by pain .75 .23 .25 .13 
Uncertain .77 .13 .08 .24 
Depressed .59 .29 .06 .29 
Frustrated .55 .29 .11 .32 
Interfered with enjoyment .69 .31 .18 .24 
Positive ouUook .79.22 .17 .26 
Difficult to plan .71 .32 .13 .25 
Family overprotective 3 .33 .23 .05 .35 
Feeling a burden .48 .41 .15 .35 
Restricted in social activities 1 .48.53 20 .32 
Too far from home .52 .49 .20 .24 
1 Item loads higher on the 'wrong factor'. 2 Values in bold indicate items crossloading on more than one factor with a difference <.20~ 3 Item doesn't load on a factor> .35. 
w 
~ 
w 
UI 
UI 
TABLE 6.19b Principal Axis Factor Analysis: CROQ-PTCA Core Items Post-Revascularisation (Final Field Test) 
Factor 
CROQ-PTCA item 1 2 3 4 
Chest pain .26 .27 .85 .14 
Chest discomfort .21 .25 .85 .12 
Shortness of breath 1 .19 .52 2 .42 .13 
Radiating pain .26 .27 .61 .13 
Palpitations .24.26 .39 .03 
Nitroglycerin .19 29 .70 .08 
Trouble .35 .43 .67 .11 
Moderate activities .30.72 .29 .14 
Ufting & carrying .32 .68 .27 .12 
Climbing fligh1s of stairs .24.74 .19 .20 
Climbing one flight of stairs .22.75 .22 .14 
Bending, keeling, stooping .22 .63 .18 .21 
Walk half a mOe .21.71 .35 .08 
Walk 100 yards .23 .66 .28 .07 
Bathing or dressing .26 .63 .20 .04 
Reason .48 .18 .15 .69 
Forget .28 .20 .12 .81 
Concentration .36 .21 .16 .83 
Worry heart condition .79 .21 .27 .11 
Over-doing it .71 .27 .22 .13 
Heart attack .76 .12 .20 .11 
Frightened by pain .70 .27 .35 .16 
Uncertain .84 .14 .22 .14 
Depressed .66 .19 .13 .25 
Frustrated .65 .32 .22 .24 
. Interfered with enjoyment .69 .33 .25 .29 
Positive outlook .76 .25 .22 .21 
Difficult to plan .71 .33 .17 .30 
Family overprotective .47 .32 .10 .08 
Feeling a burden .55 .37 .15 .15 
Restricted in social activities .59 .48 .22 .23 
Too far from home .59.44 .16 .28 
1 Item loads higher on the 'wrong factor'. 2 Values in bold indicate items crossloading on more than one factor with a difference < .20. 
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TABLE 6.20a Principal Axis Factor Analysis: CROQ-CABG Post-Revascularisation 
Outcome Only Items (Final Field Test) 
CROQ-CABG item 
Satisfied with results 
Satisfied with info about op 
Satisfied with recovery info 
Overall 
Speed of recovery 
Expectation of results 
Symptoms return 
Pain in chest wound 
Infection in chest wound 1 
Tender chest wound 
Numb chest wound 
Bruising on chest 
Pain leg wound 
Other pain in leg 
Infection in leg wound 
Numb leg 
Bruising on leg 
Swollen feet 
Factor 
1 
.24 
.13 
.09 
.16 
.23 
.17 
.40 
.61 
.28 
.56 
.51 
.55 
.76 
.71 
.44 
.63 
.55 
.49 
2 
.65 
.59 
.68 
.51 
.62 
.63 
.23 
.24 
.05 
.22 
.08 
.19 
.17 
.22 
.13 
.15 
.19 
.08 
1 Item doesn't load on a factor> .35. 
Co.) 
01 
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TABLE 6.20b Principal Axis Factor Analysis: eROQ-PTeA Post-Revascularisation 
Outcome Only Items (Final Field Test) 
eROQ-PTeA item 
Satisfied with results 
Satisfied with info about op 
Satisfied with recovery info 
Overall 
Speed of recovery 
Expectation of results 
Symptoms return 
Pain in groin wound 
Tender groin wound 
Numb groin 
Bruised groin wound 
Problems from catheter 
Concern over bruises 
Factor 
1 2 
.11 .79 
.11 .59 
.13 .57 
.16 .65 
.09 .68 
.04 .72 
.19 .39 
.86 .07 
.84 .13 
.61 .22 
.53 .10 
.74 .07 
.61 .20 
W 
01 
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TABLE 6.21 Known Group Differences: CROQ Global Improvement Post-Revascularisation (Final Field Test) 
Mean scores 
Scale Improved (n) '---Unimproved(n) 2 p 
:::::-mll"tl£II§'::\N%I:I:~~::::::::::::::::::::::::::::::-::I:::::I:::::::::::::::::::::::::::::::::::::::: ::::::::::::::::::::::::::::::-::::::::::::::::::::::-::::::::-::::::::I:::::::::::::::-::::::::::::::I:::.::::::::i:r:\::::::::::::::::);:-:-::::: :::::::::::;:::::I::::::::::::::-:::- ::-:::-::::::::: 
Symptoms 89_05 (378) 68.41 (30) _ODD 
Physical Functioning 81 _23 (375) 68.34 (30) .039 
Psychosocial Functioning 78.99 (378) 67.03 (30) .020 
Cognitive Functioning 78.69 (381) 72.00 (30) .251 
Core Total 50.34 (378) 44.84 (30) .004 
Complications 81.00 (379) 72.08 (30) .057 
Satisfaction 85.42 (382) 53.94 (30) .000 
Total Outcome 50.48 (379) 43.63 (30) .000 
::::::lllltSiQa;::fBiml:::::::::::::::::::::::::::::::::ill:::::::::::::::::::::::::::::::::::::::::::::::::::it::::::::::::::::::::::::::::::::::::::::::::::::::::::::::L:::::::::::::::::}:::::~::::::::::::::i:::::{ :::::::::::::;:;:::::::(:::::::::::::::t:::::::::::::::::::::::::::::::::: 
Symptoms 81 .98 (267) 56.65 (67) .000 
Physical Functioning 74.90 (257) 55.51 (64) _ODD 
Psychosocial Functioning 73.32 (261) 52.47 (66) .000 
Cognitive Functioning 78.62 (266) 64.78 (67) .003 
Core Total 51.29 (262) 44.56 (66) .000 
Complications 
Satisfaction 
Total Outcome 
95.15 (259) 
83.09 (270) 
51.45 (266) 
87.45 (67) 
50.86 (66) 
44.10 (67) 
.008 
.000 
.000 
1 Patients who reported global improvement in heart condition at 3-months post-revascularisation 
(scored 4 "a little better" , or 5 "much better" on 012). 
2 Patients who reported no global improvement in heart condition at 3-months post-revascularisation 
(scored 1 "much worse", 2 "a little worse", or 3 "about the same" on 012) . 
(.t.) 
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TABLE 6.22 Known Group Differences: CROQ Bothered by Chest Pain Post-Revascularisation (Final Field Test) 
Mean scores 
CROQ scale Bothered (n) 1 Not bothered (n) Z p 
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Symptoms 66.41 (63) 92.05 (340) .000 
Physical Functioning 63.60 (60) 84.12 (335) .000 
Psychosocial Functioning 58.18 (61) 82.16 (338) .000 
Cognitive Functioning 60.85 (63) 81.53 (340) .000 
Core Total 42.30 (61) 51.56 (338) .000 
Complications 67.18 (64) 83.03 (337) .000 
Satisfaction 73.98 (64) 85.23 (340) .000 
Total Outcome 45.37 (64) 50.95 (337) .000 
:I:pllltBiwt\::iamljt:::!!:::ii:::::i:::i :i:::i::::i:::::i::::i::i:i:I::i::iiIi:i::i:::i!::i::::::::::ii::::::i: :i: ::::::::::ii::::i::i::::::::i:!i:::i:i::::i!::::::i::.:ii:I::::::::ii:i:i:iii:ii::::i!::ii::::::i:::i:i::::ii:::I::::i:i::i:i::ii:::i:i:i:::i!::::i::i:ii:i::::i:::::i::::::i::::::::',::':::i:iIi::::::::::i:::i:i:::i:::i:i::r:}i 
Symptoms 60.09 (152) 91 .93 (179) 
Physical Functioning 58.20 (147) 84.06 (169) 
Psychosocial Functioning 58.65 (149) 79.29 (174) 
Cognitive Functioning 65.56 (150) 85.51 (176) 
Core Total 45.87 (149) 53.80 (175) 
Complications 91.41 (144) 95.65 (173) 
Satisfaction 69.51 (150) 83.40 (176) 
Total Outcome 48.08 (149) 51 .77 (174) 
.000 
.000 
.000 
.000 
.000 
.011 
.000 
.000 
1 Patients who reported they were bothered by chest pain due to angina at 3-months post-revascularisation 
(scored 1 "a lot", 2 "quite a bit", 3 "moderately", or 4 "a little" on 01 a). 
2 Patients who reported they were not bothered at all by chest pain due to angina at 3-months post-revascularisation 
(scored 5 "not at all" on 01 a). 
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TABLE 6.23 Construct Validity: Comparison with Other HRQoL Measures at Pre-Revascularisation (Final Field Test) 
SF-36 SAQ QLMI-2 LlhFEl 
Exertional Anginal Anginal Disease 
CROQ scale PCS MCS capacity stability frequency perception Global Total 
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Symptoms .71 .34 .68 .63 .78 .72 .56 -.84 
PhYSical Functioning .75 .22 .90 .22 .48 .68 .63 -.82 
Psychosocial Functioning .38 .70 .74 .27 .34 .83 .83 -.86 
Cognitive Functioning .29 .58 .53 .24 .32 .53 .64 -.75 
Core Total .65 .62 .87 .39 .53 .85 .82 -.94 
Physical Functioning .81 .31 .90 .48 .56 .68 .75 -.87 
Psychosocial Functioning .53 .60 .81 .38 .53 .77 .91 -.92 
Cognitive Functioning .35 .57 .58 .19 .39 .42 .76 -.79 
Core Total .71 .56 .89 .49 .65 .76 .90 -.93 
1 Values in bold indicate correlations between scales that purport to measure the same aspect of HRQoL. 
2 The LlhFE is scored in the opposite direction to the other measures; high scores indicate poorer heaHh outcomes. 
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TABLE 6.24 Construct Validity: Correlations Between CROQ and SF-36 Dimension Scores 
at Pre-Revascularisation (Final Field Test) 
SF-36 scale 1 
CROQ scale PF RP BP GH VT SF RE M H 
:!!!!§{illtllll:!!frna1.!Q1.!l !:!:!:!!!:!:::::':::::!:!!::!::!!:::::!:!:!:::::::!::!:!:!!!!!!!!!!!!!!:!:!:::::::!::::!!::!:::::::!:!!!!::!!::!!::!::!!!:!::!:::!!:::::::::::::!:!:!:::!:::::!!!!::!::::!:::::::::::::!!:!:!:!!:::::!::!!::::!!!!!:::::!::::::::!:!!!:!!:!:::!!::!:!!I::::::!:::::::::!:::':!!:!:!::::::::!::::!:::!:::::::::::!::!::::::::!:!:::!!!:!:::::::!:::I::!:::::!::::::!!:::I::!!:!::!:!!::::::::: :;:;':;:;:;:;:;::':;;:::::\:;:::!::)':::/::::::::: 
Symptoms .65 .54 .75 .48 .47 .48 .45 .31 
Physical Functioning .89 2 .48 .54 .36 .41 .48 .44 .1 5 
Psychosocial Functioning .47 .37 .56 .49 .61 .71 .56 .62 
Cognitive Functioning .34 .39.43 .32 .46 .53 .53 .47 
Core Total .73 .54 .72 .55 .64 .73 .63 .53 
Symptoms 
Physical Functioning 
Psychosocial Functioning 
Cognitive Functioning 
Core Total 
.73 
.94 
.71 
.48 
.87 
.38 
.50 
.44 
.39 
.51 
.76 
.69 
.53 
.44 
.72 
.35 
.39 
.37 
.26 
.43 
.36 
.49 
.54 
.46 
.57 
.60 
.72 
.77 
.53 
.82 
.39 
.35 
.58 
.37 
.55 
1 PF = Physical Functioning scale; RP = Role-Physical scale; BP = Bodily Pain scale; GH = General Health scale ; 
VT = Vitality scale; SF = Social Functioning scale; RE = Role-Emotional scale; MH = Mental Health scale. 
2 Values in bold indicate correlations between scales that purport to measure similar aspects of HRQoL. 
.38 
.38 
.46 
.68 
.53 
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TABLE 6.25 Discriminant Validity: Correlations Between CROQ and Age, Sex, Social Class 
at Pre-Revascularisation (Final Field Test) 
CROQ scale Age Sex 1 Social class 
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Symptoms .03 -.15 -.16 
Physical Functioning -.03 -.22 -.12 
Psychosocial Functioning .15 -.10 -.08 
Cognitive Functioning .02 -.06 -.04 
Core Total .08 -.16 -.12 
:::::R :BIIBigIItlffil :i!}:::::::::::::::::::·:::::::::·:.:':.::::::':::::::::.:::.:::::::::':,::::.:::::::,::::.:::::::::::::':::::::::::::':.::::::::::,::::::::::::::::::::.:·:1::::.:':':·:::::::::::::::::::::::::·:::::::::::::::::::·:::::::::::::,:::::::::,:::::1::::::: 
Symptoms .04 -.11 -.14 
Physical Functioning -.05 -.21 -.16 
Psychosocial Functioning .12 -.06 -.16 
Cognitive Functioning .04 -.02 -.13 
Core Total .06 -.11 -.17 
1 Spearman's rho. 
~ 
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TABLE 6.26 Convergent Validity: Correlations Between CROQ and CCS and NYHA 
at Pre-Revascularisation (Final Field Test) 
CCS' NYHA ' 
CROQ-CABG item I scale n r n r 
CROQ-CABG Items 
Chest pain 107 _.27 2 90 -.15 
Chest discomfort 107 -.22 90 -.13 
Radiating pain 107 -.21 90 -.27 
Shortness of breath 107 -.21 90 -.27 
Nitro frequency 107 -.39 90 -.20 
CROQ-CABG Scales 
Symptoms 107 -.30 90 -.27 
Physical Functioning 105 -.20 88 -.23 
Psychosocial Functioning 107 -.22 90 -.14 
Cognitive Functioning 107 -.18 90 -.04 
COfe Total 107 -.27 90 -.21 
1 CCS and NYHA are graded classifications of angina and dyspnoea; higher grades reflect 
more severe disease. 
2 Values in bold indicate correlations between scales that purport to measure similar aspects 
ofHRQoL. 
TABLE 6.27 Construct Validity: Comparison with Other HRQoL Measures at Post-Revascularisation (Final Field Test) 
SF-36 SAQ QLMI-2 LlhFEZ 
Exertional Anginal Anginal Disease Treatment 
CROQ scale PCS MCS capacity stability frequency perception Satisfaction Global Total 
Physical Functioning .75 .36 .67 .48 .47 .47 .35 .81 -.70 
Psychosocial Functioning .59 .64 .76 .51 .52 .71 .55 .89 -.83 
Cognitive Functioning .44 .46 .73 .47 .40 .53 .41 .69 -.70 
Core Total .74 .58 .82 .63 .64 .71 .59 .92 -.87 
Complications .51.46 .44 .33 .51 .48 .52 .65 -.54 
Satisfaction .51 .37 .45 .49 .46 .53 .65 .58 -.54 
Total Outcome .57 .51 .56 .47 .61 .60 .67 .72 -.67 
Symptoms .68 .32 .69 .71 .86 .78 .70 .50 -.60 
Physical Functioning .75 .37 .90 .73 .70 .75 .56 .66 -.48 
Psychosocial Functioning.49 .73 .77 .61 .62 .83 .58 .88 -.71 
Cognitive Functioning .36 .49 .65 .40 .50 .52 .38 .76 -.68 
Core Total .69 .62 .86 .70 .74 .85 .64 .89 -.74 
Complications .25 .21 .44 .36 .45 .39 .35 .23 -.19 
Satisfaction .29 .38 .53 .70 .59 .64 .72 .42 -.28 
Total Outcome .37.46 .61 .62 .61 .62 .61 .51 -.38 
1 Values in bold indicate correlations between scales that purport to measure similar aspects of HRQoL. 
2 The LlhFE is scored in the opposite direction to the other measures; high scores indicate poorer heaHh outcomes. 
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TABLE 6.29 Discriminant Validity: Correlations Between CROQ and Age, Sex, Social Class 
at Post-Revascularisation (Final Field Test) 
CROQ scale Age Sex 1 Social class 
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Symptoms -,08 -.19 -.13 
Physical Functioning -.16 -.28 -.07 
Psychosocial Functioning .06 -.10 -.13 
Cognitive Functioning .02 -.1 9 -.09 
Core Total -.02 -.23 -.13 
Complications -.10 -.24 -.1 1 
Satisfaction -.03 -.10 .05 
Total Outcome .07 -.25 -.08 
::::::miilmmll:::(lffiIDI:::::::::::::::::':::::::':::::::::::::::::::::::::::::::::'::=:::':::'::::::::":j:':::::::::::::':::::::::::':::::l:::::l:::::::':::::::::::::::::l:::::l:::::::l:::::::::::'::::::::::::::::,::::::::::::::,'::':::::':::':::::::::l:,:l:::l:l:l:l:l:::':::: 
Symptoms .09 -.09 -.07 
Physical Functioning -.1 3 -.26 -.16 
Psychosocial Functioning .1 5 -.10 -.16 
Cognitive Functioning .06 .01 -.14 
Core Total .07 -.15 -.1 7 
Complications 
Satisfaction 
Total Outcome 
1 Spearman's rho. 
.04 
.06 
.09 
.-.02 
-.03 
-.06 
-.15 
.00 
-.1 2 
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TABLE 6.30 Known Group Differences: Mean CROQ-CABG Symptom Scores by CCS, NYHA and Ejection Fraction 
at Pre-Revascularisation (Final Field Test) 
CROQ-CABG Symptom Score 
n Mean SD p 
CCS 1 
Grade 1 3 80.14 19.4 .005 
Grade 2 35 47.88 22.2 
Grade 3 53 42.08 22.5 
Grade 4 16 33.97 15.4 
NYHA 1 
Grade 1 17 56.71 21.2 .033 
Grade 2 39 40.60 21.4 
Grade 3 52 39.23 22.1 
Grade 4 16 28.86 22.3 
Ejection Fraction 2 
Good 55 45.57 24.2 .193 
Fair 13 48.75 22.8 
Poor 3 21.01 23.6 
1 CCS and NYHA are graded classifications of angina and dyspnoea; higher grades reflect more severe disease. 
2 Defined as good if >50%, fair if 30-50%, poor if <30%. 
w 
m 
en 
TABLE 6.31 Responsiveness: CROQ Pre- to 3-Months Post-Revascularisation (Final Field Test) 
Mean (SO) Pre-to 3-months post-revascularisation 
~ - - -Responsiveness Standardised 
CROQ scale Pre 3m post Change 1 effect size 2 response mean 3 
Symptoms 48.98 (24.2) 88.29 (13.9) 39.31 (25.3) 2.83 1.56 
Physical Functioning 50.48 (26.9) 82.46 (21.8) 31 .98 (29.4) 1.47 1.09 
Psychosocial Functioning 49.59 (24.3) 79.65 (19.7) 30.05 (23.1) 1.53 1.30 
Cognitive Functioning 62.57 (29.2) 77.94 (22.8) 15.36 (25.7) 0.67 0.59 
Symptoms 51.98 (23.4) 75.07 (21 .9) 23.10 (25.2) 0.99 0.92 
Physical Functioning 53.39 (27.2) 71.42 (26.0) 18.03 (28.3) 0.66 0.64 
Psychosocial Functioning 54.32 (25.1) 71.06 (24.3) 16.74 (21 .5) 0.67 0.78 
Cognitive Functioning 68.46 (29.5) 75.45 (25.7) 6.99 (23.5) 0.24 0.30 
1 All change scores are statistically significant (p<.05). 
2 Calculated as the mean change score between pre- and 3-months post-revascularisation divided by the standard deviation of scores at the 
pre-revascularisation assessment. 
3 Calculated as the mean change score between pre- and 3-months post-revascularisation divided by the standard deviation of the change score. 
(...) 
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TABLE 6.32 Responsiveness: CROQ Pre- to 3-Months Post-Revascularisation for Subsample 
Who Reported Global Improvement (Final Field Test) 
Mean (SO) Pre-to 3-months post-revascularisation 
Responsiveness Standardised 
CROQ scale Pre 3m post Change 2 effect size 3 response mean 4 
Physical Functioning 48.91 (26.0) 83.61 (20.0) 34.70 (28.2) 1.34 1.23 
Psychosocial Functioning 80.55 (19.1) 48.18 (23.9) 32.37 (21 .7) 1.36 1.50 
Cognitive Functioning 61.66 (29.4) 78.45 (22.2) 16.80 (24.9) 0.57 0.67 
Symptoms 50.98(22.6) 81.16(16.2) 30.18(22.1) 1.34 1.37 
Physical Functioning 53.22 (26.8) 76.93 (22.6) 23.71 (27.8) 0.89 0.85 
Psychosocial Functioning 54.53 (24.2) 76.34 (19.6) 21 .81 (20.4) 0.90 1.07 
Cognitive Functioning 68.29 (29.1) 78.37 (22.0) 10.08 (23.7) 0.35 0.43 
Responsiveness subsample: Excludes patients who did not report global improvement in their heart condition compared to before their operation 
(i.e. those who scored 1 "much worse", 2 "a little worse", or 3 "about the same" on Q12). 
2 All change scores are statistically significant (p<.05). 
3 Calculated as the mean change score between pre- and 3-months post-revascularisation divided by the standard deviation of scores at the 
pre-revascularisation assessment. 
4 Calculated as the mean change score between pre- and 3-months post-revascularisation divided by the standard deviation of the change score. 
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TABLE 6.33 Responsiveness: CROa Pre- to 9-Months Post-Revascularisation (Final Field Test) 
Mean (SO) Pre-to 9-months post-revascularisation 
Responsiveness Standardised 
CROa scale Pre 9m post Change 2 effect size 3 response mean 4 
Symptoms 48.80 (24.5) 85.27 (19.5) 36.47 (26.1) 1.87 1.39 
Physical Functioning 51 .67 (28.0) 84.53 (20.4) 32.86 (28.8) 1.61 1.14 
Psychosocial Functioning 51.92 (23.7) 82.89 (21 .7) 30.97 (27.3) 1.43 1.13 
Cognitive Functioning 60.47 (27.7) 79.50 (23.6) 19.03 (28.9) 0.81 0.66 
Symptoms 52.30 (23.6) 74.06 (22.8) 21.76 (22.8) 0.95 0.91 
Physical Functioning 52.92 (28.2) 70.89 (28.4) 17.97 (25.2) 0.63 0.71 
Psychosocial Functioning 54.83 (27.3) 72.80 (27.9) 17.97 (23.8) 0.64 0.75 
Cognitive Functioning 68.86 (30.8) 77.55 (26.7) 8.69 (25.0) 0.33 0.35 
1 Responsiveness subsample who completed pre- and 9-month post-revascularisation questionnaire. 
2 All change scores are statistically Significant (p<.05) . 
3 Calculated as the mean change score between pre- and 9-months post-revascularisation divided by the standard deviation of scores at the 
pre-revascularisation assessment. 
4 Calculated as the mean change score between pre- and 9-months post-revascularisation divided by the standard deviation of the change score. 
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TABLE 6.34 Responsiveness: Comparison of CROQ Change Scores for Different Levels of Global Improvement 
(Final Field Test) 
Mean Pre-3m change scores Mean Pre-9m change scores 
CROQ scale Improved (n) 1 Unimproved (n) 2 p Improved (n) 1 Unimproved (n) 2 p 
Symptoms 42.19 (176) 6.78 (15) .000 41 .32 (88) -3.63 (10) .000 
Physical Functioning 34.70(174) 0.42(15) .000 37.70(86) -11 .11(9) .000 
Psychosocial Functioning 32.37 (177) 2.40 (15) .000 34.30 (89) 2.68 (10) .000 
Cognitive Functioning 16.80 (181) -3.56 (15) .003 22.36 (89) -12.67 (10) .000 
Symptoms 30.18(82) -4.16(21) .000 26.60(63) 0.10(13) .000 
Physical Functioning 23.71 (76) -2.66 (20) .000 22.93 (63) -2.34 (13) .000 
Psychosocial Functioning 21 .81 (80) -3.15 (20) .000 21.59 (63) -0.53 (13) .002 
Cognitive Functioning 10.08(82) -4.76(21) .010 12.60(64) -11 .28(13) .001 
Patients who reported global improvement in heart condition at 3 / 9-months-post revascularisation (scored 4 "a little better", or 5 "much better" on Q12). 
2 Patients who reported no global improvement in heart condition at 3 / 9-months-post revascularisation (scored 1 "much worse", 2 "a little worse", or 
3 "about the same- on Q12). 
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TABLE 6.35 CROQ Longitudinal Change: 3 to 9 Months Post-Revascularisation (Final Field Test) 
Mean (SO) 3-to 9-months post-revascularisation 
Responsiveness Standardised 
CROQ scale 3m post 9m post Change effect size 2 response mean 3 
Symptoms 87.81 (14.7) 85.55(19.5) -2.26(16.9) -0.12 -0.13 
Physical Functioning 81.45 (22.7) 83.38 (21.4) 1.94 (18.2) 0.09 0.11 
Psychosocial Functioning 79.35(18.8) 82.92(21.9) 3.57(18.7) 0.16 0.19 
Cognitive Functioning 79.12(19.7) 80.20(22.6) 1.08(21.6) 0.05 0.05 
Complications 81 .59(15.2) 87.82(11.7) 6.23(11 .0)4 0.53 0.57 
Satisfaction 84.82 (19.1) 84.89 (19.6) 0.07 (16.6) 0.00 0.00 
Symptoms 76.0721.60 74.06 (22.8) 
Physical Functioning 72.25 (25.9) 72.67 (27.8) 
Psychosocial Functioning 73.75 (24.2) 74.17 (26.4) 
Cognitive Functioning 75.67 (25.6) 78.01 (26.1) 
Complications 91 .98 (16.9) 93.63 (15.6) 
Satisfaction 78.65 (22.0) 79.08 (21 .7) 
-2.01 (17.0) 
0.41 (18.8) 
0.42 (13.3) 
2.34 (16.4) 
1.65 (10.5) 
0.43 (19.1) 
0.01 
0.02 
0.09 
0.11 
0.02 
-0.12 
0.02 
0.03 
0.14 
0.16 
0.02 
Responsiveness subsample who completed 3- and 9-month post-revascularisation questionnaires. 
2 Calculated as the mean change score between pre- and 9-months post-revascularisation divided by the standard deviation of scores at the 
pre-revascularisation assessment. 
3 Calculated as the mean change score between pre- and 9-months post-revascularisation divided by the standard deviation of the change score. 
4 Change score is statistically significant (p<.05) . 
TABLE 6.36 Relative Responsiveness: CROQ and SF-36 (Final Field Test) 
Mean (SO) Pre-to 3-months post-revascularisation 
Responsiveness Standardised response 
Scale Pre 3m post Change effect size 2 mean 3 
SF-36 PCS 32.79 (9.55) 42.06 (10.93) 9.27 (10.63) 0.85 0.87 
SF-36MCS 43.41 (12.16) 50.29(10.25) 6.88(11 .84) 0.67 0.58 
eRoa Symptoms 52.16 (22.70) 87.83 (14.25) 35.67 (23.76) 2.50 1.50 
eROa Physical Functioning 49.72 (24.50) 79.62 (25.18) 29.90 (30.55) 1.19 0.98 
eROa Psychosocial Functioning 49.41 (23.64) 78.91 (19.42) 29.51 (23.96) 1.52 1.23 
eROa Cognitive Functioning 57.78 (30.19) 73.89 (25.63) 16.11 (25.97) 0.63 0.62 
SF-36 PCS 32.36 (9.37) 38.26 (10.46) 5.90 (7.87) 0.56 0.75 
SF-36 MCS 45.91 (10.35) 46.65 (10.70) 0.74 (9.43) 4 0.07 0.08 
CRoa Symptoms 51.57 (24.86) 73.71 (22.82) 22.14 (3.81) 0.97 0.94 
CROa Physical Functioning 48.41 (26.99) 67.34 (26.08) 18.93 (27.04) 0.73 0.70 
CROa Psychosocial Functioning 55.85 (23.11) 70.21 (22.33) 14.36 (16.41) 0.64 0.88 
CROa Cognitive Functioning 73.69 (21.48) 74.23 (25.00) 0.54 (18.28) 4 0.02 0.03 
1 Responsiveness subsample who completed the SF-36 and the CROQ at both pre- and 3-months post-revascularisation. 
2 Calculated as the mean change score between pre- and 3-months post-revascularisation divided by the standard deviation of scores at the pre-revascularisation 
assessment. 
3 Calculated as the mean change score between pre- and 3-months post-revascularisation divided by the standard deviation of the change score. 
4 Change score is not statistically significant (p<.05). 
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TABLE 6.37 Responsiveness: sF-36 Dimension Scores (Final Field Test) 
Mean (50) Pre-to 3-months post-revascularisation 
Responsiveness Standardised 
sF-36 dimension 1 Pre 3m post Change effect size 3 response mean 4 
PF .. "" --F"""7 ,- ~ --" -- -- ,_ .. --~ -_ ..... ,-- -_ .. 
RP 17.16 (33.61) 39.34 (43.90) 22.18 (44.39) 0.66 0.50 
BP 46.5 (23.46) 64.2 (25.34) 17.69 (27.55) 0.75 0.64 
GH 53.4 (23.62) 68.0 (21 .99) 14.58 (21 .83) 0.62 0.67 
VT 35.8 (22.44) 55.9 (23.29) 20.07 (24.55) 0.89 0.82 
SF 53.99 (29.36) 78.47 (26.05) 24.48 (35.01) 0.83 0.70 
RE 40.20 (43.69) 65.20 (42.88) 25.00 (47.62) 0.57 0.52 
MH 64.9 (21 .76) 74.90 (17.38) 10.04 (18.54) 0.46 0.54 
PF 43.53 (25.29) 54.25 (25.79) 10.72 (22.48) 0.42 0.48 
RP 16.45(25.52) 34.21 (39.17) 17.76(32.31) 0.70 0.55 
BP 50.32 (25.08) 60.65 (26.16) 10.32 (20.37) 0.41 0.51 
GH 50.12 (21 .02) 57.46 (24.35) 7.34 (17.60) 0.35 0.42 
VT 34.35 (20.01) 45.46 (24.28) 11.11 (19.54) 0.56 0.57 
SF 55.26 (27.67 ) 62.83 (28.40) 7.57 (27.65)5 0.27 0.27 
RE 57.41 (46.20) 63.89 (43.19) 6.48 (46.34)5 0.14 0.14 
MH 65.33 (17.02) 67.56 (19.66) 2.22 (17.41)5 0.13 0.13 
PF = Physical Functioning scale; RP = Role-Physical scale; BP = Bodily Pain scale; GH = General Health scale ; VT = Vitality scale; 
SF = Social Functioning scale; RE = Role-Emotional scale; MH = Mental Health scale. 
2 Responsiveness subsample who completed the SF-36 and the CROa at both pre- and 3-months post-revascularisation. 
3 Calculated as the mean change score between pre- and 3-months post-revascularisation divided by the standard deviation of scores at the 
pre-revascularisation assessment. 
4 Calculated as the mean change score between pre- and 3-months post-revascularisation divided by the standard deviation of the change score. 
5 Change score is not statistically significant (p<.05). 
TABLE 6.38 Relative Responsiveness: eROQ and SAQ (Final Field Test) 
Mean (SO) Pre-to 3-months post-revascularisation 
Responsiveness Standardised 
Scale Pre 3m post Change 2 effect size 3 response mean 4 
SAO Exertional 47.09 (23.10) 79.19 (20.58) 32.10 (23.71) 1.56 1.35 
Anginal Stability 29.79 (21 .89) 90.43 (23.63) 60.64 (28.90) 2.57 2.10 
Anginal Frequency 38.43 (29.62) 89.22 (19.58) 50.78 (32.98) 2.59 1.54 
SAO Disease perception 26.84 (18.84) 74.92 (25.03) 48.08 (26.91) 1.92 1.79 
eROO Symptoms 44.13 (25.64) 88.44 (16.18) 44.31 (28.28) 2.74 1.57 
eROO Physical Functioning 49.58 (28.30) 83.50 (19.53) 33.92 (30.24) 1.74 1.12 
CROO Psychosocial Functioning 47.98 (26.96) 79.35 (22.26) 31 .37 (24.30) 1.41 1.29 
CROO Cognitive Functioning 62.10(31.56) 81.48 (22.49) 19.38 (27.93) 0.86 0.69 
SAO Exertional 44.49 (26.13) 68.06 (28.18) 23.57 (24.23) 0.84 0.97 
Anginal Stability 39.17 (33.27) 70.00 (33.73) 30.83 (43.89) 0.91 0.70 
Anginal Frequency 52.26 (27.41) 73.87 (27.04) 21.61 (31 .21) 0.80 0.69 
SAO Disease perception 30.56 (19.28) 58.59 (28.98) 28.03 (27.31) 0.97 1.03 
eROO Symptoms 51.40 (24.10) 75.78 (22.43) 24.38 (25.81) 1.09 0.94 
eROO Physical Functioning 51 .25 (29.33) 71.04 (29.70) 19.79 (30.13) 0.67 0.66 
eROO Psychosocial Functioning 50.02 (25.44) 68.19 (26.14) 18.17 (20.56) 0.57 0.67 
eROO Cognitive Functioning 56.36 (34.40) 71 .92 (27.32) 15.56 (23.31) 0.70 0.88 
w 
........ 
01 
Responsiveness subsample who completed the SAQ and the CROQ at both pre- and 3-months post-revascularisation. 
2 All change scores are statistically significant (p<.05). 
3 Calculated as the mean change score between pre- and 3-months post-revascularisation divided by the standard deviation of scores at the 
pre-revascularisation assessment. 
4 Calculated as the mean change score between pre- and 3-months post-revascularisation divided by the standard deviation of the change score. 
w 
~ 
TABLE 7.1 Generalisability of CROQ Sample 
% manual 
Study 
_. ___ Mea~ age (y~) % male % white occupations 
Schroter 200f i 
Pre-revascularisation (CABG) 63.6 85 93 48 
Pre-revascularisation (PTCA) 60.6 75 91 48 
Post-revascularisation (CABG) 65.0 83 89 49 
Post-revascularisation (PTCA) 62.3 73 88 46 
UK CABG national figures for 1998 2 62.7 76 
BARI3 trial of CABG versus PTCA in patients 
with multi vessel disease (1996) 
CABG patients 61.1 74 89 
PTCA patients 61.8 73 91 
CABRI 4 trial of CABG versus PTCA in patients 
with multi vessel disease (1995) 
CABG patients 61.5 78 
PTCA patients 61.0 78 
RITA 5 trial of CABG versus PTCA in patients 
with one, two, or three vessel disease (1993) 
CABG patients Median age =57 yrs for all 79 
PTCA patients 1011 pts 83 
1 CROa validation study (final field test). 2 Society of Caroiothoracic Surgeons adult cardiac surgical database report, 1998. 
3 The Bypass Angioplasty RevascuJarisation Investigation (BARI) trial. 4 Coronary Angioplasty versus Bypass Revascularisation 
Investigation (CABRf) trial. 5 The Randomised Intervention Treatment of Angina (RITA) trial. 
(.0.) 
....., 
....., 
TABLE 7.2 Comparison with Other Studies: SF-3S Scores (Pre-Revascularisation) 
Assessment Mean (SO) SF-36 scale scores ' 
Study (mean age ± standard deviation) N point PCS MCS PF RP BP GH VT SF RE MH 
Ware et al. 1993 normative data for the general 2474 50.0 50.0 84.2 81 .0 75.2 72.0 60.9 83.3 81 .3 74.7 
US population (not provided) (10.0) (10.0) (23.3) (34.0) (23.7) (20.3) (21.0) (22.7) (33.0) (1 8.1 ) 
Ware et al. 1994 normative data for the general 107 36.4 48.0 
US population with angina (62.6) (12.4) (12.4) 
Ware et al. 1994 normative data for comorbid 
recent angina without MI, with hypertension, 256 38.6 50.4 
MOS2 participants (59.7) (11.0) (9.7) 
Schroter2001 (67 ±8), UK 101 Pre 32.7 42.8 43.0 16.2 46.3 51.7 34.4 53.2 40.0 63.2 
(9.1) (12.0) (23.5) (31.9) (23.1) (22.5) (21.5) (27.5) (42.6) (21.5) 
Rumsfeld et al. 1999 (63 ±9), USA 2480 Pre 32.6 44.0 
(9.0) (12.0) 
McCarthy et al. 1995 (not provided), USA 4 40.0 12.0 43.0 53.0 39.0 
(-) (-) (-) (-) (-) 
54.0 38.0 66.0 
(-) (-) (-) 
321 Pre 
MacDonald et al. 1998 (78.8 ± 3), Canada 100 Pre 36.6 14.8 58.9 61 .5 41 .8 
(22.7) (30.0) (31.4) (19.8) (24.0) 
60.2 68.0 78.7 
(36.1) (41.6) (18.8) 
Schroter 2001 (63 ± 10), UK 49 Pre 32.5 46.0 44.3 17.7 49.5 
(9.9) (10.5) (26.9) (29.2) (25.0) (21.0) (22.0) (L~.O) (4o.f) p/.l} 
Krumholz et al. 1996, (60 ± 11), USA 102 
Nash et al. 1999, (63 ± 11), USA 1182 
Pre 
Pre 36.6 
( -) 
48.5 
(-) 
Seto et al. 2000, (57), USA 5 1445 Pre 40.1 49.0 
(-) (-) 
59.0 28.9 58.9 61 .6 45.7 63.3 54.9 67.6 
(25.7) (36.2) (23.4 ) (20.3) (24.3) (27.8) (42.2) (21 .8) 
I PF = Physical Functioning scale; RP = Role-Physical scale; BP = Bodily Pain scale; GH = General Health scale ; VT = Vitality scale; SF = Social Functioning 
scale; RE = Role-Emotional scale· MH = Mental Health scale; PCS = Physical Component Summary Score; MCS = Mental Component Summary Score. 
2 MOS Medical Outcomes Study. 3 CROa validation study subsample. 4 Values estimated as taken from graphical representation of data. 5 Median scores. 
w 
...... 
00 
TABLE 7.3 Comparison with Other Studies: SF-36 Scores (Post-Revascularisation) 
Assessment Mean (SO) SF-36 scale scores 1 
Study (mean age ± standard deviation) N point PCS MCS PF RP BP GH VT SF RE MH 
Ware et al. 1993 normative data for the general 2474 50.0 50.0 84.2 81 .0 75.2 72.0 60.9 83.3 81 .3 74.7 
US population (not provided) (10.0) (10.0) (23.3) (34.0) (23.7) (20.3) (21 .0) (22.7) (33.0) (1 8.1 ) 
Ware et al. 1994 normative data for the general 107 36.4 48.0 
US population with angina (62.6) (12.4) (12.4) 
Ware et al. 1994 normative data for comorbid 
recent angina w~hout MI, with hypertension, 256 38.6 50.4 
MOS2 participants (59.7) (11.0) (9.7) 
~::P.A 
Schroter 2001 ,3 (66 ± 8), UK 123 3-months 41.8 50.5 69.2 38.3 63.8 67.9 54.9 76.6 65.5 75.2 
(10.5) (10.0) (23.7) (43.1 ) (25.4) (21 .6) (22.3) (27.1 ) (43.3) (16.7) 
MacDonald et al. 1998 (78.8 ± 3), Canada 96 3-months 59.5 39.7 74.9 66.5 57.1 74.9 69.5 80.7 
(27.9) (45.7) (26.2) (20.7) (23.8) (27.0) (42.5) (1 6.5) 
Schroter2001,3(63±9), UK 84 3-months 39.7 46.9 60.7 37.7 65.7 58.1 47.5 66.7 64.2 68.8 
~~imi_IWli1;KT{:\;;;X;;;: ......§ ;;;;;;rr%WdiW£;1;:l~·;· '(' ~:~iWi.~ J;il:lEii(*;!i~;;~~~ i,l~~ii;\% ;4b;;;i;;;,7!!i:\i~£;'li 
68.0 58.9 86.3 
U:=;;WWiW4WIW@$WW$@ 0Miti:·;Q'W:;;( ,WKMe, f;0Mit;;;;;;:;1.W1i!Mf3fi\ _V";', ,·"7:C?2 ~~~:~) ':;h!T:~li \';'0i!MMm ,,1!1~ \1IW 
32 9-months 46.5 
(9.1) 
50.4 
(9.9) 
77.0 
(21.4) 
64.1 
(43.5) 
73.1 
(22.0) 
70.0 
(41.4) 
76.7 
(20.1) 
31 9-months 38.6 
(11.1) 
48.9 57.8 
(12.6) (29.4) 
37.5 
(42.9) 
64.6 
(25.3) 
56.6 
(22.9) 
49.5 
(25.7) 
73.8 
(28.9) 
1 PF = Physical Functioning scale; RP = Role-Physical scale; BP = Bodily Pain scale; GH = General Health scale; VT = Vitality scale; SF = Social Functioning 
scale; RE = Role-Emotional sca le~ MH = Mental Health scale; PCS = Physical Component Summary Score; MCS = Mental Component Summary Score. 
2 MOS Medica l Outcomes Study. CROa validation study subsample. 
64.4 
(43.6) 
71.2 
(21 .6) 
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FIGURE 4.1 CROQ Conceptual Model (Pre-test Version) 
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Symptoms 
Chest pain 
Chest tightness 
Discomfort in the chest 
Breathlessness Radiating 
pain 
Palpitations 
Disturbed sleep 
Limitations in daily 
activities 
Specific activities 
Global role limitations 
Psychological 
functioning 
Worry I anxiety 
Fear of death & pain 
Depressed mood 
Uncertainty 
Self-efficacy 
Frustration 
Irritation 
Cognitive functioning 
Reasoning (e.g. decision 
making) 
Fatigue Avoidance of activities 
Short-term memory 
Attention 
Concentration 
Problem solving 
Speed of reaction 
Activity completion 
Global impact 
Medication frequency 
Symptoms on exertion 
I ~ 
Adverse effects 
Cardiac related re-adrnissions to hospital 
Physical complications (e.g. wound related problems, new 
feelings of pain, bruising, swollen feet/ankles, nausea, 
lethargy, appetite) 
Global 
Progress made 
Result of operation 
Information given 
Satisfaction 
Social functioning 
Impact on family & friends 
Independence 
Interference with social 
activities 
J 
Psychological complications (e.g. fear of symptoms 
returning, fear of further operations, appearance of scars I 
bruises) 
Expectations (e.g. speed of recovery, results of operation) 
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FIGURE 6.1 CROQ Conceptual Model (Final Version) 
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Symptoms 
Chest pain 
Discomfort in the chest 
Breathlessness 
Radiating pain 
Palpitations 
Global impact 
Medication frequency 
Symptoms on exertion * 
Physical functioning 
Specific activities 
Psychosocial functioning 
Worry I anxiety 
Fear of death & pain 
Depressed mood 
Uncertainty 
Frustration 
Independence 
Impact on family & friends 
Interference with social activities 
Cognitive functioning 
Reasoning (e.g. decision 
making) 
Short-term memory 
Concentration 
I \t 
Adverse effects 
Complications (e.g. wound related problems, new feelings 
of pain, bruising, swollen feet/ankles appearance of scars I 
bruises) 
Cardiac related re-admissions to hospital * 
Fear of symptoms returning t 
* Descriptive item. 
t Item not scored in the subscales. 
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FIGURE 6.2 Mean CROQ-CABG Scores at Pre- and 3-Months Post-Revascularisation in 
Responsiveness Subsample n=198 
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FIGURE 6.3 Mean CROQ-PTCA Scores at Pre- and 3-Months Post-Revascularisation in 
Responsiveness Subsample n=107 
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APPENDIX 3.1 Cardiac-Specific Patient-Based Questionnaires: General Characteristics 
Response Item Method of Assessment Age of sample Validated 
. Questionnaire of items format reduction Scaling Patient group administration points (yrs) in UK? 
:H'a?tP.t@.W:]j~v~*~n~J'~§ij:::!:)tffffff::f!:!:ltr:/tfttf:::ttIIlt::M:!::::::mr:::t:r:::!:::!::::::Jlt:tMf::tJr::::::::::!:!!:!f:}::!:f}!I:::!:!:::::f!::t:::!:::!(:::::}!I:1!::::rJ:: :r!:!MM:!:::::::::::::tf::::r{::::M::t!I:!:::f!:/:::::::::!!:!!:: ::::}}::::::::::::::::::t::::::::;:.:: ::::: !::!:t :::::::::::::::::.::::::::::::::i:::: ::::://L::;::\::: 
Cleary et ai's Battery: Various Various 496 PTCA pts Telephone- Baseline & 1m Mean age =59 NO 
Cleary at al. (1991) (81% men) administered after (36-82) yrs USA 
Coronary Health 
Profile: Karlsson 
(1999) 
Experience of waiting 
for CABG: Jonsdottir & 
Baldursdottir (1998) 
Global post-operative 
questionnaire: Pinna 
Pintor at al. (1992) 
Modified Physical 
Functioning 
Questionnaire: Faris 
& Stotts (1990) & 
Papadantonaki (1994) 
** Perception of the 
Waiting Period 
Questionnaire: Pieper 
at al. (1985) 
to) 
00 
01 
49 
23 
Dichotomous 
& VAS 
Likert Summated items 
111 CABG pts I Self-
(80% male) administered 
88 pts awaiting I Self-
CABG (74% administered 
male) 
626 CABG pts I Self-
(86% male) administered 
Faris & Stotts: I Self-
20 pts administered 
undergoing 
PTCA. 
Papadantonaki: 
76 CHD pts 
undergoing 
PTCA& CABG 
28 men waiting 
for CABG 
Interview-
administered 
Week before 
angiography, 
day before 
CABG, 12m 
post CABG 
Baseline & 
10m later 
Preop & 6-
24m post 
CABG 
On admission 
& 3 wks after 
discharge 
Single 
assessment 
Mean age =54 I NO 
(40-60) yrs Sweden 
Mean age =62 I NO 
yrs Iceland 
Mean age =61 ± I NO 
8 yrs Italy 
Papadantonaki: I NO 
mean age =57.9 USA 
± 8.2 yrs. 
Faris & Stotts: 
mean age =60 
(39-76) yrs 
Mean age 
=54.29 ± 6.65 
(40-64) yrs 
NO 
USA 
Number Response Item Method of Assessment Age of sample Validated I 
Questionnaire of items format reduction Scaling Patient group administration points (yrs) in UK? 
Problems of cardiac 
- - -
-
82 pts post Interview- Single Mean age =61.8 NO I 
patients in early CABG&MI administered assessment ± 9 .. 1 yrs Nether-
recovery lands 
questionnaire: 
Jaarsma et a/. (1995) 
Prospective study of 
- Dichotomous - - 100 CABG pts Self- Preop, 3 & Mean age =51 ± YES 
QOL before & after administered 12m post 6 (37-59) yrs 
CABG: Caine et a/. surgery 
(1991 ) 
Quality of Life during 
- - - -
201 CABG Self- Preop, 6 & All < 65 yrs NO 
rehabilitation after rehabilitation administered 12m post op Finland 
CABG: Engbolm et a/. pts 
(1992) 
** Quality of Life 18 Likert 
-
Index measure. Weights 300 cardiac Interview- Preop, 6,12 & 
-
NO 
Index - Novi Sad assigned to each response. surgery pts: administered 24m post op Yugo-
(QOLi-NS): Score range 0 to 100. High Valve, CABG, & slavia 
Potic at a/. (1999) score indicates good outcome CABG + Valve 
Self-report of 41 Various 
- -
199 pts Telephone- Preop, & 1, 2, Mean age =75.8 NO 
recovery undergoing· or self- 3,6, 12m post ±4.6yrs USA 
questionnaire: open heart administered. 
Gortner et a/. (1994) surgery 
Symptoms of Illness 
-
Various 
-
Standardised & summated 463 surgical pts Self- & Baseline & 6m Age range =25- NO 
Factor Score: Jenkins responses. 9 variables (some of (374 CABG, 89 interview- post op 69 yrs USA 
et a/. (1994) which are scales) Valve) administered 
Waiting List Impact 47 Likert - Used for descriptive purposes 102 pts waiting Interview- pts who had Mean age =62 NO 
Questionnaire only forCABG administered been on (33-79) yrs Canada 
(WLIQ): and/or valve waiting list for 
Teo et a/. (1998) surgery (86% ~6 weeks 
male) 
w 
~ 
Questionnaire 
Wythenshawe 
Hospital 
Cardiothoracic 
Outcomes Study: 
Bridgewater et al. 
blished 
Zyzanski's 
Behavioural Change 
Scales: Zyzanski et al. 
(1981) 
Ar.Ui.!ftiiH:f:{::::{:::ff:{H:::f:::::H:ff:: 
Angina Impact 
Questionnaire (AIQ): 
Wilson et a/. (1991) 
Angina Pectoris 
Quality of Life 
Questionnaire 
(APQLQ): Wiklund et 
a/. (1987) - Swedish 
version 
•• French version 
Angina Pectoris 
Quality of Life 
Questionnaire 
(APQLQ): Marquis et 
a/. 
w 
en 
....... 
Number 
of items 
21 
36 
22 
22 
22 
Response Item 
format reduction Scaling 
Dichotomous - Summated scales: Total, 
& global item Symptoms, Functional activities, 
Complications, Quality of Life 
4 scales. Score zero for items 
indicating negative outcome and 
one for neutral or positive 
responses. Standardised 
summated scales High scores 
indicate positive outcome 
Likert 5 scales: Social, Sleep, 
Physical, Self-control, Impact 
VAS & Likert Global, Physical, Symptoms, 
Emotional, Life Satisfaction. 
Non-weighted sum of 
responses. High score indicates 
less disability 
VAS & Likert Global, Physical, Symptoms, 
Emotional, Life Satisfaction. 
Non-weighted sum of 
responses. High score indicates 
less disability 
Method of Assessment Age of sample Validated 
Patient group administration points (yrs) in UK? 
CABG & Valve Self- Preop. 3. & Mean ace =60.5 YES 
(75% male) administered 
724 CABG pts Self- Post surgery Mean age =56.7 I NO 
& 225 valve pts administered yrs. 4% over 70 USA 
(75% male) yrs 
I 112anginapts 
in KarQuol 
I Self-
administered 
I Baseline, 6 
wks, & 3m I ± 5.5 vrs I Finland 
Self- Single NO 
administered assessment Sweden 
170 CHD pts: Self- Single Mean age =67 ± NO 
post MI, PTCA, administered assessment 10 yrs France 
CABG (79% 
male) 
Questionnaire 
** Angina-related 
Limitations at Work 
Questionnaire: lerner 
et aI. (1998) 
Angina TyPE 
Specification Form: 
Health Outcomes 
Institute Database 
(1997) 
** Quality of life 
Questionnaire for 
Angina Pectoris: 
Marquis et aI. (1995) 
RAND Chest Pain 
(Angina) Battery: 
Berman et aI. (1981) 
Rose Questionnaire 
(london School of 
Hygiene Chest Pain I 
Cardiovascular 
Questionnaire): Rose 
at aI. (1977) 
Rose (london School 
of Hygiene Dyspnoea) 
Questionnaire: Rose 
et aI. (1982) 
w 
CD 
CD 
Number 
of items 
17 
-
70 
19 
18 
4 
Response Item 
format reduction Scaling 
Likert - Total score constructed from the 
standardised item mean 
- - -
VAS & Likert - APQlQ and three specific items 
on sleep, sexual activity & 
climatic conditions. 0 - 100 
scale. High scores indicate 
good outcome 
Likert & 
-
Impact scale: 'none' to 'great 
dichotomous deal'. Create composite impact 
Likert & 
-
Graded classes 
dichotomous 
Dichotomous 
-
Graded classes 
Method of Assessment Age of sample Validated 
Patient group administration points (yrs) in UK? 
40 employed Self- Single Aged >18 yrs NO 
individuals with administered assessment USA 
chronic stable 
angina 
(excluded post 
CABG I PTCA) 
- - -
- NO 
USA 
170 coronary Self- Single Mean age =67 ± NO 
pts (14% post administered assessment 10yrs France 
PTCA, 31% 
post CABG) 
RAND angina Clinician- or 
- -
NO 
subjects self- USA 
administered 
18,403 men Interview- A few days Age range = 40- YES 
with angina administered before 64 yrs 
and later examination 
adapted for self-
administration 
-
Interview- - - YES 
administered 
Questionnaire 
"* Seattle Angina 
Questionnaire (SAQ): 
Spertus et al. (1994, 
1995) 
** Summary Index (SI) 
for the assessment of 
quality of life in 
angina pectoris: 
Wilson at at. (1991, 
iUtffii?tl.qij:::r: 
Quality of Life 
Questionnaire: 
Wiklund at at. (1992) 
*'" Heart Patients 
Psychological 
Questionnaire: 
Erdman (1982) 
** Quality of Life after 
acute MI (QlMI): 
Oldridge et al (1991) 
Hillers at al. (1994) 
*'" Modified Quality of 
Life after acute MI 
(QlMI-1): Lim at at. 
(..) 
0) 
<0 
Number 
of items 
19 
51 
40 
26 
22 or 25 
Response Item 
format reduction Scaling 
Likert - Five scales. Sum items within 
scale & transform to 0-100 
range (subtract lowest possible 
scale score, divide by range of 
scale, multiply by 100). No 
summary score. High scores 
indicate good outcome 
Likert & VAS YES- 6 subscales and a total score. 
reduced Zero to 100 range. High score 
from 69 indicates good outcome 
items 
4 scales: Well-being, Feelings of 
disability, Displeasure, Social 
inhibition 
Likert YES 5 factors aggregated to 2 
dimensions (Limitations & 
Emotions). Add item scores & 
divide by number of items (scale 
score range 1-7. 
Likert YES 3 dimensions: Emotional, 
Physical, Social. Weighted 
average of responses. Scale 
created if answered 50% 
Method of Assessment Age of sample Validated 
Patient group administration points (yrs) in UK? 
Used different Self- Baseline and Used several YES & 12 
patient groups administered 3m later subsamples other 
to evaluate countries 
psychometric (see Table 
properties of 3.3) 
each scale 
112 angina pts I Self- I Baseline, 6 I Mean age =61 .7 I NO 
in KarQuol administered wks & 3m later ± 5.5 yrs Finland 
study 
Mean age =61 ± 
administered 9.7 yrs. 64% 
annually 65 yrs Canada, 
thereafter Sweden 
80 post M I pts Self- Baseline & Mean age = 51 NO 
administered post (35-60) yrs Nether-
rehabilitation lands 
intervention 
201 depressed Interview- Baseline, after Mean age = 52 NO 
post AMI pts administered 8wks rehab yrs Canada 
(88% male) prog, & 4, 8, & 
12m later 
375 post AMI Self- 6m after Mean age -59 ± NO 
pts (71% male) administered hospital 7.4 yrs Australia 
discharge 
Questionnaire 
•• Modified Quality of 
Life after acute MI 
(QLMI-2): Valenti et at. 
1996) 
Failure Questionnaire 
(CHQ): Guyatt et al. 
(1988, 1989) 
Disease Specific 
Questionnaire for 
Severe Heart Failure: 
at al. (1994) 
U> 
<0 
o 
Number Response 
of items format 
27 Likert 
Likert & 
dichotomous 
individual-
ised 
questions for 
5 important 
& frequent 
activities 
30 Likert 
25 Likert 
Item 
reduction Scaling 
Based on 3 dimensions: Emotional, 
QLMI-1 Physical, Social. High scores 
indicate good outcome 
Summed subscales for 
reduced dyspnoea (5-35), fatigue (4-28), 
from 123 emotional (7-49). High scores 
items indicate poor outcome 
- 6 areas of impact. Overall 
mean scores calculated. High 
score indicates better well-being 
- If activity id limited, indicate if it 
is limited by SOB, fatigue, chest 
pain, or other 
Method of Assessment Age of sample Validated 
Patient group administration points (yrs) in UK? 
352 pts with Self- 6 wks & 6m Age range =25- NO 
angina or AM I administered after hospital 74 yrs Australia 
(71% male) discharge 
53 rehabilitation Self- Baseline, 6 & NO 
pts after MI & administered 12m post Sweden 
63 controls rehabilitation 
88 pts with Interview-
heart failure administered administration I ±10.7vrs I Canada 
(70% male) s over a 4-6 
wk period 
151 pts with Self- Baseline, & 2 I - I YES 
severe heart administered weeks, 3m, 
failure 1yr after 
130 pts with Self- Single Mean age -50 ± I NO 
advanced heart administered assessment 12 yrs (15-68). USA 
failure (83% 60% were 
male) <55yrs 
Questionnaire 
- Kansas City Heart 
Failure Questionnaire 
(KCHFQ): Green et aI. 
(2000) 
- Left Ventricular 
Dysfunction 
Questionnaire: 
O'Leary & Jones 
(2000) 
- Minnesota Living 
with Heart Failure 
Questionnaire 
(UhFE): Rector at aI. 
(1987) 
Patients' Self Rating 
Scale: Tandon et aI. 
(1989) 
Quality of life in the 
treatment of heart 
failure: Blackwood et 
aI. (1990) 
w 
CD 
-.4 
Number Response 
of items format 
23 Likert 
36 Dichotomous 
21 Likert 
9 Likert 
-
VAS 
Item 
reduction Scaling 
YES Summed responses. 7 scales: 
Physical limitation, Symptoms, 
QOL, Social limitation, Self-
efficcy, KCCQ Functional status, 
KCCQ Clinical summary. 
Higher scores reflect better 
HRQoL 
YES- Responses are summed & 
reduced expressed as a percentage 
from 139 (100= worst, O=best). 
items Questionnaire not scored if any 
questions left unanswered 
-
Summed responses for 3 
scales: Total, Physical, 
Emotional. Low scores indicate 
good outcome. Max total score 
= 105 
-
Summed responses for total 
score 
-
100mm VAS. A positive change 
of 1 mm or more on the VAS 
scores was expressed as an 
improvement 
Method of Assessment Age of sample Validated 
Patient group administration points (yrs) in UK? 
Responsive- Self- Baseline and Reliability NO 
ness cohort: 39 administered 3m later cohort: mean . USA 
decompens- age =64 yrs. 
ated CHF pts. Responsiveness 
Reliability cohort: mean 
cohort: 39 age =68 yrs. 
stable pts. Validation 
Validation analyses: mean 
analyses: 129 age =64.3 
CHF pts. (67% 
male) 
60 pts with Self- & Baseline, 1 wk Mean age =60 ± YES 
heart failure telephone- & 6m later 13.3 yrs 
(77% male) inc administered 
10 with CHD 
83 pts with Left Self- Single Mean age = 61 YES & 19 
Ventricular administered assessment ± 10 yrs other 
Dysfunction countries 
(84% men) (see Table 
3.3) 
I 
111 male pts Self- Baseline, 2, 4, Mean age =60 NO I with CHF administered 6, 8, 12 wks of yrs USA 
treatment 
phase 
123 pts with Self- Baseline & 13 Median age =60 YES 
mild to administered wks after start (37 -79) yrs 
moderate heart of drug 
failure (50% treatment 
male) 
Questionnaire 
RAND Congestive 
Heart Failure 
Questionnaire 
(Shortness of Breath 
Battery): Rosenthal 
(1981 ) 
** Self Assessment of 
quality of life in 
severe heart failure 
(QLQ-SHF): Wiklund et 
a/. (1987) 
Self-Management of 
Heart Failure: Riegel 
et al. (2000) 
Cardiac Adjustment 
Scale: Rumbaugh 
(1965) 
** Cardiac Denial of 
Impact Scale: Fowers 
et a/. 1992 
W 
<0 
f\.) 
Number 
of items 
19 
26 
65 
8 
Response Item 
format reduction Scaling 
Likert & - Impact scale: 'none' to 'great 
dichotomous deal'. Create composite impact 
Likert & VAS YES Total scale and 4 subscales (5-7 
questions in each scale). Likert 
scale transformed into an 
analogue scale by division of 
by 100. High scores indicate 
poor outcome 
Likert & YES 6 subscales: Recognising a 
dichotomous change, Evaluating the change, 
Implementing a treatment 
Likert YES 
Patient group 
RAND heart 
failure subjects 
51 pts with 
severe heart 
failure (65% 
male) 
127 pts with 
heart failure 
(53.5%) 
rehabilitation 
pts (88% male) 
91 cardiac 
rehabilitation 
Method of 
administration 
Clinician-
administered . 
Can be self-
administered 
Self-
administered 
Self- & 
interview-
administered 
Self-
administered 
Assessment 
points 
-
Single 
assessment 
Baseline and 
follow-up 
Baseline to 
predict 
employment 
status at an 
average of 
33m 
Single 
assessment 
Age of sample 
(yrs) 
-
Median 64 yrs 
(44-78). 
41% ~70 yrs 
Mean age -70.9 
± 13.5 yrs 
Mean age =63.3 
± 10.9 (35-86) 
Validated 
in UK? 
NO 
USA 
I NO 
Sweden 
NO 
USA 
NO 
USA 
Questionnaire 
** Cardiac Depression 
Scale: Hare & Davis 
(1995) 
- Cardiac Health 
Profile (CHP): 
Wahrborg & 
Emanuelsson (1996) 
- Duke Activity 
status Index (DASI): 
Hlatky, at aI. (1989) 
Expectations and 
Satisfaction 
Questionnaire: 
Staniszewska & Ahmed 
(2000) 
W 
<0 
to) 
~'''-.·<,Y~·,·~~·..--__ .,-.:"v-...,.,., .~.~. 
Number Response 
of items format 
26 Likert 
19 VAS 
12 Hierarchic 
order of 
activities 
34 Likert 
Item 
reduction Scaling Patient group 
YES Summed items: 2 dimensions, 7 248 ambulatory 
subscales. Higher scores cardiac pts: 
indicate worse functioning angina, heart 
failure, post MI, 
post surgery, 
valve disease, 
arrhythmias 
(64% male) 
YES 5 factors. Measure VAS scores 76 angina (68% 
in mm & sum. Total sum is male) pts 
divided by number of answered awaiting 
items (mean). angiography 
(24 later had 
CABG & 15 
PTCA).51 
controls (73% 
male) 
YES Weights based on known 50 cardiac pts 
metabolic cost of each activity in undergoing 
METs exercise test 
- -
16 cardiac pts 
(pilot study 
only) 
Method of Assessment Age of sample Validated 
administration points (yrs) in UK? 
Self- Single Mean age =59.3 NO 
administered assessment ± 14.1 (17-88) Australia 
yrs 
I 
Self- 4 wks before Angina gp: NO 
administered angiography, mean age =62.7 Sweden 
immed before ±10.5yrs 
examination; Control gp: 
I 
18 months mean age =61.6 
after inclusion ±9.1yrs 
in study 
Self- Single Mean age =59.3 NO 
administered assessment ± 14.1 (17-88) USA 
yrs 
Self- Expectations - YES 
administered questionnaire 
administered 
before 
treatment & 
Satisfaction 
questionnaire 
after 
Number Response Item Method of Assessment Age of sample Validated Questionnaire of items format reduction Scaling Patient group administration points (yrs) in UK? 
** Ferrans & Powers 64 Likert 
- Total score & 4 subscales. Faris & Stotts: Self- Faris & Stotts: Faris & Stotts: NO Quality of Life Index: Satisfaction scores are weighted 20 pts administered Pre PTCA&6 mean age =60 USA, (QLI-Cardiac Version for importance. Lowest score: undergoing wks post (39-76) yrs Norway, 
III): Ferrans & Powers high dissatisfaction & high PTCA(85% Spain (1985), Faris & Stotts importance male). (1990) Papadantonaki: Papadanton- Papadantonaki: 
76 CHD pts aki: Pre mean age =57.9 
undergoing PTCAICABG ±8.2yrs 
PTCAICABG & 3 wks post. 
** Global Moods 20 Likert YES 
- 478 pts with Self- Single Mean age =57.8 NO 
Scale (GMS): Denollet CHD: 110 MI, administered assessment at ±8.7 yrs Belgium (1993) 302 CABG &66 3-6 wks post 
PTCA(100% MI, CABG or 
male) PTCA 
** Health Complaints 24 Likert YES Summated items: Total, 535 men with Self- Single Mean age =57.5 NO 
Scale (HCS): Denollet Cognitive & Somatic scales. CHD administered assessment at ±8.6yrs Belgium (1994) High scores indicate extremely 3-6 wks post 
bothered MI, CABG or 
PTCA 
** Multidimensional 35 Likert YES Sum the 4 items in each of the 9 348 stable Self-, telephone- Single Mean age =63 NO 
Index of Quality of domains. Total score derived by cardiovascular or interview- assessment (25-86) yrs USA 
Life (MUQ): Avis at aI. several methods pts (69% male). administered 
(1996) 43%6m post 
CABG&43% 
2m postPTCA 
** Cardiac Quality of 20 VAS - Adapted from Padilla & Granfs 222 people: 95 Interview- or 2-weeks post - NO 
Life Index (CQU): Quality of Life Instrument for cardiac pts in self- discharge Canada 
Rukholm et aI. (1998) cancer patients rehab,51 administered 
cardiac pts not 
in rehab & 76 
healthy controls 
~ 
~ 
Number 
Questionnaire of items 
Reduced Duke 8 
Activity Status Index: 
Alonso et al. (1997) 
Soderlind et ai's 
-
Quality of Life 
Questionnaire: 
Soderlind et al (1997) 
Specific Activity 13 
Questionnaire: Rankin 
et al. (1996) 
Symptom Scale: 
-
Keresztes et aI. (1993) 
- utility Based 32 
Quality of Life-Heart 
Questionnaire (UBQ-
H): Martin et aI. (1999) 
Veterans Specific 21 
Activity 
Questionnaire: Myers 
et aI. (1994) 
KEY 
Details not found 
w 
CO 
01 
Response Item 
format reduction Scaling Patient group 
Likert. Reduced Final score calculated by 46 stable CHD 
Questions in from DASI multiplying each item weight by pts &44 PTCA 
hierarchic the response category. Scores pts 
order, with range = 11.5 - 33. Imputed 
skip format missing responses 
Likert 
- -
100 pts after 
CABG, valve, 
CABG+ valve 
- -
Continuous score of metabolic 97 cardiac pts 
equivalents. The score is the (88% male). 
most demanding activity that pt 74% had 
can complete without symptoms previous MI or 
revascular-
isation 
Ukert - Summated scales: Total, 60 cardiac pts 
Angina, SOB, Fatigue. undergoing 
Low scores indicate high level of exercise test 
functional ability (70% male) 
Likert - Summated mean scores 322 
cardiovascular 
outpatients, inc. 
heart failure & 
transplant pts 
(73% male) 
ptto draw a 
-
Continuous score of metabolic 212 pts referred 
line below equivalents. The score is the for exercise 
the activities most demanding activity that pt testing 
they are able can complete without symptoms 
to do 
- --- -
- Questionnaire met minimum reliability and validity criteria. 
Method of Assessment Age of sample Validated 
administration points (yrs) in UK? 
Self- On admission PTCA gp: mean NO 
administered & 1m after age =55.5 ± 8.1 Spain 
PTCA yrs. stable gp: 
mean age =61.2 
±7.6yrs 
Self- 1 & 2 yrs post Mean age =66 NO 
administered op yrs. 38% > 70 Sweden I 
yrs I 
Self-
-
Mean age =59 ± NO i 
administered 10 yrs Australia i 
I 
I 
Self- Single Mean age =54.1 NO 
administered assessment (31-83) yrs USA 
Self- Baseline and Mean age =60 ± NO 
administered 10 days after 10 yrs Australia 
Self- Single Mean age =62 ± NO 
administered assessment 8 yrs USA 
pts Patients. CHF Chronic heart failure. 
APPENDIX 4.1 Letter of Invitation for Interview 
(Date) 
(Patient's name) 
(Patient's address) 
Dear (Patient's Name), 
Official Hospital Letterhead 
A study is currently underway at the Royal Brompton Hospital to develop a new 
questionnaire for patients who have recently undergone coronary artery bypass 
surgery or coronary angioplasty. An important part of this study involves 
interviewing people about their experiences of. these procedures. We are 
inviting you to take part in this study. Patients like you have been selected from 
those treated at this hospital. 
If you agree to participate in this study, you will be interviewed on ONE 
occasion. The interviewer will ask your views about your quality of life, 
including questions about your phYSical, emotional and social well-being, your 
ability to carry out daily activities, and about your health in general. The 
interview will be done at your home, unless you prefer the interview to be 
carried out elsewhere. 
Taking part in the study is voluntary. You may choose to take part or you may 
decide not to take part at all. If you decide not to take part or to withdraw at any 
point, your future care at the Royal Brompton Hospital will not be affected in any 
way. All information received will be treated as confidential, and all participants 
will be identified by a number, not by name. 
This study is being undertaken by a research team headed by Dr Donna 
Lamping and Sara Schroter (London School of Hygiene and Tropical Medicine), 
and includes Mr Pepper, Mr Moat, and Professor Coats (Royal Brompton 
Hospital). 
I will telephone you in a few days to enquire whether you wish to participate and 
if so to arrange a possible date for the interview. 
Yours sincerely 
Sara Schroter 
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APPENDIX 4.2 Patient Consent Form for Interviews 
TITLE OF PROJECT: 
Development of a patient-based measure of outcome for patients undergoing 
coronary revascularisation. 
EXPLANATION OF PROJECT: 
Invitation: We would like to invite you to participate in a study to develop a 
questionnaire for finding out the views of patients who are either soon to 
undergo or have recently undergone coronary artery bypass graft surgery or 
coronary angioplasty. 
If you agree to take part in this study you will be interviewed on one occasion. 
The interviewer will ask your views about your quality of life, including questions 
about your physical, emotional and social well-being, your ability to carry out daily 
activities, and about your health in general. 
All the information you give during the study will be completely confidential. In 
order to protect your privacy, a confidential study number rather than your name 
will be used on all interview forms. These forms will be kept in locked research 
files which only the research staff will have access to. None of the information 
you give will be available to any of the hospital staff, including doctors, nurses, 
and technicians, who provide the clinical care associated with your treatment. 
This study is being undertaken by a research team at the London School of 
Hygiene and Tropical Medicine in collaboration with Mr Pepper, Mr Moat, and 
Professor Coats at the Royal Brompton Hospital. Please understand that you 
need not take part in this study if you do not wish to. If you do take part, you 
may withdraw at any time, and need give no reason for doing so. If you choose 
not to take part, or if you withdraw, your normal care and treatment will be 
unaffected. 
Signed by the person in charge of the Project __________ Date ___ _ 
The Ethics Committee of the (Royal Brompton Hospital) has approved the above statement. 
Signed by the Chairman/Representative of the Committee 
________________________ Date __ _ 
FORM OF CONSENT 
I, of ___________ _ 
agree to take part in the research project outline above. I understand the nature and purpose of 
the questionnaire, and that I may withdraw from the research without It affecting my care and 
treatment at the Royal Brompton Hospital in any way. 
Signed ___________________ Date _____ _ 
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APPENDIX 4.3 Frequency of Comments Made by CABG and PTCA 
Patients For Each Content Domain 
Frequency of Frequency of 
Content domain comments made comments made 
by CABG patients by PTCA patients 
::::::§¥rnpI9.:::~::::::: ::::::::»~::::::::::::~::/\::~:::::::::'?:::::::::::::::~:~::::::::~::::::\:.}\::::::::::::::;; :::j:~ .::::::::~::(:m::::::::::::::::::::::::::::::::\:::::~:::::~~~::::::~:::~::::~::::::::::::~:::\::(::::/:::: :::;:;:;:::::~::::/;~;:::::)t::::::::":·:::\b:::\:::::\/:::: 
"Angina" 
"Chest pain" 
"Tightness in the chest" 
"Soreness / discomfort in the chest" 
Pain in the arm(s) 
Breathlessness 
"Heart attack" 
"Racing heart" / "palpitations" 
Difficulty sleeping 
Restless 
"Tired" / "exhausted" 
"Lack of energy" 
"Weak" / "drained" 
Sudden onset of symptoms 
Symptoms returned 
Medication complaints 
3 
6 
2 
2 
1 
5 
1 
2 
1 
2 
2 
1 
1 
1 
10 
1 
6 
7 
3 
2 
6 
3 
4 
4 
1 
::::::glmJtlfini:::!n~::g~!y=:j!l*=w~@i ~~:~:~~~~::~:::~::::::::~::::::::~:::~:::rj::::::~:/:::::::::::::::::::r:::::::: {:~m:m~::::::~;;;;:;:;:::::r:::/::::·· ::·:·:::::::::~:x::::::{::::·:·:::::::::;;:···::::::::::::::::::::/:::::\\::::~:::~::~ Work 4··· ····::·::::·:::6 ·······:·:::::·::·:····:·· 
"Anything exertional" 6 8 
General physical limitations 3 1 0 
Playing with children 2 2 
Carrying heavy objects 5 7 
General gardening 2 2 
Mowing the lawn 3 
Housekeeping 2 
Sweeping 3 
Shopping 1 
Dri~ng 1 
Travel 1 
DIY 2 
Sawing 
Painting / decorating 
Swimming 
Playing Frisbee 
Walking the dog 
Running 
Walking >1 mile 
Walking short distances 
Walking quickly 
Climbing stairs 
Walking up hill 
1 
1 
1 
1 
3 
6 
1 
5 
5 
1 
1 
4 
2 
1 
1 
2 
2 
1 
1 
4 
4 
4 
8 
7 
5 
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Content domain 
Cycling 
Doing light jobs 
Dressing 
Washing 
Standing for long periods 
Hospital visits 
Relaxing brings on pain 
Resting in bed 
Wouldn't go out in the wind 
Gave up work 
Difficulties at work 
Frequency of 
comments made 
by CABG patients 
3 
1 
2 
4 
1 
1 
1 
1 
2 
2 
Frequency of 
comments made 
by PTCA patients 
1 
2 
1 
1 
2 
1 
1 
1 
6 
::::::llx9n§!ggia[f,gll"mml:::::::::!:!:!:::!::::::::::::::::::::::::::!:!::!:::!::L::::::::'::::::.;;:::;:::':.:i':::::: ::::::??::::::::::::::::::::::::}:,::::::::::/\:::::,::,:;i;;:::':::::::::i:::;:;:;::;:ii;i;i::":,,,,::i:ii:i!:!:):!:!:):!:)'):)'::::!::::)!)!)ii::ii::i))ii::::,:{:::::::::::::: 
"Anxious" pre-revascularisation 
"Anxious" post-revascularisation 
Anger 
Stress 
"Panic" 
Desperation 
Embarrassment 
Denial of condition 
Fear of doing too much / own safety 
A voidance of some activities 
Frightened by the pain 
Frustrated by heart condition 
Difficult to adjust to being sick 
Learn to cope 
Irritable 
Selfish 
Depression 
Down-hearted / despondent 
"Not a happy person" 
Illness protruded all thoughts 
Needed reassurance of progress 
Importance of having confidence 
Felt safe in hospital 
Uncertain about the future 
Positive about the future 
Fear of future health 
Cause of ill health 
"My destiny" (to be sick) 
Shock of diagnosiS of CHD 
Mentioned death 
Thought they were dying 
Afraid of death 
Reference to the life saving operation 
Anxious waiting for operation 
"Relief' to have operation 
2 6 
5 3 
1 1 
3 3 
3 1 
4 5 
1 
2 
6 7 
3 6 
4 2 
5 4 
1 2 
1 
2 2 
1 
2 1 
2 3 
1 2 
1 2 
8 4 
4 3 
2 1 
4 
2 6 
5 6 
3 6 
1 3 
3 2 
4 4 
2 1 
3 2 
4 4 
3 5 
3 3 
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Content domain 
Frequency of 
comments made 
by CABG patients 
Frequency of 
comments made 
by PTCA patients 
······m:···,·,·······:·,·····t .... ···············f '·················f ;:·····:'····· .... ····························· .................... ,.,., .................... '........ . ............... ' ........ ,:. ~.:~.:i.:~:: .:-:.:.:: ::::::::::::::::::::::~.:~.:~.: ...... :.::.::.::.::.::::::: :;::::::::;::::::~:::::::::::::::::::::::: :.:.:.:.:.:.:.:.:.;.;.:.:.:.;.;.:.:.:.:.;.:.:.:.:.;.:.:.:.:.:.:.:::.:.:.:.:.:.:...... . .... :.:.:.:.:.:.:.:.:.:.:.:-;.:.:.:.: .. : ... . 
::t2PgP!.J¥f.:tJ;l.O§.M9mng:::m:mr:m:m:::mmm::::::m:::::trrtr :::::{ ::::\\\ ........ ::=:/::::::::::::{::::::::: .<.::.:.:.:::.: .. ::.:.:.:.:.:<::::::"':::::::::::::::::::::::::::tt:((ti(tttt:::))):()))))\:d>::: 
Difficulty concentrating 1 
Memory problems 1 
::::::ggSitlYP'At!IiIB.:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::.::::::::::::::::::::::::::::::::::::::::::::::::::::::::ill:::::::::::::::::::::::::::::::::::::::::::::::::::iii:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::t::::::/:-:::\::::i }::::: .?::::d::~:::j:~:': 
Impact on spouse I family I friends 6 
Restricted activities with peers 2 
Afraid to leave home 3 
Wanted their independence 5 
Felt a burden on family & friends 2 
6 
4 
1 
3 
2 
::::::B.i@glt~~!pm::~9:::n§~pt~!I::!::::A9.¥~t~~:::!:Y~~Uiiii::::::::::::::::::::::::::::::::::::::::::::::::::::::: :::::':\(//: ,:::::;:::::::::::::::::,'" ·::::::?t\?:i>\/\\/::(:,::,:··:;:::::::::::::::::::::::::::::::::;:;:;:;:::;;:;:;:: 
Readmission to hospital 1 '2 
Experienced restenosis 1 3 
Atrial fibrillation 1 1 
Pleural effusion 1 
Arrhythmia 1 
Mini fits 1 
"Water on the heart" 1 
:::::$,ympl.9.m~::@mJt.:::Pf9pilml:::@~99@t."Jt.::Ii.m::~I§tliQ.t.iii::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::w:::::::::::::::::::::::::::::::::::::::::::::::t::::::::::::::::::::::::t,::: 
Severe eating I appetite problems 4 
Nausea 2 
Swe~ng 1 
Faintness 1 
Sleep difficulties 4 
Exhaustion 2 
VVeakness 2 
Cough 1 
Soreness I discomfort in the chest 1 
Swollen feet 3 
Concern over swollen feet 
Oozing / seeping wound(s) 
Wound infection 
Wound pain I soreness I tenderness 
Wound related concern 
Swelling around wound 
Bleeding at wound site 
CABG Only 
Muscle pains from opening chest 
Pain from artery removal 
Chest wall pain 
"Pain in the chest" 
Sore I painful leg 
Numb or cold leg 
Bruising of the leg 
Bruising on chest 
2 
1 
4 
4 
1 
2 
1 
2 
1 
4 
3 
1 
1 
1 
1 
2 
3 
2 
2 
1 
1 
1 
1 
400 

/ 
APPENDIX 4.4 Pre-test Versid'tt of Post-Revascularisation 
CROQ-CABG ,Q1'CJestionnalre 
nly 
Patient: IL--____ ..... Op Date: 
Hospital: 1...1 ____ ---' Received: ... 1 _____ -' 
CORONARY REVASCULARISATION OUTCOME QUESTIONNAIRE 
(CROQ-CABG) 
INSTRUCTIONS: We are interested in finding out how you have been since your heart 
operation (coronary .artery bypass graft .surgery) which you had 3 months ago. We 
would be grateful if you could help us by filling out this questionnaire. All of the information 
you provide is COMPLETELY CONFIDENTIAL. Please be sure to answer ill questions. 
1. During the past 4 weeks, how much were you bothered by each of the following problems 
related to your heart condition? 
(Please tick one box on each line) 
A lot Quite a Moderately A little Not at 
bit all 
Chest pain 0 0 0 0 0 
Chest tightness 0 0 0 0 0 
Discomfort in the chest 0 0 0 0 0 
Shortness of breath 0 0 0 0 0 
Pain that radiates to other parts of 
0 0 0 0 0 your body (eg arms, shoulders, 
back neck throat jaw. hands) 
Palpitations (strong or irregular 0 0 0 0 0 heart beat) 
Disturbed sleep 0 0 0 0 0 
Feeling worn out or low in energy 0 0 0 0 0 
2. During the past 4 weeks, on average, how many times have you taken nitros (nitroglycerin 
tablets or spray) for your chest pain, chest tightness or angina? (Please tick only one box). 
0 0 0 0 0 0 
4 or more 1-3 times 3 or more 1 .. 2 times Less than None over 
times per day per day times per per week once a week the past 4 
week but not weeks 
every day 
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3. During the past 4 weeks, have you had chest pain. chest tightness or angina: 
(Please tick only one box) 
o o o 
At rest? Only on exertion? Not at all? 
4. During the past 4 weeks, how much trouble has your heart condition caused you? 
(Please tick only one box) 
o o o o o 
A lot Quite a bit Some A little None 
6. The following questions ask about activities which you might do during a typical day. 
During the past 4 weeks, has your heart condition Umited you in your usual daily 
activities? Please indicate whether your heart condition limits you a lot, limits you a little, 
or does not Itmit you at all in the activities listed below. 
(Please tick one box on each line) 
Yes. Yes. No. Not 
ACTIVITIES Limited A Limited A Limited At 
Lot Little All 
Vigorous activities, such as running, lifting heavy D 0 0 objects partiCipating in strenuous sports 
Moderate activities, such as moving a table, pushing D D 0 a vacuum cleaner bowling, or playing golf 
Lifting or carrying groceries 0 0 0 
Climbing several flights of stairs 0 0 0 
Climbing one flight of stairs 0 0 0 
Bending, kneeling or stooping 0 0 0 
Walking more than a mile 0 0 0 
Walking half a mile 0 0 0 
Walking one hundred yards 0 0 0 
Bathing or dressing yourself 0 0 0 
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,t 
6. During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of your heart condition? 
(Please tick one box on each line) 
YES NO 
Cut down the amount of time you spent on work or other activities 0 0 
Accomplished less than you would like 0 0 
Were limited in the kind of work or other activities 0 0 
Had difficulty performing the work or other activities (for example, 0 0 it took extra effort) 
7. The next questions ask about your feelings about your heart condition. During the ~. 
~. how often have you felt: 
Please tick one box on each line) 
All of the Most of Some of A little of None of 
time the time the time the time the time 
Worried about your heart condition? 0 0 0 0 0 
Worried about doing too much or over- 0 0 0 0 0 doina it? 
Worried that you might have a heart 0 0 0 0 0 attack or die suddenlv? 
Worried that your symptoms might 0 0 0 0 0 retum? 
Worried that you might need another 0 0 0 0 0 heart operation in the future? 
Frightened by the pain or discomfort of 0 0 0 0 0 your heart condition? 
Out of control of your life? 0 0 0 0 0 
Uncertain about the future? 0 0 0 0 0 
Unsure of yourself or lacking in self- 0 0 0 0 0 
confidence? 
Low in morale? 0 0 0 0 0 
Depressed? 0 0 0 0 0 
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During the past 4 weeks, how often have you felt: 
Please tick one box on each line) 
All of the Most of Some of A little of None of 
time the time the time the time the time 
Frustrated or impatient? 0 0 0 0 0 
Irritated? 0' 0 0 0 0 
/ 
That you had to avoid certain activities 0 0 0 0 0 because of your heart condition? 
That your heart condition interfered 0 0 0 0 0 with your enjoyment of life? 
That it was .difficult to keep a positive 0 0 0 D ·0 outlook about your health? 
8. During the past 4 weeks, how much of the time did you: ."' 
(please tick one box on each line) 
All of the Most of A good Some of A little of None of 
.tlme the time bit of the the time ' tbetime the time 
time 
Have difficulty reasoning and 
0 0 0 D 0 0 solving problems, for example 
making plans, making decisions, 
learning new things? 
Forget, for example things that 
0 0 0 0 0 0 happened recently, where you 
put thing~ or appointments? 
Have trouble keeping your 
0 0 0 0 D 0 attention on any activity for 
long? 
Have difficulty doing activities 
D 0 0 0 0 D involving concentration and 
thinking? 
Become confused and start 0 0 0 0 0 0 several actions at a time? 
React slowly to things that were D D D 0 0 0 done or said? 
Not complete things or activities 0 0 0 0 D D you started? 
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9. This question is about the impact of your heart condition on your family and friends and the 
extent to which it has interfered with your social activities. During the past 4 weeks. how 
often have you experienced the following as a result of your heart condition: 
(Please tick one box on each line) 
All of Most of Some of A little of None 
the time the time the time the time of the 
time 
Difficulties with your personal 0 0 0 0 0 relationships? 
Family or friends being overprotective 0 0 0 0 0 toward you? 
Feeling like you are a burden on others? 0 0 0 0 0 
Feeling restricted in your social activities 0 0 0 0 0 (like visiting with friends relatives etc) 
Feeling excluded from doing things with 0 0 0 0 0 other people? 
Feeling worried about going too far from 0 0 0 0 0 home? 
10. The next section asks about problems you might have had aince your heart operation. 
During the past 4 weeks, how much were you bothered by the following problems? 
If you did not have the problem, tick the last box "Not at all". 
(Please tick one box on each line)_ 
A lot Quite a bit Moderately A little Not at 
all 
Pain in your cheat wound 0 0 0 0 0 
Any other pain in your cheat or neck 0 0 0 0 0 due to your operation 
Infection, oozing or tenderness in 0 0 0 0 0 your chest wound 
Numbness or tingling in your cheat 0 0 0 0 0 
Pain in your leg or arm wound 0 0 0 0 0 
Any other pain in your leg or arm 0 0 0 0 0 due to your operation 
Infection, oozing or tenderness in 0 0 0 0 0 your leg or arm wound 
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During the past 4 weeks, how much were you bothered by the following problems? 
If you did not have the problem, tick the last box "Not at all.· 
(Please tick one box on each line) 
A lot Quite a bit Moderately A little Not at all 
Numbness or tingling in your .eg or 0 0 0 0 0 
arm 
Bruising on your chest 0 0 0 0 0 
Bruising on your leg or arm where a 0 0 0 0 0 
vein was removed 
Swollen feet or ankles 0 0 0 0 ·0 
Weakness or lethargy 0 0 0 0 0 
Nausea 0 0 0 0 0 
Loss of appetite 0 0 0 0 0 
Concern over the appearance of 0 0 0 0 0 your surgical scars 
11. Since your heart operation, have you been re-admitted to hospital (for an overnight stay) for 
any reason to do with your heart condition or your heart operation? Please give as many 
details as you can below. 
o 
o 
Date 
No 
Yes, I was in hospital for .... 1 __ --' days 
Hospital name Reason for hospital stay 
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12. The next question asks about how satisfied you ar-e with your heart operation. How satisfied 
are you with the: 
(Please tick one box on each line) 
Very Somewhat Somewhat Very 
dissatisfied dissatisfied satisfied satisfied 
Progress you have made since your 0 0 0 0 heart operation? 
Results of your heart operation? 0 0 0 0 
Information you were given about your 0 0 0 0 heart operation? 
Information you were given about how , 
you might feel while recovering from your 0 0 0 0 
heart operation? 
13. Were you given the information about your .heart operation at the right time? (Tjck one box) 
o No 
DYes 
14. Overall, how would you describe your heart condition now CQmpared to before your heart 
operation? 
0 Much worse 
0 A little worse 
0 About the same 
0 A little better 
0 Much better 
15. Has your recovery from your heart operation so far been: 
o Slower than you expected? 
o About what you expected? 
o Faster than you expected? 
o Did not know how long it would taka? 
16. Are the results from your heart operation: 
o Worse than you expected? 
o About what you expected? 
o Better than you expected? 
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Finally, It would be helpful If you could answer a few general questions about 
yourself. (Please tick the boxes that best describe your situation). 
1
17
. 
Are you: 0 Male 
0 Female 
18. What is your date of birth? 
DO DO DO 
Day Month Year 
19. PJease fill in the date you completed this questionnaire: 
DO DO DO 
Day Month Year 
20. To which ethnic group do you belong? 
0 White 0 Pakistani 
0 Black/Caribbean 0 Bangladeshi 
0 Black/African 0 Chinese 
0 Black/Other 0 Any other ethnic group 
0 Indian (please specify) I 
21. Do you have any other long-standing illness, disability or infirmity? By long-standing I mean 
anything that has troubled you over a period of time, or that is likely to affect you over a period 
of time? 
o No 
o Yes (If yes, what is the matter with you?) 
22. What is your current work situation? 
0 Employed full-time 0 Retired 
0 Employed part-time 0 Unable to work/disabled 
0 Voluntary work 0 Unemployed 
0 Homemaker 0 Other (please specify) I 
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23. What is (or was) your majn occupation? 
Full job title: _________________________ _ 
What do (did) you actually do in this job? ________________ _ 
What does (did) your employer make or do? _______________ _ 
OR 0 I do not work outside the home 
24. For women onlv. What is (or was) your husband's/partner's majn occupation? 
Full job title: _________________________ --
What does (did) he actually do in this job? ________________ _ 
What does (did) his employer make or do? ________________ _ 
OR 0 I do not have a husband/partner 
The next question asks about your work. If you do not work outside the home, please put a tick in 
the first box. 
25. Did you return to work after your heart operation? Please tick one box only and state how 
many weeks you were off work after your operation. 
0 I do not work outside the home 
OR 0 Yes, I returned to the same job after L:J weeks 
OR 0 Yes, I returned to a different job after L:J weeks 
OR 0 No, I have not returned to work yet 
OR 0 No, I have stopped working 
26. Do you live: (You may tick more than one box.) 
o Alone? 
o With your husband or partner? 
o With children? 
o With family members? 
o Other? (please specifyl 
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27. Can you tell us approximately when you were first diagnosed as having heart disease? 
Month Year 
o I can not remember when I was first diagnosed 
28. Did you need any help in completing this questionnaire? If so, who helped and why? 
29. Is there anything else you would like to tell us about your heart condition or heart operation 
that is not covered in this questionnaire? Please write.in the box below. 
Please check that you have answered all the questions on each page. 
THANK YOU FOR YOUR HELP 
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APPENDIX 4.5 Pre-test Version of Post-Revascularisation 
CROQ-PTCA Questionnaire 
ny 
Patient: Op Date: .... 1 ____ ---' 
Hospital: Received: .... L ____ ---' 
CORONARY REVASCULARISATION OUTCOME QUESTIONNAIRE 
iCROQ·PTCA) 
INSTRUCTIONS: We are interested in finding out how you have been since your heart 
operation (percutaneous tr.ansluminal ~ronary .angiopJasty) which you had 3 months ago. 
We 'NOuld be grateful if you could help us by filling out this questionnaire. All of the information 
you provide is COMPLETELY CONFIDENTIAL. Please be sure to answer ill questions. 
1. During the past 4 weeks, how much were you bothered by each of the following problems 
related to your heart condition? 
(Please tick one box on each line) 
A lot Quite a Moderately A little Not at all 
bit 
Chest pain D D D D D 
Chest tightness D D D D D 
Discomfort in the chest D D D D D 
Shortness of breath D D D D D 
Pain that radiates to other parts of 
D 0 D 0 0 your body (eg arms, shoulders, 
back neck throatiaw hands) 
Palpitations (strong or irregular D D 0 0 0 heart beat) 
Disturbed sleep D D D D D 
Feeling 'NOm out or low in energy 0 0 0 0 0 
2. During the past 4 weeks, on average, how many times have you taken nitros (nitroglycerin 
tablets or spray) for your chest pain, chest tightness or angina? (Please tick only one box). 
D D D 0 D D 
4 or more 1-3 times 3 or more 1-2 times Less than None over 
times per day per day times per per week once e week the past 4 
week but not weeks 
every day 
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3. During the past 4 weeks, have you had chest pain, chest tightness or angina: 
(Please tick only one box) 
o o o 
At rest? Only on exertion? Not at all? 
4. During the past 4 weeks, how much trouble has your heart condition caused you? 
(Please tick only one box) 
o o o o o 
A lot Quite a bit Some A little None 
5. The follOwing questions ask about activities which you might do during a typical day. 
During the past 4 weekS, has your heart condition limited you in your usual daily 
activities? Please indicate whether your heart condition limits you a lot, limits you a little, 
or does not limit you at all in the activities listed below. 
JPlease tick one box on each line) 
Yes, Yes, No, Not 
ACTIYITIES Limited A Limited A Limited At 
Lot Little All 
Vigorous activities, such as running, lifting heavy 0 0 0 objects participating in strenuous sports 
Moderate activities, such as moving a table, 0 0 0 pushing a vacuum cleaner bowling, or playing golf 
Lifting or carrying groceries 0 0 0 
Climbing several flights of stairs 0 0 0 
Climbing one flight of stairs . 0 0 0 
Bending, kneeling or stooping 0 0 0 
Walking more than a mile 0 0 0 
Walking half a mile 0 0 0 
Walking one hundred yards 0 0 0 
Bathing or dressing yourself 0 0 0 
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S. During the past 4 weeks. have you had any of the following problems with your work or other 
regular daily activities as a result of your heart condition? 
(Please tick one box on each line) 
YES NO 
Cut down the amount of time you spent on work or other activities 0 0 
Accomplished less than you would like 0 0 
" 
Were limited in the kind of work or other activities 0 0 
Had difficulty performing the work or other activities (for example. it 0 0 took extra effort) 
7. The next questions ask about your feelings about your heart condition. During the ~ 
weeks. how often have you felt: 
JPJease tick one box on each line) 
All of the Most of Some of A little of None of 
time the time the time the time the time 
Worried about your heart condition? 0 0 0 0 0 
Worried about doing too much or over- 0 0 0 0 0 dOing it? 
Worried that you might have a heart 0 0 0 0 0 attack or die suddenly? 
Worried that your symptoms might 0 0 0 0 0 return? 
Worried that you might need another 0 0 0 0 0 heart operation in the future? 
Frightened by the pain or discomfort of 0 0 0 0 0 your heart condition? 
Out of control of your life? 0 0 0 0 0 
Uncertain about the future? 0 0 0 0 0 
Unsure of yourself or lacking in self- 0 0 0 0 0 
confidence? 
Low in morale? 0 0 0 0 0 
Depressed? 0 0 0 0 0 
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During the past 4 weeks, how often have you felt: 
(Please tick one box on each line) 
All of the Most of Some of A little of None of 
time the time the time the time the time 
Frustrated or impatient? D D D D D 
Irritated? D 0 D 0 0 
/ 
That you had to avoid certain activities 0 0 0 0 0 because of your heart condition? 
That your heart condition interfered 0 0 0 0 0 with your enjoyment of life? 
That it was difficult to keep a positive 0 D 0 0 D outlook about your health? 
8. During the past 4 weeks, how much of the time did you: 
(Please tick one box on each line) 
All of the Most of A good Some of A little of None of 
time the time bit of the the time the time the time 
time 
Have difficulty reasoning and 
0 0 D D 0 D solving problems, for example 
making plans, making decisions, 
learning new things? 
Forget, for example things that 
0 0 D 0 0 0 happened recently, where you 
put things or appointments? 
Have trouble keeping your 
0 0 0 0 0 0 attention on any activity for long? 
Have difficulty doing activities 
0 D 0 0 0 D involving concentration and 
thinking? 
Become confused and start 0 0 0 0 0 0 several actions at a time? 
React slowly to things that were D 0 D 0 0 0 done or said? 
Not complete things or activities 0 0 0 0 0 0 you started? 
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9. This question is about the impact of your heart condition on your family and friends and the 
extent to which it has interfered with your social activities. During the past 4 weeks, how often 
have you experienced the following as a result of your heart condition: 
~(Please tick one box on each line) 
.AU of Most of Some of AUttie of None of 
the time the time the time the time the time 
Difficulties with your personal 0 0 0 0 0 relationships? 
/ 
Family or friends being overprotective 0 0 0 0 0 toward you? 
Feeling like you are a burden on others? 0 0 0 0 0 
Feeling restricted in your social activities 0 0 0 0 0 (like visiting with friends relatives etc) 
Feeling excluded from dOing things with 0 0 0 0 0 other people? 
Feeling worried about going too far from 0 0 0 0 0 home? 
10. The next section asks about problems you might have had since your heart operation. 
During the past 4 'vV8eks, how much 'vV8re you bothered by the following problems? 
If you did not have the problem, tick the last box "Not at all-. 
~ Please tick one box on each line) 
A lot Quite a bit Moderately A little Not at all 
Pain in your groin wound 
0 0 0 0 0 
Infection, oozing or tenderness in 
0 0 0 0 0 your groin wound 
Numbness or tingling in your groin 
0 0 0 0 0 area 
Bruising around your groin wound 
0 0 0 0 0 
Bruising on your thigh 
0 0 0 0 0 
Discomfort in your chest due to your 
0 0 0 0 0 operation 
Swollen feet or ankles 
0 0 0 0 0 
Concern over the appearance of your 
0 0 0 0 0 surgical scar 
Concern over the appearance of your 
0 0 0 0 0 bruises 
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11. Since your heart operation, have you been re-admitted to hospital (for an overnight stay) for 
any reason to do with your heart condition or your heart operation? Please give as many 
details as you can below. 
No o 
o Ves, I was in .hospital for 1 ....__ ---1 days 
Date Hospital name Reason for hospital stay 
12. The next question asks about how satisfied you are with your heart operation. How satisfied 
are you with the: 
(Please tick one box on each line) 
Very Somewhat Somewhat Very 
dissatisfied dissatisfied satisfied satisfied 
Progress you have made since your 0 0 0 0 heart operation? 
Results of your heart operation? 0 0 0 0 
Information you were given about your 0 0 0 0 heart operation? 
. 
Information you were given about how 0 0 0 0 you might feel while recovering from your 
heart operation? 
13. Were you given the information about your heart operation at the right time? (Tick one box) 
o No 
o Ves 
417 
/ 
14. Overall, how would you describe your heart condition now compared to before your heart 
operation? 
0 Much worse 
0 A little worse 
0 About the same 
0 A little better 
0 Much better 
15. Has your recovery from your heart operation so far been: 
o Slower than you expected? 
o About what you expected? 
o Faster than you expected? 
o Did not know how long it would take? 
16. Are the results from your heart operation: 
o Worse than you expected? 
o About what you expected? 
o Better than you expected? 
Finally, It would be helpful If you could answer a few general questions about 
yourself. (Please tick the boxes that best describe your situation). 
1
17
. 
Are you: 0 Male 
0 Female 
18. What is your date of birth? 
DO DO DO 
Day Month Year 
19. Please fill in the date you completed this questionnaire: 
DO DO DO 
Day Month Year 
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20. To which ethnic group do you belong? 
0 White 0 Pakistani 
0 Black/Caribbean 0 Bangladeshi 
0 Black/African 0 Chinese 
0 Black/Other 0 Any other ethnic group 
0 Indian (please specify) I 
21. Do you have any other long-standing illness, disability or infumity? By long-standing I mean 
anything that has troubled you over a period of time, or that is likely to affect you over a period 
of time? 
o No 
o Yes (If yes, what is the matter with you?) 
22. What is your current work situation? 
0 Employed full-time 0 Retired 
0 Employed part-time 0 Unable to work/disabled 
0 Voluntary work 0 Unemployed 
0 Homemaker 0 Other (please specify) I 
23. What is (or was) your J!!!ia occupation? 
Full job title: ____________ ....... - ___________ _ 
What do (did) you actually do in this job? ________________ _ 
What does (did) your employer make or do? _______________ _ 
~R 0 I do not work outside the home 
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24. For women onlv. What is (or was) your husband's/partner's main occupation? 
Full job title: __________________________ _ 
What does (did) he actually do in this job? ________________ _ 
What does (did) his employer make or do? ________________ _ 
OR 0 I do not have a husband/partner 
The next question asks about your work. If you do not work outside the home, please put a tick in 
the first box. ' 
25. Did you return to work after your heart operation? Please tick one box only and state how 
many weeks you were off work after your operation. 
0 I do not work outside the home 
OR 0 Yes, J returned to the same job after 
OR 0 Yes, J returned to a different job after I 
OR 0 No, I have not returned to work yet 
OR 0 No, I have stopped working 
26. Do you live: (You may tick more than one box.) 
o Alone? 
o 
o 
With your husband or partner? 
With children? 
o With family members? 
o Other? (please specify) 
I weeks 
I weeks 
27. Can you tell us approximately when you were first diagnosed as having heart disease? 
Month Year 
o J can not remember when I was first diagnosed 
28. Did you need any help in completing this questionnaire? If so, who helped and why? 
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29. Is there anything else you would like to tell us about your heart condition or heart operation 
that is not covered in this questionnaire? Please write in the box below. 
Please check that you have answered all the questions on each page.· 
THANK YOU FOR YOUR HELP 
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CROQ item (description) 
Q1: 
(Chest pain) 
(Chest tightness) 
(Chest discomfort) 
(Shortness of breath) 
(Radiating pain) 
(palpitations) . 
(Disturbed sleep) 
(Worn out) 
02: 
(Nitros) 
03: 
(Symptoms on exertion) 
04: 
(Trouble) 
.,. 
t.) 
t.) 
Source 
of item 
New 
SAO 
New 
New 
c 
APPENDIX 4.6 CROQ Items (Pre-test Version) 
Original phrasing of borrowed item Items in CROQ (pre-test version) 
NA During the past 4 weeks, how much were you bothered by 
each of the following problems related to your heart 
condition? 
• Chest pain? 
• Chest tightness? 
• Discomfort in the chest? 
• Shortness of breath? 
• Pain that radiates to other parts of your body (e.g. arms, 
shoulders, back, neck, throat, jaw, hands)? 
• Palpitations (strong or irregular heart beat)? 
• Disturbed sleep? 
• Feeling worn out or low in energy? 
Over the past 4 weeks, on average, how many times During the past 4 weeks, on average, how many times have 
have you had to take nitros (nitroglycerin tablets) for you taken nitros (nitroglycerin tablets or spray) for your chest 
your chest pain, chest tightness or angina? pain, chest tightness or angina? 
NA During the past 4 weeks, have you had chest pain, chest 
tightness or angina: 
• At rest? 
• Only on exertion? 
• Not at all? 
NA During the past 4 weeks, how much trouble has your heart 
condition caused you? 
CROQ item (description) 
Q5a-j: 
(Vigorous activities) 
(Moderate activities) 
(Lifting & Carrying) 
(Climbing flights of stairs) 
(Climbing one flight of stairs) 
(Bending, kneeling, stooping) 
(Walk> 1 mile) 
(Walk half a mile) 
(Walk 100 yards) 
(Bathing or dressing) 
Q6a-d: 
(Time spent) 
(Accomplish) 
(KInd of wOrk) 
(Performing) 
Q7a-b: 
(Worry heart condition) 
(Over-doing it) 
.,. 
I\) 
w 
----- ----- -------- --
Source 
of item 
SF-36 
SF-36 
New 
- --
Original phrasing of borrowed item 
The following questions are about activities you might 
do during a typical day. Does your health now limit you 
in these activities? If so, how much? 
• Vigorous activities, such as running, lifting heavy 
objects, participating in strenuous sports 
• Moderate activities, such as mOving a table, 
pushing a vacuum cleaner, bowling, or playing golf 
• Lifting or carrying groceries 
• Climbing several flights of stairs 
• Climbing one flight of stairs 
• Bending, keeling, stooping 
• Walking more than a mile 
• Walking half a mile 
• Walking one hundred yards 
• Bathing or dressing yourself 
During the past 4 weeks, have you had any of the 
following problems with your work or other regular daily 
activities as a result of your physical health? 
• Cut down the amount of time spent on work or 
other activities 
• Accomplished less than you would like 
• Were limited in the kind of work or other activities 
• Had difficulty performing the work or other activities 
(for example, it took extra effort) 
NA 
- - -- - -- -
Items in CROQ (pre-test version) 
The following questions ask about activities which you might do 
during a typical day. During the past 4 weeks, has your heart 
condition limited you in your usual daily activities? Please 
indicate whether your heart condition limits you a lot, limits you 
a little, or does not limit you at all in the activities listed below. 
• Vigorous activities, such as running, lifting heavy objects, 
participating in strenuous sports? 
• Moderate activities, such as moving a table, pushing a 
vacuum cleaner, bowling, or playing golf? 
• Lifting or carrying groceries? 
• Climbing several flights of stairs? 
• Climbing one flight of stairs? 
• Bending, keeling, stooping? 
• Walking more than a mile? 
• Walking half a mile? 
• Walking one hundred yards? 
• Bathing or dressing yourself? 
During the past 4 weeks, have you had any of the following 
problems with your work or other regular daily activities as a 
result of your heart condition? 
• Cut down the amount of time spent on work or other 
activities? 
• Accomplished less than you would like? 
• Were limited in the kind of work or other activities? 
• Had difficulty performing the work or other activities (for 
example, it took extra effort)? 
The next questions ask about your feelings about your heart 
condition. During the past 4 weeks, how often have you felt: 
• Worried about your heart condition? 
• Worried about doing too much or over-doing it? 
-L... -- - ----------
(,. 
Source 
CROQ item (description) of item Original phrasing of borrowed item Items in CROQ (pre-test version) 
07c: SAO How often do you worry that you may have a heart During the past 4 weeks, how often have you felt: 
(Heart attack) attack or die suddenly? • Worried that you might have a heart attack or die , 
suddenly? ! 
07d-h: New NA The next questions ask about your feelings about your heart 
(Symptoms return) condition. During the past 4 weeks, how often have you felt: 
(Another operation) • Worried that your symptoms might return? (Frightened by pain) 
• Worried that you might need another heart operation in the (Out of controO Mure? (Uncertain) 
• Frightened by the pain or discomfort of your heart 
condition? 
• Out of control of your life? ! 
• Uncertain about the future? 
071: OLMI-2 How often during the last two weeks, have you felt During the past 4 weeks, how often have you felt: I (Unsure) unsure of yourself and lacking in self-confidence? • Unsure of yourself or lacking in self-confidence? 
07j-k: New NA The next questions ask about your feelings about your heart I (Morale) condition. During the past 4 weeks, how often have you felt: 
(Depressed) • Low in morale? ! 
• Depressed? I 
071: OLMI-2 In general, how much of the time during the last 2 weeks During the past 4 weeks, how often have you felt: I (Frustrated) have you felt frustrated, impatient or angry? • Frustrated or impatient? 
07m-n: New NA The next questions ask about your feelings about your heart I 
(Irritated) condition. During the past 4 weeks, how often have you felt: 
(Avoid activities) • Irritated? 
• That you had to avoid certain activities because of your 
heart condition? 
070: SAO Over the past 4 weeks, how much has your chest pain, During the past 4 weeks, how often have you felt: 
(Interfered with enjoyment) chest tightness or angina interfered with your enjoyment • That your heart condition interfered with your enjoyment of 
of life? life? 
--- -- L-- - - -- -----_._--- -- -- -- - --------------L...--
~ 
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CROQ item (description) 
Q7p: 
Positive outlook 
Q8a-f: 
(Reason) 
(Forget) 
(Attention) 
(Concentration) 
(Confusion) 
(React slowly) 
Q8g: 
(Not complete) 
Q9a: 
(Personal relationships) 
Q9b: 
(Family overprotective) 
.,. 
N 
0'1 
Source 
of item 
New 
MOS 
AIQ 
New 
QLMI-2 
t, 
Original phrasing of borrowed item 
NA 
How much of the time during the past month did you: 
• Have difficulty reasoning and SOlving problems, for 
example making plans, making decisions or learning 
new things? 
• Forget, for example things that happened recently, 
where you put things or appointments? 
• Have trouble keeping your attention on any activity 
for long? 
• Have difficulty doing activities involving 
concentration and thinking? 
• Become confused and start several actions at a 
time? 
• React slowly to things that were said or done? 
How often did you complete things, activities you 
started? 
NA 
How often during the last 2 weeks have you felt as if 
your family is being overprotective toward you? 
-.~-
Items in CROQ (pre-test version) 
The next questions ask about your feelings about your heart 
condition. During the past 4 weeks, how often have you felt: 
• That it was difficult to keep a positive outlook about your 
health? 
During the past 4 weeks, how much of the time did you: 
• Have difficulty reasoning and solving problems, for 
example making plans, making decisions or learning new 
things? 
• Forget, for example things that happened recently, where 
you put things or appointments? 
• Have trouble keeping your attention on any activity for 
long? 
• Have difficulty doing activities involving concentration and 
thinking? 
• Become confused and start several actions at a time? 
• React slowly to things that were said or done? 
During the past 4 weekS, how much of the time did you not 
complete things or activities you started? 
This question is about the impact of your heart condition on 
your family and friends and the extent to which it has interfered 
with your social activities. During the past 4 weeks, how often 
have you experienced the following as a result of your heart 
condition: 
• Difficulties with your personal relationships? 
During the past 4 weeks, how often have you experienced the 
follOWing as a result of your heart condition: , 
• Family or friends being overprotective toward you? 
Source 
CROQ item (description) of item Original phrasing of borrowed item Items in CROQ (pre-test version) 
Q9c: QLMI-2 How often, during the past 2 weeks, have you felt as if During the past 4 weeks, how often have you experienced the 
(Feeling a burden) you are a burden on others? following as a result of your heart condition: 
• Feeling like you are a burden on others? 
Q9d: SF-36 During the past 4 weeks, how much of the time has your During the past 4 weeks, how often have you experienced the 
(Restricted in social activities) phy:sical health or emotional problems interfered with following as a result of your heart condition: I 
your social activities ~ike visiting with friends, relatives, • Feeling restricted in your social activities (like visiting with 
etc)? friends, relatives, etc)? 
Qge: QLMI-2 How often during the last 2 weeks have you felt During the past 4 weeks, how often have you experienced the 
(Feeling excluded) excluded from doing things with other people because following as a result of your heart condition: 
of your heart problem? • Feeling excluded from doing things with other people? 
Q9f: New NA This question is about the impact of your heart condition on 
(Too far from home) your family and friends and the extent to which it has interfered 
with your social activities. During the past 4 weeks, how often 
have you experienced the following as a result of your heart 
condition: 
• Feeling worried about going too far from home? 
Q10: New NA The next section asks about problems you might have had 
(Complications) since your heart operation. During the past 4 weeks, how· 
much were you bothered by the following problems? 
CABG only:: 
• Pain in your chest wound? 
• Any other pain in your chest or neck due to your 
operation? 
• Infection, oozing or tendemess in your chest wound? 
• Numbness or tingling in your chest? 
• Pain in your leg or ann wound? 
• Any other pain in your leg or ann due to your operation? 
• Infection, oozing or tendemess in your leg or ann wound? 
• Numbness or tingling in your leg or ann? 
• Bruising on your chest? 
.lao 
~ 
Source 
CROQ item (description) of item Original phrasing of borrowed item Items in CROQ (pre-test version) 
Q10 contd ... 
• Bruising on your leg or arm where a vein was removed? 
• Swollen feet or ankles? 
• Weakness or lethargy? 
• Nausea? 
• Loss of appetite? 
• Concern over the appearance of your surgical scars? 
PTCA only 
• Pain in your groin wound? 
• Infection, oozing or tenderness in your groin wound? 
• Numbness or tingling in your groin area? 
• Bruising around your groin wound? 
• Bruising on your thigh? 
• Discomfort in your chest due to your operation? 
• Swollen feet or ankles? 
• Concern over the appearance of your surgical scar? 
• Concern over the appearance of your bruises? 
Q11: New NA Since your heart operation, have you been re-admitted to 
(Readmission to hospitaQ hospital (for an overnight stay) for any reason to do with your 
heart condition or your heart operation? Please give as 
many details as you can below. 
Q12a-d: New NA The next question asks about how satisfied you are with your 
(Satisfied with progress) heart operation. How satisfied are you with the: 
(Satisfied with results) • Progress you have made since your heart operation? (Satisfied with info about op) 
• Results of your heart operation? (Satisfied with recovery info) 
• Information you were given about your heart operation? 
• Information you were given about how you might feel while 
recovering from your heart operation? 
Q13: New NA Were you given the information about your heart operation at 
(Info at the right time) the right time? 
.".. 
~ 
Source 
CROQ item (description) of item Original phrasing of borrowed item 
014: MOO Overall, how do you feel now compared to before your 
(Overall compared to before operation? 
op) 
015: MOO Has your recovery from your operation so far been: 
(Speed of recovery) 
016: POO Were the results of your prostate procedure: 
(Expectation of results) • Worse than you expected? 
• About what you expected? 
• Better than you expected? 
Key to abbreviations: 
AIO: Angina Impact questionnaire. 
MOO: Menorrhagia Outcomes Questionnaire. 
MOS: Medical Outcomes Study. 
New: Newly created item specifically for the CROQ. 
POO: Prostate Outcomes Questionnaire. 
QLMI-2: Quality of Life after Acute Myocardial Infarction. 
SAO: Seattle Angina Questionnaire. 
SF-36: Short-Form 36. 
~ 
f\) 
()C) 
Items in CROQ (pre-test version) 
Overall, how would you describe your heart condition now 
compared to before your heart operation? 
Has your recovery from your heart operation so far been: 
• Slower than you expected? 
• About what you expected? 
• Faster than you expected? 
• Did not know how long it would take? 
Are the results from your heart operation: 
I 
• Worse than you expected? 
• About what you expected? 
• Better than you e~cted? 
APPENDIX 4.7 3-Months Post-Revascularisation CROQ-CABG 
Questionnaire (Preliminary Field Test) 
For 
Patient 10: Date of operation: _ _ ____ _ 
Hospital: Date received: 
CORONARY REVASCULARISATION OUTCOME QUESTIONNAIRE 
(CROQ-CABG) 
/ INSTRUCTIONS: We are interested in finding out how you have been since the heart 
operation (coronary artery bypass graft surgery) you had 3 months ago. We would be 
grateful if you could help us by filling out this questionnaire. All of the information you 
provide is COMPLETELY CONFIDENTIAL. Please be sure to answer all questions. 
1. During the past 4 weeks, how much were you bothered by each of the following problem s 
related to your heart condition? (Please tick one box on each line.) 
A lot Quite Moderately A Not at all 
a bit little 
Feeling worn out or low in energy D D D D D 
2. During the past 4 weeks, on average, how many times have you taken nitros (nitroglycerin 
tablets or spray) for your chest pain, chest tightness or angina? (Please tick only one box.) 
D D D D D D 
4 or more 1-3 times 3 or more 1-2 times Less than None over 
times per day per day times per per week once a week the past 4 
week but not weeks 
every day 
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3. During the past 4 weeks, have you had chest pain, chest tightness or angina: 
(Please tick only one box.) 
o o o 
At rest? Only on exertion? Not at all? 
4. During the past 4 weeks, how much trouble has your heart condition caused you? 
(Please tick only one box.) 
o o o o o 
A lot Quite a bit Some A little None 
5. The following questions ask about activities which you might do during a typical day. During 
the past 4 weeks, has your heart condition limited you in your usual daily activities? Please 
indicate whether your heart condition limits you a lot, limits you a little, or does not limit you at 
all in the activities listed below. (Please tick one box on each line.) 
ACTIVITIES 
Bathing or dressing yourself 
Yes, 
Limited A 
Lot 
D 
Yes, 
Limited A 
Little 
D 
No, Not 
Limited At 
All 
D 
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6. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of your heart condition? (Please tick one box on each line.) 
Had difficulty performing the work or other activities (for example, it 
took extra effort) 
YES NO 
D D 
7. The next questions ask about problems related to your heart condition. During the past 4 
weeks, how much of the time did you: (Please tick one box on each line.) 
Have difficulty doing activities 
involving concentration and 
thi 
React slowly to things that were 
done or said? 
All 
of the 
time 
D 
Most 
of the 
time 
D 
A good 
bit of 
the time 
o 
Some of 
the time 
o 
A little 
of the 
time 
D 
None 
of the 
time 
o 
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8. The next questions ask about your feelings about your heart condition. During the past 4 
weeks, how often have you felt: (Please tick one box on each line.) 
All 
of the 
time 
Most 
of the 
time 
Some 
of the 
time 
o 
A little 
of the 
time 
o 
:= . 
None 
of the 
time 
432. 
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9. The next questions ask about the impact of your heart condition on your family and friends 
and the extent to which it has interfered with your social activities. During the past 4 weeks) 
how often have you experienced the following as a result of your heart condition: 
(Please tick one box on each line.) 
Feeling worried about going too far from 
home? 
All 
of the 
time 
D 
Most 
of the 
time 
D 
Some 
of the 
time 
D 
A little 
of the 
time 
D 
None 
of the 
time 
D 
10. Since your heart operation, have you been re-admitted to hospital for an overnight stay for any 
reason to do with your heart condition or heart operation? Please give as many details as 
you can below. 
D No 
D Yes, I was in hospital for _____ days 
Date of adm iss ion Name of hospital Reason for hospital stay 
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11. The next questions ask about problems you might have had since your heart operation. 
During the past 4 weeks, how much were you bothered by the following problems? If you did 
not have the problem, tick the last box "Not at all". (Please tick one box on each line.) 
Infection in your leg or arm 
wound 
Tenderness around your leg or 
arm wound 
Bruising on your leg or arm where 
a vein was removed 
Weakness or lethargy 
Loss of appetite 
A lot 
o 
o 
o 
D 
Quite a Moderately 
bit 
o o 
o o 
o o 
D D 
A little Not at all 
o o 
o 
o o 
o o 
D o 
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12. The next question asks about how satisfied you are with your heart operation. How satisfied 
are you with the: (Please tick one box on each line.) 
Information you were given about how 
you might feel while recovering from your 
heart operation? 
Very Somewhat Somewhat 
dissatisfied dissatisfied satisfied 
D D 
D D D 
Very 
satisfied 
D 
D 
13. Were you given the information about your heart operation at the time you needed it? 
o No 
DYes 
14. Overall. how would you describe your heart condition now compared to before you had your 
heart operation? (Please tick one box.) 
0 Much worse 
0 A little worse 
0 About the same 
0 A little better 
0 Much better 
15. Has your recovery from your heart operation so far been: (Please tick one box.) 
o Slower than you expected? 
o About what you expected? 
o F aster than you expected? 
o Did not know how long it would take? 
16. Are the results from your heart operation: (Please tick one box.) 
o Worse than you expected? 
o About what you expected? 
o Better than you expected? 
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Finally. It would be very helpful If you could answer a few general questions about yourself. 
(Please tick the boxes that best describe your situation.) 
17. Are you: o Male 
o Female 
18. What is your date of birth? 
Day Month Year 
19. Please fill in the date you completed this questionnaire: 
Day Month Year 
20. To which ethnic group do you belong? 
0 White 0 Pakistani 
0 Black/Caribbean 0 Bangladeshi 
0 Black/African 0 Chinese 
0 Black/Other 0 Any other ethnic group 
0 Indian (please specify) 
21. Do you have any other long-standing illness, disability or infirmity? By long-standing I mean 
anything that has troubled you over a period of time, or that is likely to affect you over a period 
of time? 
·0 No 
o Yes (If yes, what is the matter with you?) 
22. What is your current work situation? 
o Employed I self-employed full-time o Retired 
o Employed I self-employed part-time o Unable to work/disabled 
o Voluntary work o Unemployed 
o Homemaker o Other (please specify) 
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23. What is (or was) your nwo occupation? 
Full job title: ________________________ _ 
What do (did) you actually do in this job? ________________ _ 
What do (did) your employer make or do? ________________ _ 
OR D· I do not work outside the home 
24. For women onlv. What is (or was) your husband's/partner's main occupation? 
Full job title: _________________________ _ 
What does (did) he actually do in this job? ________________ _ 
What does (did) his employer make or do? ________________ _ 
OR 0 I do not have a husband/partner 
25. This question asks about changes in your work situation after your heart operation. If you do 
not work outside the home, please put a tick in the first box. (Please tick one box only.) 
0 I do not work outside the home 
OR 0 I returned to the same job with the same number of hours after weeks 
OR 0 I returned to the same job with reduced number of hours after weeks 
OR 0 I returned to a different job after weeks 
OR ·0 I have not returned to work yet 
OR 0 I have stopped working 
26. Do you live: (You may tick more than one box.) 
o Alone? 
o With your husband or partner? 
o With children? 
o With family members? 
o Other? (please specify) _____ _ 
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27. Can you tell us approximately when you were first diagnosed as having heart disease? 
Month Year 
o I can not remember when I was first diagnosed 
28. Did you need any help in completing this questionnaire? If so, who helped and why? 
29. Is there anything else you would like to tell us about your heart condition or heart operation 
that is not covered in this questionnaire? If so, please write below. 
Please check that you have answered all the questions on each page. 
THANK YOU FOR YOUR HELP' 
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APPENDIX 4.8 3-Months Post-Revascularisation CROQ-PTCA 
Questionnaire (Preliminary Field Test) 
Patient 10: Date of operation: ______ _ 
Hospital: Date received: 
CORONARY REVASCULARISATION OUTCOME QUESTIONNAIRE 
(CROQ-PTCA) 
INSTRUCTIONS: We are interested in finding out how you have been since the heart 
operation (percutaneous transluminal coronary angioplasty) you had 3 months ago. We 
would be grateful if you could help us by filling out this questionnaire. All of the information 
you provide is COMPLETELY CONFIDENTIAL. Please be sure to answer all questions. 
1. During the past 4 weeks, how much were you bothered by each of the following problems 
related to your heart condition? (Please tick one box on each line.) 
A lot Quite Moderately A Not at all 
a bit little 
iili:l:IM:ii i@4'i;::i!' iW 
Feeling worn out or low in energy o o o o o 
2. During the past 4 weeks, on average, how many times have you taken nitros (nitroglycerin 
tablets or spray) for your chest pain, chest tightness or angina? (Please tick only one box.) 
0 D D 0 D 0 
4 or more 1-3 times 3 or more 1-2 times Less than None over 
times per day per day times per per week once a week the past 4 
week but not weeks 
every day 
4.39 
3. During the past 4 weeks, have you had chest pain, chest tightness or angina: 
(Please tick only one box.) 
D o D 
At rest? Only on exertion? Not at all? 
4. During the past 4 weeks, how much trouble has your heart condition caused you? 
(Please tick only one box.) 
D D o D o 
A lot Quite a bit Some A little None 
5. The following questions ask about activities which you might do during a typical day. During 
the past 4 weeks, has your heart condition limited you in your usual daily activities? Please 
indicate whether your heart condition limits you a lot, limits you a little, or does not limit you at 
all in the activities listed below. (Please tick one box on each line.) 
ACTIVITIES 
Bathing or dressing yourself 
Yes, 
Limited A 
Lot 
D 
Yes, 
Limited A 
Little 
D 
No, Not 
Limited At 
All 
o 
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6. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of your heart condition? (Please tick one box on each line.) 
Accomplished less than you would like 
Had difficulty performing the work or other activities (for example, it 
took extra effort) 
YES NO 
o o 
7. The next questions ask about problems related to your heart condition. During the past 4 
weeks, how much of the time did you: (Please tick one box on each line.) 
Forget, for example things that 
happened recently, where you 
thi intments? 
React slowly to things that were 
done or said? 
All 
of the 
time 
o 
o 
Most 
of the 
time 
o 
o 
A good 
bit of 
the time 
o 
o 
Some of 
the time 
o 
o 
A little 
of the 
time 
o 
o 
None 
of the 
time 
o 
o 
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8. The next questions ask about your feelings about your heart condition. During the past 4 
weeks, how often have you felt: (Please tick one box on each line.) 
. . .: . . ~~ ;: :' :: . 
. ·;i ;~ :~ .~ :~: " 
All 
of the 
time 
Most 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
o 
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9. The next questions ask about the impact of your heart condition on your family and friends 
and the extent to which it has interfered with your social activities. During the past 4 weeks, 
how often have you experienced the following as a result of your heart condition: 
(Please tick one box on each line.) 
Family or friends being overprotective 
toward you? 
Feeling restricted in your social activities 
(like visiting with friends, relatives, etc)? 
Feeling worried about going too far from 
home? 
All 
of the 
time 
D 
D 
D 
Most 
of the 
time 
D 
D 
D 
Some 
of the 
time 
D 
D 
D 
A little 
of the 
time 
D 
None 
of the 
time 
D 
10. Since your heart operation, have you been re-admitted to hospital for an overnight stay for any 
reason to do with your heart condition or heart operation? Please give as many details as 
you can below. 
D No 
D Yes, I was in hospital for _____ days 
Date of admission Name of hospital Reason for hospital stay 
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11. The next questions ask about problems you might have had since your heart operation. 
During the past 4 weeks, how much were you bothered by the following problems? If you did 
not have the problem, tick the last box "Not at all" . (Please tick one box on each line.) 
A lot Quite a Moderately A little Not at all 
bit 
.'. ~. :. 
0 
,':'.:' ..... 
Infection in your groin wound 0 0 0 0 
Bruising around your groin wound o 
Discomfort in your chest due to 
your operation o 
Problems in your groin where the 
catheter was inserted 
. ',' " ;~. :~ ::. :;' .: ,', 
12. The next question asks about how satisfied you are with your heart operation. How satisfied 
are you with the: (Please tick one box on each line.) 
Information you were given about how 
you might feel while recovering from your 
heart operation? 
Very 
dissatisfied 
o 
Somewhat 
dissatisfied 
D 
Somewhat 
satisfied 
D D 
" 
13. Were you given the information about your heart operation at the time you needed it? 
o No 
DYes 
14. Overall, how would you describe your heart condition now compared to before you had your 
heart operation? (Please tick one box.) 
0 Much worse 
0 A little worse 
0 About the same 
0 A little better 
0 Much better 
15. Has your recovery from your heart operation so far been: (Please tick one box.) 
o Slower than you expected? 
o About what you expected? 
o Faster than you expected? 
o Did not know how long it would take? 
16. Are the results from your heart operation: (Please tick one box.) 
o Worse than you expected? 
o About what you expected? 
o Better than you expected? 
Finally. It would be very helpful If you could answer a few general questions about yourself. 
(Please tick the boxes that best describe your situation.) 
17. Are you: o Male 
o Female 
18. VVhat is your date of birth? ( Day Month Year 
18. Please fill in the date you completed this questionnaire: 
Day Month Year 
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20. To which ethnic group do you belong? 
0 White 0 Pakistani 
0 Black/Caribbean 0 Bangladeshi 
0 Black/African 0 Chinese 
0 Black/Other 0 Any other ethnic group 
0 . Indian (please specify) 
21. Do you have any other long-standing illness, disability or infirmity? By long-standing I mean 
anything that has troubled you over a period of time, or that is likely to affect you over a period 
of time?· 
o No 
o Yes (If yes, what is the matter with you?) 
22. What is your current work situation? 
0 Employed I self-employed full-time 0 Retired 
0 Employed I self-employed part-time 0 Unable to work/disabled 
0 Voluntary work 0 Unemployed 
0 Homemaker 0 Other (please specify) 
23. What is (or was) your miin occupation? 
·Fulljob title: _________________________ _ 
What do (did) you actually do in this job? ________________ _ 
What do (did) your employer make or do? ________________ _ 
OR 0 I do not work outside the home 
24. For women onlY. What is (or was) your husband'slpartner's JD.Ii.o occupation? 
Fulljobtitle: ________________________ _ 
What does (did) he actually do in this job? _______________ _ 
What does (did) his employer make or do? _______________ _ 
OR 0 I do not have a husband/partner 
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25. This question asks about changes in your work situation after your heart operation. If you do 
not work outside the home, please put a tick in the first box. (Please tick one box only.) 
o 
OR 0 
OR 0 
OR 0 
OR 0 
OR D· 
I do not work outside the home 
I retumed to the same job with the same number of hours after ___ weeks 
I retumed to the same job with reduced number of hours after weeks 
I retumed to a different job after ___ weeks 
I have not retumed to work yet 
I have stopped working 
26. Do you live: (You may tick more than one box.) 
o Alone? 
o With your husband or partner? 
o With children? 
. 0 With family members? 
o Other? (please specify) _____ _ 
27. Can you tell us approximately when you were first diagnosed as having heart disease? 
Month Year 
o I can not remember when I was first diagnosed 
28. Did you need any help in completing this questionnaire? If so, who helped and why? . 
29. Is there anything else you would like to tell us about your heart condition or heart operation 
that is not covered in this questionnaire? If so, please write below. 
Please check that you have answered all the questions on each page. 
THANK YOU FOR YOUR HELP 
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APPENDIX 4.9 Pre-Revascularisation CROQ-CABG Questionnaire 
(Preliminary Field Test) 
Patient 10: 
Hospital: Date received: 
CORONARY REVASCULARISATION OUTCOME QUESTIONNAIRE 
(CROQ-CABG) 
INSTRUCTIONS: We are interested in finding out how you are now before the heart 
operation (coronary artery bypass graft surgery) you are going to have. We would be 
grateful if you could help us by filling out this questionnaire. All of the information you 
provide is COMPLETELY CONFIDENTIAL. Please be sure to answer all questions. 
1. During the past 4 weeks, how much were you bothered by each of the following problems 
related to your heart condition? (Please tick one box on each line.) 
A lot Quite Moderately A Not at all 
a bit little 
Feeling worn out or low in energy o o o o o 
2. During the past 4 weeks, on average, how many times have you taken nitros (nitroglycerin 
tablets or spray) for your chest pain, chest tightness or angina? (Please tick only one box.) 
0 0 0 0 0 0 
4 or more 1-3 times 3 or more 1-2 times Less than None over 
times per day per day times per per week once a week the past 4 
week but not weeks 
every day 
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3. During the past 4 weeks, have you had chest pain, chest tightness or angina: 
(Please tick only one box.) 
o o o 
At rest? Only on exertion? Not at all? 
4. During the past 4 weeks, how much trouble has your heart condition caused you? 
(Please tick only one box.) 
o o o o o 
A lot Quite a bit Some A little None 
5. The following questions ask about activities which you might do during a typical day. During 
the past 4 weeks, has your heart condition limited you in your usual daily activities? Please 
indicate whether your heart condition limits you a lot, limits you a little, or does not limit you at 
all in the activities listed below. (Please tick one box on each line.) 
ACTIVITIES 
Yes, 
Limited A 
Lot 
Yes, 
Limited A 
Little 
No, Not 
Limited At 
All 
Bathing or dressing yourself o o o 
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6. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of your heart condition? (Please tick one box on each line.) 
Had difficulty performing the work or other activities (for example, it 
took extra effort) D D 
7. The next questions ask about problems related to your heart condition. During the past 4 
weeks, how much of the time did you: (Please tick one box on each line.) 
All 
of the 
time 
Most 
of the 
time 
A good 
bit of 
the time 
Some of 
the time 
A little 
of the 
time 
None 
of the 
time 
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8. The next questions ask about your feelings about your heart condition. During the past 4 
weeks, how often have you felt: (Please tick one box on each line.) 
Frustrated or impatient? 
That you had to avoid certain activities 
because of your heart condition? 
That it was difficult to keep a positive 
outlook about your health? 
All 
of the 
time 
D 
D 
Most 
of the 
time 
D 
Some 
of the 
time 
o 
A little 
of the 
time 
D 
D 
None 
of the 
time 
o 
D 
"" 0 ~:::. 
D 
o 
D 
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9. The next questions ask about the impact of your heart condition on your family and friends 
and the extent to which it has interfered with your social activities. During the past 4 weeks. 
how often have you experienced the following as a result of your heart condition: 
(Please tick one box on each line.) 
Feeling restricted in your social activities 
(like visiting with friends, relatives, etc)? 
All 
of the 
time 
o 
Most Some 
of the of the 
time time 
o o 
iiiB-=~lma6i(;: 
Feeling worried about gOing too far from 
home? o o o 
A little None 
of the of the 
time time 
..... ,0 . 
o 
o o 
Finally, it would be very helpful if you could answer a few general questions about yourself. 
(Please tick the boxes that best describe your situation.) 
10. Are you: D Male 
D Female 
11. What is your date of birth? 
Day Month 
12. Please fill in the date you completed this questionnaire: 
13. To which ethnic group do you belong? 
0 White 0 Pakistani 
0 Black/Caribbean D Bangladeshi 
D Black/African D Chinese 
Year 
Day 
0 Black/Other 0 Any other ethnic group 
D Indian (please specify) 
Month Year 
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14. Do you have any other long-standing illness, disability or infirmity? By long-standing I mean 
anything that has troubled you over a period of time, or that is likely to affect you over a period 
of time? 
o No 
o Yes (If yes, what is the matter with you?) 
15. VVhat is your current work situation? 
o Employed I self-employed full-time o Retired 
o Employed I self-employed part-time o Unable to work/disabled 
o Voluntary work o Unemployed 
o Homemaker o Other (please specify) 
16. VVhat is (or was) your mAiD occupation? 
Full job title: _________________________ _ 
VVhat do (did) you actually do in this job? ________________ _ 
VVhat do (did) your employer make or do? ________________ _ 
OR 0 I do not work outside the home 
17. For women only. VVhat is (or was) your husband'slpartner's mAiD occupation? 
Full job title: _________________________ _ 
VVhatdoes (did) he actually do in this job? _______________ _ 
VVhat does (did) his employer make or do? _______________ _ 
OR 0 I do not have a husband/partner 
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18. Do you live: (You may tick more than one box.) 
D Alone? 
D With your husband or partner? 
D With children? 
D With family members? 
D . Other? (please specify) _____ _ 
19. Can you tell us approximately when you were first diagnosed as having heart disease? 
Month Year 
D I can not remember when I was first diagnosed 
20. Did you need any help in completing this questionnaire? If so, who helped and why? 
21. Is there anything else you would like to tell us about your heart condition or heart operation 
that is not covered in this questionnaire? If so, please write below. 
Please check that you have answered all the questions on each page. 
THANK YOU FOR YOUR HELP 
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APPENDIX 4.10 Pre-Revascularisation CROQ-PTCA Questionnaire 
(Preliminary Field Test) 
For 
Patient 10: 
Hospital: Date received: 
CORONARY REVASCULARISATION OUTCOME QUESTIONNAIRE 
(CROQ-PTCA) 
INSTRUCTIONS: We are interested in finding out how you are now before the heart 
operation (percutaneous transluminal coronary angioplasty) you are going to have. 
We would be grateful if you could help us by filling out this questionnaire. All of the 
information you provide is COMPLETELY CONFIDENTIAL. Please be sure to answer all 
questions. 
1. During the past 4 weeks, how much were you bothered by each of the following problems 
related to your heart condition? (Please tick one box on each line.) 
A lot Quite Moderately A Not at all 
a bit 
Feeling worn out or low in energy o o o o o 
2. During the past 4 weeks, on average, how many times have you taken nitros (nitroglycerin 
tablets or spray) for your chest pain, chest tightness or angina? (Please tick only one box.) 
0 0 0 0 0 0 
4 or more 1-3 times 3 or more 1-2 times Less than None over 
times per day per day times per per week once a week the past 4 
week but not weeks 
every day 
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3. During the past 4 weeks, have you had chest pain, chest tightness or angina: 
(Please tick only one box.) 
o o o 
At rest? Only on exertion? Not at all? 
4. During the past 4 weeks, how much trouble has your heart condition caused you? 
(Please tick only one box.) 
o o o o o 
A lot Quite a bit Some A little None 
5. The following questions ask about activities which you might do during a typical day. During 
the past 4 weeks, has your heart condition limited you in your usual daily activities? Please 
indicate whether your heart condition limits you a lot, limits you a little, or does not limit you at 
all in the activities listed below. (Please tick one box on each line.) 
ACTIVITIES 
Yes, 
Limited A 
Lot 
Yes, No, Not 
Limited A Limited At 
Little All 
~'"~',"~",''''~~n''m'',m~,~~~"?n%??~~f:n"~0%p~20~lli@HW'~2%n8W~em~?~"~' Vigoro~$ ,activlti.,~; ' 
objeftSt Pflrt.i9!Pjfing . 
Moderate activities, such as moving a table, 
push in a vacuum cleaner or ",,,,v,r,n 
!";'~"'~""'~' n "i ,. "i:~' t ".;'i ., " I~""~i .!. ~ ··"~~·;ifii~~~~~~':i~!l@.rlJ ill!1111~;\;'I~II~~il~~]~~~~~~I~~;~]r~='~~;~J;l! 
Climbing several flights of stairs o 
Bathing or dreSSing yourself o D 
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6. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of your heart condition? (Please tick one box on each line.) 
Accomplished less than you would like 
Had difficulty performing the work or other activities (for example, it 
took extra effort) 
o 
o 
o 
o 
7. The next questions ask about problems related to your heart condition. During the past 4 
weeks, how much of the time did you: (Please tick one box on each line.) 
Forget, for example things that 
happened recently, where you 
thin intments? 
Have difficulty doing activities 
involving concentration and 
React slowly to things that were 
done or said? 
All 
of the 
time 
D 
o 
D 
Most 
of the 
time 
o 
o 
o 
A good 
bit of 
the time 
D 
o 
D 
Some of 
the time 
D 
o 
D 
A little 
of the 
time 
D 
o 
D 
None 
of the 
time 
D 
o 
o 
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8. The next questions ask about your feelings about your heart condition. During the past 4 
weeks, how often have you felt: (Please tick one box on each line.) 
• ••.. :,':,., ...•• ::,> ... :,.:::.,:.:;: 
,;' '. , ..... ,.. .,' '.: .:: •• '. i ': ..... 
Worried about doing too much or over-
doing it? 
All Most 
of the of the 
time time 
::' : , 
, 
.. 
;> i~ i: : ., 
, 
. , 
o o 
,: :' :." : : " ::: :. .: :.' .. '.' . ~. .:. " 
::: '; ';.:' 
:.: :: 
Some A little None 
of the of the of the 
time time time 
··.:i" ·t!i~ '<. 
0 0 
o 
o 
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9. The next questions ask about the impact of your heart condition on your family and friends 
and the extent to which it has interfered with your social activities. During the past 4 weeks, 
how often have you experienced the following as a result of your heart condition: 
(Please tick one box on each line.) 
All 
of the 
time 
o 
Feeling restricted in your social activities 
(like visiting with friends, relatives, etc)? 0 
Feeling worried about going too far from 
home? o 
Most 
of the 
time 
o 
Some 
of the 
time 
o 
A little 
of the 
time 
o 
None 
of the 
time 
o 
Finally, it would be very helpful if you could answer a few general questions about yourself. 
(Please tick the boxes that best describe your situation.) 
10. Are you: o Male 
o Female 
11. What is your date of birth? 
Day Month Year 
12. Please fill in the date you completed this questionnaire: 
Day Month Year 
13. To which ethnic group do you belong? 
0 White 0 Pakistani 
0 Black/Caribbean 0 Bangladeshi 
0 Black/African 0 Chinese 
0 Black/Other 0 Any other ethnic group 
0 Indian (please specify) 
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14. Do you have any other long-standing illness, disability or infirmity? By long-standing I mean 
anything that has troubled you over a period of time, or that is likely to affect you over a period 
of time? 
o No 
o Yes (If yes, what is the matter with you?) 
15. What is your current work situation? 
o Employed / self-employed full-time o Retired 
o Employed / self-employed part-time o Unable to work/disabled 
o Voluntary work o Unemployed 
o Homemaker o Other (please specify) 
16. What is (or was) your main occupation? 
Full job title: _________________________ _ 
What do (did) you actually do in this job? ________________ _ 
What do (did) your employer make or do? ________________ _ 
. OR 0 I do not work outside the home 
17. For women onlv. \'IJhat is (or was) your husband'slpartner's miiD occupation? 
Full job title: _________________________ _ 
What does (did) he actually do in this job? _______________ _ 
What does (did) his employer make or do? _______________ _ 
OR 0 I do not have a husband/partner 
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18. Do you live: (You may tick more than one box.) 
D Alone? 
D With your husband or partner? 
D With children? 
o Wrth family members? 
D . Other? (please specify) _____ _ 
19. Can you tell us approximately when you were first diagnosed as having heart disease? 
Month Year 
D I can not remember when I was first diagnosed 
20. Did you need any help in completing this questionnaire? If so, who helped and why? 
21. Is there anything else you would like to tell us about your heart condition or heart operation 
that is not covered in this questionnaire? If so, please write below. 
Please check that you have answered all the questions on each page. 
THANK YOU FOR YOUR HELP 
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APPENDIX 5.1 Letter of Invitation 1: Pre-Revascularisation 
(Preliminary Field Test) 
Official Hospital Letterhead 
Dear (Patient's Name) 
Re: Validation of a coronary revascularisation questionnaire 
This hospital is developing a short questionnaire to help in evaluating the outcome of 
coronary revascularisation (coronary artery bypass graft surgery and coronary 
angioplasty). We are asking you to take part in our evaluation by filling in the 
enclosed questionnaire before you have your heart operation. If you agree to 
participate in this study we will also send you a similar questionnaire three months 
after the date of your heart operation. 
All the information we collect from you will remain confidential, and no individual will 
be named in any report. We hope you will be willing to help us in our effort to 
improve the service we offer to our patients. Agreeing to take part in this study will 
not alter your treatment in any way. Similarly, if you do not wish to take part, this will 
not alter your treatment in any way. 
The enclosed patient information sheet provides details about the study. If you are 
willing to take part, please sign the enclosed consent form and return it with your 
completed questionnaire, as soon as you possibly can, to Sara Schroter in the 
stamped addressed envelope provided. 
Thank you for your help. If you have any queries please contact Sara Schroter on 
0171 4365816. 
Yours sincerely 
Consultant Cardiothoracic Surgeon I Cardiologist 
Enclosed: Coronary Revascularisation Questionnaire 
Patient Information Sheet 
Patient Consent Form 
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APPENDIX 5.2 Letter of Invitation 1: Pre-Revascularisation 
(Final Field Test) 
Official Hospital Letterhead 
Dear (Patient's Name) 
Re: Validation of a coronary revascularisation questionnaire 
This hospital is developing a short questionnaire to help in evaluating the outcome of 
coronary revascularisation (coronary artery bypass graft surgery and coronary 
angioplasty). We are asking you to take part in our evaluation by filling in the 
enclosed questionnaire before you have your heart operation. If you agree to 
participate in this study we will also send you a similar questionnaire three, and nine 
months after the date of your heart operation. 
All the information we collect from you will remain confidential, and no individual will 
be named in any report. We hope you will be willing to help us in our effort to 
improve the service we offer to our patients. Agreeing to take part in this study will 
not alter your treatment in any way. Similarly, if you do not wish to take part, this will 
not alter your treatment in any way. 
The enclosed patient information sheet provides details about the study. If you are 
willing to take part, please sign the enclosed consent form and return it with your 
completed questionnaire, as soon as you possibly can, to Sara Schroter in the 
stamped addressed envelope provided. 
Thank you for your help. If you have any queries please contact Sara Schroter on 
0171 436 5816. 
Yours sincerely 
Consultant Cardiothoracic Surgeon I Cardiologist 
Enclosed: Coronary Revascularisation Outcome Questionnaire 
Patient Information Sheet 
Patient Consent Form 
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APPENDIX 5.3 Patient Information Sheet 1: Pre-Revascularisation 
(Preliminary Field Test) 
Official Hospital Letterhead 
Patient Information Sheet 1 
The purpose of this study is to develop a new questionnaire to evaluate patients' 
views of coronary revascularisation (coronary artery bypass graft surgery and 
coronary angioplasty). This study is being undertaken by (name of hospital) in 
collaboration with researchers at the London School of Hygiene and Tropical 
Medicine. 
We are inviting you and other patients who are waiting to undergo coronary 
revascularisation at the (name of hospital) to help us by completing a series of 
questionnaires. The enclosed questionnaire asks questions about your current 
health and includes questions about your symptoms and quality of life before your 
heart operation. Three months after the date of your heart operation, you will be 
sent another questionnaire. This questionnaire will be very similar to the one 
enclosed but there will be additional questions concerning the impact your heart 
operation has on your quality of life and your satisfaction with the treatment. 
It is important that we have your opinions to ensure that the results of our study will 
represent the views of all patients who have these operations. The questionnaires 
will be used in making recommendations for improving care provided to cardiac 
patients. 
Taking part in this study is entirely voluntary. Whether you decide to take part or 
not will not in any way affect the way you are treated. All the information you give 
will be completely confidential. In order to protect your privacy, a confidential study 
number rather than your name will be used on all questionnaire forms. These 
forms will be kept in locked research files which are only accessible to the research 
staff. None of the information you give will be available to any of the hospital staff, 
including doctors, nurses, and technicians, who provide the clinical care associated 
with your treatment. 
We hope that you will agree to complete this questionnaire and we would like to 
thank you in advance for helping us in participating in this study. If you have any 
queries please contact our Project Co-ordinator, Sara Schroter, on 0171 436 5816. 
Research Team: 
Dr Donna Lamping (Principal Investigator) 
Miss Sara Schroter (Project Co-ordinator) 
Health Services Research Unit, London School of Hygiene & Tropical Medicine 
Consultant Cardiothoracic Surgeons I Cardiologists: 
Names of participating consultants 
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APPENDIX 5.4 Patient Information Sheet 1: Pre-Revascularisation 
(Final Field Test) 
Official Hospital Letterhead 
Patient Information Sheet 1 
The purpose of this study is to develop a new questionnaire to evaluate patients' 
views of coronary revascularisation (coronary artery bypass graft surgery and 
coronary angioplasty). This study is being undertaken by (name of hospital) in 
collaboration with researchers at the London School of Hygiene and Tropical 
Medicine. 
We are inviting you and other patients who are waiting to undergo coronary 
revascularisation at the (name of hospital) to take part in a research study by 
completing a series of three questionnaires over the next nine months. The 
enclosed questionnaire asks about how you are feeling, physically and emotionally 
and about your ability to carry out daily activities. You will notice some repeated 
questions in Section 2. This is intentional as we are comparing the performance of 
two different questionnaires - so please answer every question. We will also be 
sending you this questionnaire three and nine months after the date of your 
operation. 
The questionnaires will be used in making recommendations for improving care 
provided to cardiac patients. Taking part in this study is entirely voluntary. 
Whether you decide to take part or not will not in any way affect the way you are 
treated. All the information you give will be completely confidential. In order to 
protect your privacy, a confidential study number rather than your name will be 
used on all questionnaire forms. These forms will be kept in locked research files 
which are only accessible to the research staff. None of the information you give 
will be available to any of the hospital staff, including doctors, nurses, and 
technicians, who provide the clinical care associated with your treatment. 
We hope that you will agree to complete this questionnaire and we would like to 
thank you in advance for helping us in participating in this study. If you have any 
queries please contact our Project Co-ordinator, Sara Schroter, on 0171 4365816. 
Research Team: 
Dr Donna Lamping (Principal Investigator) 
Miss Sara Schroter (Project Co-ordinator) 
Health Services Research Unit, London School of Hygiene & Tropical Medicine 
Consultant Cardiothoracic Surgeons I Cardiologists: 
Names of participating consultants 
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APPENDIX 5.5 Patient Consent Form: Pre-Revascularisation 
(Preliminary and Final Field Tests) 
PATIENT CONSENT FORM 
TITLE OF PROJECT: 
Validation of a patient-based measure of outcome for patients undergoing 
coronary revascularisation. 
EXPLANATION OF PROJECT: 
Invitation: This hospital is developing a questionnaire to help us understand better 
how you are feeling after your heart operation (coronary artery bypass graft surgery 
and coronary angioplasty). We are asking you to take part in our research by filling in 
the enclosed questionnaire before you have your heart operation. The questionnaire 
asks about how you are feeling, physically and emotionally, and about your ability 
to carry out daily activities, and about your health in general. 
All the information you give during the study will be completely confidential. In 
order to protect your privacy, a confidential study number rather than your name 
will be used on the questionnaires. These questionnaires will be kept in locked 
research files which only the research staff will have access to. None of the 
information you give will be available to any of the hospital staff, including doctors, 
nurses, and technicians, who provide the clinical care associated with your 
treatment. 
This study is being undertaken by a research team at the London School of 
Hygiene and Tropical Medicine in collaboration with (name and hospital of leading 
collaborating consultants). Please understand that you need not take part in this 
study if you do not wish to. If you do take part, you may withdraw at any time, and 
need give no reason for doing so. If you choose not to take part, or if you 
withdraw, your normal care and treatment will be unaffected. 
Signed by the person in charge of the Project __________ Date ___ _ 
The Ethics Committee of the (name of hospital) has approved the above statement. 
Signed by the Chairman/Representative of the Committee 
_________________________ Dme ________ _ 
FORM OF CONSENT 
I, Of-:--~~--:-~ ___ -------
agree to take part in the research project outline above. I understand the nature and purpose of the 
questionnaire, and that I may withdraw from the research without it affecting my care and treatment 
at this hospital in any way. 
Signed _________________ Date _______ _ 
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APPENDIX 5.6 Pre-Revascularisation CROQ-CABG Questionnaire 
(Final Field Test) 
For Office Use Only 
Patient 10: Date of operation: ______ _ 
Hospital: Date received: 
CORONARY REVASCULARISATION OUTCOME QUESTIONNAIRE 
(CROQ-CABG) 
INSTRUCTIONS: We are interested in finding out how you are now before the heart 
operation (coronary artery bypass graft surgery) you are going to have. We would be 
grateful if you could help us by filling out this questionnaire. All of the information you 
provide is COMPLETELY CONFIDENTIAL. Please be sure to answer all questions. 
1. During the past 4 weeks, how much were you bothered by each of the following problems 
related to your heart condition? (Please tick one box on each line.) 
A lot Quite Moderately A Not at all 
a bit little 
2. During the past 4 weeks, on average, how many times have you taken nitros (nitroglycerin 
tablets or spray) for your chest pain, chest tightness or angina? (Please tick only one box.) 
0 0 0 0 0 0 
4 or more 1-3 times 3 or more 1-2 times less than None over 
times per day per day times per per week once a week the past 4 
week but not weeks 
every day 
Copyright: London School of Hygiene & Tropical Medicine, 1999 (do not use without permission). 
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3. During the past 4 weeks, have you had chest pain, chest tightness or angina: 
(Please tick only one box.) 
o o 
At rest? On exertion? 
o 
At rest and on 
exertion? 
o 
Not at all? 
4. During the past 4 weeks, how much trouble has your heart condition caused you? 
(Please tick only one box.) 
o o o o o 
A lot Quite a bit Some A little None 
5. The following questions ask about activities which you might do during a typical day. During 
the past 4 weeks, has your heart condition limited you in your usual daily activities? Please 
indicate whether your heart condition limits you a lot, limits you a little, or does not limit you at 
all in the activities listed below. (Please tick one box on each line.) 
ACTIVITIES 
Bathing or dressing yourself 
Yes, 
limited A 
Lot 
o 
Yes, 
Limited A 
Little 
o 
No, Not 
Limited At 
All 
o 
Copyright: London School of Hygiene & Tropical Medicine, 1999 (do not use without permission) . 
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6. The next questions ask about the impact of your heart condition on your family and friends and 
the extent to which it has interfered with your social activities. During the past 4 weeks, how 
often have you experienced the following as a result of your heart condition: 
(Please tick one box on each line.) 
Feeling worried about going too far from 
home? 
All 
of the 
time 
D 
Most 
of the 
time 
D 
Some 
of the 
time 
A little 
of the 
time 
: .• :li:: .• ·.·!I···::·.·. :  :t! 
D D 
None 
of the 
time 
D 
7. The next questions ask about your feelings about your heart condition. During the past 4 
weeks, how often have you felt: (Please tick one box on each line.) 
That it was difficult to plan ahead (eg 
vacations, social events, etc.)? 
All 
of the 
time 
D 
Most 
of the 
time 
D 
Some 
of the 
time 
D 
A little 
of the 
time 
D 
Copyright: London School of Hygiene & Tropical Medicine, 1999 (do not use without permission) . 
None 
of the 
time 
D 
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8. The next questions ask about problems related to your heart condition. During the past 4 
weeks, how much of the time did you: (Please tick one box on each line.) 
Forget, for example things that 
happened recently, where you put 
ora 
All 
of the 
time 
o 
Most 
of the 
time 
o 
A good 
bit of 
the time 
o 
Some of 
the time 
o 
A little 
of the 
time 
o 
None 
of the 
time 
o 
Finally, it would be very helpful if you could answer a few general questions about yourself. 
(Please tick the boxes that best describe your situation.) 
9. Are you: o Male 
o Female 
10. What is your date of birth? 
Day Month Year 
11. Please fill in the date you completed this questionnaire: 
Day Month Year 
12. To which ethnic group do you belong? 
0 White 0 Pakistani 
0 Black/Caribbean 0 Bangladeshi 
0 Black/African 0 Chinese 
0 Black/Other 0 Any other ethnic group 
0 Indian (please specify) 
Copyright: London School of Hygiene & Tropical Medicine, 1999 (do not use without pennission). 
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13. Do you have any other long-standing illness, disability or infirmity? By long-standing I mean 
anything that has troubled you over a period of time, or that is likely to affect you over a period 
of time? 
o No 
o Yes (If yes, what is the matter with you?) 
14. Do you live: (You may tick more than one box.) 
o Alone? 
o With your husband I wife or partner? 
o With children? 
o With family members? 
o Other? (please specify) ________ _ 
15. Can you tell us approximately when you were first diagnosed as having heart disease? 
Month Year 
o I can not remember when I was first diagnosed 
16. What is your current work situation? 
0 Employed I self-employed full-time 0 Retired 
0 Employed I self-employed part-time 0 Unable to work/disabled 
0 Voluntary work 0 Unemployed 
0 Homemaker 0 Other (please specify) 
Copyright: London School of Hygiene & Tropical Medicine, 1999 (do not use without permission). 
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17. What is (or was) your main occupation? 
Full job title: ______________________ _ 
What (did) you actually do in this job? 
What do (did) your employer make or do? _____________ _ 
OR D I do not work outside the home 
18. This question (Q18) is for women only: 
What is (or was) your husband's/partner's main occupation? 
Full job title: _______________________ _ 
What does (did) he actually do in this job? _____________ _ 
What does (did) his employer make or do? 
OR D I do not have a husband/partner 
19. Did you need any help in completing this questionnaire? If so, who helped and why? 
20. Is there anything else you would like to tell us about your heart condition or heart 
operation that is not covered in this questionnaire? If so, please write below. 
Please check that you have answered all the questions on each page. 
THANK YOU FOR YOUR HELP 
Copyright: London School of Hygiene & Tropical Medicine, 1999 (do not use without pennlsslon). 
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APPENDIX 5.7 Pre-Revascularisation CROQ-PTCA Questionnaire 
(Final Field Test) 
For Office Use Only 
Patient ID: Date of operation: ______ _ 
Hospital: Date received: 
CORONARY REVASCULARISATION OUTCOME QUESTIONNAIRE 
(CROQ-PTCA) 
INSTRUCTIONS: We are interested in finding out how you are now before the heart 
operation (percutaneous transluminal coronary angioplasty) you are going to have. We 
would be grateful if you could help us by filling out this questionnaire. All of the infonnation 
you provide is COMPLETELY CONFIDENTIAL. Please be sure to answer all questions. 
1. During the past 4 weeks, how much were you bothered by each of the following problems 
related to your heart condition? (Please tick one box on each line.) 
A lot Quite Moderately A Not at all 
a bit little 
IJ,~;i;~~;!!!~II~;'~j~:li"ti~I~::i[:~(! 
2. During the past 4 weeks, on average, how many times have you taken nitros (nitroglycerin 
tablets or spray) for your chest pain, chest tightness or angina? (Please tick only one box.) 
D D D D D D 
4 or more 1-3 times 3 or more 1-2 times Less than None over 
times per day per day times per per week once a week the past 4 
week but not weeks 
every day 
Copyright: London School of Hygiene & Tropical Medicine, 1999 (do not use without permission). 
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3. During the past 4 weeks, have you had chest pain, chest tightness or angina: 
(Please tick only one box.) 
D D 
At rest? On exertion? 
D 
At rest and on 
exertion? 
D 
Not at all? 
4. During the past 4 weeks, how much trouble has your heart condition caused you? 
(Please tick only one box.) 
D D D D D 
A lot Quite a bit Some A little None 
5. The following questions ask about activities which you might do during a typical day. During 
the past 4 weeks, has your heart condition limited you in your usual daily activities? Please 
indicate whether your heart condition limits you a lot, limits you a little, or does not limit you at 
all in the activities listed below. (Please tick one box on each line.) 
ACTIVITIES 
Bathing or dressing yourself 
Yes, 
Limited A 
Lot 
D 
Yes, 
Limited A 
Little 
D 
No, Not 
Limited At 
All 
o 
Copyright: London School of Hygiene & Tropical Medicine, 1999 (do not use without permission) . 
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6. The next questions ask about the impact of your heart condition on your family and friends and 
the extent to which it has interfered with your social activities. During the past 4 weeks. how 
often have you experienced the following as a result of your heart condition: 
(Please tick one box on each line.) 
Feeling worried about going too far from 
home? 
All 
of the 
time 
D 
D 
Most 
of the 
time 
D 
Some 
of the 
time 
D 
A little 
of the 
time 
o 
......... , .................... :' ...... i··, .' .. ' ..... ' . 
D o o 
None 
of the 
time 
D 
7. The next questions ask about your feelings about your heart condition. During the past 4 
weeks, how often have you felt: (Please tick one box on each line.) 
That it was difficult to plan ahead (eg 
vacations, social events, etc.)? 
All 
of the 
time 
D 
Most 
of the 
time 
D 
Some 
of the 
time 
D 
A little 
of the 
time 
D 
Copyright: London School of Hygiene & Tropical Medicine, 1999 (do not use without pennission) . 
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of the 
time 
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8. The next questions ask about problems related to your heart condition. During the past 4 
weeks, how much of the time did you: (Please tick one box on each line.) 
Finally, it would be very helpful if you could answer a few general questions about yourself. 
(Please tick the boxes that best describe your situation.) 
9. Are you: D Male 
o Female 
10. What is your date of birth? 
Day Month Year 
11. Please fill in the date you completed this questionnaire: 
Day 
12. To which ethnic group do you belong? 
D White D Pakistani 
D Black/Caribbean D Bangladeshi 
D Black/African D Chinese 
D Black/Other D Any other ethnic group 
D Indian (please specify) 
Month Year 
Copyright: London School of Hygiene & Tropical Medicine, 1999 (do not use without permission) . 
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13. Do you have any other long-standing illness, disability or infirmity? By long-standing I mean 
anything that has troubled you over a period of time, or that is likely to affect you over a period 
of time? 
o No 
o Yes (If yes, what is the matter with you?) 
14. Do you live: (You may tick more than one box.) 
o Alone? 
o With your husband I wife or partner? 
o With children? 
o With family members? 
o Other? (please specify) ________ _ 
15. Can you tell us approximately when you were first diagnosed as having heart disease? 
Month Year 
o I can not remember when I was first diagnosed 
16. What is your current work situation? 
0 Employed I self-employed full-time 0 Retired 
0 Employed I self-employed part-time 0 Unable to work/disabled 
0 Voluntary work 0 Unemployed 
0 Homemaker 0 Other (please specify) 
Copyright: London School of Hygiene & Tropical Medicine, 1999 (do not use without pennlsslon). 
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17. What is (or was) your main occupation? 
Full job title: ______________________ _ 
What (did) you actually do in this job? 
What do (did) your employer make or do? _____________ _ 
OR 0 I do not work outside the home 
18. This question (Q18) is for women only: 
What is (or was) your husband's/partner's main occupation? 
Full job title: _______________________ _ 
What does (did) he actually do in this job? _____________ _ 
What does (did) his employer make or do? 
OR D I do not have a husband/partner 
19. Did you need any help in completing this questionnaire? If so, who helped and why? 
20. ,Is there anything else you would like to tell us about your heart condition or heart 
operation that is not covered in this questionnaire? If so, please write below. 
Please check that you have answered all the questions on each page. 
THANK YOU FOR YOUR HELP 
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APPENDIX 5.8 Letter of Invitation 2: 3-Month Post-Revascularisation 
(Preliminary Field Test) 
Official Hospital Letterhead 
Dear (Patient's Name) 
Re: Validation of a coronary revascularisation questionnaire 
Thank you for sending back the first questionnaire before you had your 
operation. It has now been approximately 3 months since your heart operation 
and we would be grateful if you could complete the enclosed questionnaire and 
return it, as soon as you possibly can, to Sara Schroter in the stamped 
addressed envelope provided. 
All the information we collect from you will remain confidential, and no individual 
will be named in any report. We hope you will be willing to help us in our effort 
to improve the service we offer to patients. Agreeing to take part in this study 
will not alter your treatment in any way. Similarly, if you do not wish to continue 
to take part, this will not alter your treatment in any way. 
Thank you for your continued help. If you have any queries please contact me 
on 0171 4365816. 
Yours sincerely 
Sara Schroter 
Enclosed: Coronary Revascularisation Outcome Questionnaire 
Patient Information Sheet 
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APPENDIX 5.9 Letter of Invitation 2: 3-Month Post-Revascularisation 
(Final Field Test) 
Official Hospital Letterhead 
Dear (Patient's Name) 
Re: Validation of a coronary revascularisation questionnaire 
Thank you for sending back the first questionnaire before you had your heart 
operation. This is the second in a series of three questionnaires which we will 
send you for this study. Approximately three months have passed since your 
operation and we would be grateful if you would complete the enclosed 
questionnaire and return it, as soon as you possibly can, to Sara Schroter in 
the stamped addressed envelope provided. We will be sending you the last 
questionnaire in three months time. 
All the information we collect from you will remain confidential, and no individual 
will be named in any report. We hope you will be willing to help us in our effort 
to improve the service we offer to patients. Taking part in this study will not 
alter your treatment in any way. Similarly, if you do not wish to continue to take 
part, this will not alter your treatment in any way. 
Thank you for your continued help. If you have any queries please contact me 
on 0171 4365816. 
Yours sincerely 
Sara Schroter 
Enclosed: Coronary Revascularisation Outcome Questionnaire 
Patient Information Sheet 
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APPENDIX 5.10 Letter of Invitation 3: 9-month Post-Revascularisation 
(Final Field Test) 
Official Hospital Letterhead 
Dear (Patient's Name) 
Re: Validation of a coronary revascularisation questionnaire 
This is the last in a series of three questionnaires which we have sent you for 
this study. Approximately nine months have passed since your operation and 
we would be grateful if you would complete the enclosed questionnaire and 
return it, as soon as you possibly can, to Sara Schroter in the stamped 
addressed envelope provided. Once you have sent back this questionnaire, 
that will be the end of your participation in this study. 
All the information we collect from you will remain confidential, and no individual 
will be named in any report. We hope you will be willing to help us in our effort 
to improve the service we offer to patients. Taking part in this study will not 
alter your treatment in any way. Similarly, if you do not wish to continue to take 
part, this will not alter your treatment in any way. 
Thank you for your continued help. If you have any queries please contact me 
on 0171 4365816. 
Yours sincerely 
Sara Schreter 
Enclosed: Coronary Revascularisation Outcome Questionnaire 
Patient Information Sheet 
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APPENDIX 5.11 3-Months Post-Revascularisation CROQ-CABG 
Questionnaire (Final Field Test) 
For Office Use Only 
Patient 10: Date of operation: ______ _ 
Hospital: Date received: 
CORONARY REVASCULARISATION OUTCOME QUESTIONNAIRE 
(CROQ-CABG) 
INSTRUCTIONS: We are interested in finding out how you have been since the heart 
operation (coronary artery bypass graft surgery) you had 3 months ago. We would be 
grateful if you could help us by filling out this questionnaire. All of the infonnation you 
provide is COMPLETELY CONFIDENTIAL. Please be sure to answer all questions. 
1. During the past 4 weeks, how much were you bothered by each of the following problems 
related to your heart condition? (Please tick one box on each line.) 
A lot Quite Moderately A Not at all 
a bit little 
2. During the past 4 weeks, on average, how many times have you taken nitros (nitroglycerin 
tablets or spray) for your chest pain, chest tightness or angina? (Please tick only one box.) 
D D D D D D 
4 or more 1-3 times 3 or more 1-2 times Less than None over 
times per day per day times per per week once a week the past 4 
week but not weeks 
every day 
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3. During the past 4 weeks, have you had chest pain, chest tightness or angina: 
(Please tick only one box.) 
D D 
At rest? On exertion? 
D 
At rest and on 
exertion? 
o 
Not at all? 
4. During the past 4 weeks, how much trouble has your heart condition caused you? 
(Please tick only one box.) 
o o o o o 
A lot Quite a bit Some A little None 
5. The following questions ask about activities which you might do during a typical day. During 
the past 4 weeks, has your heart condition limited you in your usual daily activities? Please 
indicate whether your heart condition limits you a lot, limits you a little, or does not limit you at 
all in the activities listed below. (Please tick one box on each line.) . 
ACTIVITIES 
Lifting or carrying groceries 
Climbing one flight of stairs 
Walking half a mile 
...... ';.:. :.:: .: 
Bathing or dressing yourself 
Yes, 
Limited A 
Lot 
o 
Yes, 
limited A 
Little 
o 
No, Not 
Limited At 
All 
.'.' ':',' :-" 
o 
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6. The next questions ask about the impact of your heart condition on your family and friends and 
the extent to which it has interfered with your social activities. During the past 4 weeks. how 
often have you experienced the following as a result of your heart condition: 
(Please tick one box on each line.) 
All 
of the 
time 
Most 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
!!11!1 l~i,{~~IIII~~~lii~I'~~~~i;;::1::;::!:::!::~:: 
Feeling worried about going too far from 
home? o o 
o 
o 
7. The next questions ask about your feelings about your heart condition. 
weeks, how often have you felt: (Please tick one box on each line.) 
All Most Some 
of the of the of the 
time time time 
o o 
o o 
During the past 4 
A little 
of the 
time 
D 
None 
of the 
time 
o 
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8. The next questions ask about problems related to your heart condition. During the past 4 
weeks, how much of the time did you: (Please tick one box on each line.) 
Forget, for example things that 
happened recently, where you put 
or 
All 
of the 
time 
D 
Most 
of the 
time 
D 
A good 
bit of 
the time 
D 
Some of 
the time 
D 
A little 
of the 
time 
D 
None 
of the 
time 
D 
9. Since your heart operation, have you been re-admitted to hospital for an overnight stay for any 
reason to do with your heart condition or heart operation? Please give as many details as 
you can below. 
D No 
DYes 
Date of 
Admission 
Name of 
hospital 
Reason for 
hospital stay 
Number of 
days 
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10. The next questions ask about problems you might have had since your heart operation. 
During the past 4 weeks, how much were you bothered by the following problems? If you did 
not have the problem, tick the last box "Not at all". (Please tick one box on each line.) 
A lot Quite a Moderately 
bit 
A little Not at all 
11. The next question asks about how satisfied you are with your heart operation. How satisfied 
are you with the: (Please tick one box on each line.) 
Very Somewhat Somewhat Very 
dissatisfied dissatisfied satisfied satisfied 
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12. Overall, how would you describe your heart condition now compared to before you had your 
heart operation? (Please tick one box.) 
D D D D D 
Much worse A little worse About the same A little better Much better 
13. Has your recovery from your heart operation so far been: (Please tick one box.) 
D D D D 
Slower than you 
expected? 
About what you 
expected? 
F aster than you 
expected? 
Did not know how 
long it would take? 
14. Are the results from your heart operation: (Please tick one box.) 
D 
Worse than you 
expected? 
o 
About what you 
expected? 
o 
Better than you 
expected? 
Finally, It would be very helpful If you could answer a few general questions about yourself. 
(Please tick the boxes that best describe your situation.) 
15. Are you: o Male 
o Female 
16. What is your date of birth? 
-Day Month Year 
17. Please fill in the date you completed this questionnaire: 
Month Year 
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18. To which ethnic group do you belong? 
0 \Nhite 0 Pakistani 
0 Black/Caribbean 0 Bangladeshi 
0 Black/African 0 Chinese 
0 Black/Other 0 Any other ethnic group 
0 Indian (please specify) 
19. Do you have any other long-standing illness, disability or infirmity? By long-standing I mean 
anything that has troubled you over a period of time, or that is likely to affect you over a period 
of time? 
o No 
o Yes (If yes, what is the matter with you?) 
20. Do you live: (You may tick more than one box.) 
o Alone? 
o With your husband I wife or partner? 
o With children? 
o With family members? 
o Other? (please specify) _______ _ 
21. Can you teU us approximately when you were first diagnosed as having heart disease? 
Year 
o I can not remember when I was first diagnosed 
22. \Nhat is your current work situation? 
o Employed I self-employed full-time 
o Employed I self-employed part-time 
o Voluntary work 
o Homemaker 
o Retired 
o Unable to work/disabled 
o Unemployed 
o Other (please specify) 
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23. What is (or was) your main occupation? 
Full job title: ___________ ---------------
What (did) you actually do in this job? 
What do (did) your employer make or do? ________________ _ 
OR 0 I do not work outside the home 
24. This question (Q24) is for women only: 
What is (or was) your husband's/partner's main occupation? 
Full job title: _________________________ _ 
What does (did) he actually do in this job? _______________ _ 
What does (did) his employer make or do? ________________ _ 
OR 0 I do not have a husband/partner 
25. This question asks about changes in your work situation after your heart operation. If you do 
not work outside the home, please put a tick in the first box. (Please tick one box only.) 
0 I do not work outside the home 
OR 0 I have stopped working 
OR 0 I returned to the same job with the same number of hours after weeks 
OR 0 I returned to the same job with reduced number of hours after weeks 
OR 0 I returned to a different job after weeks 
OR 0 I have not returned to work yet 
26. Did you need any help in completing this questionnaire? If so, who helped and why? 
27. Is there anything else you would like to tell us about your heart condition or heart operation 
that is not covered in this questionnaire? If so, please write below. 
Please check that you have answered all the questions on each page. 
THANK YOU FOR YOUR HELP 
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APPENDIX 5.12 3-Months Post-Revascularisation CROQ-PTCA 
Questionnaire (Final Field Test) 
For Office Use Only 
Patient 10: Date of operation: ______ _ 
Hospital: Date received: 
CORONARY REVASCULARISATION OUTCOME QUESTIONNAIRE 
(CROQ-PTCA) 
INSTRUCTIONS: We are interested in finding out how you have been since the heart 
operation (percutaneous transluminal coronary angioplasty) you had 3 months ago. 
We would be grateful if you could help us by filling out this questionnaire. All of the 
information you provide is COMPLETELY CONFIDENTIAL. Please be sure to answer all 
questions. 
1. During the past 4 weeks, how much were you bothered by each of the following problems 
related to your heart condition? (Please tick one box on each line.) 
A lot Quite Moderately A Not at all 
a bit little 
2. During the past 4 weeks, on average, how many times have you taken nitros (nitroglycerin 
tablets or spray) for your chest pain, chest tightness or angina? (Please tick only one box.) 
0 D 0 D D 0 
4 or more 1-3 times 3 or more 1-2 times Less than None over 
times per day per day times per per week once a week the past 4 
week but not weeks 
every day 
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3. During the past 4 weeks, have you had chest pain, chest tightness or angina: 
(Please tick only one box.) 
o o 
At rest? On exertion? 
o 
At rest and on 
exertion? 
o 
Not at all? 
4. During the past 4 weeks, how much trouble has your heart condition caused you? 
(Please tick only one box.) 
o o o o o 
A lot Quite a bit Some A little None 
5. The following questions ask about activities which you might do during a typical day. During 
the past 4 weeks, has your heart condition limited you in your usual daily activities? Please 
indicate whether your heart condition limits you a lot, limits you a little, or does not limit you at 
all in the activities listed below. (Please tick one box on each line.) 
ACTIVITIES 
Bathing or dressing yourself 
Yes, 
Limited A 
Lot 
.: .... ,' " 
o 
o 
Yes, 
Limited A 
Little 
. " ~" 
o 
No, Not 
Limited At 
All 
o 
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6. The next questions ask about the impact of your heart condition on your family and friends and 
the extent to which it has interfered with your social activities. During the past 4 weeks, how 
often have you experienced the following as a result of your heart condition: 
(Please tick one box on each line.) 
Feeling like you are a burden on others? 
Feeling worried about going too far from 
home? 
All 
of the 
time 
D 
D 
Most 
of the 
time 
D 
D 
Some 
of the 
time 
D 
D 
A little 
of the 
time 
D 
D 
None 
of the 
time 
o 
7. The next questions ask about your feelings about your heart condition. During the past 4 
weeks, how often have you felt: (Please tick one box on each line.) 
All Most Some A little 
of the of the of the of the 
time time time time 
~:-~;~jr;~:~]~~i~~;~iiIBi:~ll1~iii.~I~II[~r~~11~,i!i~I~·';~~l;:~I]ll~rl[lf(~i~~~~ r;~:]~III]ll:~: 
None 
of the 
time 
That it was difficult to keep a positive DOD D 0 
outlook about your health? 
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8. The next questions ask about problems related to your heart condition. During the past 4 
weeks, how much of the time did you: (Please tick one box on each line.) 
All Most A good Some of A little None 
of the of the bit of the time of the of the 
time time the time time time 
:~ :~~ ;~ ':':: ':":.:~: ~:, ;;;:::::=. 
}!:[] 
D D D 
9. Since your heart operation, have you been re-admitted to hospital for an overnight stay for any 
reason to do with your heart condition or heart operation? Please give as many details as 
you can below. 
D No 
DYes 
Date of 
Admission 
Name of 
hospital 
Reason for 
hospital stay 
Number of 
days 
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10. The next questions ask about problems you might have had since your heart operation. 
<. 
During the past 4 weeks, how much were you bothered by the following problems? If you did 
not have the problem, tick the last box "Not at all". (Please tick one box on each line.) 
Tenderness around your groin 
wound 
Concern over the appearance of 
your bruises 
A lot 
D 
D 
Quite a Moderately 
bit 
D D 
D D 
A little Not at all 
;"';.:.: 
" .. 
.:," 0 
D D 
D D 
11. The next question asks about how satisfied you are with your heart operation. How satisfied 
are you with the: (Please tick one box on each line.) 
Very Somewhat Somewhat Very 
dissatisfied dissatisfied satisfied satisfied 
12. Overall, how would you describe your heart condition now compared to before you had your 
heart operation? (Please tick one box.) 
D D D D D 
Much worse A little worse About the same A little better Much better 
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13. Has your recovery from your heart operation so far been: (Please tick one box.) 
D D D D 
Slower than you 
expected? 
About what you 
expected? 
Faster than you 
expected? 
Did not know how 
long it would take? 
14. Are the results from your heart operation: (Please tick one box.) 
D 
Worse than you 
expected? 
D 
About what you 
expected? 
D 
Better than you 
expected? 
Finally. It would be very helpful If you could answer a few general questions about yourself. 
(Please tick the boxes that best describe your situation.) 
15. Are you: o Male 
o Female 
16. What is your date of birth? 
Day Month Year 
17. Please fill in the date you completed this questionnaire: 
Day Month Year 
18. To which ethnic group do you belong? 
0 White 0 Pakistani 
0 Black/Caribbean 0 Bangladeshi 
0 Black/African 0 Chinese 
0 Black/Other 0 Any other ethnic group 
0 Indian (please specify) 
Copyright: London School of Hygiene & Tropicsl Medicine, 1999 (do not use wIlhout permisSion). 
495 
/ 
19. Do you have any other long-standing illness, disability or infirmity? By long-standing I mean 
anything that has troubled you over a period of time, or that is likely to affect you over a period 
of time? 
o No 
o Yes (If yes, what is the matter with you?) 
20. Do you live: (You may tick more than one box.) 
o Alone? 
o With your husband I wife or partner? 
o With children? 
o With family members? 
o Other? (please specify) _______ _ 
21. Can you tell us approximately when you were first diagnosed as having heart disease? 
Month Year 
o I can not remember when I was first diagnosed 
22. What is your current work situation? 
o Employed I self-employed full-time 
o Employed I self-employed part-time 
o Voluntary work 
o Homemaker 
23. What is (or was) your IDIiD occupation? 
D Retired 
D Unable to work/disabled 
D Unemployed 
D Other (please specjfy) 
Full job title: ________________________ _ 
What (did) you actually do in this job? 
What do (did) your employer make or do? _______________ _ 
OR 0 I do not work outside the home 
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24. This question (Q24) is for women only: 
What is (or was) your husband's/partner's main occupation? 
Full job title: _________________________ _ 
What does (did) he actually do in this job? _______________ _ 
What does (did) his employer make or do? _______________ _ 
OR D· I do not have a husband/partner 
25. This question asks about changes in your work situation after your heart operation. If you do 
not work outside the home, please put a tick in the first box. (Please tick one box only.) 
0 I do not work outside the home 
OR 0 I have stopped working 
OR 0 I returned to the same Job with the same number of hours after weeks 
OR 0 I returned to the same job with reduced number of hours after weeks 
OR 0 I returned to a different Job after weeks 
OR 0 I have not returned to work yet 
26. Did you need any help in completing this questionnaire? If so, who helped and why? 
27. Is there anything else you would like to tell us about your heart condition or heart operation 
that is not covered in this questionnaire? If so, please write below. 
Please check that you have answered all the questions on each page. 
THANK YOU FOR YOUR HELP 
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APPENDIX 5.13 Patient Information Sheet 2: 
3-Months Post-Revascularisation (Preliminary Field Test) 
Official Hospital Letterhead 
Patient Information Sheet 2 
The purpose of this study is to develop a new questionnaire to evaluate 
patients' views of coronary revascularisation (coronary artery bypass graft 
surgery and coronary angioplasty). This study is being undertaken by (name of 
hospital) in collaboration with researchers at the London School of Hygiene and 
Tropical Medicine. 
We sent you a questionnaire before you had your heart operation and we 
notified you at the time that we would send you another. Approximately three 
months have passed since your operation and we are interested in how you are 
feeling now. The enclosed questionnaire asks about the impact your heart 
operation has had on your day-to-day life and includes questions about 
symptoms, quality of life, and satisfaction with treatment. 
It is important that we have your opinions to ensure that the results of our study 
will represent the views of all patients who have undergone coronary 
revascularisation. The questionnaire will be used in making recommendations 
for improving care provided to cardiac patients. 
Taking part in this study is entirely voluntary. Whether you decide to take part 
or not will not in any way affect the way you are treated. All the information you 
give will be completely confidential. In order to protect your privacy, a 
confidential study number rather than your name will be used on all 
questionnaire forms. These forms will be kept in locked research files which are 
only accessible to the research staff. None of the information you give will be 
available to any of the hospital staff, including doctors, nurses, and technicians, 
who provide the clinical care associated with your treatment. 
We hope that you will agree to complete this questionnaire and we would like to 
thank you in advance for helping us in partiCipating in this study. If you have 
any queries please contact our Project Co-ordinator, Sara Schroter, on 0171 
4365816. 
Research Team: 
Dr Donna Lamping (Principal Investigator) 
Miss Sara Schroter (Project Co-ordinator) 
Health Services Research Unit, London School of Hygiene & Tropical Medicine 
Consultant Cardiothoracic Surgeons I Cardiologists: 
Names of partiCipating consultants 
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APPENDIX 5.14 Patient Information Sheet 2: 
3-Months Post-Revascularisation (Final Field Test) 
Official Hospital Letterhead 
Patient Information Sheet 2 
The purpose of this research project is to develop a new questionnaire to 
evaluate patients' views of coronary revascularisation (coronary artery bypass 
graft surgery and coronary angioplasty). This study is being undertaken by 
(name of hospital) in collaboration with researchers at the London School of 
Hygiene and Tropical Medicine. . 
This is the second in a series of three questionnaires which we have sent you 
as part of this study. Approximately three months have passed since your 
operation and we are interested in how you are feeling now. The enclosed 
questionnaire asks about the impact your heart operation has had on your day-
to-day life and asks about how you are feeling physically and emotionally. You 
will notice some repeated questions in Section 2. This is intentional as we are 
comparing the performance of two different questionnaires - so please answer 
every question. We will also be sending you this questionnaire nine months 
after the date of your operation. 
The questionnaires will be used in making recommendations for improving care 
provided to cardiac patients. Taking part in this study is entirely voluntary. 
Whether you decide to take part or not will not in any way affect the way you are 
treated. All the information you give will be completely confidential. In order to 
protect your privacy, a confidential study number rather than your name will be 
used on all questionnaire forms. These forms will be kept in locked research 
files which are only accessible to the research staff. None of the information 
you give will be available to any of the hospital staff, including doctors, nurses, 
and technicians, who provide the clinical care associated with your treatment. 
We hope that you will agree to complete this questionnaire and we would like to 
thank you in advance for helping us in participating in this study. If you have 
any queries please contact our Project Co-ordinator, Sara Schroter, on 0171 
4365816. 
Research Team: 
Dr Donna Lamping (Principal Investigator) 
Miss Sara Schroter (Project Co-ordinator) 
Health Services Research Unit, London School of Hygiene & Tropical Medicine 
Consultant Cardiothoraclc Surgeons I Cardiologists: 
Names of partiCipating consultants 
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APPENDIX 5.15 Patient Information Sheet 3: 
9-Months Post-Revascularisation (Final Field Test) 
Official Hospital Letterhead 
Patient Information Sheet 3 
The purpose of this research project is to develop a new questionnaire to 
evaluate patients' views of coronary revascularisation (coronary artery bypass 
graft surgery and coronary angioplasty). This study is being undertaken by 
(name of hospital) in collaboration with researchers at the London School of 
Hygiene and Tropical Medicine. 
This is the last in a series of. three questionnaires, which we have sent you as 
part of this study. Approximately nine months have passed since your 
operation and we are interested in how you are feeling now. The enclosed 
questionnaire asks about the impact your heart operation has had on your day-
to-day life and asks about how you are feeling physically and emotionally. You 
will notice some repeated questions in Section 2. This is intentional as we are 
comparing the performance of two different questionnaires - so please answer 
every question. Once you have sent back this questionnaire, that will be the 
end of your partiCipation in this study. 
The questionnaires will be used in making recommendations for improving care 
provided to cardiac patients. Taking part in this study is entirely voluntary. 
Whether you decide to take part or not will not in any way affect the way you are 
treated. All the information you give will be completely confidential. In order to 
protect your privacy, a confidential study number rather than your name will be 
used on all questionnaire forms. These forms will be kept in locked research 
files, which are only accessible to the research staff. None of the information 
you give will be available to any of the hospital staff, including doctors, nurses, 
and technicians, who provide the clinical care associated with your treatment. 
We hope that you will agree to complete this questionnaire and we would like to 
thank you in advance for helping us in participating in this study. If you have 
any queries please contact our Project Co-ordinator, Sara Schroter, on 0171 
4365816. 
Research Team: 
Dr Donna Lamping (Principal Investigator) 
Miss Sara Schroter (Project Co-ordinator) 
Health Services Research Unit, London School of Hygiene & Tropical Medicine 
Consultant Cardiothoracic Surgeons I Cardiologists: 
Names of partiCipating consultants 
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APPENDIX 5.16 Letter of Invitation: 3-Months Post·Revascularisation 
Only (Preliminary and Final Field Tests) 
.~ 
Official Hospital Letterhead 
Dear (Patient's Name) 
Re: Validation of a coronary revascularisation questionnaire 
We are inviting you to take part ina research project. This hospital is developing 
a short questionnaire to help in evaluating the outcome of coronary 
revascularisation (coronary artery bypass graft surgery and coronary angioplasty). 
It has now been three months since your heart operation and we would be grateful 
if you would complete the enclosed questionnaire. 
All the information we collect from you will remain confidential, and no individual 
will be named in any report. Agreeing to take part in this study will not alter your 
treatment in any way. Similarly, if you do not wish to take part, this will not alter 
your treatment in any way. . 
The enclosed patient information sheet provides details about the study. If you 
are willing to take part, please sign the enclosed consent form and retum it with 
your completed questionnaire, as soon as you possibly can, to Sara Schroter in 
the stamped addressed envelope provided. 
Thank you for your help. If you have any queries please contact our Project Co-
ordinator Sara Schroter on 0171 4365816. 
Yours sincerely 
Consultant Cardiothoracic Surgeon I Cardiologist 
Enclosed: Coronary Revascularisation Questionnaire 
Patient Information Sheet 
Patient Consent Form 
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APPENDIX 5.17 Patient Information Sheet: 3-Month Post-
Revascularisation Only (Preliminary and Final Field Tests) 
Official Hospital Letterhead 
Patient Information Sheet 
The purpose of this study is to develop a new questionnaire to evaluate 
patients' views of coronary revascularisation (coronary artery bypass graft 
surgery and coronary angioplasty). This study is being undertaken by (name of 
hospital) in collaboration with researchers at the London School of Hygiene and 
Tropical Medicine. 
It has now been three months since your heart operation and we are inviting 
you and other patients who have had coronary revascularisation at the (name of 
hospital) to help us by completing the enclosed questionnaire. . The 
questionnaire asks about how you are feeling, physically and emotionally, and 
about your ability to carry out daily activities, and your satisfaction with the 
treatment. 
It is important that we have your opinions to ensure that the results of our study 
will represent the views of all patients who have had these operations. The 
questionnaire will be used in making recommendations for improving care 
provided to cardiac patients. 
Taking part in this study is entirely voluntary. Whether you decide to take part 
or not will not in any way affect the way you are treated. All the information you 
give will be completely confidential. In order to protect your privacy, a 
confidential study number rather than your name will be used on all 
questionnaire forms. These forms will be kept in locked research files which are 
only accessible to the research staff. None of the information you give will be 
available to any of the hospital staff, including doctors, nurses, and technicians, 
who provide the clinical care associated with your treatment. 
We hope that you will agree to complete this questionnaire and we would like to 
thank you in advance for helping us in participating in this study. If you have 
any queries please contact our Project Co-ordinator, Sara Schroter, on 0171 
4365816. 
Research Team: 
Dr Donna Lamping (Principal Investigator) 
Miss Sara Schroter (Project Co-ordinator) 
Health Services Research Unit, London School of Hygiene & Tropical Medicine 
Consultant Cardiothoracic Surgeons I Cardiologists: 
Names of participating consultants 
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APPENDIX 5.18 Patient Consent Form: 3 Months Post-Revascularisation 
Only (Preliminary and Final Field Tests) 
PATIENT CONSENT FORM 
TITLE OF PROJECT: 
Validation of a patient-based measure of outcome for patients undergoing 
coronary revascularisation. 
EXPLANATION OF PROJECT: 
Invitation: This hospital is developing a questionnaire to help us understand better 
how you are feeling after your heart operation (coronary artery bypass graft 
surgery and coronary angioplasty). We are asking you to take part in our 
research by filling in the enclosed questionnaire. The questionnaire asks about 
how you are feeling, physically and emotionally, and about your ability to carry 
out daily activities, and about your health in general. 
All the information you give during the study will be completely confidential. In 
order to protect your privacy, a confidential study number rather than your name 
will be used on the questionnaires. These questionnaires will be kept in locked 
research files which only the research staff will have access to. None of the 
information you give will be available to any of the hospital staff, including 
doctors, nurses, and technicians, who provide the clinical care associated with 
your treatment. 
This study is being undertaken by a research team at the London School of 
Hygiene and Tropical Medicine in collaboration with (name and hospital of 
leading collaborating consultants). Please understand that you need not take 
part in this study if you do not wish to. If you do take part, you may withdraw at 
any time, and need give no reason for doing so. If you choose not to take part, 
or if you withdraw, your normal care and treatment will be unaffected. 
Signed by the person in charge of the Project __________ Date __ _ 
The Ethics Committee of the (name of hospitaO has approved the above statement. 
Signed by the Chairman/Representative of the Committee 
_________________________________________ Dme _______ _ 
FORM OF CONSENT 
I, of~--:---~-------
agree to take part in the research project outline above. I understand the nature and purpose of 
the questionnaire, and that I may withdraw from the research without it affecting my care and 
treatment at this hospital in any way. 
Signed ________________________ Date _____ _ 
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APPENDIX 5.19 3-Week Reminder Letter: 3-Months Post-
Revascularisation 
(Preliminary and Final Field Tests) 
Official Hospital Letterhead 
Dear (Patient's Name) 
Re: Validation of a coronary revascularisation questionnaire 
Three weeks ago, we sent you a package consisting of a questionnaire and the 
letter reproduced below. In case this has gone astray, we are taking the 
opportunity of sending you another questionnaire, as your information would be of 
great help to us, and eventually to other patients. If you have already completed 
and returned the questionnaire to us, please accept our thanks. 
Approximately three months have passed since your operation and we would 
be grateful if you would complete the enclosed questionnaire and return it, as 
soon as you possibly can, to Sara Schroter in the stamped addressed 
envelope provided. 
All the information we collect from you will remain confidential, and no individual 
will be named in any report. We hope you will be willing to help us in our effort 
to improve the service we offer to patients. Taking part in this study will not 
alter your treatment in any way. Similarly, if you do not wish to continue to take 
part, this will not alter your treatment in any way. 
Thank you for your help. If you have any queries please contact me on 0171 
4365816. 
Yours sincerely 
Sara Schroter 
Project Co-ordinator 
Enclosed: Coronary RevascuJarisation Outcome Questionnaire 
Patient Information Sheet 
Patient Consent Form 
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APPENDIX 5.20 5-Week Reminder Letter: 3·Months Post-Revascularisation 
(Preliminary and Final Field Tests) 
Official Hospital Letterhead 
Dear (Patient's Name) 
Re: Validation of a coronary revascularisation questionnaire 
Five weeks ago, we sent you a questionnaire asking you about the state of your 
health following your heart operation (coronary artery bypass graft surgery· or 
coronary angioplasty). We then sent you a duplicate questionnaire three weeks 
ago, in case the first package had gone astray. We do not seem to have 
received either of them back, so we are taking this opportunity to remind you 
once more. Your information would be of great help to us, and eventually to 
other patients. 
If you have already completed and retumed the questionnaire to us, please accept 
our thanks. If you have still to do so, could we please ask you to complete it as 
soon as you can. 
If by some chance you did not receive the questionnaire, or it has been misplaced, 
please telephone me on 0171 436 5816 and I will send you another copy of the 
questionnaire. . 
Thank you for your co-operation. 
Yours sincerely 
Sara Schroter 
Project Co-ordinator 
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Scale 
Symptoms 
Physical Functioning 
Psychosocial 
Functioning 
Cognitive Functioning 
Satisfaction 
I ( 
\ 
Complications (CROO-
CABG) 
Complications (CROO-
PTCA) 
Core Total 
Total Outcome 
(CROQ-CABG) 
8 
APPENDIX 5.21 Formulae for Scoring and Transforming the eRDQ 
Number of 
items in 
scale 
7 
8 
14 
3 
6 
11 
6 
32 
18 
Item 
Q1a + Q1b +Q1c + Q1d + 
Q1e+Q2+Q4 
Q5a + Q5b + Q5c + Q5d + 
Q5e + Q5f + Q5g + Q5h 
Q6a + Q6b + Q6c + Q6d + 
Q7a + Q7b + Q7c + Q7e + 
Q7f + Q7g + Q7h + Q7i + 
Q7k 
Q8a + Q8b + Q8c 
Q11a + Q11b + Q11c + 
Q12 + Q13 + Q14 
Q10a + Q10b + Q10c + 
Q10d + Q10e + Q10f + 
Q10g + Q10h Q10i + Q10j 
+Q10k 
Q10a + Q10b + Q10c + 
Q10d + Q10e + Q10f 
Q1a + Q1b +Q1c + Q1d + 
Q1e+ Q2 + Q4 +Q5a + 
Q5b + QSc + Q5d + Q5e + 
Q5f + Q5g + QSh + Q6a + 
Q6b + Q6c + Q6d + Q7a + 
Q7b + Q7c + Q7e + Q7f+ 
Q7g+ Q7h + Q7i +Q7k+ 
Q8a + Q8b + Q8c 
Q11a + Q11b + Q11c + 
Q12 + Q13 + Q14 + Q10a 
+ Q10b + Q10c + Q10d + 
Q10e + Q10f + Q10g + 
Q10h Q10i + Q10j + Q10k 
+Q7d 
Item recalibration 
Q2: (1=1) (2=1.66) (3=2.50) (4=3.33) (5=4.16) (6=5) 
Qi2: (1=1) (2=1.75) (3=2.50) (4=3.25) (5=4). 
Qi3: (4=missing) (1=1) (2=2.5) (3=4). 
Q14: (1=1)(2=2.5)(3=4). 
Lowest and 
highest possible 
raw scores for 
scale 
7, 35 
8, 24 
14, 70 
3, 18 
6,24 
11,55 
6, 30 
Possible raw 
score range for 
scale 
28 
16 
56 
15 
18 
44 
24 
01 
~ 
Scale 
Total Outcome 
(CROQ-PTCA) 
Number of 
items in 
scale 
13 
Item 
Q11a + Q11b + Q11c + 
Q12 + Q13 + Q14 + Q10a 
+ Q10b + Q10c + Q10d + 
Q10e + Q10f + Q7d 
Fonnula for transfonnation of raw scale scores: 
Item recalibration 
Transformed scale = \ (actual raw score -lowest possible raw score range) X 100 
possible raw score range 
Fonnula for transfonnation of raw item scores to z-scores: 
Zscore= X-X 
so 
Fonnula for transfonnation of z-scores to f-scores: 
(T= 50+ 10z) 
Lowest and 
highest possible 
raw scores for 
scale 
Possible raw 
score range for 
scale 
APPENDIX 6.1a Item Descriptive Statistics: CROQ-CABG Pre-Revascularisation (Preliminary Field Test) 
% missing Endorsement frequencies by response category % Item-total correlation 
Item data 1 2 3 4 5 6 Mean (SO) n r 
Chest pain 0.7 18.5 20.5 19.928.1 12.3 2.95(1.3) 146 .73 
Chest discomfort 0.7 13.7 28.1 23.3 23.3 11.0 2.93 (1.3) 146 .75 
Shortness of breath 0.7 17.8 26.0 25.3 21.9 8.2 2.77 (1.2) 146 .55 
Radiating pain 1.4 13.0 15.8 20.5 28.8 20.5 3.28 (1.3) 146 .61 
Palpitations 2.1 3.4 14.4 17.1 26.0 37.0 3.80 (1.2) 146 .60 
Nitroglycerin 0.0 13.0 20.5 23.3 10.3 9.6 23.3 3.53 (1.8) 146 .58 
Trouble 0.0 16.4 37.7 24.0 17.8 4.1 2.55 (1.1) 146 .76 
Moderate activities 3.4· 37.0 43.8 ·-fO:S-- - - 1.78 (O.7) 143 .71 
Ufting & carrying 3.4 32.2 42.5 21.9 1.89 (O.7) 143 .82 
Climbing lIigh1s of stairs i 2.7 61.6 28.8 6.8 1.44 (0.6) 
Climbing one ftight of stairs 2.7 22.6 47.9 26.7 2.04 (O.7) 
143 .68 
143 .78 
Bending, keeling, stooping 2.1 21.2 39.0 37.7 2.17(0.8) 143 .70 
Walk half a mile 5.0 46.0 28.1 21.9 1.76 (0.8) 143 .72 
Walk 100 yards 2.7 20.5 33.6 432 2.23 (O.8) 143 .71 
Bathing or dressing 2.1 13.7 26.7 57.5 _2.45(0.7) 143 .68 
Reason 0.7 2.7-10:3--10~3-- - 21.9 16.4 37.7 4.53 (1.5) 146 .75 
Forget 0.0 4.1 8.2 10.3 26.0 19.2 32.2 4.45 (1.5) 146 .78 
Concentration 0.0 4.1 6.8 11.6 24.7 19.9 32.9 4.48 (1.4) 146 .77 
Worry hearCcondi1ion 0.0·21.2 21.2 39.0 12.3 6.2 2.61 (1.1) 146 .77 
Over-doingit 0.0 17.8 24.7 342 15.8 7.5 2.71 (1.2) 146 .59 
Heart attack 0.0 15.8 11.0 26.0 28.1 19.2 3.24 (1.3) 146 .63 
Frightened by pain 0.0 13.0 14.4 31.5 26.0 15.1 3.16(1.2) 146 .77 
Uncertain 2.1 10.3 26.7 21.9 27.4 11.6 3.04 (1.2) 146 .78 
Depressed 0.7 7.5 11.0 29.5 23.3 28.1 3.54 01.2 146 .70 
Frustrated 0.0 14.4 18.5 30.1 25.3 11.6 3.01 (1.2) 146 .58 
Interfered with enjoyment 0.0 32.9 22.6 28.8 9.6 6.2 2.34 (1.2) 
Positive outlook 0.0 10.3 28.8 27.4 212 12.3 2.97 (12) 
146 .69 
146 .70 
Difficult to plan 0.0 342 26.0 24.0 8.9 6.8 2.28 (1.2) 
Family overprotective 0.7 10.3 18.5 28.8 21.9 19.9 323 (1.3) 
Feeling a burden 1.4 4.8 17.8 21.9 24.7 29.5 3.57 (1.2) 
Restricted in social activities 0.7 14.4 21.2 21.9 16.4 25.3 3.17 (1.4) 
146 .61 
146 .56 
146 .63 
146 .73 
Too far from home 0.7 17.1 15.8 21.9 13.7 30.8 3.26 (1.5) 146 .67 
~ 
APPENDIX 6.1b Item Descriptive Statistics: CROQ-PTCA Pre-Revascularisation (Preliminary Field Test) 
% missing Endorsement frequencies by response category % Item-total correlation 
Item data 1 2 3 4 5 6 Mean (SO) n r 
Chest pain 3.9 8.8 25.8 26.6 20.3 14.8 3.07 (1.2) 128 .75 
Chest discomfort 3.9 11.7 23.4 26.6 22.7 11.7 3.18(1.3) 128 .75 
Shortness of breath 0.0 25.8 27.3 14.1 21.9 10.9 2.65 (1.4) 128 .62 
Radiating pain 0.8 13.3 25.0 15.6 26.6 18.8 3.13(1.4) 128 .65 
Palpitations 3.1 3.9 10.9 21.1 24.2 26.7 3.81 (1.2) 128 .53 
Nitroglycerin 0.0 9.4 17.2 25.0 10.9 12.5 25.0 3.75 (1.7) 128 .58 
Trouble 0.0 14.8 32.0 26.6 15.6 10.9 2.76 (1.2) 128 .80 
Moderate activities 1.6 27.3 52.3 18.8 1.91 (0.7) 128 .71 
Uffing & carrying 4.7 28.1 44.5 22.7 1.94 (0.7) 128 .70 
Climbing ligh1s of stairs ! 3.1 56.3 30.5 10.2 1.52 (0.7) 128 .65 
Climbing one light of stairs 1.6 18.8 45.3 34.4 2.16 (0.7) 128 .78 
Bending, keeling, stooping 1.6 17.2 41.4 39.8 223 (0.7) 128 .60 
Walk half a mile 3.9 35.2 35.9 25.0 1.89 (0.8) 128 .73 
Walk 100 yards 2.3 11.7 37.5 48.4 2.38 (0.7) 128 .67 
Bathin9 or dressing 1.6 6.3 31.3 60.9 2.56 (0.6) 128 .61 
Reason 1.6 3.9 8.6 13.3 18.8 18.8 35.2 4.48 (1.5) 126 .79 
Forget 0.8 6.3 8.6 10.9 20.3 19.5 33.6 4.40 (1.6) 126 .72 
, Concentration 1.6 3.9 9.4 10.2 19.5 14.1 41.4 4.57 (1.5) 126 .82 
Worry heart condition 0.0 18.0 19.5 36.7 18.8 7.0 2.77 (1.2) 127 .81 
Over-doing it 0.0 14.8 23.4 31.3 18.0 12.5 2.90 (1.2) 127 .77 
Heart attack 2.3 13.3 7.8 26.6 26.6 23.4 3.40 (1.3) 127 .73 
Frightened by pain 0.0 11.7 14.1 24.2 29.7 20.3 3.33 (1.3) 127 .75 
Uncertain 0.8 11.7 14.8 28.9 32.8 10.9 3.17 (1.2) 127 .80 
Depressed 0.8 7.8 10.9 27.3 25.8 27.3 3.54 (1.2) 127 .65 
Frustrated 0.8 12.5 14.1 35.9 21.9 14.8 3.13 (1.2) 127 .62 
Interfered with enjoyment 1.6 22.7 25.0 24.2 16.4 10.2 2.66 (1.3) 127 .73 
Positive outlook 3.1 12.5 23.4 22.7 24.2 14.1 3.04 (1.3) 127 .85 
Difficult to plan 1.6 26.6 20.3 22.7 17.2 11.7 2.67 (1.4) 127 .74 
Family overprotective 1.6 8.6 14.8 25.0 29.7 20.3 3.39 (1.2) 127 .52 
Feeling a burden 0.8 5.5 10.2 25.0 18.0 40.6 3.79 (1.2) 127 .72 
Restricted in social activities 1.6 10.2 17.2 21.1 25.0 25.0 3.38 (1.3) 127 .74 
Too far from home 0.8 13.3 12.5 18.8 19.5 35.2 3.51 (1.4) 127 .71 
at 
0 
<0 
APPENDIX 6.2a Item Descriptive Statistics: CROQ-CABG Post-Revascularisation (Preliminary Field Test) 
% missing Endorsement frequencies by response categOry%-- item-total correlation 
Item data 1 2 3 4 5 6 Mean (SO) n r 
Chest pain 1.4 1.7 3.5 3.1 10.7 79.6 4.65(0.8) 286 .73 
Chest discomfort 3.1 2.1 3.5 3.1 12.1 76.1 4.62 (0.9) 286 .73 
Shortness of breath 2.8 6.9 10.0 10.7 36.7 32.9 3.81 (1.2) 286 .54 
Radiating pain 2.4 1.4 52 5.5 12.1 73.4 4.55 (0.9) 286 .58 
Palpitations 4.5 2.8 4.8 11.1 27.0 49.8 4.22 (1.0) 286 .54 
Nitroglycerin 2.1 0.0 1.4 2.4 2.4 4.5 87.2 5.77 (0.7) 286 .55 
Trouble 1.4 2.1 5.9 9.7 34.3 46.7 4.19 (1.0) 286 .60 
Moderate activities 2.8 13.8 43.9 39.4 ._----- 2.26 (0.7) 284 .67 
Ufting & canying 3.5 11.8 41.9 42.9 2.32 (0.7) 284 .66 
Climbing flights of stairs ~ 3.8 17.0 40.5 38.8 2.23 (0.7) 284 .64 
Climbing one flight ofstairs 3.8 4.2 20.4 71.6 2.70 (0.5) 284 .73 
Bending, keeling, stooping 2.4 8.0 33.2 56.4 2.50 (0.6) 284 .54 
Walk haifa mile 4.2 11.1 13.1 71.6 2.63 (0.7) 284 .71 
Walk 100 yards 3.8 4.2 9.0 83.0 2.82 (0.5) 284 .69 
Bathing or dressing 1.4 3.5 12.5 82.7 2.80 (0.5) 284 .61 
Reason . -~ ----U-. 2.1 4.5 ·7.6 13.5 20.1 50.9 5.00(1.3) 287 .84 
Forget 0.7 3.5 4.5 7.619.0 21.8 42.9 4.81 (1.4) 287 .80 
Concentration 0.7 1.4 6.2 7.6 13.5 23.5 47.1 4.94(1.3) 287 .82 
WorryheartconcJitjon 0.7 3.8 6.2 21.1 34.3 33.9 3.89 (1.1) 287 .69 
Over-doingit 1.7 3.8 11.1 28.7 36.7 18.0 3.55(1.0) 287 .69 
Heart attack 1.0 2.1 2.4 12.1 21.1 61.2 4.38(0.9) 287 .60 
Frightened by pain 1.0 1.0 3.1 13.5 21.8 59.5 4.37 (0.9) 287 .65 
Uncertain 1.0 3.5 6.2 12.5 33.2 43.6 4.08 (1.1) 287 .77 
Depressed 1.0 3.1 4.2 15.9 30.1 45.7 4.12 (1.0) 287 .72 
Frustrated 1.0 5.5 8.0 23.5 31.1 30.8 3.74 (1.2) 287 .74 
Interfered with enjoyment 1.7 2.8 9.3 19.4 27.0 39.8 3.93 (1.1) 287 ' .78 
Positive outlook 1.4 1.4 8.0 15.2 31.5 42.6 4.07 (1.0) 287 .85 
Difficu!ttoplan 1.7 3.8 9.7 17.0 22.1 45.7 3.98(1.2) 2287 .76 
Family overprotective 1.0 3.8 10.7 21.5 34.3 28.7 3.74 (1.1) 287 .42 
Feeling a burden 0.7 2.1 5.9 17.6 25.6 48.1 4.13 (1.0) 287 .67 
Restricted in social activities 1.0 2.1 7.6 15.2 18.7 55.4 4.19 (1.1) 287 .69 
Too farftom home 1.0 3.8 6.9 12.1 15.9 60.2 4.23(1.1) 287 .70 
en 
..... 
o 
U'I 
..". 
..". 
% missing Endorsement frequencies by response category % 
Item data 1 2 3 4 5 6 Mean (SO) 
Pain in chest wound 0.7 5.2 6.9 17.6 32.9 36.7 3.90 (1.1) 
Infection in chest wound 1.4 2.4 1.7 1.4 6.2 86.9 4.76 (0.8) 
Tender chest wound 0.7 6.2 12.1 15.2 44.6 21.1 3.63 (1.1) 
Numb chest wound 1.7 5.5 8.3 15.6 32.2 36.7 3.88 (1.2) 
Bruising on chest \ 2.1 1.4 3.8 3.1 14.2 75.4 4.62 (0.8) 
Pain leg wound 3.1 6.9 6.2 13.8 25.3 44.6 3.98 (12) 
Other pain in leg 3.5 3.8 5.2 5.9 15.2 66.4 4.40 (1.1) 
Infection in leg wound 1.4 3.5 3.5 4.8 4.8 82.0 4.61 (1.0) 
Numb leg 1.0 8.0 12.1 15.9 31.5 31.5 3.67 (1.3) 
Bruising on leg 1.7 2.8 3.8 8.0 16.6 67.1 4.44(1.0) 
Swollen feet . ___ 0.3 9.7 9.0 17.6 26.0 37.4 3.73 (1.3) 
Satisfied with results 1.7 1.4 3.8 14.9 78.2 3.73 (0.6) 
Satisfied with info about op 1.0 1.4 6.9 14.5 76.1 3.67 (0.7) 
Satisfied with recovery info 1.0 2.8 8.7 20.4 67.1 3.54(0.8) 
Overall compared to before op 0.7 2.1 0.7 3.1 14.2 79.2 4.69(0.8) 
Speed of recovery 0.3 21.8 31.1 28.7 18.0 2.08 (0.8) 
Expectation of results 1.0 9.3 41.5 48.1 2.39 (0.7) 
Sylllptomsretum 1.7 2.1 7.3 16.3 37.4 35.3 3.98(1.0) 
Item-total correlation 
n r 
287 .57 
287 .44 
287 .61 
287 .49 
287 .50 
287 .69 
287 .56 
287 .40 
287 .55 
287 .60 
287 .41 
287 .61 
287 .48 
287 .55 
287 .47 
287 .51 
287 .63 
APPENDIX 6.2b Item Descriptive Statistics: CROQ-PTCA Post-Revascularisation (Preliminary Field Test) 
% missing Endorsement frequencies by response Category %- Item-total correlation 
Item data 1 2 3 4 5 6 Mean (SO) n r 
Chest pain 1.1 4.6 12.1 12.5 21.1 48.6---- - 3.98 (1.2) 277 .85 
Chest discomfort 5.0 7.5 11.8 10.0 26.4 39.3 4.00 (1.3) 277 .84 
Shortness of breath 2.1 7.9 17.1 17.1 30.4 25.4 3.49 (1.3) 277 .67 
Radiating pain 3.9 4.6 10.0 13.9 19.3 48.2 4.00 (1.2) 277 .76 
Palpitations 5.4 3.2 6.4 9.3 232 52.5 4.21 (1.1) 277 .48 
Nitroglycerin 1.4 1.8 11.4 10.7 9.6 12.1 52.9 4.80 (1.5) 277 .72 
Trouble 2.1 6.8 10.0 16.1 30.7 34.3 3.77(1.2) 277 .83 
Moderate activities 2.9 16.8 39.6 40.7 2.25 (0.7) 274 .79 
Ufting & carrying, 2.1 16.4 39.3 42.1 2.26 (0.7) 274 .75 
Climbing ftigh1s of stairs ~ 3.6 34.6 36.4 25.4 1.90 (0.8) 274 .71 
Climbingoneftightofstairs' 4.3 11.1 29.3 55.4 2.46(0.7) 274 .81 
Bending, keeling, stooping 3.6 11.8 33.6 51.1 2.41 (0.7) 274 .73 
Walk haifa mile 5.0 18.2 23.2 53.6 2.37 (0.8) 274 .81 
Walk 100 yards 32 11.8 14.3 70.7 2.61 (0.7) 274 .74 
Bathing or dressing 3.6 5.0 16.4 75.0 2.73 (0.6) 274 .69 
Reason 2.5 3.6 7.1 5.4 16.1 17.9 47.5 4.85 (1.5) 275 .84 
Forget 1.8 5.7 7.1 9.6 13.6 25.0 37.1 4.59 (1.5) 275 .82 
Concentration 1.8 3.2 7.9 5.0 14.3 20.4 47.5 4.87 (1.4) 275 .89 . 
Worry heart condition 1.4 9.6 12.9 23.6 32.5 20.0 3.41 (1.2) 277 .80 
Over-doing it 1.8 9.6 182 21.4 28.6 20.4 3.32 (1.3) 277 .77 
Heart attack 1.4 10.7 6.4 18.6 26.1 36.8 3.73 (1.3) 277 .76 
Frightened by pain 1.1 8.6 8.9 20.0 23.6 37.9 3.74 (1.7) 277 .75 
Uncertain 2.1 12.1 10.7 16.4 282 30.4 3.55(1.8) 277 .81 
Depressed 1.4 7.1 7.5 22.5 23.6 37.9 3.79 (1.5) 277 .78 
Frustrated 1.4 9.3 12.1 23.9 25.0 28.2 3.51 (1.6) 277 .75 
Interfered with enjoyment 1.1 10.7 15.7 19.6 21.4 31.4 3.48(1.9) 277 .83 
Positive ou1Iook 1.4 9.3 12.9 20.7 25.0 30.7 3.56 (1.3) 277 .90 
Oifticulttoplan 1.1 12.9 16.4 16.4 20.4 32.9 3.44(1.4) 277 .83 
Family overprotective 0.7 7.9 15.7 19.3 23.6 32.9 3.58 (1.3) 277 .59 
Feeling a burden 1.4 10.0 7.9 16.8 12.5 51.4 3.89(1.4) 277 .82 
Restricted in social activities 1.1 6.4 11.8 17.5 16.4 46.8 3.86(1.3) 277 .81 
Too far frorn home 1.1 11.1 10.7 13.2 19.3 44.6 3.77 (1.4) 277.78 
<n 
..... 
I\) 
% missing Endorsement frequencies by response category % ltem-total correlation 
Item data 1 2 3 4 5 6 Mean (SO) n r 
Pain in groin wound ( 1.4 3.6 1.8 4.6 10.4 78.2 4.60 (0.9) 
Tender groin wound \ 1.4 1.4 2.5 3.2 15.4 76.1 4.64(0.8) 
277 .70 
277 .71 
Numb groin 2.1 0.4 0.7 2.1 8.9 85.7 4.83 (0.5) 277 .59 
Bruised groin wound 2.1 2.5 3.6 3.6 14.6 73.6 4.57 (0.9) 277 .58 
Problems tom ca1heter 1.4 1.1 2.5 2.1 3.9 88.9 4.80 (0.7) 277 .63 
Concem over bruises 1.4 0.4 1.1 0.7 2.9 93.6 4.91 (0.5) 277 .41 
Satisfied with results 2.5 5.7 14.3 16.8 60.7 3.36 (0.9) 274 .75 
Satisfied with info about op 2.1 3.2 7.1 15.4 72.1 3.60 (0.8) 274 .54 
Satislledwithrecoveryinfo 2.1 5.7 12.9 25.7 53.6 3.30(0.9) 274 .44 
OveraHcomparedtobeforeop 1.8 2.9 5.0 12.9 17.1 60.4 4.29(1.1) 274 .67 
Speed of recovery 2.5 23.2 30.7 16.1 27.5 2.49 (1.1) 274 .70 
Expectation of results 2.5 20.0 43.2 34.3 2.15 (0.7) 274 .69 
Symptomsretum 1.4 11.1 15.4 26.8 32.1 13.2 3.21 (1.2) 
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APPENDIX 6.3 Scale Descriptive Statistics: eROQ Pre-Revascularisation (Preliminary Field Test) 
Range of scores 
Scale % missing Scale Sample Mean SO Skewness % floor % ceiling 
Symptoms 0 0-100 0-100 50.67 23.7 -.106 1 1 
Physical Functioning 0 0-100 0-100 48.38 29.1 .039 6 4 
Psychosocial Functioning 0 0-100 0-98 50.14 22.6 -.159 1 1 
Cognitive Functioning 0 0-100 0-100 69.68 26.1 -.642 2 21 
Core Total 0 37 -62 50.00 6.2 -.079 1 1 
Symptoms 0 0-100 0-100 51.90 24.2 .118 1 3 
Physical Functioning 0 0-100 0-100 53.47 26.8 -.005 2 6 
Psychosocial Functioning 1 0-100 1-100 54.73 24.2 -.244 0 2 
Cognitive Functioning 2 0-100 0-100 69.90 27.6 -.752 1 23 
Core Total 0 35-64 49.97 6.5 -.048 1 2 
01 
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APPENDIX 6.4 Scale Descriptive Statistics: CROQ Post-Revascularisation (Preliminary Field Test) 
Range of scores 
CROQ-Scale % missing Scale Sample Mean SO Skewness % floor % ceiling 
Symptoms 1 0-100 5-100 84.96 16.9 -1.97 0 
Physical Functioning 2 0-100 0-100 76.43 23.1 -1 .26 1 
Psychosocial Functioning 1 0-100 8-100 75.69 19.7 -1 .10 0 
Cognitive Functioning 1 0-100 0-100 78.39 24.4 -1 .23 1 
Core Total 1 23-58 49.97 6.3 -1.40 1 
Complications 1 0-100 0-100 78.47 17.2 -1.41 1 
Satisfaction 1 0-100 22-10081 .02 18.7 -1.03 1 
Total Outcome 1 23-57 50.01 5.3 -1 .32 1 
17 
18 
3 
34 
1 
1 
27 
1 
Symptoms 1 0-100 3-100 72.15 25.0 -.782 0 12 
Physical Functioning 2 0-100 0-100 68.52 29.0 -.756 1 18 
Psychosocial Functioning 1 0-100 0-100 65.40 26.9 -.659 1 4 
Cognitive Functioning 2 0-100 0-100 75.16 27.7 -1.15 2 29 
Core Total 1 32-59 49.99 7.2 -.689 1 1 
Complications 
Satisfaction 
Total Outcome 
1 
2 
1 
0-100 
0-100 
12-100 92.95 13.6 
8-100 72.70 23.6 
21-57 50.04 5.9 
-2.85 
-.762 
-1 .76 
o 
o 
1 
57 
16 
2 
APPENDIX 6.5 Reliability: CROQ Pre-Revascularisation (Preliminary Field Test) 
Internal consistency 
Item-total Inter-item 
CROQ scale correlation range correlation range Cronbach's 
(mean) (mean) N alpha 
Symptoms (7 items) .60-.76 (.65) .30-.72 (.50) 146 .87 
Physical Functioning (8 items) .68-.82 (.73) .41-.73 (.58) 143 .92 
Psychosocial Functioning (14 items) .56-.78 (.67) .26-.71 (.49) 146 .93 
Cognitive Functioning (3 items) .75-.78 (.77) .70-.73 (.71) 146 .88 
Core Total (32 items) .42-.76 (.59) .05-.73 (.36) 143 .95 
::::::gllli emI:IItI51gI1:::::::::i::i::::i::::i::::::::::::::::::i:::::i::::::::::i:::i::i:::::i:i::i::i::i:::::::::i::::::::::::::i:::::i:i:::i:::i:::i:::::::::::::ii::::::i::::::I::::::::i:i:::::::i::i::i:::::i::::iii::::::::::::::i::::::::iii:i:::i:i··:i:::::::i::i:::i::::::::i:ii:i:::i:i::Ii:I:i:::iI::i:i:::ii::i:::::::::::: ::::::::::::::::::::::::::::::::::::::::::::;····:itt;;::;:::::::::::::::::: ::::·:·:;:\tr: 
Symptoms (7 items) .53-.80 (.67) .33-.72 (.52) 128 .88 
Physical Functioning (8 items) .60-.78 (.68) .33-.74 (.52) 128 .90 
Psychosocial Functioning (14 items) .52-.85 (.72) .33-.81 (.56) 127 .95 
Cognitive Functioning (3 items) .72-.82 (.78) .67-.80 (.72) 126 .89 
Core Total (32 items) .45-.79 (.62) .08-.81 (.40) 126 .96 
0'1 
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APPENDIX 6.6 Reliability: CROa Post-Revascularisation (Preliminary Field Test) 
Internal consistency Test-retest sample 
Item-total Inter-item 
CRoa scale correlation correlation N Cronbach's 
range (mean) range (mean) alpha N ICC 1 
Symptoms (7 items) .54-.73 (.61) .28-.81 (.45) 286 .85 42 .92 
Physical Functioning (8 items) .54-.71 (.66) .34-.78 (.50) 284 .89 43 .71 
Psychosocial Functioning (14 items) .42-.85 (.70) .22-.76 (.52) 287 .94 43 .83 
Cognitive Functioning (3 items) .80-.84 (.82) .74-.80 (.77) 287 .91 42 .79 
Core Total (32 items) .33-.73 (.59) .04-.83 (.37) 225 .95 43 .89 
Complications (11 items) .40-.69 (.53) .09-.65 (.33) 
Satisfaction (6 items) .45-.74 (.63) .17-.79 (.39) 
Total Outcome (18 items) .31-.63 (.47) -.08-.79.. 
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s (7 items) .48-.85 (.74) .35-.89 (.60) 277 
Physical Functioning (8 items) .73-.81 (.75) .46-.79 (.62) 274 
Psychosocial Functioning (14 items) .59-.90 (.78) .42-.84 (.64) 277 
Cognitive Functioning (3 items) .82-.89 (.85) .76-.85 (.81) 275 
Core Total (32 items) .48-.85 (.70) .21-.89 (.51) 228 
Complications (6 items) .41-.71 (.60) .19-.68 (.44) 277 .83 49 .93 
Satisfaction (6 items) .45-.74 (.63) .24-.76 (.48) 275 .85 49 .94 
Total Outcome (13 items) .40-.66 (.50) .00-.80 (.30) 187 .85 49 .96 
1 ICC: Intraclass correlation coefficient. 
01 
~ 
...., 
APPENDIX 6.7a: Item Convergent and Discriminant Correlations: CROQ-CABG Pre-Revascularisation (Preliminary Field Test) 
CROQ-CABG scale 
CROQ-CABG scale CROQ-CABG item Symptoms Physical Functioning Psychosocial Functioning Cognitive Functioning 
- ~ Symptoms Chest pain . f" .4:> .,,~ 
Physical 
Functioning 
Psychosocial 
Functioning 
Cognitive 
Functioning 
Chest discomfort .75 .52 .50 
Shortness of breath .55 .58 2 .42 
Radiating pain .61 .44 .38 
Palpitations .60 .511 .36 
Nitroglycerin .58 .39 .27 
Trouble .76 .69 .55 
Moderate activities .51 .71 .42 
Lifting & carrying - .65 .82 .50 
Climbing tigh1s of stairs .51 .68 .29 
Climbing one tight of stairs .58 .78 .38 
Bending, keeling, stooping .43 .70 .32 
Walk half a mile· .52 .72 .34 
Walk 100 yards .56.71 .30 
Bathing or dressing .55 .68 .42 
Worry heart condition .40 .24 .77 
Over-doing it .20 .15 .59 
Heart attack .38 .19 .63 
Frightened by pain .56 .41 .77 
Uncertain .35 .31 .78 
Depressed .33 .28 .70 
Frustrated .23 .27 .58 
Interfered with enjoyment .43 .47 .69 
Positive outlook .43 .45 .70 
Difficult to plan .36 .35 .61 
Family overprotective .33 .21 .56 
Feeling a burden .39 .37 .63 
Restricted in social activities .46 .51 .73 
Too far from home .56 .48 .67 
Reason .32 .37 .48 
Forget .38 .35 .37 
Concentration .36 .33 .41 
Values in bold indicate probable scaling successes. Z Values In bold and underlined indiCate probable scaling failures. 
(J'I 
-(II) 
.35 
·.37 
.30 
.29 
.15 
.41 
.39 
.37 
.30 
.31 
.30 
.25 
.28 
.36 
.25 
.23 
.17 
.32 
.36 
.42 
.38 
.35 
.46 
.35 
.29 
.32 
.39 
.45 
.75 
.78 
.77 
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APPENDIX 6.7b: Item Convergent and Discriminant Correlations: CROQ-PTCA Pre-Revascularisation (Preliminary Field Test) 
CROQ.pTCA scale 
Symptoms 
Physical 
Functioning 
Psychosocial 
Functioning 
Cognitive 
Functioning 
CROQ-PTCA item 
Chest pain 
Chest discomfort 
Shortness of breath 
Radiating pain 
Palpitations 
Nitroglycerin 
Trouble .r-
Moderate activities 
Ufting & carrying 
Climbing fligh1s of stairs 
Climbing one flight of stairs 
Bending, keeling, stooping 
Walk half a mile 
Walk 100 yards 
Bathing or dressing 
Worry heart condition 
Over-doing it 
Heart attack 
Frightened by pain 
Uncertain 
Depressed 
Frustrated 
Interfered with enjoyment 
Positive outlook 
Difficult to plan 
Family overprotective 
Feeling a burden 
Restricted in social activities 
Too far from home 
Reason 
Forget 
Concentration 
I Values in bold indicate probable scaling successes. 
c.n 
~ 
CD 
Symptoms 
.75 
.75 
.62 
.65 
.53 
.58 
.80 
.59 
.56 
.53 
.53 
.49 
.55 
.48 
.43 
.54 
.56 
.51 
.58 
.48 
.35 
.43 
.58 
.60 
.54 
.36 
.45 
.53 
.48 
.42 
.41 
.47 
CROQ.pTCA scale 
Physical Functioning Psychosocial Functioning 
.56 .50 
.56 .52 
~11 ~1 
.58 .55 
.39 .46 
.41 .32 
.55 .61 
.71 .47 
.70 .45 
.65 .35 
.78 .38 
.60 .31 
.73 .40 
.67 .40 
.61 .40 
.36 .81 
.42 .77 
.38 .73 
.~ .~ 
.36 .80 
.23 .65 
.20 .62 
.47 .73 
.48 .85 
.45 .74 
.35 .52 
.42 .72 
.52 .74 
.42 .71 
.30 .~ 
.30 .39 
A1 ~5 
Cognitive Functioning 
.32 
.40 
.38 
.35 
.41 
.24 
.48 
.31 
.23 
.33 
.31 
.30 
.25 
.28 
.25 
.38 
.40 
.28 
.41 
.53 
.40 
.48 
.41 
.47 
.44 
.25 
.33 
.42 
.37 
.79 
.72 
.82 
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APPENDIX 6.8a: Item Convergent and Discriminant Correlations: CROQ-CABG Post-Revascularisation (Preliminary Field Test) 
CROQ-CABG 
scale 
Symptoms 
Physical 
Functioning 
Psychosocial 
Functioning 
Cognitive 
Functioning 
en 
~ 
CROQ-CABG scale 
CROQ-CABG item Symptoms Ph},sical Functioning _ .. _Psycho!S~~flJ.!!~ing Cognitive Functioning Complications Satisfaction 
Chest pain .73 .38 .36 .35 .35 .31 
Chest discomfort .73 .38 .39 .35 .31 .37 
Shortness of breath .54 .531 .46 .38 .23 .31 
Radiating pain .58 .38 .31 .26 .25 .25 
Palpitations .54 .37 .36 .34 .25 .29 
Nitroglycerin .55 .34 .38 .28 .23 .30 
Trouble .60~ .55 .53 .40 .32 .43 
Moderate actiVities .40 .67 .42 .30 .27 .45 
Ufting & carrying .41 .66 .38 .33 .29 .40 
Climbing flights ofstairs .50 .64 .40 .35 .18 .36 
Climbing one flight of stairs.54 .73 .44 .37 .26 .36 
Bending, keeling, stooping .35 .54 .38 .31 .34 .28 
Walk half a mile .51 .71 .44 .37 .33 .35 
Walk 100 yards .40 .69 .42 .37 .27 .27 
Bathing or dressing .43 .61 .34 .~1 __ . .26 .28 
Worry heart condition ~ -- .49 .39 .69 .42 .34 .35 
Over-doing it .36 .40 .69 .47 .30 .34 
Heart attack .43 .27 .60 .31 .25 .17 
Frightened by pain .53 .35 ;65 .47 .36 .33 
Uncertain .47 .36 .77 .53 .33 .40 
Depressed .41 .39 .72 .59 .35 .38 
Frustrated .46 .45 .74 .55 .35 .38 
Interfered with enjoyment .43 .43 .78 .54 .30 .41 
Positive outlook .44 .46 .85 .52 .37 .49 
Difficult to plan .39 .43 .76 .55 .34 .45 
Family overprotective .24 .25 .42 .34 .33 .22 
Feeling a burden .33 .36 .67 .48 .34 , .36 
Restricted in social activities .42 .57 .69 .50 .33 .40 
Too far from home .40 .49 .70 .49 .32 .26 
Reason .46 .43 .64 .84 .36 .33 
Forget .40 .37 .57 .80 .37 .21 
Concentration .44 .44 .64 .82 .35 .35 
(\ 
CROQ-CABG CROQ-CABG scale 
scale CROQ-cABG item Symptoms" Physical Functioning Psychosocial Functioning Cognitive Functioning Complications Satisfaction 
Complications Pain in chest wound .38 .30 .42 .41 .57 .31 
Infection in chest wound .26 .19 .24 .22 .44 .10 
Tender chest wound .29 .23 .41 .31 .61 .29 
Numb chest wound .25 .12 .29 .28 .49 .19 
Bruising on chest .28 .23 .28 .25 .50 .24 
Pain leg wound .24 .34 .36 .33 .69 .27 
Other pain in leg .35 .31 .25 .25 .56 .26 
Infection in leg wound .17 .16 .13 .06 .40 .09 
Numb leg .16 .15 .29 .24 .55 .20 
Bruising on leg .22 23 .28 .25 .60 .27 
Swollen feet .11 .29 .15 .11 .41 .08 
Satisfaction Satisfied with results .49 .36 .40 .30 .32 .59 
Satisfied with info about op .16 .22 .18 .14 .10 .50 
Satisfied with recovery info .14 .24 .27 .15 .20 .57 
Overall .51' .34 .39 .26 .18 .45 
Speed of recovery .28 .35 .35 .25 .30 .53 
Expectation of results .41 .44 .43 26 .26 .64 
1 Values in bold indicate probable scaling successes. 2 Values in bold and under1ined indicate probable scaling failures. 
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APPENDIX 6.8b: Item Convergent and Discriminant Correlations: CROQ-PTCA Post-Revascularisation (Preliminary Field Test) 
CROQ-PTCA CROQ-PTCA scale 
scale CROQ-PTCA item Symptoms Physical Functioning Psychosocial Functioning Cognitive Functioning Complications Satisfaction 
Symptoms Chest pain .85 .55 .55 .39 .28 .60 
Chest discomfort .84 .56 .56 .43 .27 .59 
Shortness of breath .67 .641 .54 .43 .30 .51 
Radiating pain .76 .55 .58 .48 .37 .48 
Palpitations .48 .41 .41 .36 .34 .26 
Nitroglycerin .72 ~ .48 .51 .32 .16 .50 
Trouble .83 .61 .54 .48 .29 .67 
Physical Moderate activities .59 .79 .60 .46 .26 .47 
Functioning Ufting & carrying .56 .75 .58 .42 .30 .43 
Climbing flights of stairs .55 .71 .55 .48 .28 .46 
Climbing one flight of stairs .60 .81 .56 .49 .30 .38 
Bending, keeling, stooping .49 .73 .48 .48 .35 .31 
Walk half a mile .56 .81 .59 .50 .24 .44-
Walk 100 yards .55 .74 .52 .46 .25 .40 
Bathins or dressins .50 .69 .49 .46 .21 .30 
Psychosocial Worry heart condition .66 .58 .80 .54 .28 .56 
Functioning Over-doing it .54 .53 .77 .55 .29 .48 
Heart attack .53 .48 .76 .46 . 28 .43 . 
Frightened by pain .66 .58 .75 .51 .32 .49 
Uncertain .49 .50 .81 .55 .32 .48 
Depressed .51 .51 .78 .56 .36 .44-
Frustrated .52 .51 .75 .55 .29 .47 
Interfered with enjoyment .62 .62 .83 .57 .30 .59 
Positive ouUook .60 .62 .90 .56 .34 .52 
Difficult to plan .57 .61 .83 .52 .26 .50 
Family overprotective .42 .42 .59 .33 .31 .23 
Feeling a burden .49 .54 .82 .51 .33 .40 
Restricted in social activities .55 .61 .81 .57 .32 .44-
Too far from horne .50 .52 .78 .46 .26 .42 
Cognitive Reason .51 .55 .62 .84 .36 .40 
Functioning Forget .43 .53 .54 .82 .33 .28 
Concentration .51 .55 .62 .89 .42 .35 
c.n 
~ 
/: 
CROQ.pTCA CROQ:PTCA scale 
scale CROQ.pl"~ item Symptoms Physical Functioning Psychosocial Functioning Cognitive Functioning COI1lplications 
Complications Pain in groin wound .31 .28 .30 .37 .70 
Tender groin wound .25 .24 .29 .31 .71 
Numb groin .28 .27 .28 .30 .59 
Bruised groin wound .25 25 .26 .19 .58 
Problems from catheter .25 .23 .28 .32 .63 
Concem over bruises .19 .22 .25 .26 .41 
Satisfaction Satisfied with results .64 . .50 .... 50··· -- -.34 .21 
CJ'I 
flo.) 
CA) 
Satisfied with info about op .31 .33 .42 .33 .29 
Satisfied with recovery info .24 .20 .31 .26 .22 
Overall .63 .45 .43 .27 .30 
Speed of recovery .53 .41 .49 .28 .16 
Expectation of results .52 .33 .41 .23 .13 
Values in bold indicate probable scaling successes. 
Satisfaction 
.30 
.29 
.28 
.26 
.28 
.25 
.74 
.54 
.45 
.67 . 
.69 
.70 
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APPENDIX 6.9 Intercorrelations Between Scales: CROQ Pre-Revascularisation (Preliminary Field Test) 
CROQ scale Physical Psychosocial Cognitive 
Symptoms Functioning Functioning Functioning 
:::::ill.III::::{J.lffi:j:~Ri::::I::::::::::::::::::]::::i~::::::::::~::::::~I::::::ili::_:::::~~:::::::::: : ::::}:::::::::!::::t::::::::~::::(:::::: :~:::::::::::::;:;:::::::: :::::::::::;::::;:::::::::.:;:::::::::::::::::::i:: ::::::::C:~::::7:::~:::~:-~: :r~~::~~:!:::::r:::~~:r~:::::: :-::::::-
Symptoms (.87)1 
Physical Functioning .67 
Psychosocial Functioning .54 
Cognitive Functioning .40 
Core Total .81 
(.92) 
.47 
.39 
.79 
(.93) 
.47 
.87 
(.88) 
.61 
::~::ill~tmilgl:::tIEl:g§1::I::::::::::::::::::::::::::::::::~:::::::::::::::::::~:::::::::::::::::::::::::::::::::::::::::::::::::~:::::::::::::::::-::~:::::::::::::::::::I::::: ::::::::;:::::::::::::::_::::::::::::::::::::!:r:f):r:~;:;:;/:::::::::::::::::::::::::::::-:~::::::::::~:::::=:::/~:\:::':::::::-:::::::::::::::::::::::::::::::::~:::~:: 
Symptoms (.88) 
Physical Functioning .68 
Psychosocial Functioning .65 
Cognitive Functioning .48 
Core Total .86 
(.90) 
.52 
.37 
.78 
1 Values in brackets indicate Cronbach's alpha coefficient. 
(.95) 
.52 
.91 
(.89) 
.63 
APPENDIX 6.10 Intercorrelations Between Scales: CROQ Post-Revascularisation (Preliminary Field Test) 
CROQscaie 
CROQ scale Physical Psychosocial Cognitive Core 
Symptoms Functioning Functioning Functioning Total Satisfaction Complications 
Symptoms (.85) 
Physical Functioning .59 
Psychosocial Functioning .56 
Cognitive Functioning .47 
Core Total .78 
Satisfaction 
Complications 
Total Outcome 
.45 
.38 
.54 
Symptoms (.91) 
Physical Functioning .67 
Psychosocial Functioning .67 
Cognitive Functioning .51 
Core Total .83 
Satisfaction .64 
Complications .35 
Total Outcome .64 
(.89) 
.54 
.45 
.78 
.47 
.37 
.49 
(.93) 
.67 
.58 
.85 
.49 
.34 
.54 
1 Values in brackets indicate Cronbach's alpha coefficient. 
CJl 
M 
CJl 
(.94) 
.65 
.91 
.48 
.45 
.61 
(.96) 
.63 
.93 
.56 
.37 
.65 
(.91 ) 
.73 
.32 
.39 
.45 
(.93) 
.73 
.37 
.39 
.51 
(.95) 
.54 
.49 
.66 
(.97) 
.63 
.41 
.70 
(.80) 
.33 
.70 
(.85) 
.28 
.80 
(.85) 
.89 
(.83) 
.78 
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APPENDIX 6.11a Principal Axis Factor Analysis: CROQ-CABG Core Items Pre-Revascularisation (Preliminary Field Test) 
Factor 
CROQ-CABG item 1 2 3 4 
Chest pain .21 .21 .77 .05 
Chest discomfort .29 .30 .63 .12 
Shortness of breath 1 .25 .51 .25 .18 
Radiating pain .22 .22 .55 .15 
Palpitations .22 .37 2 .37 .17 
Nitroglycerin .12 .22 .59 -.01 
Trouble 1 .32 .57 .51 .18 
Moderate activities .20 .68 .13 .25 
Lifting & carrying .27 .81 .21 .14 
Climbing flights of stairs .04.72 .17 .13 
Climbing one flight of stairs .19.77 .21 .05 
Bending, keeling, stooping .11.73 .01 .17 
Walk half a mile .13.72.25 .04 
Walk 100 yards .10 .68 .30 .06 
Bathing or dressing .23 .65 .15 .22 
Reason .31 .23 .05 .69 
Forget .13 .23 .16 .77 
Concentration .22 .19 .08 .79 
Worry heart condition .81 .04 .28 .03 
Over-doing it .75 -.01 -.00 -.02 
Heart attack .72 -.00 .28 .02 
Frightened by pain .72 .20 .43 .11 
Uncertain .80 .18 .06 .15 
Depressed .67 .17 .18 .28 
Frustrated .54 .25 .01 .25 
Interfered with enjoyment .59 .42 .14 .12 
Positive outlook .71 .26 .15 .23 
Difficult to plan .57 .30 .05 .22 
Family overprotective .60 .16 .18 .11 
Feeling a burden .52 .27 .25 .14 
Restricted in social activities .60 .45 .24 .12 
Too far from home .60.25 .35 .18 
1 Item loads higher on the 'wrong factor' . 2 Values in bold indicate items crossloading on more than one factor with a difference <.20. 
APPENDIX 6.11 b Principal Axis Factor Analysis: CROQ-PTCA Core Items Pre-Revascularisation (Preliminary Field Test) 
Factor 
CROQ-PTCA item 1 2 3 4 
Chest pain .25 .36 .71 .04 
Chest discomfort .31 .32 .66 .16 
Shortness of breath .30 .40 1 .45 .21 
Radiating pain .39 .39 .47 .13 
Palpitations .35 .29 .37 .21 
Nitroglycerin .OS .22 .59 .06 
Trouble .33 .31 .74 .29 
Moderate activities .22 .71 .31 .04 
Lifting & carrying .25 .67 .27 -.03 
Climbing flights of stairs .03 .65 .32 .16 
Climbing one flight of stairs .14 .71 .2S .16 
Bending, keeling, stooping .OS .55 .25 .23 
Walk half a mile .12 .73 .23 .OS 
Walk 100 yards .22 .68 .09 .09 
Bathing or dressing .23 .65 .01 .11 
Reason .27 .10 .15 .84 
Forget .26 .19 .17 .67 
Concentration .34 .26 .11 .83 
Worry heart condition .82 .07 .26 .09 
Over-doing it .76 .15 .2S .16 
Heart attack .81 .15 .27 -.03 
Frightened by pain .74 .27 .24 .08 
Uncertain .77 .11 .09 .37 
Depressed .64 .03 .08 .25 
Frustrated .57 -.03 .29 .35 
Interfered with enjoyment .58 .27 .30 .27 
Positive outlook .78 .24 .21 .24 
Difficult to plan .61 .29 .19 .29 
Family overprotective .41 .38 .17 .12 
Feeling a burden .72 .32 .02 .OS 
Restricted in social activities .61 .40 .11 .25 
Too far from home .69 .32 .03 .12 
I Values in bold indicate items crossloading on more than one factor with a d ifference < .20. 
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APPENDIX 6.12a Principal Axis Factor Analysis: CROQ-CABG Core Items Post-Revascularisation (Preliminary Field Test) 
Factor 
CRoa..cABG item 1 2 3 4 
Chest pain .08.17 .10 .85 
Chest discomfort .10 .16 .1 5 .82 
Shortness of breath 1 .25 .45 2 .16 .37 
Radiating pain .02 .24 .11 .68 
Palpitations .19.20 .20 .48 
Nitroglycerin .17.21 .07 .40 
Trouble 1 .21 .43 .34 .40 
Moderate activities .14 .69 .21 .1 2 
Lifting & carrying .13.70.10 .14 
Climbing flights of stairs .19 .65 .04 .19 
Climbing one flight of stairs .15.70 .13 .31 
Bending, keeling, stooping .19 .48 .18 .07 
Walk half a mile .21.74 .09 .19 
Walk 100 yards .21 .69 .14 .12 
Bathing or dressing .10 .58 .11 .21 
Reason .72 .24 .19 .30 
Forget .74 .18 .02 .29 
Concentration .79 .22 .13 .24 
Worry heart condition .19 .19 .76 .23 
Over-doing it .32 .23 .60 .06 
Heart attack .11 .04 .70 .28 
Frightened by pain .29 .13 .56 .34 
Uncertain .51 .1 2 .62 .19 
Depressed 1 .67 .18 .37 .13 
Frustrated 1 .62 .29 .38 .1 2 
Interfered with enjoyment 1 .53 .28 .52 .06 
Positive outlook .52.23 .66 .07 
Difficult to plan 1 .55 .27 .50 .03 
Family overprotective 3 .34 .08 .23 -.00 
Feeling a burden 1 .56 .19 .34 .02 
Restricted in social activities 1 .49 .43 .37 .02 
Too far from home 1 .46 .36 .45 .06 
Item loads higher on the 'wrong fador' . z-Values in bold indicate items crossloading on more than one fador with a difference <.20. 3 Item doesn't load on a fador > .35. 
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APPENDIX 6.12b Principal Axis Factor Analysis: CROQ-PTCA Core Items Post-Revascularisation (Preliminary Field Test) 
Factor 
CROQ-PTCA item 1 2 3 4 
Chest pain .26 .26 .84 .12 
Chest discomfort .25 .28 .82 .12 
Shortness of breath 1 .28 .48 2 .43 .17 
Radiating pain .30 .27 .62 .24 
Palpitations 3 .28 .21 .24 .27 
Nitroglycerin .33 .25 .62 -.01 
Trouble .32 .34 .75 .20 
Moderate activities .28 .71 .28 .11 
Lifting & carrying .33 .66 .25 .1 0 
Climbing flights of stairs .30 .63 .24 .1 8 
Climbing one flight of stairs .28 .73 .26 .19 
Bending, keeling, stooping .22 .69 .14 .28 
Walk half a mile .27 .77 .21 .18 
Walk 100 yards .22 .67 .23 .17 
Bathing or dressing .23 .60 .1 8 .23 
Reason .34 .29 .1 8 .72 
Forget .29 .34 .12 .68 
Concentration .37 .28 .15 .81 
Worry heart condition .70 .22 .37 .23 
Over-doing it .66 .24 .20 .26 
Heart attack .71 .16 .26 .20 
Frightened by pain .60 .26 .38 .24 
Uncertain .78 .21 .16 .24 
Depressed .69 .20 .19 .38 
Frustrated .62 .23 .23 .34 
Interfered with enjoyment .67 .36 .29 .22 
Positive outlook .77 .34 .27 .23 
Difficult to plan .71 .39 .24 .1 8 
Family overprotective .55 .21 .19 .04 
Feeling a burden .77 .29 .1 8 .13 
Restricted in social activities .69 .41 .1 8 .20 
.29 .23 .1 0 Too far from home .70 
1 Item loads higher on the 'wrong factor'. 2 Values in bold indicate items crossloading on more than one factor with a difference <.20. 3 Item doesn't load on a factor >.35. 
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APPENDIX 6.13a Principal Axis Factor Analysis: CROQ-CABG Post-Revascularisation 
Outcome Only Items (Preliminary Field Test) 
CROQ-CABG item 
Satisfied with results 
Satisfied with info about op 
Satisfied with recovery info 
Overall 
Speed of recovery 
Expectation of results 
Symptoms return 1 
Pain in chest wound 
Infection in chest wound 
Tender chest wound 
Numb chest wound 
Bruising on chest 
Pain leg wound 
Other pain in leg 
Infection in leg wound 
Numb leg 
Bruising on leg 
Swollen feet 
1 Item doesn't load on a factor >.35. 
Factor 
1 2 
.23 
-.03 
.08 
.15 
.26 
.17 
.29 
.62 
.40 
.64 
.51 
.48 
.75 
.57 
.45 
.60 
.60 
.46 
.65 
.67 
.74 
.50 
.49 
.64 
.31 
.25 
.04 
.31 
.22 
.26 
.17 
.17 
.11 
.07 
.24 
-.04 
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APPENDIX 6.13b Principal Axis Factor Analysis: CROQ-PlCA Post-Revascularisation 
Outcome Only Items (Preliminary Field lest) 
CROQ-PlCA item 
Satisfied with results 
Satisfied with info about op 
Satisfied with recovery info 
Overall 
Speed of recovery 
Expectation of results 
Symptoms return 
Pain in groin wound 
Tender groin wound 
Numb groin 
Bruised groin wound 
Problems from catheter 
Concern over bruises 1 
1 Item doesn't load on a factor >.35. 
Factor 
1 2 
.85 .08 
.46 .24 
.44 .16 
.81 .20 
.78 -.01 
.82 -.04 
.52 .18 
.12 .80 
.04 .83 
.13 .66 
.16 .63 
.06 .73 
.26 .34 
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APPENDIX 6.14 Known Group Differences: CROQ Global Improvement Post-Revascularisation (Preliminary Field Test) 
Mean scores 
Scale Improved (n) 1 Unimproved (n) 2 p 
:::::el.BltI·:!t BE*=II)!!:::!:!!!::!::!:::::!:::!:::!!::::::::::::::!::::::::I;::::::!,:ili:::E:::::!::::!:::::::::!::::::::::::::::::::::::::::!:::::::::::!:!:::::::::::::::::::::' .f::::::::::: !::::::::::::::::I::::::::::::::::::::::::::::::::::::::::::::::::If:ili:I::::::::'::·:I':::':::: 
Symptoms 86.44 (268) 62.30 (16) .004 
Physical Functioning 77.88 (265) 55.03 (17) .007 
Psychosocial Functioning 77.00 (268) 58.69 (17) .015 
Cognitive Functioning 79.54 (268) 63.92 (17) .009 
Complications 78.83 (270) 72.72 (17) .338 
Satisfaction 82.95 (270) 50.33 (17) .000 
::::::~imltRmQ!IItNallli::::::::::::::::::::::::,::::::::::::::::::::::::::::::::f:::::::::i::::::::;:::::;:::::::::::::":':::c::::::::::::::::::"":'::!:':!::!::!:::::::;:;:::::::::i:i:::::::::::::::::::::::::::::::::::::::;:::::'!::::::::<::,::::::::), 
Symptoms 79.22 (213) 45.81 (57) .000 
Physical Functioning 74.19 (213) 46.30 (54) .000 
Psychosocial Functioning 71.40 (213) 43.59 (57) .000 
Cognitive Functioning 79.25 (214) 60.06 (54) .000 
Complications 95.04 (214) 84.67 (56) .001 
Satisfaction 80.73 (215) 42.77 (57) .000 
1 Patients who reported global improvement in heart condition at 3-months post-revascularisation 
(scored 4 "a little better", or 5 "much better" on Q12) . 
2 Patients who reported no global improvement in heart condition at 3-months post-revascularisation 
(scored 1 "much worse", 2 "a little worse", or 3 "about the same" on Q12) . 
APPENDIX 6.15 Known Group Differences: CROQ Bothered by Chest Pain Post-Revascularisation (Preliminary Field Test) 
<.n 
w 
w 
Mean scores 
CROQ scale Bothered (n) ,- Not bothered (n) Z p 
.:::.§llillal:!:tieg!!)·:":,:!:::!::!!:!!::::!:::!!!:::'::::::!!:!:::!:::.::!!::!!:::!::!:!!!.:!:!!':!:!::::!:!:!:!:!:!:!:!!::::::.:::!:::::::!.:':::!:!::::!:::::!':I:!':::·:::':::::::!:::!:!:::!::::!!::::!!:'!::!:::::!::::::!':,:!:::::,!:!:!:::!!::::!:::::!:!::,::::::::::!:::::::'::!::!::!:::!:::!:.!:!!:::::::::::::!:!!:I::!:::!:::!:::::::!.::!! 
Symptoms 61.96 (55) 90.52 (229) .000 
Physical Functioning 61.78 (54) 80.08 (226) .000 
Psychosocial Functioning 64.13 (55) 78.39 (228) .000 
Cognitive Functioning 65.06 (54) 81 .59 (229) .000 
Core Total 44.18 (55) 51.36 (229) .000 
Complications 71.93 (54) 80.20 (229) .014 
Satisfaction 69.91 (54) 83.79 (229) .000 
Total Outcome 46.69 (54) 50.84 (229) .000 
:::!:IBlltEll!:rlffi4.§Ql::!:::::::::::!::!:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::jill::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :::!:::::::::I!::::::::::':':::::L;:;::ri::::::::::::: :i::::: 
Symptoms 53.68 (139) 91.28 (134) .000 
Physical Functioning 54.58 (135) 82.81 (134) .000 
Psychosocial Functioning 53.81 (138) 77.57 (134) .000 
Cognitive Functioning 66.59 (135) 83.90 (135) .000 
Core Total 45.87 (138) 54.23 (135) .000 
Com plications 
Satisfaction 
Total Outcome 
90.37 (138) 
60.90 (135) 
47.57 (137) 
95.69 (134) 
84.36 (135) 
52.59 (135) 
.001 
.000 
.000 
1 Patients who reported they were bothered by chest pain due to angina at 3-months post-revascularisation 
(scored 1 "a lot", 2 "quite a bit", 3 "moderately", or 4 "a little" on 01 a). 
2 Patients who reported they were not bothered at all by chest pain due to angina at 3-months post-revascularisation 
(scored 5 "not at all" on 01a) . 
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APPENDIX 6.16 Responsiveness: CROQ Pre- to 3-Months Post-Revascularisation (Preliminary Field Test) 
Mean (SO) Pre-to 3-months post-revascularisation 
Responsiveness Standardised 
effect size 2 response mean 3 
::::::::::::::::;:::;:: .................. -................ ............................ . 
ptoms 
Physical Functioning 50.31 (28.6) 78.61 (21.4) 28.30 (28.6) 
Psychosocial Functioning 49.97 (22.0) 77.55 (16.2) 27.58 (21 .2) 
Cognitive Functioning 69.50 (25.9) 79.03 (22.1) 9.53 (20.3) 
Symptoms 51 .76 (23.8) 73.14 (24.8) 21 .38 (21 .8) 0.90 0.98 
0.67 
0.62 
0.33 
Physical Functioning 53.22 (26.1) 70.70 (28.2) 17.48 (26.0) 0.67 
Psychosocial Functioning 53.94 (24.3) 66.99 (24.3) 13.05 (21 .1) 0.54 
Cognitive Functioning 69.82 (27.9) 77.26 (27.9) 7.44 (22.7) 0.27 
All change scores are statistically significant (p<.OS). 
2 Calculated as the mean change score between pre- and 3-months post-revascularisation divided by the standard deviation of scores at the 
pre-revascularisation assessment. 
3 Calculated as the mean change score between pre- and 3-months post-revascularisation divided by the standard deviation of the change score. 
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APPENDIX 6.17 Responsiveness: CRDQ Pre- to 3-Months Post-Revascularisation for Subsample Who Reported Global 
Improvement (Preliminary Field Test) 
Mean (SO) Pre-to 3-months post-revascularisation 
Responsiveness Standardised 
CRDQ scale Pre 3m post Change 2 effect size 3 response mean .. 
Symptoms 51.02 (22.4) 88.03 (12.5) 37.01 (20.6) 1.65 1.79 
Physical Functioning 48.82 (21 .5) 79.01 (21 .5) 30.19 (27.8) 1.06 1.09 
Psychosocial Functioning 48.71 (21.6) 77.84 (16.0) 29.14 (20.3) 1.35 1.43 
Cognitive Functioning 68.54 (26.1) 78.93 (22.4) 10.39 (20.2) 0.40 0.51 
Symptoms 53.51 (22.4) 78.89 (21 .2) 25.38 (21.5) 1.13 1.18 
Physical Functioning 55.39 (25.9) 77.23 (25.0) 21.85 (25.3) 0.84 0.86 
Psychosocial Functioning 55.32 (21.9) 72.17 (23.4) 16.85 (20.7) 0.77 0.82 
Cognitive Functioning 70.96 (27.6) 82.07 (22.4) 11 .11 (23.0) 0.40 0.48 
Responsiveness subsample: Excludes patients who did not report global improvement in their heart condition compared to before their operation 
(i.e. those who scored 1 "much worsew, 2"a little worse", or 3 "about the same" on Q12). 
2 All change scores are statistically significant (p<.OS). 
3 Calculated as the mean change score between pre- and 3-months post-revascularisation divided by the standard deviation of scores at the 
pre-revascularisation assessment. 
4 Calculated as the mean change score between pre- and 3-months post-revascularisation divided by the standard deviation of the change score. 
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APPENDIX 6.18 Responsiveness: Comparison of CROQ Change Scores for Different Levels of Global Improvement 
(Preliminary Field Test) 
Mean Pre-3m change scores 
CROQ scale Improved (n) 1 Unimproved (n) 2 p 
::::::lll:lflgl::fNF~:g§)::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::'::::::::::::::: : ::::::':::: ::::::::::::::::::::::::::':::::::::::::::::::'::::::::::::':::::::::::::::::::::::::::::::::::::::::::':':::::::::::::::::::::::::::: ::::::::t:?/:::::::::!::::::::,'::::'::,,:,:,:::: 
Symptoms 37.01 (121) 0.57 (6) .000 
Physical Functioning 30.19 (117) -8.63 (6) .001 
Psychosocial Functioning 29.13 (121) -3.62 (6) .000 
Cognitive Functioning 10.39 (121) -7.78 (6) .032 
::::::§llli.ll1.:tlffi;~U!l:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::iii:::::::::::::::::::::::::::::::::::::::::::::::::::::::':::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::1:::::::: ::::::::::::::::::::::::::.:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Symptoms 25.38 (88) 7.74 (25) .000 
Physical Functioning 21 .85 (88) 2.72 (25) .001 
Psychosocial Functioning 16.85 (87) 0.40 (24) .001 
Cognitive Functioning 11 .11 (87) -5.00 (24) .002 
Patients who reported global improvement in heart condition at 3-months post-revascularisation 
(scored 4 "a little better", or 5 "much better" on Q12). 
2 Patients who reported no global improvement in heart condition at 3-months post-revascularisation 
(scored 1 "much worse", 2 "a little worse", or 3 "about the same" on Q12) . 
APPENDIX 6.19a Percentage Endorsement of the CROQ-CABG at 
Pre-revascularisation (Final Field Test) 
For Office Use Only 
Patient 10: Date of operation: ______ _ 
Hospital: Date received: 
CORONARY REVASCULARISATION OUTCOME QUESTIONNAIRE 
(CROQ-CABG) 
INSTRUCTIONS: We are interested in finding out how you are now before the heart 
operation (coronary artery bypass graft surgery) you are going to have. We would be 
grateful if you could help us by filling out this questionnaire. All of the information you 
provide is COMPLETELY CONFIDENTIAL. Please be sure to answer all questions. 
1. During the past 4 weeks, how much were you bothered by each of the following problems 
related to your heart condition? (Please tick one box on each line.) 
A lot Quite Moderately A Not at all 
Angina pain that radiates to other parts of 
your body (eg arms, shoulders, hands, 
neck, throat, 
. -- ,- ... 
15% 
a bit 
21% 18% 
2. During the past 4 weeks, on average, how many times have you taken nitros (nitroglycerin 
tablets or spray) for your chest pain, chest tightness or angina? (Please tick only one box.) 
14% 26% 19% 14% 8% 20% 
4 or more 1-3 times 3 or more 1-2 times Less than None over 
times per day per day times per per week once a week the past 4 
week but not weeks 
every day 
537 
3. During the past 4 weeks, have you had chest pain, chest tightness or angina: 
(Please tick only one box.) 
9% 39% 
At rest? On exertion? 
40% 
At rest and on 
exertion? 
11% 
Not at all? 
4. During the past 4 weeks, how much trouble has your heart condition caused you? 
(Please tick only one box.) 
16% 28% 30% 17% 8% 
A lot Quite a bit Some A little None 
5. The following questions ask about activities which you might do during a typical day. During 
the past 4 weeks, has your heart condition limited you in your usual daily activities? Please 
indicate whether your heart condition limits you a lot, limits you a little, or does not limit you at 
all in the activities listed below. (Please tick one box on each line.) 
ACTIVITIES 
Bathing or dressing yourself 
Yes, 
Limited A 
Lot 
6% 
Yes, 
Limited A 
Little 
35% 
No, Not 
Limited At 
All 
57% 
538 
6. The next questions ask about the impact of your heart condition on your family and friends 
and the extent to which it has interfered with your social activities. During the past 4 weeks. 
how often have you experienced the following as a result of your heart condition: 
(Please tick one box on each line.) 
Feeling worried about going too far from 
home? 
All 
of the 
time 
17% 
Most 
of the 
time 
19% 
Some 
of the 
time 
20% 
A little 
of the 
time 
15% 
None 
of the 
time 
.~ .. 
28% 
7. The next questions ask about your feelings about your heart condition. During the past 4 
weeks, how often have you felt: (Please tick one box on each line.) 
That it was difficult to plan ahead (eg 
vacations, social events, etc.)? 
All 
of the 
time 
34% 
Most 
of the 
time 
30% 
Some 
of the 
time 
15% 
A little 
of the 
time 
14% 
None 
of the 
time 
7% 
539 
8. The next questions ask about problems related to your heart condition. During the past 4 
weeks, how much of the time did you: (Please tick one box on each line.) 
All 
of the 
time 
Most 
of the 
time 
A good 
bit of 
the time 
Some of 
the time 
A little 
of the 
time 
None 
of the 
time 
540 
APPENDIX 6.19b Percentage Endorsement of the CROQ-PTCA at 
Pre-Revascularisation (Final Field Test) 
For Office Use Only 
Patient 10: Date of operation: ______ _ 
Hospital: Date received: 
CORONARY REVASCULARISATION OUTCOME QUESTIONNAIRE 
(CROQ-PTCA) 
INSTRUCTIONS: We are interested in finding out how you are now before the heart 
operation (percutaneous transluminal coronary angioplasty) you are going to have. 
We would be grateful if you could help us by filling out this questionnaire. All of the 
information you provide is COMPLETELY CONFIDENTIAL. Please be sure to answer all 
questions. 
1. During the past 4 weeks, how much were you bothered by each of the following problems 
related to your heart condition? (Please tick one box on each line.) 
A lot Quite Moderately A Not at all 
a bit little 
2. During the past 4 weeks, on average, how many times have you taken nitros (nitroglycerin 
tablets or spray) for your chest pain, chest tightness or angina? (Please tick only one box.) 
7% 20% 25% 11% 11% 26% 
4 or more 1-3 times 3 or more 1-2 times Less than None over 
times per day per day times per per week once a week the past 4 
week but not weeks 
every day 
541 
3. During the past 4 weeks, have you had chest pain, chest tightness or angina: 
(Please tick only one box.) 
13% 32% 
At rest? On exertion? 
45% 
At rest and on 
exertion? 
8% 
Not at all? 
4. During the past 4 weeks, how much trouble has your heart condition caused you? 
(Please tick only one box.) 
15% 26% 36% 16% 6% 
A lot Quite a bit Some A little None 
5. The following questions ask about activities which you might do during a typical day. During 
the past 4 weeks, has your heart condition limited you in your usual daily activities? Please 
indicate whether your heart condition limits you a lot, limits you a little, or does not limit you at 
all in the activities listed below. (Please tick one box on each line.) 
ACTIVITIES 
Bathing or dressing yourself 
Yes, 
Limited A 
Lot 
4% 
Yes, 
Limited A 
Little 
26% 
No, Not 
Limited At 
All 
67% 
542 
6. The next questions ask about the impact of your heart condition on your family and friends 
and the extent to which it has interfered with your social activities. During the past 4 weeks, 
how often have you experienced the following as a result of your heart condition: 
(Please tick one box on each line.) 
Feeling worried about going too far from 
home? 
All 
of the 
time 
20% 
Most 
of the 
time 
13% 
Some 
of the 
time 
19% 
A little 
of the 
time 
16% 
None 
of the 
time 
33% 
7. The next questions ask about your feelings about your heart condition. During the past 4 
weeks, how often have you felt: (Please tick one box on each line.) 
t' •.• . " . . ' .. '. 
Worried about doing too much or over-
it? 
That it was difficult to plan ahead (eg 
vacations, social events, etc.)? 
All 
of the 
time 
30% 
Most 
of the 
time 
18% 
Some 
of the 
time 
20% 
A little 
of the 
time 
16% 
20% 
14% 
None 
of the 
time 
18% 
543 
8. The next questions ask about problems related to your heart condition. During the past 4 
weeks, how much of the time did you: (Please tick one box on each line.) 
All 
of the 
time 
Most 
of the 
time 
A good 
bit of 
the time 
Some of 
the time 
A little 
of the 
time 
None 
of the 
time 
544 
APPENDIX 6.20a Percentage Endorsement of the CROQ-CABG at 
3-Months Post-Revascularisation (Final Field Test) 
For Office Use Only 
Patient 10: Date of operation: ______ _ 
Hospital: Date received: 
CORONARY REVASCULARISATION OUTCOME QUESTIONNAIRE 
(CROQ-CABG) 
INSTRUCTIONS: We are interested in finding out how you have been since the heart 
operation (coronary artery bypass graft surgery) you had 3 months ago. We would be 
grateful if you could help us by filling out this questionnaire. All of the information you 
provide is COMPLETELY CONFIDENTIAL. Please be sure to answer all questions. 
1. During the past 4 weeks, how much were you bothered by each of the following problems 
related to your heart condition? (Please tick one box on each line.) 
A lot Quite Moderately A little Not at all 
a bit 
2. During the past 4 weeks, on average, how many times have you taken nitros (nitroglycerin 
tablets or spray) for your chest pain, chest tightness or angina? (Please tick only one box.) 
1% 1% 1% 1% 5% 89% 
4 or more 1-3 times 3 or more 1-2 times Less than None over 
times per day per day times per per week once a week the past 4 
week but not weeks 
every day 
545 
/ 
3. During the past 4 weeks, have you had chest pain, chest tightness or angina: 
(Please tick only one box.) 
5% 11% 
At rest? On exertion? 
15% 
At rest and on 
exertion? 
66% 
Not at all? 
4. During the past 4 weeks, how much trouble has your heart condition caused you? 
(Please tick only one box.) 
1% 3% 7% 30% 57% 
A lot Quite a bit Some A little None 
5. The following questions ask about activities which you might do during a typical day. During 
the past 4 weeks, has your heart condition limited you in your usual daily activities? Please 
indicate whether your heart condition limits you a lot, limits you a little, or does not limit you at 
all in the activities listed below. (Please tick one box on each line.) 
Yes, Yes, 
ACTIVITIES Limited A Limited A 
Lot Little 
"'=m'-f'!"'-'-·~·~'~·~' 
Bathing or dressing yourself 3% 11% 
No, Not 
Limited At 
All 
84% 
546 
6. The next questions ask about the impact of your heart condition on your family and friends 
and the extent to which it has interfered with your social activities. During the past 4 weeks, 
how often have you experienced the following as a result of your heart condition: 
(Please tick one box on each line,) 
Feeling worried about going too far from 
home? 
All 
of the 
time 
4% 
Most 
of the 
time 
6% 
Some 
of the 
time 
10% 
7. The next questions ask about your feelings about your heart condition. 
weeks, how often have you felt: (Please tick one box on each line,) 
All Most Some 
of the of the of the 
time time time 
A little 
of the 
time 
18% 
None 
of the 
time 
61% 
During the past 4 
A little 
of the 
time 
None 
of the 
time 
547 
/ 
8. The next questions ask about problems related to your heart condition. During the past 4 
weeks, how much of the time did you: (Please tick one box on each line.) 
Forget, for example things that 
happened recently, where you 
or ents? 
All 
of the 
time 
2% 
Most 
of the 
time 
5% 
A good Some of 
bit of the time 
the time 
9% 19% 
A little 
of the 
time 
28% 
None 
of the 
time 
9. Since your heart operation, have you been re-admitted to hospital for an overnight stay for any 
reason to do with your heart condition or heart operation? Please give as many details as 
you can below. 
82%0 No 
16%0 Yes 
Date of 
Admission 
Name of 
hospital 
Reason for 
hospital stay 
Number of 
days 
548 
/ 
10. The next questions ask about problems you might have had since your heart operation. 
During the past 4 weeks, how much were you bothered by the following problems? If you did 
not have the problem, tick the last box "Not at all". (Please tick one box on each line.) 
A lot 
Infection in your chest wound 
2% 
Quite a Moderately 
bit 
A little Not at all 
7% 80% 
71% 
11. The next question asks about how satisfied you are with your heart operation. How satisfied 
are you with the: (Please tick one box on each line.) 
Very Somewhat Somewhat Very 
dissatisfied dissatisfied satisfied satisfied 
""""""""""""-""""""""",,,,,,,,,,,,,,,""""" 
549 
12. Overall, how would you describe your heart condition now compared to before you had your 
heart operation? (Please tick one box.) 
1% 1% 5% 11% 81% 
Much worse A little worse About the same A little better Much better 
13. Has your recovery from your heart operation so far been: (Please tick one box.) 
17% 28% 32% 22% 
Slower than you 
expected? 
About what you 
expected? 
Faster than you 
expected? 
Did not know how 
long it would take? 
14. Are the results from your heart operation: (Please tick one box.) 
7% 
Worse than you 
expected? 
42% 
About what you 
expected? 
50% 
Better than you 
expected? 
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APPENDIX 6.20b Percentage Endorsement of the CROQ-PTCA at 
3-Months Post-Revascularisation (Final Field Test) 
For Office Use Only 
Patient 10: Date of operation: ______ _ 
Hospital: Date received: 
CORONARY REVASCULARISATION OUTCOME QUESTIONNAIRE 
(CROQ-PTCA) 
INSTRUCTIONS: We are interested in finding out how you have been since the heart 
operation (percutaneous transluminal coronary angioplasty) you had 3 months ago. 
We would be grateful if you could help us by filling out this questionnaire. All of the 
information you provide is COMPLETELY CONFIDENTIAL. Please be sure to answer all 
questions. 
1. During the past 4 weeks, how much were you bothered by each of the following problems 
related to your heart condition? (Please tick one box on each line.) 
Angina pain that radiates to other parts of 
your body (eg arms, shoulders, hands, 
neck 
A lot Quite Moderately A Not at all 
a bit little 
3% 7% 10% 21% 54% 
2. During the past 4 weeks, on average, how many times have you taken nitros (nitroglycerin 
tablets or spray) for your chest pain, chest tightness or angina? (Please tick only one box.) 
1% 7% 10% 6% 19% 55% 
4 or more 1-3 times 3 or more 1-2 times Less than None over 
times per day per day times per per week once a week the past 4 
week but not weeks 
every day 
551 
/ 
3. During the past 4 weeks, have you had chest pain, chest tightness or angina: 
(Please tick only one box.) 
7% 26% 
At rest? On exertion? 
22% 
At rest and on 
exertion? 
42% 
Not at all? 
4. During the past 4 weeks, how much trouble has your heart condition caused you? 
(Please tick only one box.) 
3% 5% 17% 33% 39% 
A lot Quite a bit Some A little None 
5. The following questions ask about activities which you might do during a typical day. During 
the past 4 weeks, has your heart condition limited you in your usual daily activities? Please 
indicate whether your heart condition limits you a lot, limits you a little, or does not limit you at 
all in the activities listed below. (Please tick one box on each line.) 
ACTIVITIES 
Walking half a mile 
Bathing or dressing yourself 
Yes, 
Limited A 
Lot 
19% 
3% 
Yes, 
Limited A 
Little 
29% 
19% 
No, Not 
Limited At 
All 
73% 
552 
6. The next questions ask about the impact of your heart condition on your family and friends 
and the extent to which it has interfered with your social activities. During the past 4 weeks. 
how often have you experienced the following as a result of your heart condition: 
(Please tick one box on each line.) 
Feeling worried about going too far from 
home? 
All 
of the 
time 
7% 
Most 
of the 
time 
9% 
Some 
of the 
time 
12% 
A little 
of the 
time 
23% 
None 
of the 
time 
46% 
7. The next questions ask about your feelings about your heart condition. During the past 4 
weeks, how often have you felt: (Please tick one box on each line.) 
All 
of the 
time 
: ~ii~~r;jl~ii'l~ill;I.~lillli1;ltl~~~illllil~~i~i~;~~:11 
Worried about doing too much or over-
doin it? 
Most 
of the 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
553 
8. The next questions ask about problems related to your heart condition. During the past 4 
weeks, how much of the time did you: (Please tick one box on each line.) 
Forget, for example things that 
happened recently, where you 
nl'v,intrnents? 
All 
of the 
time 
5% 
Most 
of the 
time 
6% 
A good 
bit of 
the time 
10% 
Some of 
the time 
14% 
A little 
of the 
time 
24% 
None 
of the 
time 
9. Since your heart operation, have you been re-admitted to hospital for an overnight stay for any 
reason to do with your heart condition or heart operation? Please give as many details as 
you can below. 
80% D No 
17% DYes 
Date of 
Admission 
Name of 
hospital 
Reason for 
hospital stay 
Number of 
days 
554 
10. The next questions ask about problems you might have had since your heart operation. 
During the past 4 weeks, how much were you bothered by the following problems? If you did 
not have the problem, tick the last box "Not at all". (Please tick one box on each line.) 
.Pain 
:, ... ;.",".";.'. 
Tenderness around your groin 
wound 
Bruising around your groin wound 
Concern over the appearance of 
your bruises 
A lot Quite a 
bit 
1% 2% 
1% 1% 
Moderately A little Not at all 
80% 
4% 13% 76% 
74% 
85% 
1% 4% 90% 
11. The next question asks about how satisfied you are with your heart operation. How satisfied 
are you with the: (Please tick one box on each line.) 
Very Somewhat Somewhat Very 
dissatisfied dissatisfied satisfied satisfied 
1"~hP=:rrt 6~~;f.:~bH11~;ili01;:!if'I(·g:iNi::!)~ ",,' . ~ 
12. Overall, how would you describe your heart condition now compared to before you had your 
heart operation? (Please tick one box.) 
3% 4% 13% 15% 64% 
Much worse A little worse About the same A little better Much better 
555 
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13. Has your recovery from your heart operation so far been: (Please tick one box.) 
14% 25% 21% 37% 
Slower than you 
expected? 
About what you 
expected? 
Faster than you 
expected? 
Did not know how 
long it would take? 
14. Are the results from your heart operation: (Please tick one box.) 
15% 
Worse than you 
expected? 
40% 
About what you 
expected? 
42% 
Better than you 
expected? 
'. 
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APPENDIX 6.21 a Percentage Endorsement of the CROQ-CABG at 
9-Months Post-Revascularisation (Final Field Test) 
For Office Use Only 
Patient ID: Date of operation : _____ _ 
Hospital: Date received: 
CORONARY REVASCULARISATION OUTCOME QUESTIONNAIRE 
(CROQ-CABG) 
INSTRUCTIONS: We are interested in finding out how you have been since the heart 
operation (coronary artery bypass graft surgery) you had 9 months ago. We would be 
grateful if you could help us by filling out this questionnaire. All of the information you 
provide is COMPLETELY CONFIDENTIAL. Please be sure to answer all questions. 
1. During the past 4 weeks, how much were you bothered by each of the following problems 
related to your heart condition? (Please tick one box on each line.) 
Angina pain that radiates to other parts 
your body (eg arms, shoulders, hands, 
neck, throat, ba 
• '~~.~~< •. ;-' .. '.' '.. • 
A lot Quite Moderately A little 
a bit 
!1,!liliJI~:~[lliil'~;;~~II!I~]~~~!'~~~ ~~ 1·1;f'!ii1;~I ·i~~ 
2% 7% 2% 13% 74% 
2. During the past 4 weeks, on average, how many times have you taken nitros (nitroglycerin 
tablets or spray) for your chest pain, chest tightness or angina? (Please tick only one be 
2% 1% 7% 3% 7% 80% 
4 or more 1-3 times 3 or more 1-2 times Less than None over 
times per day per day times per per week once a week the past 4 
week but not weeks 
every day 
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3. During the past 4 weeks, have you had chest pain, chest tightness or angina: 
(Please tick only one box.) 
2% 21% 
At rest? On exertion? 
11% 
At rest and on 
exertion? 
64% 
Not at all? 
4. During the past 4 weeks, how much trouble has your heart condition caused you? 
(Please tick only one box.) 
1% 9% 4% 26% 59% 
A lot Quite a bit Some A little None 
5. The following questions ask about activities which you might do during a typical day. During 
the past 4 weeks, has your heart condition limited you in your usual daily activities? Please 
indicate whether your heart condition limits you a lot, limits you a little, or does not limit you at 
all in the activities listed below. (Please tick one box on each line.) 
Yes, Yes, No, Not 
ACTIVITIES Limited A Limited A Limited At 
Lot Little All 
Lifting or carrying groceries 8% 63% 
':':~' . 
".'". N 
Climbing one flight of stairs 
Walking half a mile 5% 19% 75% 
, .!: .: ... 
Bathing or dressing yourself 3% 8% 87% 
558 
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6. The next questions ask about the impact of your heart condition on your family and friends 
and the extent to which it has interfered with your social activities. During the past 4 weeks , 
how often have you experienced the following as a result of your heart condition: 
(Please tick one box on each line.) 
Feeling worried about going too far from 
home? 
All 
of the 
time 
4% 
Most 
of the 
time 
3% 
Some 
of the 
time 
5% 
7. The next questions ask about your feelings about your heart condition. 
weeks, how often have you felt: (Please tick one box on each line.) 
Worried about doing too much or over-
doing it? 
.... .., ... ,,,.,' ....... ', .;" .. , ...... , ...• 
Worried that your symptoms might 
return? 
", ;: ;~::: " . . .... ; .;. " " ,::: i: F~: .:' :. . 
All Most Some 
of the of the of the 
time time time 
1% 4% 14% 
2% 5% 16% 
2% 3% 12% 
A little 
of the 
time 
11% 
None 
of the 
time 
77% 
During the past 4 
A little 
of the 
time 
36% 
30% 
26% 
None 
of the 
time 
45% 
47% 
56% 
64% 
62% 
559 
8. The next questions ask about problems related to your heart condition. During the past 4 
weeks, how much of the time did you: (Please tick one box on each line.) 
All 
of the 
time 
Most 
of the 
time 
A good Some of 
bit of the time 
the time 
A little 
of the 
time 
None 
of the 
time 
9. Since your heart operation, have you been re-admitted to hospital for an overnight stay for any 
reason to do with your heart condition or heart operation? Please give as many details as 
you can below. 
76%0 No 
21%0 Yes 
Date of 
Admission 
Name of 
hospital 
Reason for 
hospital stay 
Number of 
days 
560 
10. The next questions ask about problems you might have had since your heart operation. 
During the past 4 weeks, how much were you bothered by the following problems? If you did 
not have the problem, tick the last box "Not at all". (Please tick one box on each line.) 
Bruising on your leg or arm where 
a vein was removed 
" . . :;:" ... ~.~ .:,~: 
",: .;. :;,;.,. 
. " ;.' ,:;: .~. .;: :: ::' ", 
A lot 
2% 
Quite a Moderately 
bit 
A little Not at all 
11. The next question asks about how satisfied you are with your heart operation. How satisfied 
are you with the: (Please tick one box on each line.) 
Very Somewhat Somewhat Very 
dissatisfied dissatisfied satisfied satisfied 
""':"'<m"?;"";:;cU~.mEi"X:::":"?)"~"-"')';<''"'' ~, oW 
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12. Overall, how would you describe your heart condition now compared to before you had your 
heart operation? (Please tick one box.) 
1% 3% 6% 6% 83% 
. Much worse A little worse About the same A little better Much better 
13. Has your recovery from your heart operation so far been: (Please tick one box.) 
12% 25% 36% 27% 
Slower than you 
expected? 
About what you 
expected? 
Faster than you 
expected? 
Did not know how 
long it would take? 
14. Are the results from your heart operation: (Please tick one box.) 
6% 
Worse than you 
expected? 
32% 
About what you 
expected? 
62% 
Better than you 
expected? 
•• 
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APPENDIX 6.21 b Percentage Endorsement of the CROQ-PTCA at 
9-Months Post-Revascularisation (Final Field Test) 
For Office Use Only 
Patient 10: Date of operation: _____ _ 
Hospital: Date received: 
CORONARY REVASCULARISATION OUTCOME QUESTIONNAIRE 
(CROQ-PTCA) 
INSTRUCTIONS: We are interested in finding out how you have been since the heart 
operation (percutaneous transluminal coronary angioplasty) you had 9 months ago. 
We would be grateful if you could help us by filling out this questionnaire. All of the 
information you provide is COMPLETELY CONFIDENTIAL. Please be sure to answer all 
questions. 
1. During the past 4 weeks, how much were you bothered by each of the following problems 
related to your heart condition? (Please tick one box on each line.) 
A lot Quite Moderately . A Not at all 
a bit little 
~~~~~:ill!!(~~~!~:~ I::I~I~II~i"~I!'~llj~fl;.'111~~~lii!!~~illi!I~~I:lii~~,~;il!~~l~~il~i l! i.:~~lj~)~II[~~I~~II<II! 
Angina pain that radiates to other parts of 
your body (eg arms, shoulders, hands, 
4% 5% 
4% 9% 
.. : .. ' 
•••••••••••••• 
2. During the past 4 weeks, on average, how many times have you taken nitros (nitroglycerin 
tablets or spray) for your chest pain, chest tightness or angina? (Please tick only one box.) 
4% 
4 or more 
times per day 
4% 
1-3 times 
per day 
13% 
3 or more 
times per 
week but not 
9% 
1-2 times 
per week 
19% 
Less than 
once a week 
53% 
None over 
the past 4 
weeks 
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3. During the past 4 weeks, have you had chest pain, chest tightness or angina: 
(Please tick only one box.) 
4% 30% 
At rest? On exertion? 
26% 
At rest and on 
exertion? 
38% 
Not at all? 
4. During the past 4 weeks, how much trouble has your heart condition caused you? 
(Please tick only one box.) 
3% 11% 11% 40% 35% 
A lot Quite a bit Some A little None 
5. The following questions ask about activities which you might do during a typical day. During 
the past 4 weeks, has your heart condition limited you in your usual daily activities? Please 
indicate whether your heart condition limits you a lot, limits you a little, or does not limit you at 
all in the activities listed below. (Please tick one box on each line.) 
ACTIVITIES 
Lifting or carrying groceries 
Climbing one flight of stairs 
Bathing or dressing yourself 
Yes, 
Limited A 
Lot 
Yes, 
Limited A 
Little 
No, Not 
Limited At 
All 
'~m~m~lli'~,~,~~t"~~~m~~;~'<c~~;', 
16% 38% 43% 
5% 14% 79% 
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/ 
6. The next questions ask about the impact of your heart condition on your family and friends 
and the extent to which it has interfered with your social activities. During the past 4 weeks, 
how often have you experienced the following as a result of your heart condition : 
(Please tick one box on each line.) 
:. ,:: .;. ;: ,: ::'., ::.:: ;: :: ;: ~i :: := .: .: ': :: ;: ;. .;" :' .: " .:. :. .' .' :' ,: 
........ , ...... ,. '. " ... " .' ......... . 
Feeling worried about going too far from 
home? 
All 
6% 
Most 
of the 
time 
5% 
Some 
of the 
time 
A little 
of the 
time 
@J!{.4f7d7~~m:WWt 
13% 16% 
None 
of the 
time 
58% 
7. The next questions ask about your feelings about your heart condition. During the past 4 
weeks, how often have you felt: (Please tick one box on each line.) 
All 
of the 
time 
Most 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
565 
8. The next questions ask about problems related to your heart condition. During the past 4 
weeks, how much of the time did you: (Please tick one box on each line.) 
All 
of the 
time 
Most 
of the 
time 
A good 
bit of 
the time 
Some of 
the time 
A little 
of the 
time 
None 
of the 
time 
9. Since your heart operation, have you been re-admitted to hospital for an overnight stay for any 
reason to do with your heart condition or heart operation? Please give as many details as 
you can below. 
73% 0 No 
28% 0 Yes 
Date of 
Admission 
Name of 
hospital 
Reason for 
hospital stay 
Number of 
days 
566 
10. The next questions ask about problems you might have had since your heart operation. 
During the past 4 weeks, how much were you bothered by the following problems? If you did 
not have the problem, tick the last box "Not at all". (Please tick one box on each line.) 
Bruising around your groin wound 
Concern over the appearance of 
your bruises 
A lot 
0% 
Quite a Moderately 
bit 
3% 
1% 0% 
A little Not at all 
:,' 
'83% 
11% 78% 
0% 95% 
11. The next question asks about how satisfied you are with your heart operation. How satisfied 
are you with the: (Please tick one box on each line.) 
Very Somewhat Somewhat Very 
dissatisfied dissatisfied satisfied satisfied 
12. Overall, how would you describe your heart condition now compared to before you had your 
heart operation? (Please tick one box.) 
4% 1% 11% 18% 64% 
Much worse A little worse About the same A little better Much better 
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13. Has your recovery from your heart operation so far been: (Please tick one box.) 
5% 
Slower than you 
expected? 
33% 
About what you 
expected? 
25% 
Faster than you 
expected? 
35% 
Did not know how 
long it would take? 
14. Are the results from your heart operation: (Please tick one box.) 
16% 
Worse than you 
expected? 
38% 
About what you 
expected? 
45% 
Better than you 
expected? 
- .. 
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